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Abstract
Aberrant regulation of macrophage recruitment and activation by M-CSF is integral to 
inflammatory disease and cancer. M-CSF stimulated responses are mediated by the c- 
fins gene product found on monocytes and macrophages. A key component of 
signalling pathways immediately downstream of c-fins is Phosphatidylinositol 3- 
kinase. The research data presented in this thesis examined the role of PI 3-kinase in 
various M-CSF stimulated responses in a murine macrophage cell line, BAC1.2F5.
Analysis of the expression profile for PI 3-kinase identified p85a/pllO a as the 
predominant PI 3-kinase isoforms present in BAC1.2F5 cells which was activated 
upon M-CSF stimulation. The PI 3-kinase specific inhibitors wortmannin and 
LY294002 were used to characterise the M-CSF stimulated responses in BAC1.2F5 
cells. It was found that PI 3-kinase activity is required for protection of BACI.2F5 
macrophages against apoptosis, but not for the proliferation signal. It was observed 
that PI 3-kinase inhibitws prevented die correct transport of internalised c-fins fixim 
the plasma membrane to the endosomal/lysosomal compartments. In addition, PI 3- 
kinase inhibition also resulted in aberrant reorganisation of the actin cytoskeleton, 
characterised by the absence of fine actin cables within the cytoplasm of BACI.2F5 
cells.
In addition to the characterisation of c-fins signalling with respect to PI 3-kinase, this 
thesis also reports the production of human c-fins expression constructs containing 
mutations at critical PI 3-kinase binding sites and possessing C-terminal epitope tags 
for identification and purification. These constructs were expressed in HEK 293 cells 
and demonstrated to be recognised by both gene and epitope specific antibodies. 
Thus these constructs represent novel tools for the investigation of PI 3-kinase 
signalling.
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1.1.0. Macrophages in the immune system
1.1.1. The immune system
In humans and other mammals the immune system facilitates defence against 
pathogens and infectious agents such as bacteria, viruses, fungi, protozoa as well as 
multicellular parasites. The innate and ad^tive immune systems not only protect us 
fiom these potentially infectious agents but also from ourselves during episodes of 
potentially uncontrolled growth such as malignancy or autoimmune diseases 
(Clancey, 1998). In order to combat certain pathogens, multicellular organisms have 
developed a group of cells which circulate through the bloodstream, lymphatic system 
and infiltrate tissues which possess specific receptors that recognise immunogenic 
peptide firagments of both intracellular and extracellular pathogens. When these 
receptors are triggered, the immune cells secrete various soluble mediators such as 
antibodies or perforin granules which attack pathogens directly or stimulate other 
cells to do so via the production of cytokines. This circulatmg army of cells includes 
B and T lymphocytes and various antigen presenting cells like monocytes, 
macrophages and dendritic cells such as basophils, eosinophils, neutrophils and mast 
cells (Clemens, 1991).
1.1.2. Macrophages and Immunity
The macrophage is an extremely important mediator of the immune response. 
Macrophages develop and mature from bone marrow precursors before entering the 
bloodstream as monocytes (Clemens, 1991). Monocytes are recruited into different 
tissues where they further differentiate into resident tissue macrophages vsfrich 
perform important functions in tissue homeostasis and the immune response (Lewis, 
1992). Macrophages are found in all tissues and primarily act as scavengers during
1
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the innate immune response, phagocytosing large particles such as bacteria, yeast and
dying cells (Lewis, 1992). The macrophage, although a very competent phagocyte 
during innate immunity, also plays an important role as an antigen presenting cell and 
as an effector cell during cell-mediated immunity (Lewis, 1992). Macrophages also 
process foreign antigens and present them to T-lymphocytes allowing development of 
a specific immune response. In addition macrophages produce chemokines and 
cytokines, signalling molecules that orchestrate the immune response and stimulate 
the secretion of proteases and growth factors, which are important for tissue 
remodelling and wound repair after injury (Lewis, 1992). Thus macrophages respond 
to a wide variety of inflammatory mediators and play a central role in acute and 
chronic inflammation (Lewis, 1992).
1.13. Macrophage phagocytosis and vésiculation.
Macrophages phagocytose small particulate matter including small latex beads and 
large polymer beads, up to twice the diameter of the cell, which are ingested by 
surrounding the particle with extrusions from the cell membrane. Although 
phagocytosis usually results in the destruction of the ingested particle by production 
of reactive oxygen or nitrogen metabolites or by proteolysis, some pathogens, 
including the mycobacteria Wiich cause tuberculosis or leprosy, evade immune 
destruction by surviving inside the macrophage iMiich is an important feature of their 
pathogenesis. In general, most cells in culture take up small volumes of culture 
medium by a process called pinocytosis (Swanson and Watts, 1995). However 
macrophages constitutively take-up large volumes of external fluid via 
macropinocytotic vesicles (Swanson and Watts, 1995). Macrophages can also be 
stimulated to form macropinocytotic vesicles by growth factors and cytokines such as 
IL-6, GM-CSF or M-CSF (Araki et al., 1996; Swanson and Watts, 1995). The role of
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macropinocytosis is still unclear but various benefits to macrophages include routine
turnover of plasma membrane proteins; a mechanism for re-routing membrane traffic; 
and importantly the non-specific capture of antigens prior to expression of high 
affinity antibodies (Swanson and Watts, 1995).
1.1.4. Cytokines secreted bv macrophages
Macrophages can be stimulated by various agonists to secrete tumour necrosis factor 
alpha (TNFa), interleukin (IL) -ip , IL-6, IL-8, IL-10 and IL-12 (Lewis, 1992). The 
binding of TNFa to its receptor on macrophages initiates the production of various 
cytokines ) ^ c h  mediate the inflammatory response and induces the expression of 
many genes important for the host response to inflection (Lewis, 1992). IL-ip and IL- 
6 are pro-inflammatory cytokines that act either in an autocrine manner or 
systemically to elicit production and recruitment of neutrophils, the synthesis of acute 
phase proteins by the liver and the activation of T-cells (Lewis, 1992). IL-8 is also 
produced by macrophages and is the main cytokine involved in neutrophil recruitment 
to sites of tissue damage or infection (Clemens, 1991). Not only is IL-10 a potent 
modulator of monocyte and macrophage function, involved in the deactivation of 
macrophages, but it also siq>presses IL-2 and interferon gamma (IFNy) production by 
Thl T-cells. Production of IL-12 stimulates the growth of activated natural killa* 
(NK) cells, CD8^ and CD4^ T-cells (Lewis, 1992).
1.1.5. Cvtokines and growth factors that activate macrophages
Macrophage activation and function is regulated by an array of proteins and small 
molecules including IFNy, IL-4, IL-13, TGFp and the colony stimulating factors 
(CSFs). IFNy, produced by Thl T-cells and NK cells, activates macrophage 
pathogenicity and also upregulates expression of the macrophage major
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histocompatability complex (MHC) class I, IL-1, platelet activating factor (PAF) and
H2O2 production (Lewis, 1992). In addition, IFNy can act in concert with 
lipopolysaccharide (LPS) to upregulate nitric oxide production (Lewis, 1992). IL-4 
and IL-13 have similar biological effects and stimulate macrophage fusion in culture 
to form multi-nucleate giant cells (Lewis, 1992). TGFp stimulates macrophage 
secretion of various growth factors including platelet derived growth factor beta 
(PDGFP) and extracellular matrix (ECM) components (Lewis, 1992). TGFp has both 
positive and negative effects on macrophages including stimulating chemotaxis and 
the secretion of tissue inhibitors of metalloproteinases (TIMPs) and inhibition of nitric 
oxide synthesis (Lewis, 1992).
The colony stimulating factors are a family of haematopoietic cell growth factors that 
stimulate the growth and differentiation of cells of the granulocyte and macrophage 
cell lineages (Das and Stanley, 1982). The macrophage colony stimulating factor (M- 
CSF or CSF-1) is produced by many cells including macrophages and is important for 
the survival, proliferation and differentiation of monocytes, macrophages, osteoclasts 
and their precursors (Stanley et al., 1997; Stanley et al., 1976). M-CSF also stimulates 
macrophages to produce plasminogen activator, prostaglandin £  and also enhances 
both phagocytic and tumoricidal activities (Clemens, 1991). The role of M-CSF and 
its receptor in macrophage function will be discussed later in greater detail.
1.1.6. Macrophages and disease
One of the most common causes of death in the westem world is cardiovascular 
disease. Atherosclerosis, the principal cause of myocardial and cerebral infarction^ 
accounts for the majority of these deaths. Monocyte recruitment is a key event in the 
formation of the earliest vascular lesions, the fatty streak in atherosclerotic plaques
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(Campbell and Campbell, 1997; Lewis, 1992). It has been shown that uptake of
modified low-density lipoproteins (LDLs) by monocyte-derived macrophages gives
rise to the foam cells present in the atheroma > ^ch  accumulate in the latter stages of
plaque formation and release Upids into the intima of the blood vessel (Campbell and
Campbell, 1997). Vascular smooth muscle cells in the plaque proliferate in response
to growth factors such as PDGPp released by macrophages and this leads to plaque
fibrosis (Lewis, 1992). In addition, macrophages secrete other chemotactic cytokines
(chemokines) ^ ^ c h  lead to further macrophage recruitment, infiltration and the onset
of chronic inflammation (Lewis, 1992). A model of atherosclerosis can be created
either by feeding mice a diet containing high fat and cholesterol (Qiao e/ a/., 1997) or
by crossing the mouse knockout for M-CSF (op/op), Wiich will be discussed later in
greater detail, with the apolipoprotein E (apo E) knockout mouse (Qiao et al.i 1997).
In both the dietary and apo E knockout models of atherogenesis, the M-CSF knockout
resulted in significantly reduced atherogenesis (Qiao et al., 1997) and in LDL
receptor-deficient mice both heterozygous (+/-) iand homozygous osteopetrotic
phenotypes (-/-) reduced atherosclerosis (Rajavashisth et al., 1998). Therefore M-
CSF regulates recruitment of circulating monocytes and macrophages to the
atherosclerotic lesion and their contribution to atherogenesis.
Aberrant macrophage function is also imphcated in other disease states including 
rheumatoid arthritis (RA). Macrophage activation and recruitment in synovial tissue 
participate in the development of RA lesions and mediate of cartilage and bone 
destruction (Amento et al., 1982). The use of anti-TNF antibodies or soluble TNF 
receptor fusion proteins to reduce circulating and localised TNF levels within joints 
dramatically decreases the severity of the disease (Arend and Dayer, 1995; Williams
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et al., 1992). Therefore disruption of aberrant monocyte/macrophage recruitment to
RA joints is therapeutically beneficial.
Monocytes and macrophages also possess tumouricidal, cytocidal and microbicidal 
edacity. As a consequence of their broad range of functions macrophage dysfunction 
is also involved in a wide variety of immunodeficient conditions, including common 
variable immunodefficiency (CVID) and chronic granulomatous disease (CGD), 
although this is predominantly a neutrophil deficiency disease (Donowitz and 
Mandell, 1982; Eibl et a l, 1982).
Abnormal monocyte and macrophage function has been detected in many human 
cancers. During the progression of Hodgkin’s disease there is increased macrophage 
expression of Fc receptor, phagocytosis and an increase in peripheral blood monocyte 
population (Sciborski, 1989). Macrophages normally respond chemotactically to 
growth factors, but this is reduced in lung and prostate cancers, renal cell carcinoma 
and melanomas (Lewis, 1992). Enhancement of macrophage tumouricidal activity 
represents a valuable area for th e r^ u tic  intervention. Augmentation of monocyte 
and macrophage cytostatic and cytotoxic activity towards tumour cells is currently 
being extensively investigated in many laboratories. To date IFNa and GM-CSF 
have shown positive ther^)eutic benefits in a number of cancer patients (Borden and 
Sondel, 1990; Fuithe/a/., 1989; Steward ef a/., 1989).
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1.2.0. Bidlogv and action of Macrophage-Colonv Stimulating Factor
1.2.1. Macrophage-Colonv Stimulating Factor
M-CSF was originally identified by Stanley and colleagues as a potent growth factor 
activity present in L-cell conditioned medium that promoted the survival and 
proliferation of macrophages in vitro, and stimulated the formation of macrophage 
colonies in soft agar (Sheir, 1988; Stanley et aL, 1976). M-CSF is a disulphide-linked 
homodimeric glycoprotein produced by a number of cell types, principally monocytes 
and macrophages, but also fibroblasts, epithelial and endothelial cells, activated B- 
and T-cells and some tumour cell lines (Sherr, 1988; Sherr et al., 1985). M-CSF is 
also secreted by a number of establidied cell lines in vitro including the L-929 murine 
fibroblast-like line (L-cell) (Stanley et al., 1976). Synthesis of the growth factor by 
macrophages is stimulated by the individual or collective presence of IL-1, PDGF, 
granulocyte-macrophage colony stimulating factor (GM-CSF), y-interferon (y-IFN) 
and tumour necrosis factor-a (TNF-a) (Sherr, 1988). In addition the synthesis of M- 
CSF is negatively regulated by prostaglandins, glucocortcoids and TGFP (Blake et al., 
1998).
M-CSF stimulated responses include; enhancement of antibody dependent cell- 
mediated cytotoxicity by monocytes and macrophages, inhibition of bone resorption 
by osteoclasts, stimulation of microglial cell proliferation and the regulation o f 
placental function via the action of decidual cells and trophoblasts (Hattersley et al., 
1988; Mufson et al., 1989; Welte et al., 1985). Synergism of M-CSF with IL-1, IL-3 
and IL-6 stimulates primitive haematopoietic cells to proliferate and differentiate into 
mature macrophages (see Fig. 1.2.1.) (Ibelgauft, 1998). M-CSF is also required by 
tissues that are undergoing r^ id  morphogenesis or tissue remodelling (Stanley et al.,
1997).
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Fig. 1.2.1. M-CSF, a growth footer that acts during haematopoiesis.
Secreted human and murine M-CSF are highly homologous at the amino acid level 
(>80%), and although human M-CSF exhibits cross species activity with the murine 
receptor the murine M-CSF does not act on the human receptor (Das and Stanley, 
1982). Indeed, it ^)pears that human M-CSF is a more potent stimulator of murine 
macrophage activity in vitro (Das and Stanley, 1982). M-CSF binds with high 
affinity (Kd = 0.4x10'^ ° for human M-CSF and Kd = «2x10'^ ° for murine M-CSF) to 
its specific cell-surface receptor, which is found on virtually all mononuclear 
phagocytes (Das and Stanley, 1982; Welte et a/., 1985). In M-CSF deprived, 
phagocytic cells, cell-cycle arrest occurs with prolonged starvation leading to 
apoptosis (Li and Stanley, 1991). Re-introduction of M-CSF, following short periods 
of deprivation (12-18 hrs) induces re-entry into the cell-cycle with concomitant 
expression of immediate early gene expression including fos, myc and jun  (Li and 
Stanley, 1991). The transcription of delayed early genes then follows, which includes 
the D-type cyclins and their catalytic partners \^4iich are crucial for Gi progression 
and the initiation of DNA synthesis (Sherr, 1993). A continual requirement for M- . 
CSF fi’om initiation of immediate early gene expression through Gi has been
8
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demonstrated, and therefore it is believed that M-CSF acts as a progression factor as
well as a competence factor (Sherr, 1993).
Human M-CSF is encoded by a single gene composed of 10 exons located on human 
chromosome Ip21-lpl3, (chromosome 3 in mice) (Gisselbrecht et al., 1989; Yaar,
1998). Molecular cloning data has determined that two alternatively spliced mRNA 
species exist for the human M-CSF which code for three M-CSF species (Hampe et 
aL, 1989; Ibelgauft, 1998). The sm ^er transcript of 1.8-2.0kb lacks the 5'-end of 
exon 6, and codes for a 36-52kDa membrane bound, disulphide-linked homodimer 
(Ibelgauft, 1998; Roussel, 1994). The larger, 4.0kb mRNA species containing the 5' 
end of exon 6, codes for a secreted 70-90kDa disulphide linked homodimer (Welte et 
aL, 1985). The 4.0kb transcript is also processed as a proteoglycan, soluble, secreted 
form with an apparent molecular weight of 150-200kDa (Ibelgauft, 1998). Both 
secreted and membrane bound M-CSF play diverse physiological roles in stimulation 
of receptor-bearing cells, by either endocrine or paracrine mechanisms or through 
direct cell-cell contact (Sherr and Stanley, 1990). The secreted proteoglycan form of 
M-CSF may also be sequestered to specific locations by virtue of its 
glycosaminoglycan chains (Stanley et aL, 1997). Deletion mapping experiments have 
demonstrated that the first 149 amino acids of human M-CSF are minimally required 
for biological activity (Clemens, 1991).
1.2.2. riinical relevance of M-CSF
In the past 15 years the application of growth factor therapy to a variety of diseases 
has been explored by several laboratories and clinics. At present a number of clinical 
trials are being conducted using Granulocyte-CSF (G-CSF) and Granulocyte/ 
Macrophage-CSF (GM-CSF) as treatments for various diseases including
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chemotherapy-induced neutropenia in cancer patients (Nemunaitis, 1997). Both GM-
CSF and G-CSF have been approved by the United States food and drug
administration (US FDA) for clinical trials (Nemunaitis, 1997). The Japanese FDA
have also ^)proved recombinant M-CSF for th e r^ u tic  use in acceleration of
granulocyte recovery following allogenic transplant, dose-intensive therapy of ovarian
cancer and induction ther^y  of acute myelogenous leukaemia (AML) (Nemunaitis,
1997). M-CSF has also been evaluated as an anti-microbial agent since in mice it
promotes survival of pathogen-infected mice (Nemunaitis, 1998). Clinical trials on
M-CSF have also been conducted in patients with fungal infection following bone
marrow transplantation (BMT). Co-administration of amphotericin B with M-CSF
enhanced patient survival in pathogen-infected patients compared to patients treated
with only amphotericin B (Nemunaitis, 1997). Elevated M-CSF levels have also been
reported in malaria infection which results in niacrophage activation and leads to the
increased macrophage-mediated platelet destruction associated with disease
progression (Lee et al., 1997).
1.23. M-CSF signalling and carcinogenesis
Increased levels of circulating M-CSF have been associated in niyeloproliferative 
diseases including myeloid m et^lasia, peripheral bone marrow extension (Gilbert et 
al., 1989) and in an experimental mouse model of AML (Haran-Ghera et al., 1997). 
Increased levels of circulating M-CSF have also been detected in myelodysplastic 
syndrome (MDS), chronic myelogenous leukemia (CML), chronic lymphocytic 
leukemia (CLL), non-Hodgkin's lymphoma (NHL), Hodgkin's disease (HD), and 
multiple myeloma (MM) (Janowska-Wieczorek et al., 1991). Taken together, it has 
become apparent that M-CSF is an important factor for tumour progression, 
particularly in tumours of the haematopoietic lineage, and may play a regulatory role
10
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in the maintainence of these disease states. In.addition a number of different tumour
types also express the M-CSF receptor, c-fins, which suggests that M-CSF regulation
of tumour progression may be controlled, at least in part, through an autocrine loop.
Elevated levels of M-CSF may potentially be a more accurate indicator of the 
presence and activity of either primary endometrial adenocarcinoma or recurrent 
disease than the established marker, CA 125 (Hakala et al., 1995; Kacinski et al., 
1989). Circulating levels of M-CSF have also been investigated as a potential 
indicator of the response to chemotherapy in acute type adult T-cell leukaemic (ATL) 
patients (Yamada et al., 1996). Circulating M-CSF levels declined vdien patients 
achieved complete or partial remission but increased again when partial remission 
patients showed renewed disease progression (Yamada et al., 1996). Gene transfer 
trials o f human M-CSF expression in tumour transplantation models have shown that 
\s^en the human M-CSF gene is expressed in J558 plasmacytoma cells it does hot 
suppress tumour gmwth, but expression in B16 melanoma cells and 3LL lung cancer 
cells induced immunity against the parent tumour cells (Motoyoshi, 1998). Therefore 
it appears that therapeutically, M-CSF can also be used to treat certain types of cancer 
in addition to chemotherapy side affects such as neutropenia, but its use is limited to 
the type of disease being treated.
1 .2 .4 , The M-CSF knockout mouse; osteopetrotic I od/ od)
The mouse knock-out for M-CSF, (osteopetrotic or op/op) is a classical mutation with 
a homozygous genotype caused by a null allele for M-CSF expression (Wiktor- 
Jedrzejczak et al., 1990). Analysis of cDNA isolated from op/op fibroblasts suggests 
that a single base insertion causes a frame-shift mutation in the coding region of the 
M-CSF gene introducing a stop codon which gives rise to synthesis of a non-
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functional polypeptide (Pollard, 1997). Homozygous op/op mice have a viable
phenotype, but exhibit severe macrophage deficiency resulting in a reduced 
haematopoietic activity, neurological defects and an absence of a functional osteoclast 
population (Yoshida et al., 1990). However, by about forty weeks the symptoms of 
M-CSF deficiency ^p ear to be corrected. This apparent partial reversal of phenotype 
is thought to occur through an adaptation to the absence of M-CSF by other growth 
factors which also stimulate macrophage development (Yoshida et al., 1990).
Op/op mice do not respond normally to external stimuli and the phenotype is 
characterised by cortical processing problems including excitatory and inhibitory 
processing problems in nerve signals from the retina along the optic nerve (Cecchini 
et al., 1994; Pollard, 1997). However, there are no apparent morphological 
differences between the brains of op/op mice or their normal littermates, but. in normal 
mouse development a unique mRNA splice variant encoding a secreted form of M- 
CSF found only in brain tissue is absent in op/op mice (Cecchini et al., 1994). The 
op/op phenotype, including the observed developmental abnormalities, can be rescued 
by daily injection of recombinant M-CSF (Cecchini et al., 1994). The age-related 
recovery of haematopoietic function and resolution of osteopetrosis observed in the 
op/op phenotype also seems to indicate that the developing haematopoietic system has 
the capacity to use alternative mechanisms to M-CSF signalling and can compensate 
for its absence. Interestingly, there is an elevated level of splenic haematopoietic 
activity during the period of time in > ^ch  the immune system develops and coincides 
with the period of reduced haematopoietic activity in the bone marrow of developing 
op/op mice (Begg et al., 1993). Op/op mice are also capable of mounting an 
apparently normal T-cell-dependent immune response (Chang et al., 1995). In 
addition, op/op mice are able to induce Ag-specific proliferation of naïve T-cells,
12
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generate cytotoxic T-lymphocytes, siq)ply spleen cells to serve as stimulators in a
mixed lymphocyte reaction and produce IgM and IgG, similar to their normal
littermates (Chang et al., 1995). However, M-CSF-deficient mice do not develop
autoimmune haemolytic anaemia on injection with anti-red blood cell monoclonal
antibodies or autoimmune tfarombocytopaenia on injection of anti-platelet monoclonal
antibodies (Clynes and Ravetch, 1995) > ^ch  is probably due to an absence of an Fc
gamma receptor bearing, circulating macrophage population > ^ch  normally regulates
opsonised phagocytosis of red blood cells and platelets (Begg et al., 1993; Michaelson
et al., 1996; Pollard and Hennighausen, 1994; Stanley et al., 1997; Wiktor-
Jedrzejczak et al., 1990). Therefore it may be concluded that macrophage populations
^hich are either M-CSF independent or have adapted to the absence of M-CSF have
developed in the op/op phenotype and th ^  can participate in a limited number of
macrophage functions but the full macrophage repertoire remains unavailable in the
op/op mouse.
1.2.5. Requirement for M-CSF diiriny pregnancy
During pregnancy M-CSF concentrations in the mouse uterus are elevated up to a 
thousand fbld  ^A^ereas serum levels remain relatively normal (Pollard, 1997). In situ 
hybridisation has shown that all four M-CSF transcripts are expressed but only in the 
uterine luminal and glandular epithelium (Pollard, 1997). However, in the op/op 
mouse female absence of M-CSF in the uterine epithelium correlates with lower 
fertility compared to their normal littermates, and is characterised by defective 
folliculogenesis and ovulation, wh@"e the number of ovulated ova is significantly 
smaller compared to normal females (Stanley et al., 1997). M-CSF participation in 
folliculogenesis and ovulation appears to be indirect, controlling the numbers of 
ovarian macrophages present, but it may have a direct effect on granulosa cells and
13
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oocytes (Stanley et al., 1997). Rescue of the op/ap placental phenotype can be
achieved by M-CSF therapy and also by opportunistic stimulation of Q-fins by steel
factor, a structural relative of M-CSF (Stanley et al., 1997).
Macrophages are also found throughout the male reproductive tract and its accessory 
glands (Pollard et al., 1997). Interestingly the op/op males exhibit reduced libido 
compared to normal males as well as a significantly lower density of macrophages in 
the testis, epididymis, prostate, seminal vesicles and vas deferens (Pollard et al., 
1997). This suggests that occurrence of macrophages is regulated by M-CSF in male 
reproductive tissues and addition of M-CSF restored the numbers of resident 
macrophages to that normally present in all tissues except the prostate (Pollard et al., 
1997). The male op/op phenotype also shows a seven fold decrease in the 
concentration of circulating testosterone with significantly reduced intratesticular 
testosterone levels compared to their normal littermates (Cohen et al., 1996). 
Reduced testosterone levels are consistent with the reduction in mating c^ability and 
reduced sperm viability observed in op/op males and this phenotype can be rescued 
by treatment with either recombinant testosterone or M-CSF, > ^ch  suggests that M- 
CSF regulates testosterone levels as well as the presence of testicular macrophages 
(Cohen et al., 1996).
1.2.6. M-CSF during development
Through studies in normal and op/op mice it has become apparent that M-CSF 
expression is developmentally regulated and is required for tissue morphogenesis. 
Table 1.2.6. is modified firom Cecchini et al, 1994 and shows a summary of the 
requirement for M-CSF during tissue morphogenesis in the developing mouse 
(Cecchini et al., 1994). The first three months of postnatal development in op/op
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mice and their normal (+/op or 4-/4-) littermates were monitored for expression of
tissue F4/80-positive (F4/804-) cells, a macrophage cell marker antigen, which 
generally correlates with organogenesis and/or cell turnover. Depending on the 
tissue, the F4/804- cell density either decreases, transiently increases or gradually 
increases with age and in op/op mice, tissues that normally contain F4/804- cells were 
classified into those in which F4/804- cells were absent and those in Wiich the F4/804- 
cell densities were either reduced, normal or initially normal then subsequently 
reduced. Macrophages of the dermis, bladder, bone marrow and salivary gland, 
together with a subpopulation in the gut can be partially restored by subcutaneous 
injection of recombinant M-CSF >^ diich restored circulating M-CSF levels (Cecchini 
et al., 1994). However, macrophages found in muscle, tendon, periosteum, synovial 
membrane, adrenals and the epithelia of the digestive tract, are not corrected by 
restoration of circulating M-CSF, which suggests that they have an absolute 
requirement for and are locally regulated by M-CSF (Cecchini et al., 1994).
Important differences exist among macrophages in their dependency on M-CSF and 
the manner of M-CSF presentation. M-CSF influences organogenesis and tissue 
turnover by stimulating the production of tissue macrophages with local trophic 
and/or scavenger functions (Cecchini et al., 1994). In addition Roth et al, 1996 have 
characterised the levels of M-CSF protein and mRNA expression in foetal, neonatal 
and maternal mice (Roth and Stanley, 1996). M-CSF levels increase in liver, kidney 
and lung tissue but decrease in brain and serum with increasing age (Roth and 
Stanley, 1996). However, embryonic M-CSF concentrations are higher in liver, 
kidney and serum but lower in lung, brain, intestine and heart compared to adult mice 
(Roth and Stanley, 1996).
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Tissue M-CSF
Requirement
Pre-natal Post-natal Response to post-natal 
circulating M-CSF
Muscle Absolute + - None
Tendon Absolute + - None
Dermis Absolute + - Partial/none
Periostium Absolute + + (early) None
Synovium Absolute + + (early) None
Kidney Absolute + + (early) Complete
Retina Absolute + + (early) Complete
Adrenals Partial - + None
Bladder Partial - + Partial/none
Salivary gland Partial - + Partial
BM macrophage Partial + + Partial
Liver Partial + + Complete
Stomach Partial - + Partial/none
Gut Partial - + Partial/none
Spleen Partial + + Complete
Epidermis None ? - None
Thymus None ? - None
Lymphnode None - - None
BM monocyte None - None
Table 1.2.6. Summary of flie efkcÊ» of M-CISF on the regulation of tissue macrophage 
development Modified from Cecchini ésr n/., 1994.
During development, M-CSF expression is detected in the embryonic whole brain, 
except in the hippocampus and striatum (day 16) while c-Jms transcripts are detectable 
in microglial cells and in cells of the hippocampus, striatum, cerebellum and cortex 
(day 16) (Pollard, 1997). Expression of the unique neuronal M-CSF splice variant 
may regulate cell growth, proliferation or differentiation of neuronal cells that express 
c-Jms (Pollard, 1997) and it has been demonstrated that M-CSF stimulates survival 
and neurite outgrowth in neurons from embryonic brain explants in a dose dependent 
manner (Michaelson et aL, 1996).
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1.3.0. The receptor for M-CSF
13.1. Protein tvrosine kinases
P ro te in  ty ro s in e  k in ases  (P T K s) a re  en zy m es lh a t ca ta ly se  th e  tran sfe r o f  Üie y- 
phosphate of adenosine trisphosphate (ATP) to tyrosine residues of protein substrates 
(Hubbard et al,, 1998). PTKs are critical components of signalling pathways that 
control cell proliferation, differentiation, locomotion and other specific cell functions 
in response to the extracellular environment (Hubbard et al., 1998). PTK activities 
can be subdivided into two large families; receptor tyrosine kinases (RTKs) and non­
receptor tyrosine kinases (NRTKs). NRTKs possess no extracellular or trans­
membrane domains but contain modular domains responsible for subcellular targeting 
and regulation of catalytic activity (Hubbard et al., 1998). RTKs however, possess 
extracellular domains that facilitate interaction with the external environment and are 
broadly divided into two groups, depending on their covalent organisation (Hubbard 
et aL, 1998) Most RTKs are a single polypeptide chain which rqnains monomeric in 
the absence of ligand. Ligand binding to the extracellular portion of the receptor 
leads to dimérisation of the monomeric receptor or rearrangement within the 
quaternary structure of heterotetrameric receptors, which results in 
autophosphorylation of specific tyrosine residues in the cytoplasmic portion of the 
receptor (Hubbard et al., 1998). In general, tyrosine phosphorylation stimulates 
intrinsic receptor kinase activity generating recruitment sites for downstream 
signalling proteins containing phosphotyrosyl motif recognition domains such as src 
homology 2 (SH2) or phosphotyrosine binding (PTB) domains (Hubbard et al., 1998). 
Therefore each cell contains mechanisms by which changes in the extracellular 
environment can be recognised by specific cell surface proteins which then become 
phosphorylated within their cytoplasmic regions, thus allowing intracellular proteins
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to associate and further transduce a signal. Binding of dimeric ligands such as M- 
CSF or PDGF to their receptors induces a symmetric receptor dimérisation within the 
extracellular domains and leads to RTK autophosphorylation and activation of kinase 
activity (Fig. 1.3.1.). The ligand-induced activation of the receptor for M-CSF, Q-Jms 
will be discussed below in greater detail.
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13.2. The M-CSF receptor; e-fms
The cell surface receptor for M-CSF is the protein product of the c-fins proto­
oncogene, and is expressed in blood, spleen, liver, brain and iW e marrow of adult 
animals, reflecting the distribution of monocytes and macrophages (Rettenmier et al., 
1988; Sherr et al., 1985). C-fins expression has been detected in breast carcinoma 
tissue, smooth muscle cells from atherosclerotic lesions, B-lymphocytes and 
transcripts have been detected in placental trophoblasts and uncharacterised 
embryonic cells suggesting that c-jms signalling is also required outside 
haematopoiesis (Baker et al., 1995; Inaba et al., 1992; Kacinski et al., 1991; 
Rettenmier et al., 1988; Sherr, 1988).
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The Qrjms protein product is a transmembrane glycoprotein composed of an
extracellular ligand-binding domain and a cytoplasmic domain that possesses an
intrinsic tyrosine kinase activity (Sherr et al., 1985). Binding of M-CSF to Crfim
results in receptor auto-phosphorylation followed by r^ id  internalisation and
degradation of the ligand-receptor complex (Ohtsuka et al., 1990; Roussel, 1994;
Tapley et al., 1990). Ligand binding causes immediate changes in the membrane
structure of macrophages, including the formation of filopodia, vésiculation and
enhancement of phagocytic activity (Boocock et al., 1989; Rettenmier et al., 1988).
M-CSF binding to o-fins on macrophages also results in the rapid increase in
intracellular pH levels and secondary stimulation of Na /^K* ATPase activity, via
activation of the Na^ /K"^  antiporter (Sherr, 1988). Auto-phosphorylation occurs at
specific tyrosine residues on ojms and represents the initial event in receptor
activation and hence signal-transduction (T ^ley et al., 1990). It has been
demonstrated that PI 3-kinase and various other effector proteins bind to the activated
c-Jms (Sherr, 1990; Varticovski et al., 1989). C-fins signalling has not been
investigated as extensively as other haematopoietic growth factor receptors, however
subtle differences have been observed in ofins signalling that distinguish it fi*om other
RTK family members (Rettenmier et al., 1988; Roussel, 1994).
13.3. The genomic location of c-fms
Multiple alleles exist for human c-fins, which is located on chromosome 5q33.3-34 
approximately Ikbp downstream fi'om the PDGFr (Yaar, 1998). The close proximity 
between PDGFr and c-fins on chromosome 5 suggests expression of both these 
receptors may be controlled by common regulatory sequences, since c-fins qjpears to 
have no regulatory sequences of its own possibly arising fi-om gene duplication (Blake 
et al., 1998). In other species, c-fins is localised to chromosome 7 in cattle,
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chromosome 5 in dogs, chromosome 2 in Chinese hamsters, chromosome 3 in Owl 
monkeys and chromosome 18 in mice and rats (Yaar, 1998).
13.4. The structural homologs of c-fms
C-Jms has been classified as a member of the class m  sub-class of the tyrosine kinase 
growth factor receptor family based on its homology to the PDGFr, and it is also 
related to epidermal growth factor (EGF), fibroblast growth factor (FGF), insulin, 
insulin-like growth factor (IGF-1) and c-ht receptors (Roussel, 1994). Table 1.3.4. 
represents different properties of c-fins compared to the PDGFr.
PROPERTIES PDGFr p c-fins
Expression Fibroblasts, Smooth Muscle Cells, 
Capillary Endothelial Cells, 
Neurones Meningeal Cells and Ito 
cells
Monocytes, Macrophages and their 
progenitors, B Cells, Osteoclasts, 
Placental Trophoblasts and in 
. Smooth Muscle Cells from Rabbit 
Atherosclerotic lesions.
Chromosomal
Location
Sq33-q3S(human) C’some 18 in 
mouse
5q33.3-q34 (human) 
C*some 18 in mouse
Amino Acid
• Precursor
• Mature
Human Mouse 
1106 1098 
1074 1067
Human Mouse 
972 976 
953 957
M,(K)
• Predicted
• Expressed
120.6 119.6 
180 180
106 109 
150 165
Potential N-Iinked 
glycosylation sites 11 11 11 9
Affinity Ad (M) « 10'" * 10'"
Autophosphmylation
Sites
Tyr579, 581, 740,751, 771,857, 
1009 and 1021 (human)
Tyr561, 571, 699, 708, 723 809 and 
969 (human)
Tyr559, 569, 697, 706, 721 807 and 
967(murine)
Table 13.4. Comparison of PropertiM associated with the PDGFr and c-/ms.
The overall sequence homology that exists between the M-CSF and PDGF receptors, 
including spacing of Cys residues and short segments of sequence homology in the 
extracellular ligand-binding domain reflect a common ancestry and it is likely that one 
or the. other arose fi’om gene diq)lication (Roussel, 1994). A CLUSTALW 1.7 protein 
alignment of the PDGFr and c-fins illustrates the shared homology between these two 
growth factor receptors (Appendix A).
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The cDNAs for murine, feline and human Crfms have all been cloned (Accession No.
X06368, J03149 and X03663, respectively) (Roussel, 1994). The primary translation 
product of the human c-jms gene is a 972aa precursor peptide (976aa in murine cells) 
(Stanley et al., 1997). The human c-fins precursor protein is composed of a 19aa 
signal peptide sequence wdiich is post-translationally cleaved, a 493aa sequence 
corresponding to the extracellular domain, a 26aa transmembrane domain and a 434aa 
sequence coding for the cytoplasmic domain (Stanley et al., 1997). After post- 
translational modification the mature form of the receptor is 953aa (957aa in murine 
cells) in length (Table. 1.3.4.) (Stanley et al., 1997). The human c-fins is synthesised 
as an immature 130kDa transmembrane glycoprotein that undergoes modification via 
N-linked glycosylation at up to 11 Canonical sequences (Asn-X-Ser/Thr) clustered in 
the amino-terminal extracellular domain (Sherr, 1990). The mature 150kDa cell 
surface form is generally produced within an hour following translation (Rettenmier et 
a l, 1988; Sherr, 1990). The mature murine receptor is larger (165kDa), possibly due 
to differences in the processing of the carbohydrate side-chains (Li and Stanley, 
1991).
1.3.5. M-CSF activation of c-fms
In the absence of extracellular ligand c-fins, present at the cell surface, is turned over 
with a half-life of 2-3 hours after which down-regulation of receptor expression 
occurs (Sherr, 1988). This is then followed by a period of several hours of de novo 
synthesis during which receptors re-accumulate at the cell surface (Sherr, 1988). M- 
CSF stimulation of c-fins results in receptor internalisation and short-term 
replacement of plasma membrane receptor by mobilisation of intracellular pools of 
immature or newly synthesised c-fins, however the net effect of M-CSF stimulation is 
down-regulation of receptor expression (Munn and Cheung, 1992). When M-CSF
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binds to c-Jms, a non-covalent receptor dimérisation event proceeds in conjunction
with an initial wave of receptor tyrosine phosphorylation (Li and Stanley, 1991; 
Tsq)ley et al., 1990). Receptor tyrosine dephosphorylation occurs concurrently with 
tyrosine phosphorylation of specific cytosolic proteins prior to extracellular, inter­
chain disulphide linkage of receptor monomer subunits (Li and Stanley, 1991; Stanley 
et al., 1994). Blockage of extracellular disulphide bonding inhibits receptor 
internalisation and causes an eight-fold increase in the rate of appearance of tyrosine 
phosphorylated proteins (Li and Stanley, 1991). A second wave of receptor tyrosine 
phosphorylation then occurs in conjunction with increased receptor serine 
phosphorylation and in the case of murine c-fins formation of either a 38ÛkDa or 
450kDa disulphide linked heterodimer occurs (Stanley et al., 1994). These 
heterodimers are composed of the 165kDa receptor mohonier and/or modified forms 
of the 165kDa monomer (215kDa and 250kDa) (Stanley et al., 1994). Kinase 
inactivation then follows as a result of receptor déphosphorylation and poly^ 
ubiquitination occurs prior to internalisation of the ligand-receptor complex (Stanley 
et al., 1994). Ubiquitination is a prerequisite for degradation of the c-fins 
cytoplasmic domain (Stanley et al., 1994). Internalisation of the ligand-receptor 
coinplex proceeds via clathrin coated vesicles, which are transported to secondary 
lysosomes for degradation of the receptor-ligand complex (Li and Stanley, 1991; 
Sherr and Stanley, 1990). Studies of a chimeric c-fins, in which the cytoplasmic tail 
of c-fims is fused to Glycophorin A suggest that structural features in the extracellular 
domain determine lysosomal targeting and degradation of internalised receptor (Lee 
and Nienhuis, 1992) Internalisation and degradation of the c-fins down-regulates the 
M-CSF signal (Ohtsuka et al., 1990; Rettenmier et al., 1988).
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Therefore, ligand-induced non-covalent dimérisation activates the intrinsic protein
kinase activity of c-Jms and leads to covalent dimérisation of non-covalently
associated receptor monomers. Dimeric c-Jms is subsequently modified, resulting in
inactivation of receptor kinase activity and receptor dephosphorylation prior to
internalisation, ubiquitination, and trafficking to the lysosome (Li and Stanley, 1991;
Stanley era/., 1994).
13.6. The functional domains of c-fms
The extracellular domain of c-Jms is composed of five immunoglobulin-like (Ig-like) 
loops designated Di->Ds from the amino-terminus (Fig. 1.3.6.) (Roussel, 1994). All 
the Ig-like domains of the receptor, with the exception of D4 contain intra-domain 
disulphide bonds (Roussel, 1994). The M-CSF binding site consists of Loops Di-> 
D3. Due to the absence of a disulphide bond in the D4 loop the receptor possesses a 
degree of flexibility which permits conformational changes iqx)n ligand binding 
which facilitate receptor dimérisation (Roussel, 1994).
The cytoplasmic tail of c-Jms can be divided into five distinct sub-domains; the 
juxtamembrane region, the ATP-binding lobe, the kinase insert region, the main 
tyrosine kinase domain and the carboxyl-terminal tail (Fig. 1.3.6.) (Roussel, 1994). 
Upon activation, human c-Jms is phosphorylated, on specific tyrosine residues, Tyr^^, 
Tyr^ ^  ^ and Tyr^ *^ in the juxta-membrane region, T y r^ , Tyr^ ®* and Tyr^^ within the 
kinase insert domain, T y r^  within the core kinase domain and T y r^  in the carboxyl 
tail region, (residues 541, 559, 569, 697, 706, 721, 807, 967 in murine cells, 
respectively) (Clark et al., 1992; Courtneidge et al., 1993; Joos et al., 1996; Roussel 
et al., 1990; Shurtleff er a/., 1990).
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Flg. 13.6. Domain stractore of the M-CSF receptor and important sites of tyrosine 
phosphorylation.
It has been demonstrated that in common with other RTK's, c-fins binds to src-family 
kinases (src, fyn  and yes), She, Grb2 and PI 3-kinase (Alonso et al., 1995; Cantley et 
al., 1991; Courtneidge et al., 1993; Rohrschneider et al., 1997). Following c-fins 
activation in macrophages, various cellular proteins are transiently tyrosine 
phosphorylated, including She, Sosl, PTP-IC (SHP-1) and SHIP (Li and Stanley, 
1991; Neel and Tonks, 1997; Yeung et al., 1992). She, Sosl, SHIP and Grb2 have 
been shown to form complexes following receptor activation in myeloid cells and 
appear to be downstream effectors of numerous signalling mechanisms in addition to 
the c-fins signalling pathway (Rohrschneider et al., 1997). Thus, although c-fins does
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not bind directly with She, Sosl and the 150kDa protein it does regulate their
intracellular functions possibly through the Grb2 adapter protein (Stanley et al., 
1997). SHP-1, a protein tyrosine phosphatase, is activated downstream of various 
cytokine receptors and regulates the tyrosine phosphorylation state of cellular proteins 
(Neel and Tonks, 1997).
A more detailed review of c-fins signalling will be discussed in section 1.6.0., 
following a discussion of Phosphatidylinositol 3-Kinase (PI 3-kinase), a key 
component in signalling including that activated by M-CSF.
1.4.0. Phosphatidylinositol 3-kinase
1.4.1. Lipid signalling
When a stimulatory molecule binds to a receptor at the exterior of the cell membrane, 
second messengers such as those derived from membrane-associated phospholipids 
transduce signals to the interior of the cell (Toker and Cantley, 1997). Multiple 
phospholipid species are generated by the actions of various enzymes with intrinsic 
lipase, lipid kinase and lipid phosphatase activities such as phospholipase C and 
Phosphatidylinositol (PI) 3-kinase (Toker and Cantley, 1997). K ^lan et al were first 
to demonstrate that lipid second messenger signalling was associated with growth 
factor receptor activation and observed that a PI kinase activity was recruited into 
anti-phosphotyrosine immunoprecipitates following PDGF stimulation of NIH 3T3 
cells or cells transformed with v-fins (K ^lan et al., 1987).
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1.4.2. Phosphoinositide Synthesis
A key event in growth factor signalling cascades is the metabolism of 
phosphoinositides (PI) ( K il le r  and Cantley, 1994). Phosphoinositide kinases (PI- 
kinases) phosphorylate the D3, D4 and D5 positions of the inositol ring of 
phosphatidylinositol (PI), (Fig. 1.4.2.), generating various polyphosphorylated PI 
species (Fig. 1.4.3.) (K^)eller and Cantley, 1994).
o ----
o —
OH
OH
OH
OH
Fig. 1.4.2. The Structure of Phosphatidyiinosit<d.
Growth factors tightly modulate the kinases, phosphata^s and lipases involved in the 
regulation of phosphoinositide levels in cellular sub-compartments and two pathways 
are implicated in production of these phosphorylated lipids; the canonical 
phosphoinositide turnover pathway and the 3-phosphoinositide pathway (Kapeller and 
Cantley, 1994). In the canonical pathway, PI is sequentially phosphorylated by PI 4- 
kinase and PI4P 5-kinase to generate Pl4^ 2, the major substrate for phosphoinositide- 
spccific phospholipase-C (PI-PLC) (K ^llo*  and Cantley, 1994) and PI 3-kinase (Fig.
1.4.3.).
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The rapid activation of this Pl-specific PLC activity in response to ligand-receptor 
interaction results in hydrolysis of Pl4^P2 generating two second messengers, inositol 
trisphosphate (IP3) and diacylglycerol (DAG) (Fig. 1.4.3.) (Kzqwller and Cantley,
1994). IP3 promotes release of Ca^  ^ from intracellular stores and DAG activates 
protein kinase C (PKC) ( K il le r  and Cantley, 1994). The increases in both 
intracellular [Ca^^ and PKC activity are important in the step-wise propagation of 
signals from the cell surface to the nucleus ( K il le r  and Cantley, 1994).
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Fig. 1.43. Phosphoinositides and the enzymes invcdved in thdr metabolism.
For a number of years the canonical pathway was considered the only pathway 
employed in response to extracellular stimuli. PI 3-kinase was discovered over ten 
years ago and is described as an enzymatic activity capable of phosphorylating 
phosphatidylinositol (PI) at the D-3 position of the inositol ring to form PI3P 
(Whitman et al., 1988). This activity was originally found in an immunoprecipitated 
complex containing \-src and middle-T-antigen of the polyoma virus obtained from
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transformed cells (Whitman et a l, 1988). Almost at the same time another
phospholipid species, PI3A5P3 was isolated from neutrophils (Traynor-Kaplan et al., 
1988) and has since been demonstrated to be an important PI 3-kinase product, 
involved in various cellular responses.
1.43. PI 3-kinase
The PI kinase family has been divided into three classes; class 1, ) ^ c h  contains the 
classical PI 3-kinases that produce PI3 4.5P3, class 2 PI 3-kinases, ) ^ c h  cannot utilise 
Pl4 ^ 2  as a substrate (Shibasaki et al., 1993) and class 3 which have been identified as 
containing the Pl-specific 3-kinases that generate PI3P (Volinia et al., 1995). Class 1 
PI 3-kinases can be further subdivided into class la  which contain the classical 
p85/pllO PI 3-kinases and class lb which contain the G-protein-regulated PI 3- 
kinases (Shepherd et al., 1998). PI 3-kinase activity is stimulated by various 
cytokines including IL-3, IL-4, IL-5, GM-CSF and SLF (Gold e/ a/., 1994). PI 3- 
kinase has an associated protein serine kinase activity which is inhibited by non-ionic 
detergents but not by adenosine, distinguishing it from other Pl-kinases (Cantley et 
a/., 1991; Carpenter e/a/., 1990).
PI, PI4P and Pl4 ^ 2  are all substrates of PI 3-kinase, and leads to the production of 
PI3P, PI3.4P2 and Pl3,4.sP3, respectively (Fig. 1.4.3.) ( K il le r  and Cantley, 1994). 
Products of the 3-PI pathway are implicated in various cellular mechanisms including 
mitogenesis, cell motility, vesicle trafficking, Ras activation, the secretory pathway 
and apoptosis which will be discussed in greater detail later (Cantley et al., 1991; 
Valius and Kazlauskas, 1993).
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Recently a novel phosphatidylinositol species has been isolated from murine
fibroblasts, PI34P2 > ^ch  is the product of an agonist-independent, wortmannin 
sensitive pathway in resting fibroblasts (Whiteford et al., 1997). The formation and 
degradation of PI3.5P2 appears to be controlled by two enzymes, a PI3P specific 5- 
kinase and a PI3.5P2 specific 5-phosphatase, respectively (Whiteford et al., 1997). At 
present a mammalian function for PI3.SP2 has yet to be elucidated but in the yeast, S. 
cerevisiae and S. pombe and in Cos-7 cells Pl3 ^ 2  is produced in response to changes 
in external osmotic pressure (Dove et al., 1997).
PI 3-kinase lipid products can directly associate with proteins and it has been shown 
that Pl3,4 ^ 3  can bind to the SH2 domains of src and p85 (Rameh et al., 1995). The 
residues critical for SH2 domain binding to phosphotyrosine motifs do not appear to 
be required for lipid binding (Rameh et al., 1995). PI 3-kinase products PI3 4P2 and 
Pl3,4 ^ 3  also bind to the pleckstrin homology (PH) domain of PKB causing its 
translocation to the plasma membrane (Stephens et al., 1998). This suggests that PI 
3-kinase products are involved in recruitment or localisation of SH2 domain and PH 
domain containing proteins to areas of PI 3-kinase activity.
In growth factor receptor signalling the activation of PI 3-kinase is stimulated by the 
binding of ligand to the extracellular domain of RTKs such as the EGF, PDGF and c- 
flns (Hu et al., 1992; K ^lan et al., 1987). Receptor auto-phosphorylation at specific 
tyrosine residues in the cytoplasmic domain enables PI 3-kinase and other 
cytoplasmic effector proteins to bind and propagate the r e c to r  signal (Chou et al., 
1987; Escobedo and Williams, 1988; McClain et al., 1987; Moolenaar et al., 1988). 
PI 3-kinase also associates with various PTKs and in some instances acts downstream 
of receptors that are not RTKs (Panayotou et al., 1992).
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1.4.4. PI 3-kinase activity in disease
Elevated PI 3-kinase activity has been detected in over 90% of colorectal carcinoma 
tumours compared to normal mucosa from the same patient (Phillips et al., 1998). 
Effective inhibitors of PI 3-kinase inhibitors may be of ther^)eutic benefit in 
treatment of certain aggressive cancers. The most frequently observed mutation of 
the EGFr in human tumours is a deletion of exons 2-7, which yield a truncated 
receptor termed EGFr v i n  (Moscatello et al., 1998). EGFr v i n  can transform NIH 
3T3 fibroblasts and the relative frequency of detection in tumours suggests that it has 
a selective advantage upon tumour cells in vivo (Moscatello et al., 1998). Although 
EGFr v i n  is a constitutively active tyrosine kinase there are no observable increase in 
GTP-Ras levels or MAPK activity when expressed in NIH 3T3 cells (Moscatello et 
al., 1998). However, there is an eight fold increase in detected PI 3-kinase activity in 
EGFr v i n  transformed fibroblasts compared to only a three fold increase in cells 
expressing normal receptor (Moscatello et cd., 1998). Therefore activation of PI 3- 
kinase is a key mediator of EGFr vIH  transformation of human tumours.
1.5.0. Structure and régulation of PI 3-kinase
1.5.1. The p8S adaptor/regulatorv subunit of PI 3-kmase
Initial molecular characterisation of PI 3-kinase has revealed it is a heterodimer,
consisting of an 85kDa adapter subunit (p85) (Ruiz-Larrea et al., 1993) and a 1 lOkDa
ca ta ly tic  su b u n it ( p i  10) (W o sch o lsk i et al, 1994). T o  date, fo u r d is tin c t m am m alian
p85 subunits, p85a, p8Sp, p85y, and the homolog of vpsl5p have been discovered for
which the cDNA's have been cloned (Daduang et a l, 1995; Escobedo et al., 1991; Hu
et a l, 1995; Otsu et a l, 1991; Panayotou et a l, 1997; Pons et a l, 1995; Skolnik et a l,
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1991). A 60kDa drosophila homolog of the p85 subunit of PI 3-kinase has also been 
purified from a YxxM motif affinity matrix and co-precipitates Dpi 10, the drosophila 
homolog of p i 10 (Weinkove et al., 1997).
Fig. 1.5.1a. represents a nearest neighbour tree obtained from a CLUSTALW 1.7 
(Corpet, 1988) multiple alignment of the protein sequences available for the homologs 
of p85 from mammals, drosophila and yeast.
p8Sa Human 
p8Sa Bovine 
p85a Marine 
p85a Rat
p8SP Human 
p8Sp Bovine 
p8Sp M a^e 
p8Sp Rat 
pSSy Bovine 
p55 Murine 
p5S Rat
’ pSSy Human 
p4S Rat
' p60 D. melanogaiter
plSO Human 
VpslSp S. pombe
Fig. 1.5.1a. Nearest ndghbour tree reprMemtimg the homologies shared between PI 3- 
kinase regulatory subunits.
Both p85a and p85p are 724aa polypeptides with two SH2 domains and an amino- 
terminal jrc-homology 3 (SH3) domain (Fig 1.5.1b.) (Daduang et al., 1995; Piccione 
et al., 1993). Using a yeast two hybrid system the minimal determinant of p i 10 
subunit association with p85 was mapped to a 192 amino acid portion between the N 
and C-terminal SH2 domains of p85, residues 429-621 and has the predicted structure
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of an independently coiled-coil of two long anti-parallel a  helices (Dhand et al., 1994; 
Holt et a i, 1994; Hu et al., 1993; Klippel et al., 1993; Zhang et al., 1993).
The p85 inter-SH2 domain alone is not sufficient on its own to stimulate PI 3-kinase 
activity and requires either one or both SH2 domains as well as the inter-SH2 domain 
to reconstitute PI 3-kinase activity in vitro (Holt et al., 1994). SH2 domains were 
originally identified as conserved regulatory regions in src family-like kinases 
(Sadowski et al., 1986), and mediate the associations of various proteins including 
PLCy, Ras-GAP and adapter proteins such as Grb2, She and p85 (Marengere and 
Pawson, 1994). SH2 domains were initially characterised as an amino acid sequence 
of approx. lOOaa that possessed no catalytic activity (Marengere and Pawson, 1994; 
Sadowski et al., 1986).
RBD LIpId KD
SH3 PP
pllO  Binding Sitr
SH2
Fig. 1.5.1b. Diagram of Functional Domains Found in p85 and pi 10 Subunits of PI 3-kinase.
It has been demonstrated that synthetic phosphopeptides introduced into fibroblasts
block the binding of PI 3-kinase to both PDGFr and polyoma middle T (Escobedo et
al., 1991; Fanti et al., 1992; Kazlauskas et al., 1992; Piccione et al., 1993; Yoakim et
al., 1992). Through the use of a degenerate phosphopeptide library the consensus
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recognition sequence for the p85 SH2 domains was mapped (Songyang et al., 1993).
The p85 SH2 domains select peptides with either Met, Val, lie, or Glu at the +1 
position relative to the phosphotyrosine and methionine at the +3 position (eg. pY- 
M/V/I/E-X-M) (Songyang et al., 1993). The binding affinities of these synthetic 
phosphopeptides to the SH2 domains of p85 are one order of magnitude greater than 
unphosphorylated peptides or +3 Met mutant peptides with Kd*s of 0.3-3nM and 1-10 
pM, respectively (Felder et al., 1993).
Another feature located between the SH3 domain and the amino-tmninal SH2 
domain is a region homologous to the carboxyl-terminal part of the Break-cluster 
region (Bcr) gene product (Kfq)eller et al., 1994; Liu et al., 1993). The Bcr homology 
(BH) domain is flanked on either side by two proline rich motifs (Fig 1.5.1b.) 
( K il le r  et al., 1994; Liu et al., 1993). A speculative role for the BH domain of p85 
has been proposed in the stimulation of OTP hydrolysis on Rho, Rac and/or cdc42 
(See below) (Diekmann et al., 1991; Matsuo et al., 1996; Tolias et al., 1995). The 
SH2 domains bind to specific phosphotyrosine^containing motifs and the SH3 
domains bind to short amino acid sequences that are rich in proline residues ( K il le r  
and Cantley, 1994). Through these binding sites p85 mediates the association of 
p i 10, and its intrinsic kinase activity, with target proteins (Dhand et al., 1994; Klippel 
et al., 1993; Rickies et al., 1994). The ubiquitously expressed drosophila p60 adapter 
subunit, possesses two SH2 domains and an inter-SH2 domain but lacks the SH3 
domain and BCR homology (BH) domain ^ ^ c h  are found in p85 (Weinkove et al., 
1997).
The SH3 domain of p85 is a member of a family of non-catalytic protein modules 
approx. 60aa in length Wiich are common to many proteins that also possess SH2
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domains (Fig. 1.5.1b.) (Rickles et al., 1994; Sadowski et al., 1986). SH3 domains
bind to two classes of recognition sequence; class I ligands contain the consensus 
sequence RXLPP5PXX, Wiere 5 is L for src and R for PI 3-kinase and class II 
ligands contain a XXXPPLPXR motif for both src and PI 3-kinase (Cohen et al., 
1995). All high affinity SH3 ligands identified to date have a conserved PXXP motif 
and the p85a SH3 domain of PI 3-kinase exhibits a preference for a 
RXXRPLPPLPPP \Wiich has been identified by screening a modified phage display 
library (Rickies e/a/., 1994).
The SH3 domain of p85 is involved in mediating the association of PI 3-kinase with 
other proteins via association with proline rich motifs (Parker and Waterfield, 1992). 
SH3 domains are also present in a variety of cytbskeletal proteins such as spectrin, 
fodrin, myosin IB and actin-binding protein (ABP-1) (Kapeller and Cantley, 1994). 
The SH3 domains of c-abl and Grb2 bind to 3BP1, a protein with regions of 
homology to sequences of Rho-GAP A ^ch also associates with PI 3-kinase (Hartley 
et al., 1995; Wang et al., 1995). The SH3 domains of c-abl, Ick, lyn, fyn and src can 
also associate with the proline-rich sequences flanking the BH domain of p85 
( K il le r  et al., 1994; Liu et al., 1993). This demonstrates that SH3 domain 
containing proteins have the ability to link PTKs to effector molecules that activate 
various downstream signalling pathways ( K il le r  et al., 1994; Liu et al., 1993; 
Skorski et al., 1995). The SH3 domain of p85 and its proline-rich target sequences 
play an important regulatory function by targeting PI 3-kinase activity to specific 
cellular compartments, linking PI 3-kinase activity to both iq)stream and downstream 
elements. It has also been observed that p85 can bind directly to the SH3 domains of 
Abl, Lck, Fyn, and p85 itself (Kapeller et al., 1994). Kapeller et al have 
demonstrated that two proline-rich sequences in the N-terminal region of p85 mediate
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its interaction with SH3 domains Wiich suggests that the SH3 domain of p85 may
associate with other p85 subunits, or possibly fold back upon itself forming a self- 
association with the proline-rich motifs of the same subunit. This property of the p85 
subunit may be part of the PI 3-kinase regulatory mechanism and recent data has 
suggested that the specific conformation of p85 is important for regulation of PI 3- 
kinase activity (Yu e/ a/., 1998), vM ie Pleiman et al have demonstrated that 
activation of PI 3-kinase occurs in vitro following the association of the SH3 domains 
of either lyn or fyn, two jrc-family kinases (Pleiman et al., 1994).
The p85 subunit may also be involved in regulation and translocation of proteins other 
than p i 10. For example, in insulin receptor signalling the p85a sUbunit forms 
separate complexes with p62 and an 1RS-1-GAP complex (Pleiman et al., 1994; Sung 
et al., 1994). Analysis has shown that the amino and carboxyl terminal SH2 domains 
of p85a associate with the insulin receptor and IRS-1 respectively and may provide a 
mechanism for the translocation of PI 3-kinase and possibly other proteins to the 
plasma membrane, into close proximity with the insulin receptor (Baltensperger et al., 
1994; Pleiman et al., 1994; Sung et al., 1994). In IGF-1 signalling p85 associates 
with IRS-1 and the IGF-1 receptor via both SH2 domains and is possibly mediated by 
IFN-a occurring after the initial phosphorylation event on IRS-1 (Baltensperger et al., 
1994; Kooijman et al., 1995; Sanchez-Margalet et al., 1995; Uddin et al., 1995).
1.5.2. The catalvtic activity o f FT 3-ldnaae
To date, five human PI 3-kinase activities have been identified; p i 10a, p i lOp, p i lOy, 
p i 10Ô and the human homolog of vps34 (Fry et al., 1992; Hu and Schlessinger, 1994; 
Schu et a/ , 1993; Stoyanov et a i, 1995; Vanhaesebroeck et al., 1997; Volinia et al., 
1995). Many more PI 3-kinase homologs have been cloned from other species and
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Fig. 1.5.2. is a nearest neighbour tree obtained from a CLUSTALW 1.7 multiple 
alignment of the available pi 10 protein sequences and illustrates the homology 
between PI kinase activities isolated from mammals, plants, drosophila, slime mould 
and yeast.
pllOa Bovtnc 
pllOa Hunaa 
pllOa MbiIm  
pllO C. gmlhM
'pllOS Hiunan 
'pllOS Murine
'p l ie p  Hamas
’ pUO a
‘pllOy H asns
'  PI SpadflcSK D. ssfasagaatm 
*Tpi34Hasaui
"pllOBayabaas 
*api34 A. IkaUasa 
'PISpadflcSK  adbcaU iB B  
'vpf34 S. pasAs 
'vpiM  C  alMcau 
'P M K H s a u  
'P M K ad b caU h im  
'AGE-1 C.i
'PI3K-3 D. dbceldlBB 
'  Cpk (6ID) D. SMlaBegastfr
'C p k  Marine 
* plTO Marine 
*pllO-C2 Haraan 
*pllO-C2 Marine
'PI3K-31XdlftàUiHm 
'  STT4 8. om ridaa 
'F K S l 8. caraririaa 
■ E8R1 8. canntalae
ATM Homan 
'ATM Marine
PKAP Homan
' TOHl 8. cararblae 
'TOR2 8.
Fig. 1.5.2. Nearest ndghbour tree reprinting the homologies shared between PI 3-kinase 
catalytic subunits.
1.53. The pllO catalvtic subunit of PI 3-kinase
pi 10a and pi lOp, two related but distinct p85-associated 1 lOkDa proteins have been 
identified in isolates of PI 3-kinase activity from rat liver (Fry et al., 1992; Hiles et 
al., 1992; Whitman et al., 1988). The cDNA clones of both p i 10a and p i lOp were 
obtained from bovine brain libraries and they predict a mature protein of 1068aa. 
(Hiles et al., 1992). Comparison of the predicted amino acid sequences of p i 10
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isoforms with the catalytic domains of various protein kinases reveals several motifs
(Fig. 1.5.1b). Residues at Asp’^^ , Asn^^ and an Asp^^^-Phe^^-Gly”  ^ triplet may be 
homologous to residues present in the VI and VII catalytic subdomains of cyclic 
AMP-dependent protein kinase and therefore is implicated in phosphotransferase 
activity (Fry et al., 1992).
A third p i 10 isoform is pllOy, Wiich shares close homology to both p i 10a and 
pllOP but does not associate with p85 (Stoyanov et al., 1995). Its activity is 
regulated by G-proteins and, for example, is activated by the a  and p/y subunits of the 
G-protein, transducin in myeloid cells (Stephens et al., 1994; Stoyanov et al., 1995). 
pllOy, in contrast to p i 10a and pllOp also possesses a PH domain at its aminos 
terminus. PH domains are known to associate with the phosphprylated lipid products 
of PI 3-kinase activity and are involved in signalling downstream of PI 3-kinase, 
however its function in pllOy remains unclear (Stoyanov et al., 1995; Zhou et al.,
1995).
A new class I homolog, p i 105, has recently been cloned and characterised from 
leukocytes (Vanhaesebroeck et al., 1997). Like the p i 10a and plIOp isoforms, 
pi 105 also displays a broad phosphatidylinositol specificity and interacts with 
SH2/SH3 domain containing p85 proteins and also GTP-Ras (Vanhaesebroeck et al.,
r
1997). Although p i 105 associates with the p85 adapter proteins like other class I
isoforms, it does not phosphorylate p85 but harbours an intrinsic autophosphorylation
capacity and also contains unique protein motifs (Vanhaesebroeck et al., 1997).
These motifs include potential protein-protein interaction modules in the catalytic
domain such as poly-proline regions and a basic region-leucine zipper (bZIP)-like
domain (Vanhaesebroeck et al., 1997). Expression of this pi 10 isoform is restricted
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to cells of haematopoietic origin ^ ^ c h  confers haematopoietic cells with the potential
to stimulate all three class I PI 3-kinase activities (Vanhaesebroeck et al., 1997). No 
other functions for p i 105 have been ascribed to date but it has been observed that it is 
differentially expressed in migratory but not non-migratory platelets (Vanhaesebroeck 
et al., 1997). This apparent requirement in a motile phenotype may hint to an 
involvement of pi 105 during cytoskeletal events (Vanhaesebroeck et al., 1997).
Several S. cerevisiae proteins have been discovered that also share homology to PI 3- 
kinase (Kapeller and Cantley, 1994; Stack and Emr, 1994; Takegawa et al., 1995). 
The yeast PI 3-kinase homolog vps34p is critical in targeting soluble hydrolases to the 
yeast vacuole and for correct vacuolar protein sorting and is also required in vacuole 
morphogenesis during budding (Hiles et al., 1992; Stack and Emr, 1994; Takegawa et 
al., 1995). Unlike mammalian p i 10, vps34p is specific only for PI, with other 3- 
kinase products, PI3.4P2 and Pl3,4^P3 absent in yeast (Schu et al., 1993; Stack and Emr,
1994). Vps34p also exhibits an intrinsic protein kinase activity similar to p i 10a 
(Stack and Emr, 1994). A mammalian, Pl-specific 3-kinase, homologous to Vps34p 
has been cloned which also specifically phosphorylates only PI, and therefore by 
analogy to its yeast counterpart, may be required for correct vesicle and protein 
trafficking in mammals (Schu et al., 1993; Volinia et al., 1995).
The cDNA of a homolog closely related to yeast Vps34p has been cloned from 
Arabidopsis thaliana, >4fVPS34 (Welters et al., 1994), and recently, PI3K_59F, a 
drosophila homolog of vps34/PI specific 3-kinase, has also been cloned (Linassier et 
al., 1997). The other yeast PI 3-kinase homolog, TOR2, is a target protein for the 
rapamycin-FKBP 12 receptor complex (Kapeller and Cantley, 1994). Since rapawycin 
causes Gi arrest in both T cells and yeast, T0R2 and its non-essential homolog TORI
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may be required for maintaining progression through Gi phase (Kapeller and Cantley,
1994). However no associated PI kinase activity has yet been found for TORI or 2.
In both drosophila and mouse another new class of PI 3-kinases has been discovered 
(Molz et al., 1996; Virbasius et al., 1996). In murine cells the proteins pl70 and Cpk 
and in drosophila dCpk (68DV) share homology to p i 10 but differ from p i 10 at their 
N- and C- termini, possessing a C2 domain at their C- termini and lacking N- terminal 
p85 and Ras binding domains (Molz et al., 1996; Shepherd et al., 1998; Virbasius et 
al., 1996). Closely related to these C2 domain containing proteins are human and 
murine pllO-C2 ^Aliich have only recently been cloned (Brown et al., 1997; Misawa 
et al., 1998). C2 domains are similar to th e  phosphoinositide-binding domains of 
PKC isoforms, and synaptotagmins (Molz et al., 1996). C2 domain containing PI 3- 
kinases q>pear to phosphorylate the D3 position of the inositol ring of 
phosphoinositides but are selective for both PI and to a lesser extent PI 4-P but do not 
phosphorylate PI 4,5-P2 which makes them unique PI 3-kinases (Molz et al., 1996; 
Virbasius et al., 1996). One other distant relative of PI 3-kinase is the Ataxia 
telangiectasia gene product, (ATM), is a DNA-dependent protein kinase (DNA-PK) 
Wiich shows sequence homology with PI 3-kinase, but is more closely related to 
TORI and TOR2 of S. cerevisiae (Fig. 1.4.8.) (Lavin et al., 1995; Savitsky et al.,
1995). Although Ataxia telangiectasia is a severely debilitating disease, clinically 
characterised by cerebellar degeneration, immunodeficiency, cell-cycle abnormalities 
and chromosomal instability, little is known about the function of ATM at present 
(Lavin e/a/., 1995; Savitsky e/a/., 1995).
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1.5.4. PI 3-Kinase Inhibitors
PI 3-kmase inhibitors have been instrumental in the discovery of various properties of 
PI 3-kinase and receptor signalling. One such inhibitor, wortmannin, a fungal 
metabolite, has been used extensively to investigate the role of PI 3-kinase (Fig.
1.5.4.) (Woscholski et al,, 1994). It is known that wortmannin inhibits the PI 3-kinase 
of p i 10a with a low nanomolar ICso but has no inhibitory effect on mammalian PI 4- 
kinase or S. pombe Vps34p (Vlahos et al., 1994; Wymann et al., 1996). Wortmannin 
was originally thought to specifically inhibit PI 3-kinase activity but this has recently 
been brought into doubt by evidence that wortmannin also inhibits Phospholipase A: 
(PLA2) activity in fibroblasts (Cross et al., 1995). Wortmannin binds to PI 3-kinase 
via formation of an enamine bond Wiich couples the fiiran ring of wortmannin 
(labelled with red hatched box in Fig. 1.5.4.) with Lys^°  ^in the lipid binding site on 
p i 10 (Wymann et al., 1996). This lysine residue appears to be essential in the 
transfer of phosphate to the PI substrate of PI 3-kinase (Wymann et al., 1996). Once 
bound, wortmannin irreversably blocks both the lipid and protein kinase functions of 
PI 3-kinase (Arcaro and Wymann, 1993; Barker et al., 1995; Martys et al., 1996).
Another PI 3-kinase inhibitor, LY294002 (Fig. 1.5.4.), (2-(4-morpholinyl)-8-phenyl- 
4H-1 -benzopyran-4-one) is not as potent as wortmannin, however it competes for the 
ATP-binding site on the p i 10 catalytic subunit vdiich makes its mechanism of action 
distinct to that for wortmannin (Reif et al., 1996; Vlahos et al., 1994; Woscholski et 
al., 1994). In addition, wortmannin is relatively unstable, whereas LY294002 is far 
more chemically stable and can be used for assays which require long incubations 
(Vlahos et al., 1994). Wortmannin and LY294002 inhibit both lipid and protein 
kinase activities of PI 3-kinase at concentrations similar to that obtained for the p i 10a 
isoform in vitro (Vanhaesebroeck et al., 1997). The IC50 for wortmannin is in the low
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nanomolar range (1-lOnM) (Arcaro and Wymann, 1993), A^ diereas the IC50 for 
LY294002 is found in the low micromolar range (O.l-lO^iM) (Vlahos et al., 1994).
Wortmannin LY294002
MolKtiv -  428.44 Motocuta-WalgM -  307.35 EactMsM ■ 0
MoiKuiv Formula -  C23H2408 Motocular FormUa « C1BH17N03
MolactivCompcMUon-C -  64.48 % H ■ 5.65% O -29.87 % MohcdmrConvo#Won-C -  74.26 % H » 5.58% N = 4.56 % O -  15.62 %
Fig. 1.5.4. Chemical structnre of PI B-kinase inhibitors wortmannin and LY294002.
Wortmannin is a potent and specific inhibitor for PI 3-kinase activity v^en  used at 
concentrations comparable to its IC50 value. However at higher concentrations its 
specificity has been drawn into question and therefore interpretation of data obtained 
from inhibitor studies must be done carefriUy and > ^ lst always bearing in mind the 
non-specific effects of PI 3-kinase inhibitors. It has been demonstrated that 
wortmannin blocks various signalling pathways in vivo and in vitro, including vesicle 
trafficking, cell adhesion, cytoskeletal and actin rearrangements and differentiation in 
a variety of cell types including, adiopocytes, erythroid cells and macrophages 
(Kilgour etal., 1996; Tomiyama e taL, 1995; Vemuri eta!., 1996; Zell etal., 1996).
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1.5.5. Regulation of PI 3-Kinase Activity
As previously mentioned, the activity of PI 3-kinase has been found to increase in 
response to growth factors including M-CSF and PDGF (Cantley et al., 1991; Herbst 
et al., 1995). PI 3-kinase activity is also regulated by NRTKs {e.g.jyn, yes and src) in 
response to cellular activators such as Lipopolysaccharide (LPS) (Cantley et al., 1991; 
Herrera-Velit and Reiner, 1996). The association of p85 with activated receptors, 
promotes the localisation of PI 3-kinase to the plasma membrane, bringing tiie p i 10 
subunit into close proximity with its substrates (Rordorf-Nikolic et al., 1995). The 
association of both SH2 domains of p85 with activated receptors appears essential for 
PI 3-kinase activation since doubly phosphorylated peptides, which mimic the 
receptor binding domain for p85, are more effective in vitro at activating PI 3-kinase 
than singly phosphorylated peptides (Kapeller and Cantley, 1994). Full occupancy of 
both amino and carboxyl terminal SH2 domains of p85 are required to produce full 
activation of PI 3-kinase activity by growth factors, since removal of either or both 
SH2 domains results in either a 50% reduction or complete abrogation of kinase 
activity (Rordorf-Nikolic e/a/., 1995).
This may be due to conformational changes in the p85 subunit which in turn 
influences/activates the catalytic activity of p i 10, and recently it has been 
demonstrated that the conformation and physical properties of p85 may regulate p i 10 
activity in vitro (Yu et al., 1998). In sf9 insect cells infected with a baculovirus 
containing the p i 10 subunit, p i 10 is expressed as an active monomer whose activity 
is inhibited by co-expression of the p85 subunit (Yu e/ al., 1998). Insect cells are 
routinely cultured at 28-30°C and addition of a bulky N-terminal Glutathione S- 
transferase (GST) tag to p i 10 or expression in HEK 293 cells at 30°C also abrogated 
the requirement for p85 (Yuef al., 1998). These data suggest that the p85 regulatory
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subunit may function to stabilise the overall conformation of p i 10, rather than by
inducing a specific activated conformation. A physically bulky structure at the N-
terminus of p i 10, A^ether it be p85 or a GST tag, q)pears to stabilise and activate, in
part, p i 10 catalytic activity. Incubation at temperatures at or below 30°C may also
permit stabilisation of the p i 10 monomer and therefore may have important
implications for in vitro lipid kinase assays.
PI 3-kinase activity is also negatively regulated by an intrinsic serihe/threonine kinase 
activity present on the p i 10 catalytic subunit, Wiich phosphorylates p85 on serine and 
results in ah 80% inhibition of activity (Carpenter et al., 1993; Dhand et al., 1994; 
K^)eller and Cantley, 1994). N-ta-minal sequence analysis has shown that 
phosphorylation of S e r^  in p85 is critical for regulation of PI 3-kinase activity 
(Carpenter et al., 1993; Dhand et al., 1994). Inhibition of PI 3-kinase activity by its 
intrinsic protein kinase can be reversed by treatment, in vitro, with Protein 
Phosphatase 2A (PP2A), > ^ch  may be involved, to some degree, in the basal level 
activation of PI 3-kinase present in the cytosol but this remains to be conclusively 
determined in vivo (Carpenter et al., 1993; Dhand et al., 1994). In T-cells, p85a, A^en 
bound to p i 10, also appears to be differentially phosphorylated on serine and 
threonine residues compared to p85p which suggests a divergent function and 
regulatory role for p85a and p85p in T cells (Reif e/ al., 1993). Therefore PI 3-kinase 
regulation may not only depend on the specific isoforms of p85 and p i 10 present and 
the subcellular compartment to vMch they are recruited during activation but also 
^)pears to depend on cell type and species differences. Therefore p85 subunit 
isoforms confer specificity during the association of specific PI 3-kinase activity with 
various specific substrates and adapter molecules, in vivo (Dhand et al., 1994; Parker 
and Waterfield, 1992; Pleiman et al., 1994; Reif et al., 1993).
43
General Introduction Chapter I
1.6.0. Cellular Functions of PI 3-Kinase
Studies using employing PI 3-kinase inhibitors, dominant-negative and constitutively 
active PI 3-kinase mutants have indicated four functional areas, (Fig. 1.6.1.), in which 
PI 3-kinase is involved;
1. Proliferation
2. Survival/Apoptosis
3. Intracellular vesicle trafficking/secretion
4. Regulation of the cytoskeleton
A kt PKBOther 
SH2 doni«n 
PH  domain 
C2 domaan
Exrhange farter P I5-K SH 2 PKC-e,A 
(PH) \  /
PDK-1,2
Traffirking Cell growth Cell survival
Fig. 1.6.1. Role of PI 3-kinase in cellular function.
1.6.1. Mitogenesis
PI 3-kinase is involved in mitogenic signalling in a cell type and stimulus dependent 
manner. The requirement for PI 3-kinase activity during growth factor receptor- 
mediated mitogenic signalling is not explicitly clear because of contradictions in the 
published data. It has been demonstrated that p85/pII0a PI 3-kinase activity is 
required by the PDGF receptor for induction of DNA synthesis in NIH 3T3 cells 
(Roche et al., 1994). However, in a separate study expression of a mutant PDGFr in 
either NIH 3T3 or 32D haematopoietic cells, which is unable to associate with PI 3-
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kinase, did not impair PDGF stimulated mitogenesis (Yu e/ a/., 1994). In addition, PI
3-kinase is not required for the propagation of a mitogenic signal by G-protein 
coupled receptors Bombesin and Lysophosphatidic Acid (LPA) (Roche et al., 1994) 
or for thrombin stimulated mitogenesis in vascular smooth muscle cells (Weiss and 
Apostolidis, 1995).
A polyclonal antibody (pAb), raised against die N-SH2 of p85a, has been shown to 
activate PI 3-kinase activity when microinjected into CHO cells and stimulates a three 
fold increase in PI 3-kinase activity of recombinant dimers, in vitro (Mcllroy et al., 
1997). Activation of PI 3-kinase is sufficient to stimulate DNA synthesis in quiescent 
CHO cells and this activity requires both the p21 Ras/MAPK pathway and p70^^, a 
protein essential for progression th ro u ^  Gi phase of the cell cycle (Alessi et al., 
1998; Mcllroy era/., 1997).
Activation of p21™ (Ras), a small molecular weight G-protein, is central to regulation 
of cell proliferation stimulated by various receptors, including the PDGFr and EGFr 
(Valius and Kazlauskas, 1993; Wiese et al., 1995). The Ras protein family is a groiq) 
of small monomeric GTP-binding proteins ) ^ c h  are key regulators in cell 
proliferation, capable of causing cellular transformation Wien constitutively activated 
by the presence of point mutations (Rodriguez-Viciana et al., 1996). In general, Ras 
has low intrinsic GTPase activity, Wiich is stimulated by GTPase activating proteins 
(GAPs) including pl20Ras#GAP (van der Geer et al., 1997). PDGF stimulation of 
GAP^ '^ '^  fibroblasts induces abnormal increases in GTP-Ras levels and the duration of 
MAPK activation compared to normal cells with tyrosine phosphorylation of 
pl90Rho»GAP dependent on functional pl20Ras*GAP (van der Geer et al., 1997). 
Therefore pl20Ras#GAP appears to downregulate activation of Ras and the MAPK
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pathway following growth factor stimulation and also modulates phosphorylation of
pl90Rho*GAP but does not ^>pear to be involved in mitogenic signalling in this
model (van der Geer et al., 1997).
Whether PI 3-kinase is an upstream or downstream effector of Ras is not completely 
clear. To date, it has been diown that GTP-bound Ras associates with both p i 10a 
and p i lOp subunits of PI 3-kinase involving Lys^^ of p i 10 (Rodriguez-Viciana et al.,
1996). Association of Ras with PI 3-kinase may also be mediated indirectly through 
the Grb2#Sos complex via the Grb2 SH2 domain which can associate with PI 3- 
kinase (Kodaki et al., 1994; Saleem et al., 1995). Therefore Grb2 functions as an 
ad^yter molecule, binding Sos-associated. Ras and then PI 3-kinase, thereby bringing 
Ras and PI 3-kinase within proximity of one another (Hu et al., 1995; Saleem et al.,
1995). In COS-7 cells binding of tyrosine containing phosphopeptides to p85 occurs 
synergistically with GTP-Ras binding, suggesting that in Cos-7 cells activation of PI 
3-kinase is dep%dmt o n  R as  (R o d rig u ez -V ic ian a  et aL, 1996). A decrease in Ras 
association with PI 3-kinase resulted in a reciprocal increase in basal levels of PI 3- 
kinase activity (Rodriguez-Viciana et al., 1996). Introduction of a dominant-negative 
Ras mutant into NIH 3T3 cells also prevents the PDGF-dependent increase in cellular 
lipid levels suggesting, PI 3-kinase is a downstream effector of Ras (Carpenter and 
Cantley, 1996; Hu et al., 1995).
The small GTPase R-ras displays a less potent transforming activity than the closely 
related Ras oncogene product but, like Ras, it can activate PI 3-kinase in vitro, but 
unlike Ras, R-ras cannot activate Raf-1 or MAPK in fibroblasts (Marte et al., 1997). 
In co-transfection assays, /Akt is effectively stimulated by either R-ras, Ras, mutants 
of Ras which can only activate PI 3-kinase or constitutively active PI 3-kinase (Marte
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et al., 1997). Moreover, constitutive activation of PI 3-kinase, although sufficient for
Akt activation, is not capable of activating MAPK, Jnk/SAPK or Erk (Marte et al.,
1997). Thus it appears that although Ras can activate both Raf-l/MAPK and PI 3-
Kinase/Akt pathways, R-ras can only activate the PI 3-kinase/Akt pathway (Marte et
a l, 1997).
Protein Kinase C (PKC) isoforms such as PKCs or PKCA, are activated directly by 
PIa,4P2 and PIa,4 ^ 3  and may lead to activation of Ras/Raf pathway (Toker and 
Cantley, 1997). PKC6 specifically associates with PI 3-kinase in platelets following 
cytokine stimulation, however although the PI 3-kinase inhibitor LY294002 did not 
inhibit this association, wortmannin did (Ettinger et al., 1996). It is possible that 
while wortmannin specifically targets the lipid binding pocket (Wymann et al., 1996), 
LY294002 inhibits PI 3-kinase protein kinase activity by binding within the ATP- 
binding site (Vlahos et al., 1994). Therefore, it is likely that PKC6 association with 
PI 3-kinase possibly requires only substrate binding and not lipid kinase activation 
since the only difference between wortmannin and LY294002 are their respective 
target sites on PI 3-kinase.
1.6.2. Apoptosis
It is known that PI 3-kinase is an integral part of pathways by which insulin and NGF 
prevent apoptosis (Minshall et a l, 1996). PI 3-kinase products are involved in 
activation of PKB (Akt), a homolog of PKC and the cellular homolog of viral v-Akt, 
which possesses a PH domain that binds to PI 3-kinase products with high affinity 
(Alessi et a l, 1997). PKB activation in various cell lines has been shown to stimulate 
survival/proliferation, differentiation, GLUT4 translocation. Glycogen Synthase 
Kinase 3 (GSK3) downregulation and upregulation of E2F transcription factor
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expression (Marte and Downward, 1997). Four PKB isoforms which bind to PIP3
containing vesicles have been cloned to date; PKBa, PKBpi and PKB|32 in humans 
and PKBy in rats (Marte and Downward, 1997). Recently Alessi et al have isolated a 
PIP3-dependent protein kinase-1 (PDK-1) from rabbit skeletal muscle which relies on 
the PI 3-kinase product, PIP3 for activation (Alessi et al., 1997). PDKs contain an N- 
terminal catalytic domain and a C-terminal PH domain Wiich facilitates their 
association with PI 3-kinase products (Stephens et al., 1998). PDK-1 phosphorylates 
PKB on Thr^ °* and Ser^^ in response to insulin or IGF-1 stimulation (Alessi et al., 
1997). PDK-1 activation in vitro by Pl3,4^,P3 and PI3.4P2 is not inhibited by 
wortmannin, and confirms that PDK-1 is not a PI 3-kinase family member (Alessi et 
al., 1997). It also appears that phosphorylation and activation of p70^^ in vivo and 
vitro, a role previously ascribed to PKB, may also be performed by PDK-1 (Alessi et 
al., 1998). Cells Wiich require growth factors for their survival also require PI 3- 
kinase activity, but this appears to be mediated via PKB and not p70^^ (Yao and 
Cooper, 1996). It is interesting to note that PKB isoforms are over-expressed in 
various ovarian, pancreatic and breast carcinomas therefore may play a part in cell 
transformation and aberrant growth responses in these tumours (Alessi et al., 1997).
In vitro studies have demonstrated that vesicles containing the phospholipid PI3 4P2 
specifically bind to PKB via its PH domain and causes it to dimerise resulting in its 
activation (Franke et al., 1997; Klippel et al., 1997). Activation was not observed 
with vesicles containing PI3P or Pl3,4^P3 and activation required fimctional PH 
domains on PKB (Klippel et al., 1997). PI3 4.5P3 as well as PI3 4P2 cause translocation 
of PKB to the plasma membrane, thus enabling PDKs to phosphorylate and activate 
its kinase activity (Stephens et al., 1998). Therefore the PI 3-kinase product Pl3,4P:
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and possibly Pl3,4^P3 provide a mechanism of recruitment for PKB to PDK-1 resulting
in further PKB activation.
Both wortmannin and LY294002 induce sqyoptosis in healthy cells suggesting PI 3- 
Idnase is also important in the survival pathway as well as in the differentiation 
pathway (Stoyanov et al., 1995; Yao and Cooper, 1995). Serum starvation or 
incubation with PI 3-kinase inhibitors, wortmannin or LY294002, has been shown to 
induce apoptosis in PC 12 cells, Rat-1 cells and REF52 cells but not in NIH 3T3 or 
Balb 3T3 cells (Yao and Cooper, 1996; Yao and Cooper, 1995). In addition, neuronal 
cells transfected with wild-type PDGFr enter into ^xyptosis in the absence of PDGF 
or when the receptor possesses a mutated PI 3-kinase binding site (Carpenter and 
Cantley, 1996). Ras activation of PI 3-kinase activity also leads to suppression of c- 
wyc-induced apoptosis through PKB, but not p 7 0 ^  (KaufiBnami-Zeh et al., 1997). 
However, a complicating frtctor is that Ras is also an effective promoter of qxyptosis 
through the Raf pathway (Kauffinann-Zeh et al., 1997). In Rat-1 fibroblasts apoptosis 
induced by serum starvation cannot be rescued by Ras, Raf or src activation (Kennedy 
et al., 1997). However protection against apoptosis is conferred by PKB activation, 
and apoptosis is accelerated by PI 3-kinase inhibitors wortmannin and LY294002 
(Kennedy et al., 1997).
A dominant negative, kinase-deficient PKB can inhibit BCR/ABL-dependent 
transformation in vitro and suppresses leukaemia development in SCID mice (Skorski 
et al., 1997). Inhibition of PI 3-kinase activity with wortmannin also siqypresses the 
BCR/ABL-dependent colony formation of murine bone marrow cells in culture 
suggesting that the PI 3-kinase/PKB pathway is essential for BCR/ABL 
leukaemogenesis (Skorski et al., 1997). Yin et al have recently reported the
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possibility that the p85 alone, without associated PI 3-kinase activity may participate
in qyoptosis induced by oxidative stress in a fibroblastic cell line (Yin et al., 1998). 
However, this still remains to be confirmed.
1.63. Vesicle Trafficking
It was first demonstrated that PI 3-kinase activity was important for vesicle trafficking 
by the essential role for vps34p in late Golgi-vacuole trafficking in S. cerevisiae 
(Herman and Emr, 1990; Roth and Stemweis, 1997; Stack and Emr, 1994). Vps34p is 
known to associate with vpsl5p, Wiich recruits vps34p to the plasma membrane 
Wiere it is activated, vpsl5p appearing to ftmction in an analogous manner to p85 
(Stack and Emr, 1994). In mammalian cells there is substantial evidence for a 
separate but similar protein to vpslSp Wiich fimctions in trafficking of vesicles to 
lysosomes which are the mammalian fimctional equivalent of yeast vacuoles (Stack 
and Emr, 1994), and a 150kDa mammalian homolog of vpsl5 has recently been 
cloned (Panayotou et al., 1997). Therefore there is a mechanism for sorting of 
vacuolar proteins Wiich is highly conserved between yeast and mammals. 
Wortmannin has been demonstrated to block Golgi to lysosome trafficking of Pro- 
cathepsin D, resulting in the accumulation of large vesicle-like structures similar to 
pre-lysosomes (Davidson, 1995; Joly et al., 1995). This implies PI 3-kinase may 
regulate trafficking of lysosomal enzymes, possibly by interference with the mannose 
6-phosphate receptor-dependent sorting event in the trans-golgi network (Brown et 
al., 1995). Since Pl-specific 3-kinase is homologous to vps34p and so only produces 
one lipid product it has been proposed that it and its product, PI3P, are important in 
the correct control of trans-golgi network-lysosome trafficking, late endosome - 
lysosome trafficking and endosomal recycling (Rameh et al., 1995). However, 
although wortmannin inhibits PI 3-kinase activity causing an almost complete
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decrease in cellular levels of PI3.4P2 and PÏ3,4.5P3, there is only a 70% decrease in the
levels of PI3P suggesting that the Pl-specific 3-kinase is wortmannin insensitive and
continues to synthesise PI3P (Zell et al., 1996). Therefore PI3.4P2 and/or Pl3,4^P3 are
also involved in late endosome to lysosome trafficking and endosomal recycling
(Downward, 1995) and Pl3,4 ^ 3  may be involved the activation of an
ARNO/cytohesin-l/Grp-1 family member Wiich regulates the assembly of coated
vesicles (Toker and Cantley, 1997). In D. discoidium deficient for the two p i 10
homologs DdPIKl or DdPIK2, there is impaired vesicle trafficking as well as a
disorganised actin cytoskeleton (Roth and Stemweis, 1997).
The most compelling evidence in support of a role for PI 3-kinase activity during 
vesicle trafficking in mammalian cells comes firom studies conducted with PDGFr 
mutants (Zell et al., 1996). Mutation of the PI 3-kinase binding site on the PDGFr 
expressed in fibroblasts results in blockage of PDGF-dependent receptor lysosomal 
degradation (Shpetner et al., 1996). In addition detailed study carried out in 
fibroblasts the has shown that in the presence of wortmannin, trafficking of the 
internalised PDGF receptor is arrested at a juxtanaembrane site, prior to reaching the 
sorting endosome (Joly et al., 1995). This suggests that trafficking of inta-nalised 
PDGFr and its degradation is dépendit on products of a PI 3-kinase activity rather 
than a Pl-specific 3-kinase.
Inhibitors of PI 3-kinase also block endocytosis in macrophages by preventing 
completion of vesicle formation, although initiation of vesicle still occurs (Araki et 
al., 1996). Wortmannin and LY294002 inhibit fiuid-phase pinocytosis and Fc 
receptor mediated phagocytosis, but have little effect on receptor mediated 
endocytosis of LDL (Araki et al., 1996). Wortmannin also partially inhibited
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transferrin receptor internalisation and endosome recycling back to the cell surface in
CHO cells (Martys et al., 1996). Therefore it spears that PI 3-kinase activity is 
required at three stages; internalisation; transit from early endosomes to the recycling 
and lysosomal compartments; and transit from recycling compartments to the cell 
surface (Martys et al., 1996).
1.6.4. The Cvtoskeieton
Pl4 ^ 2  is an important molecule in the regulation of the actin cytoskeleton (Toker and 
Cantley, 1997; Welch et al., 1997). Studies in fibroblasts demonstrate that Pl4 ^ 2  can 
promote actin filament growth by binding to gelsolin and other actin capping proteins 
thereby releasing these proteins from actin termini (Wymann and Arcaro, 1994), and 
synthesis of PL^ 2  can be stimulated by addition of constitutively active Rac to 
permeabilised platelets (Parker, 1995). In addition, wortmannin does not inhibit 
thrombin dependent actin uncapping suggesting that PI 3-kinase activity may not be 
required for this effect. However PDGFr signalling in fibroblasts depends on PI 3- 
kinase for the activation of Rac (Parker, 1995). GTP binding to Rac is inhibited by 
wortmannin Wien cells are stimulated Wth PDGF, suggesting that Rac lies 
downstream of PI 3-kinase (Parker, 1995), and it has been reported that addition of 
constitutively active Rac reverses wortmannin inhibition in SWss 3T3 cells (Bokoch 
et al., 1996). The primary product of PI 3-kinase, Pl3,4^Pa, Wiich may remain 
associated Wth PI 3-kinase, causes GDP-Rac to dissociate from its binding protein 
Rac-guanine nucleotide dissociation inhibitor (Rac-GDI) again placing Rac 
downstream of PI 3-kinase (Bokoch et al., 1996; Nobes et al., 1995; Parker, 1995). 
Dissociation of Rac from Rac-GDI facilitates phosphate-transfer and leads to 
formation of membrane-associated GTP-Rac which stimulates actin polymerisation
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and membrane ruffling or blebbing in PDGFr, IGFr, insulin and thrombin receptor
signalling (Kundra etal., 1994; Parker, 1995; Ridley etal., 1992).
The PH-domain containing protein, profilin is involved in the regulation of actin 
assembly and interacts with Pl3,4 ^ 3  and PI3 4P2 (Toker and Cantley, 1997). Binding of 
PI3 4P2 to profilin results in actin polymerisation, Wiile PI3.4P2 also inhibits the actin 
severing activity of gelsolin and in permeabilised platelets has been shown to 
stimulate actin uncapping (Toker and Cantley, 1997). P%4^P2 also binds to other 
proteins Wiich regulate or bind to the actin cytoskeleton including, cap-2, and a- 
actinin as well as gelsolin, and possibly serves as an attachment site for PH-domain- 
containing proteins involved in actin regulation (Bae et al., 1998; Rhee and Bae, 
1997; Tapon and Hall, 1997). Therefore PI 3rkinase products may provide a more 
selective mechanism for inducing reorganisation of the actin cytoskeleton, whereas 
the ubiquitous Pl4^P2 may have more of a general house-keeping role in actin 
organisation. In addition to being a substrate for PI 3-kinase, Pl4^P2 is also a substrate 
for PLCy, and hydrolysis of Pl4 ^ 2  by PLCy is one of the early events during 
signalling leading to the formation of DAG and IP3 which activate PKC and calcium 
mobilisation, respectively (Bae et al., 1998). Recently it has been demonstrated that 
the PI 3-kinase product Pl3,4 ^ 3  activates PLCy in vitro (Bae et al., 1998). Therefore 
stimulation of PI 3-kinase activity results in activation of various pathways Wiich all 
appear to have the net effect of depleting cellular PL^P2 levels Wiich may also affect 
the organisation of the actin cytoskeleton.
Actin dynamics in lamellepodia are driven by continuous cycles of actin 
polymerisation, retrograde flow and actin depolymerisation (Welch et al., 1997). The 
leading edge of a motile cell or cells responding to a chemotactic g ré e n t are
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composed of thin protrusions of membrane which continuously extend and retract,
mediating the initial stage of cell movement Wiilst also determining the direction of
eventual movement (Welch et al., 1997). M-CSF stimulates actin reorganisation in
BAC1.2F5 cells leading to formation of filopodia, lamellepodia and membrane ruffles
as well as iSne actin cables within the cell (Allen et al., 1997). These changes in cell
morphology are mediated by Rho family proteins that are regulated by a combination
of GAPs, GEFs and GDIs (Allen et al., 1997). Formation of lamellepodia, membrane
ruffling and focal adhesion complexes are mediated by Rac Wiich is also regulated
indirectly by cdc42 which also regulates filopodia formation (Allen et al., 1997). In
turn Rac activation activates Rho leading to formation of actin cables (Allen et al.,
1997). Interestingly, the formation of filopodia negatively regulates further
lamellepodia, focal complex and actin cable formation as well as membrane ruffling
(Allen et al., 1997), Expression of a constitutively active p i 10a PI 3-kinase in NIH
3T3 cells induces Rac-mediated lamellepodia and focal complex formation and Rho-
mediated stress fibres and focal adhesion formation (Reif et al., 1996). However PI
3-kinase activity is not required for Ras/Rac/Rho signalling pathways that lead to
gene transcription thus PI 3-kinase activity acts selectively on Rho family GTPases to
initiate some but not all of their responses (Reif et al., 1996).
PI 3-kinase is believed to mediate the initial steps leading to increased membrane 
ruffling following activation of cell surface receptors such as those for PDGF and M- 
CSF (Araki et al., 1996; Ruusala et a l, 1998). PI 3-kinase is also required for some 
forms of cell motility and adherence since fibroblasts containing PDGFr mutants 
which do not possess the PI 3-kinase binding site do not undergo plasma membrane 
ruffling, nor do they respond chemotactically to PDGF gradients (Chong et a l, 1994; 
Kundra et al., 1994; Wennstrom et al., 1994).
r
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The Rho family proteins Rho and Rac are responsible for cell migration in response to
M-CSF in the BAC1.2F5 macrophage cell line (Allen et al., 1998). It is known that 
PI 3-kinase is an effector for Rho, since GTP-boimd Rho stimulates the production of 
Pl3,4,sP3 in platelet lysates (see below) (Stephens et al., 1993; Zhang et al., 1993). The 
other Rho family member, cdc42, is required for the chemotactic response to M-CSF 
but not for locomotion (Allen et al., 1998). This suggests that PI 3-kinase activity 
may be involved in stimulating Rac and mediating Rho activity and therefore is 
involved in the re-organisation of the actin cytoskeleton and cell locomotion.
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1.7.0. Signal transduction via the M-CSF receptor
C-fins has numerous tyrosine phosphorylation sites on its cytoplasmic tail that 
facilitate its association with various intracellular proteins that mediate M-CSF 
stimulated responses in cells. Each tyrosine phosphorylation site has the ability to 
recruit specific cytosolic proteins and protein complexes and it is these interactions 
and cytosolic proteins, recruited to c-fins A^ch will be discussed below. Figure 1.7.1. 
summaries the c-fins tyrosine phosphorylation sites and the proteins that associate 
with them.
Potential Ram activation through SoiY543 She
MItogenetIm and cell cycle progreiilonY561N Src
Y571
Ram activation through So:
Gene transcriptionY708- STATsKI
MKogeneiii (Yes/No)Y723 PI 3-K
Regulation of receptor auto phosphorylationY809
Y969
Fig. 1.7.1. Intracdlniar tyrosine phosphorylation sites on the c-fins ^toplasmlc tall and 
cytosohc proteins that associate with them.
1.7.1. The iuxtamembrane tvrosine phosphorylation sites 
The first 50aa of the cytoplasmic tail, the juxta-membrane region, contains two 
tyrosine-based activation motifs, at Tyr^^ and Tyr^ ^^  and it is possible that a third is 
present at Tyr^ ^  ^ (Fig. 1.7.1.) (Joos et al., 1996; Stanley et al., 1997). Tyr^^ is the 
main site of interaction with 5rc-family kinases, including yes and src which are 
activated as a result of binding to c-fins via their SH2 domains (Alonso et al., 1995;
Courtneidge et al., 1993). Inhibitory antibodies of src family kinases block M-CSF-
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stimulated cell-cycle progression from early Gi phase but are not required prior to
commitment to S phase (Roussel, 1994). This suggests that 5rc-family kinases are 
required during the o-fins mediated mitogenic signal.
In osteoclasts, M-CSF stimulates cytoskeletal reorganisation, motility and 
cytoplasmic spreading (Insogna et al., 1997). M-CSF stimulation also increases the 
detected levels of tyrosine phosphorylation including o-Jms and src and an 
unidentified 85 kDa protein with a concomitant three-fold increase in frc-kinase 
activity (Insogna et al., 1997). In jrc-negative cells, M-CSF fails to induce cell 
spreading or change F-actin distribution and the 85kDa phosphoprotein was not 
tyrosine phosphorylated in response to M-CSF stimulation (Insogna et al., 1997). Src 
kinase therefore ^>pears to be required for correct cytoskeletal architecture in the 
osteoclast.
The second site of tyrosine phosphorylation, Tyr^^\ also has an SH2 domain 
recognition sequence and mutation of Tyr^ ^^  has been shown to inhibit receptor- 
mediated endocytosis possibly by blocking the c-fins tyrosine kinase activity 
(Carlberg and Rohrschneider, 1994).
A third, putative phosphorylation site at Tyr^^ has been shown to be phosphorylated 
in \-fins and is required for association of a 55kDa protein (Joos et al., 1996). Tyr^ '*^  
fails to associate with SH2 domain containing proteins, however it appears to be a 
phosphotyrosine binding (PTB) recognition sequence which binds to She, a 55kDa 
phosphoprotein (Joos et al., 1996). She is an adaptor protein that is also found in 
many recruitment complexes associated with c-fins (Rohrschneider et al., 1997). C- 
cbl, a 120kDa protein which is constitutively associated with Grb2 in unstimulated
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BAC1.2F5 macrophages, becomes tyrosine phosphorylated within a minute of M-
CSF stimulation and is found in a complex with tyrosine phosphorylated She and an 
unidentified 80kDa phosphoprotein (Wang et al., 1996). Simultaneously, 
phosphorylated o-cbl is ubiquitinated and translocated to the plasma membrane and 
after ten minutes is de-ubiquitinated, de-phosphorylated, and relocalises to the cytosol 
but remains complexed with She for up to one hour (Wang et al., 1996).
1.7.2. Tvrosine residues in the kinase insert domain
One of the defining features of the class IQ RTK family is an insert in the catalytic 
domain, the kinase insert domain (KI domain), that disrupts the homology the 
catalytic domain shares with src-frmily kinases (Carlberg et al., 1991; Roussel et al., 
1990). This 72 amino acid insert contains three sites of tyrosine auto-phosph(^lation 
at Tyr^^'^^'^^ (Fig. 1.7.1.) (Carlberg et a l, 1991; Reedijk et al., 1990; Roussel et d .,
1990).
Phosphorylation of T y r^  results in the association of the Src Homology 2 (SH2) 
domain of the adapter molecule Grb2 (Lioubin et al., 1994; van der Geer and Hunter,
1993). Grb2 has been shown to be associated with various other signalling molecules 
in macrophages including She, c-cbl, SHP-1, Sos, and pl50™* (Chen et a l, 1996; 
Lioubin et a l, 1994; Rohrschneider et a l, 1997). The association of Grb2 with Sos 
^jpears to be constitutive and independent of M-CSF stimulation (Lioubin et a l,
1994).
Tyr^^ is an unusual site of phosphorylation in the Crfins because its flanking 
sequences, which are composed of mostly basic residues, are not homologous to any 
known tyrosine phosphorylation sites (van der Geer and Hunter, 1990). This hints
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towards a more a more specific function than merely a recruitment site for SH2 or
PTB domain containing proteins. M-CSF stimulated FDC-Pl cells that express 
murine ofins exhibit increased STAT-1 and STAT-3 (signal transducers and 
activators of transcription) activation (Novak et al., 1995; Novak et al., 1996). 
Activation of STAT-1 requires an intact Tyr^^ in the murine receptor but this residue 
does not appear to be required for STAT-3 activation (Novak et al., 1996). In 
addition, an intact T y r^  in the murine receptor is also required for STAT activation 
although this residue does not recruit STATs directly (Fig. 1.7.1.) (Novak et al.,
1996). The involvement of residue T y r^  will be discussed in more detail later 
(sections 1.7.3 and 1.7.4.). Tyk-2 , a member of the Jak family kinases, is a possible 
regulator of STAT activation and is tyrosine phosphorylated after M-CSF stimulation 
of BMMs. Tyk-2 phosphorylation is also accompanied by Jak-1 phosphorylation in 
fibroblasts transfected with c-fins (Novak et al., 1995). However, phosphorylation of 
Jak-1 or Jak-2 is not detected in either BMMs or BAC1.2F5s in response to M-CSF 
> ^ch  suggests that Tyk-2 phosphorylation is the only regulator of STAT activity in 
macrophages, or myeloid cells (Novak et al., 1995).
M-CSF stimulates PI 3-kinase activity in murine bone marrow derived macrophages 
with maximum PI 3-kinase activity observed after ten minutes (Yusoff et al., 1994). 
The association of PI 3-kinase with c-fins was originally m^)ped using anti-c^^w 
peptide anti-sera i^ c h  detected a potential PI 3-kinase binding site between residues 
701 and 721 in the kinase insert region (Downing et al., 1991). In Wiole cells only a 
small minority of ligand activated receptors ^)pear to form a stable complex with PI 
3-kinase (Downing et al., 1991) and this interaction was eventually mapped to Tyr^^ 
in the KI domain (Reedijk et al., 1992). In BAC1.2F5 cells M-CSF stimulates 
tyrosine phosphorylation of p85a and its association with ofins and other cytosolic
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proteins including o-cbl, p95 and p55-60 in a rapid but transient manner
(Kanagasundaram et al., 1996). The involvement of PI 3-kinase in c-fins signalling 
will be discussed in greater detail in sections 1.7.6. and 1.7.7.
In a yeast two hybrid study an autophosphorylated cytoplasmic domain of murine c- 
fins was used to screen an expression library for clones containing SH2 domains 
which recognised the tyrosine phosphorylation site at Tyr^^ (Bourette et al., 1997). 
From this the SH2 domains of PLOy2 were repeatedly isolated and were shown to 
interact with T yr^\ directly (Bourette et al., 1997). In o-fins expressing FDC-Pl cells 
M-CSF stimulated the rapid (5minutes^l50minutes) but transient phosphorylation of 
PLCy2 and this event appeared to be required for activation of the PI 3-kinase 
pathway (Bourette et al., 1997). It is possible that PI 3-kmase competes with PLCy2 
for the same residue on c-fins.
1.7.3. Tvr*” in the C-terminaltvnwine kinase domain
The catalytic domain of c-fins also contains a kinase lobe with a tyrosine 
phosphorylation site at T y r^  (Fig. 1.7.1.) (Roussel et al., 1990). This site is common 
to all receptor tyrosine kinases and on ofins, its auto-phosphorylation is involved in 
the M-CSF-dependent induction of c-myc expression (Fig. 1.7.4.) (Roussel et al.,
1991). In studies on the murine receptor a phenylalanine mutation at Tyr^^ abrogated 
the differentiation signal but increased the rate of M-CSF-stimulated proliferation in 
FDC-Pl cells (Bourette et al., 1995). However, mutation of the equivalent residue in 
the human c-fins inhibited M-CSF-induced proliferation in NIK 3T3s with concurrent 
cell cycle arrest during the early Gi phase (Courtneidge et al., 1993; Roussel et al., 
1990). Additional experiments have shown that antibodies \^ c h  bind to and
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inactivate src family kinases also prevent cell cycle progression from early Gi phase
but are not required prior to commitment to S phase (Roussel, 1994).
Mutation of Tyr^^ in the murine receptor also appears to reduce the c-fins in vitro 
kinase activity (Bourette et al., 1995). Mutating Tyr^^ to phenylalanine inhibits 
receptor autophosphorylation suggesting that T y r^  is essential for phosphorylation of 
other tyrosine residues on c-fins (Novak et al., 1996). These mutational studies have 
underscored the importance of receptor autophosphorylation to recruitment of 
cytosolic proteins (Reith et al., 1993).
The association of .src-family kinases with activated c-fins also appears to require 
phosphorylation of T y r^  (Courtneidge èt al., 1993). Although there is an increase in 
jrc-family kinase activity associated with the phosphorylation of T y r^  there is no sh: 
kinase association, including Jyn and yes, with Crfins unless Tyr^^ is also 
phosphorylated (Courtneidge et al., 1993). As stated previously, STAT-1 and STAT- 
3 associate with c-fins in BMMs, BAC1.2F5 macrophages and transfected fibroblasts 
(Novak et al., 1995). Mutation of Tyr*°  ^ in the murine receptor blocked PLCy2 
binding and phosphorylation but had no afreet on the binding or phosphorylation of 
the p85 subunit of PI 3-kinase (Bourette et al., 1997). The T y r^  mutation also 
abrogated die differentiation signal in FDC-Pl cells, > ^ch  is mimicked by PLC/2 
inhibitors.
1.7.4. T vr^ and the immediate earlv gene response
As previously mentioned the Tyr*^he mutation abolishes M-CSF-stimulated 
mitogenesis which is characterised by a significant reduction in c-myc expression, 
although the transcription of immediate early-response genes c-fos and c-jun^ are still
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induced (Barone and Courteneidge, 1995; Reedijk et al., 1990; Roussel et al., 1990; 
Saleh et al., 1995). The importance of c-myc expression in c-fins signalling is 
illustrated by demonstration that ectopic c-myc expression in NIH 3T3 cells 
expressing a mutant c-fins restores the loss of M-CSF-dependent proliferation (Fig.
1.7.4.) (Barone and Courteneidge, 1995; Downing et al., 1989).
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C fos
O ilie r Signals
Fig. 1.7.4. Receptor Stimulation Results in Cell-Cycie Progression.
In macrophages M-CSF rapidly induces transiently high levels of c-fos expression 
within 15 minutes of stimulation followed by a lower but sustained level of c-fos 
expression for 4-12hrs (Downing et al., 1989). Stimulation of quiescent BAC1.2F5 
macrophages with M-CSF results in transient elevation of c-fos and subsequent levels 
of c-myc mRNA (Orlofsky and Stanley, 1987).
M-CSF is required by BMMs throughout Gi for progression into S phase and
persistent c-fms kinase activity is required not only for the expression of the
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immediate early genes (Fig. 1.7.4.), but also for expression of delayed early response
genes such as D-type cyclins (Roussel, 1997). Mutational analysis has shown that 
Tyr^ ^^  and Tyr*°  ^are required for induction of c-n^c expression, and Tyr^^\ T y r^ , 
Tyr^ ®* and Tyr^ ^  ^ are required for c-fos and c-jun expression (Roussel, 1997). This 
evidence suggests that the c-fins mitogenic signal occurs via two pathways. One 
pathway which leads to transcription/translation of o-fos and c-JunB and is 
independent of the phosphorylation state of T y r^  but involves tyrosine residues in 
the KI domain, and a second pathway Wiich is phosphorylation-dependent and leads 
to c-wyc transcription which requires src kinase activity.
1.7.5. The oncogenic receptor: \-fm s
The v-fins homologue of c-fins was originally identified as the oncogene carried by 
the SM and HZ5 strains of feline sarcoma virus, FeSV, (Genbank accession number 
K01643) (Hampe et al., 1984). Feline v-fins differs fix>m the feline c-fins by 12 amino 
acid substitutions distributed throughout the protein and by the replacement of a 50aa 
sequence close to the carboxyl-terminal tail region by 14 unrelated amino acids (Shar 
and Stanley, 1990). The carboxyl-terminal tail region of c-fins is 24aa in length and 
appears to fimction as a negative regulator of receptor tyrosine kinase activity, 
controlled to some degree by phosphorylation at Tyr^^ (van der Geer and Hunter, 
1990). Modification of this tail region resulting in the loss of T y r^  prevents 
regulation of receptor autophosphorylation, implying that T y r^  is involved in the 
negative regulation of receptor tyrosine kinase activity (Sherr and Stanley, 1990). 
The carboxyl-terminal deletion in conjunction with two point mutations present in the 
D4 loop at positions 301 and 374, abolishes the dependence on M-CSF for initiation 
of receptor signalling (Sherr and Stanley, 1990). Mutation of Leu^* in the 
extracellular domain, in the D4 loop, has also been shown to be sufficient for
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activation of the c-jms transforming potential (Roussel et al., 1988). Cells
transformed by \-fins also exhibit increased levels of PI turnover with conversion of 
Pl4^P2 to inositol trisphosphate (IP3) to mobilise Ca^  ^ and Diacylglycerol (DAG) to 
activate Protein Kinase C (PKC). This is associated with the increased activities of 
membrane associated Pl4^ 2-PLC and PI kinase activity A^ch implies there is a role 
for Pl4^ 2-derived secondary messengers in c-fins signalling (Whetton et al., 1986).
A second, potential Grb2 binding site has been mapped on oncogenic v-fins at Tyr^^ 
vMch appears to bind to Grb2 with higher affinity than T y r^  (Mancini et al., 1997). 
NIH 3T3 cells expressing v-fins containing a mutation at Tyr^^ have an increased 
fibronectin network and have lost serum-independent growth typically observed in 
wild type v-fins transformed NIH 3T3 cells (Mancini et al., 1997). Further 
investigation of this phosphorylation site may reveal alternative mechanisms for cell 
transformation.
Mutational analysis has shown that phosphorylation of Tyr*®^  on v-fins controls cell 
morphology and the association of pl20Ras#GAP in transformed NIH 3T3 cells, 
although mitogenesis was not blocked by this mutation (Trouliaris et al., 1995). 
However this conflicts with earher reports on the effects of mutation at T y r^  of c-fins 
expressed in fibroblasts (Roussel et al., 1990), therefore it is possible that the physical 
differences between v-fins and c-fins also affects how mitogenic signals are 
transduced. Additionally, phosphorylation of pl20Ras#GAP does not occur in 
BAC1.2F5 macrophages (Reedijk et al., 1990). Thus fi*om studies of v-fins, T y r^  
and the equivalent residue on the murine and human receptors, ^>pears to regulate the 
intrinsic tyrosine kinase properties of c-fins and the actin cytoskeleton via Ras#GAP. 
The association of the Ras#GAP with v-fins and its apparent non-involvement in v-
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fins mediated mitogenesis is something of a paradox. However, it is possible that
other sites are involved in Ras activation or that the cell type in which a mutated c-fins 
is expressed also determines the biological outcome of the mutation. There are data 
that seem to indicate that cell type influences the results obtained with respect to PI 3- 
kinase and must therefore be considered during their interpretation and this will be 
discussed below.
1.7.6. Evidence for the involvement of PI 3-kinase in c-fnts signalling
Expression studies in NIH 3T3 cells with the PDGFr mutated at the binding sites for 
PI 3-kinase and either Ras«GAP, SIff-2 or PLCy have shown that binding of PI 3- 
kinase to tyrosine phosphorylated PDGFr was necessary for full PI 3-kinase activity 
(Klinghoffer et al., 1996). In addition, accumulation of GTP-Ras was also required 
for full PI 3-kinase activition (Klinghoffer et al., 1996).
In corollary experiments performed in transfected rat fibroblasts (208F) a mutation at
721 •Tyr in murine c-fins resulted in a marked decrease in the ability of c-fins to bind the 
SH2 domain of the p85 subunit of PI 3-kinase with a concomitant loss in PI 3-kinase 
activity (Reedijk et al., 1992; van der Geer and Hunter, 1993). Metabolic labelling of 
BAC1.2F5 macrophages suggested only a minor PI 3-kinase activity in c-fins 
immunoprecipitates but indicates that they exist as a stable complex since the 
interaction between p85a and the tyrosine phosphorylated proteins survived anion 
exchange chromatography (Kanagasundaram et al., 1996).
M-CSF stimulation of a stable transfectant CHO cell line expressing human ofins 
induces sustained tyrosine phosphorylation of c-cbl and its subsequent association 
with Crk-n, and the p85 subunit of PI 3-kinase (Husson et al., 1997). In this study it
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appears that p85 exists as a constitutively associated complex with Grb2 (Husson et
al., 1997). Both p85 SH2 domains are required for this complex formation and it 
appears that in this cell model c-cbl immunoprecipitates contain the major fraction of 
PI 3-kinase activity in c-fins transformed CHO cells stimulated with M-CSF (Husson 
etal., 1997).
As described earlier PLCy2 can associate with Tyr^^ of c-fins. In addition, mutation 
of Tyr^^ abrogates the (>/W-mediated differentiation signal in FDC-Pl cells, which 
is mimicked by PLCy2 inhibitors (Bourette et al., 1997). However, it is also possible 
that PI 3-kinase activates PLCy2 via production of PIs4 ^ 3  from their shared 
substrate, Pl4^P2. It has been shown that Pl3,4,5P3 activates PLCy2 in vitro by 
interfering with its SH2 domains. Therefore it is more likely that Tyr^^ associates 
with PI 3-kinase in preference to PLCy2 because T y r^  contains a classical YXXM 
motif which has been shown to asso c i^  with the p85 SH2 domain with high affinity 
and it has been demonstrated that the PLCy binding site on the PDGFr binds the p85 
SH2 domain with 30-40 fold lower affinity than that for PLCy (Piccione et al., 1993). 
Therefore in vitro associations may not be truly representative of physiological 
interactions and it is more likely that the observed activation of PLCy2 occurs 
sequentially after PI 3-kinase activation in myeloid cells.
As for a role for PI 3-kinase in the proliferative response, early data suggested that 
mutation of Tyr^ ^^  in the murine receptor when expressed in Rat-2 fibroblasts, or 
expression in NIH 3T3 cells of a human c-fins lacking the entire KI domain resulted 
in a concomitant loss of PI 3-kinase activity and cell proliferation (Reedijk et al., 
1992; van der Geer and Hunter, 1993). However, there is a paucity of data on the 
involvement of PI 3-kinase in other M-CSF-stimulated cell responses, but it has been
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observed that in macrophages, PI 3-kinase inhibitors block endocytosis not by
interfering with the initiation of the process but rather by preventing its completion
(Araki et al,, 1996). What is apparent from this study is that wortmannin had a
greater affect on macropinocytosis than micropinocytosis. Since macropinocytosis is
an actin-mediated process, it is possible that the effects of wortmannin on
macropinocytosis in macrophages may not indicate a direct requirement of PI 3-
kinase activity in vesicle integrity or formation but rather in the correct reorganisation
of the actin cytoskeleton on which macropinocytosis relies (Araki et al., 1996).
1.7.7. Evidence against PI 3-ldnaae Involvement in c-fkts signalling 
It has been demonstrated in o-jms transfected NIH 3T3 cells that deletion of the KI 
domain only slightly impaired M-CSF induced cell proliferation, suggesting that 
tyrosine residues involved in PI 3-kinase and Grb2 binding alone are not essential for 
the mitogenic signal (Shurtleff et al., 1990). Furthermore, in FDC-Pl cells 
transfected with a Crjms mutant lacking the entire KI domain, M-CSF still stimulated 
cell proliferation at levels similar to wild type o-fins transfected cells 
(Kanagasundaram et al., 1996). These data seem to suggest that PI 3-kinase activity, 
after all, is not required during M-CSF stimulated cell proliferation.
Grb2#Sos activation may be required during growth signals of c-fins expressed in
I
fibroblasts, this seems to be only a minor or alternative pathway in myeloid cells 
(Lioubin et al., 1994). Recently in a review, J. Hamilton claimed to have unpublished 
data Wiich suggested that PI 3-kinase activity, when inhibited by wortmannin, was 
not required for M-CSF stimulated DNA synthesis in bone marrow derived 
macrophages (Hamilton, 1997). In studies of murine ofins expressed in the FDC-Pl 
cell line, mutations at Tyr^^, Tyr and Tyr^ ^^  did not prevent cell differentiation, but
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intriguingly seemed to augment this M-CSF stimulated process (Bourette et al.,
1995).
1.8.0. Further analysis of PI 3-kinase in c-fms signalling
It is ^)parent that further analysis of c-fins signalling pathways is required before a 
clear understanding of its biology is achieved. Various gaps exist in relation to the 
activation of PI 3-kinase downstream of c-fins and it is the intention of this thesis to 
try to address some of these issues. Firstly, the existing data is inconsistent and can 
be interpreted differently, depending on various parameters including the cells in 
which c-fins is expressed, the various approaches to mutational analysis employed and 
even the species of receptor investigated. It is impossible to address all these issues in 
one study, however the most important aspect to consider in resolution of these 
discrepancies must lie in the model cell system used for investigation.
To date, a large proportion of c-fins analysis has occurred in transfected fibroblasts or 
epithelial cells which, dthough a suitable model for other RTKs such as the PDGFr, 
may not mimic closely enough the relevant cellular background in which c-fins is 
normally found. A more suitable model for investigation of c-fins signalling would be 
a cell line that normally expresses c-fins, but would also provide new insights into 
macrophage function. One such cell line is BAC1.2F5, a macrophage-like adherent 
cell line that is dependent on M-CSF for survival and proliferation (Morgan et al., 
1987). This cell line has been characterised for its morphological and proliferative 
responses to M-CSF and has revealed some interesting results. In BAC1.2F5 cells M- 
CSF stimulation has been reported to stimulate the phosphorylation and activation of 
various cytosolic proteins including; Rho family GTPases which are involved in 
regulation of the actin cytoskeleton (Allen et al., 1997); the transcription factors
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STAT-1 and STAT-3; the formation of a complex contain She, c-cbl and Grb2
(Novak et al., 1995) and SHP-1 which contains tyrosine phosphatase activity (Yeung 
et al., 1992). In addition, through in vitro studies of BAC1.2F5 cells and analysis of 
other macrophage cell models it has been demonstrated that src-family kinases (Li et 
al., 1997) and PI 3-kinase (Kanagasundaram et al., 1996) also associate with activated 
c-fms. The nuqiping of available binding sites on c-fms has allowed various models of 
Crjms signalling to be proposed, however it is difficult to ratify all the published 
observations based on this limited data. Therefore it is necessary to further explore 
the function of PI 3-kinase activation during c-fins signalling. To do this a cellular 
and molecular approach has been employed throughout this study.
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2.0.0. Aims of thesis
The initial aim of this thesis was to characterise the involvement of PI 3-kinase in the 
various M-CSF stimulated responses observed in BAC1.2F5 macrophages. 
Expression of ofins in BAC1.2F5 cells was initially characterised by biochemical 
means, as well as expression of various cytosolic components that have been reported 
to be involved in ofins signalling in BAC1.2F5 and other cell systems. It was also 
important to identify the PI 3-kinase subunit isoforms present and activated in 
BAC1.2F5 cells since only classical p8Sa/pll0a have been reported in ofins 
signalling and discovery of other PI 3-kinase subunits would confer alternative 
mechanisms for phoq)holipid synthesis.
Requirements for PI 3-kinase activity in vesicle trafficking and the morphological 
changes observed in BACI.2F5 cells was characterised using PI 3-kinase-specific 
inhibitors, wortmannin and LY294002. At concentrations at or near their respective 
ICso both inhibitors specifically inhibit D3 phoq)hoinositide synthesis, but not the 
activity of Pl-specific 3-kinase. Trafficking of internalised receptor was investigated 
by immunofluorescent microscopy and PI 3-kinase inhibitors were employed to 
identify A ether PI 3-kinase activity is required for receptor trafficking after 
internalisation of ofins. In addition it has previously been reported that Rac is a 
downstream mediator of PI 3-kinase activity (Bokoch et al., 1996) and therefore may 
be involved in the regulation of the actin cytoskeleton. Thus the requirement of PI 3- 
kinase activity in the actin-mediated morphological changes observed by Allen et al, 
1997 was also investigated using the PI 3-kinase inhibitor, LY294002.
PI 3-kinase inhibitors were also used to investigate PI 3-kinase function in cell 
proliferation and survival in an attempt to reconcile the previously published
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conflicting data. The role of PI 3-kinase in M-CSF stimulation of DNA synthesis and
cell proliferation was investigated using non-radioactive BrdU incorporation assays.
The M-CSF stimulated survival of BAC1.2F5 cells was also investigated using PI 3-
kinase inhibitors and this was characterised by an assay for apoptosis, since PI 3-
kinase has been shown to activate PKB, v/bich contributes to protection against
£q)optosis in various cell models.
The specificity of PI 3-kinase inhibitors when used at their ICso concentrations makes 
them extremely useful tools for characterising PI 3-kinase activation downstream of 
ofms. However it is not possible to investigate how PI 3-kiuase interacts with c-fms 
whether direct or indirect. It has been shown that PI 3-kinase associates directly with 
phosphorylated c-fms via Tyr^^ and this interaction may also involve an additional 
tyrosine phosphorylated residue, at Tyr^^. In addition PI 3-kinase has also been 
found in a complex with Grb2«Sos (Saleem et a l, 1995) and the potential to form this 
complex exists in BAC1.2F5 cells providing an indirect mechanism for PI 3-kinase 
activation.
Analysis of PI 3-kinase association with tyrosine phosphorylated c-fms, was 
investigated with a series of expression constructs based on human c-fms that harbour 
amino acid substitutions at Tyr^^ and Tyr °^  ^ mutated either alone or in tandem. 
Construction of these expression constructs also involved introducing C-terminus 
epitope tags to facilitate identification and purification of receptor complexes. Over­
expression of these receptor constructs in BAC1.2F5 cells was intended to compete 
for M-CSF with endogenous receptor and therefore inhibit PI 3-kinase activation in a 
dominant/negative manner.
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Reagents and Methods    Chapter 3
3.1.0. Reagents and equipment
3.1.1. Cell Culture
RPMI medium 1640 (Gibco-BRL, Paisley, Scotland)
DMEM medium (Gibco-BRL)
Foetal Bovine Serum, heat inactivated, (Gibco-BRL)
Trypsin-EDTA (Imperial Laboratories, Hampshire, England)
Accutase (Innovative Cell Technologies, California, USA)
L-Glutamine 200mM (Gibco-BRL)
HEPES buffer IM (Gibco-BRL)
Penicillin/Streptomycin solution (Gibco-BRL)
3.1.2. Cgll L ines
A431 Human epithelial carcinoma (ECACC, #85090402) |
NIH 3T3 Murine fibroblast (ECACC, #93061524)
U937 Human histiocytic lymphoma CRL-1593 (ATCC)
HEK 293 Human transformed primary embryonic kidney CRL-1573 (ATCC)
BACI Murine macrophage (G.E. Jones, Randall Inst. London, England)
BAC1.2F5 Murine macrophage, subclone of BACI cell line (E.R. Stanley, AECOM, 
New York, USA)
3 .U . Microscopy
Microscope slides 1.0-1.2mm (BDH Laboratory Supplies, Leics., England)
Circular 13mm glass coverslips No. 1 (BDH)
FluoroGuard™ anti-fade reagent, (Bio-Rad Laboratories, California, USA)
Axiovert 135 inverted microscope, x40, x63 and X-100 (Zeiss,
Axiovert 35 inverted microscope, x32 (Zeiss)
Axioplan inverted microscope, xlO, x20, x40, x63 and X-100 (Zeiss)
3.1.4. Prîmarv Antibodies
e-fins Rat mAb clone 3-4A4 human reactive, (Santa Cruz Biotechnology, CA, USA) 
c-fms Rabbit pAb clone C-20 human and murine reactive, (Santa Cniz) 
c-fms Rabbit pAb human reactive, (Upstate Biotechnology, NY, USA)
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c-fms Rat mAb clone AFS-10-6-1 human reactive, (Pharmingen, CA, USA) 
c-fins Rat mAh clone 2-4A5 human reactive, (Santa Cruz) 
p llO a Rabbit pAb human reactive, (Santa Cruz)
p llO a Rabbit pAb human and murine reactive, (Transduction Labs., KY, USA)
pllO p Rabbit pAb human and murine reactive, (Santa Cruz)
pllO y Rabbit pAb human and murine reactive, (Santa Cruz)
p85a Murine mAb human and murine reactive, (Transduction Laboratories)
p85a-Protem A/Agarose Rabbit pAb human and murine reactive, (Upstate Biotech.)
p8 Sp Murine mAb human and murine reactive, (Serotec Ltd., Oxford, England)
p85y Murine mAb clone V-2 human and murine reactive, (Serotec Ltd)
SHIP Goat pAb clone M-14 murine reactive, (Santa Cruz)
She Rabbit pAb human and murine reactive, (Transduction Laboratories)
Grb2 Murine mAb clone 81 human and murine reactive, (Transduction 
Laboratories)
Sosl Murine mAb clone 25 human and murine reactive, (Transduction Laboratories) 
Phosphotyrosine Murine mAb human and murine reactive, (Upstate Biotech.) 
c-src Rabbit pAb human and murine reactive, (Santa Cruz) 
c-myc Murine mAb clone 9E10 human reactive, (Calbiochem, Notts, England) 
c-cbl Rabbit pAb human and murine reactive, (Santa Cruz)
3.1.5. Secondary Antibodies
HRP-conjugated Goat anti-mouse IgG pAb, (Bio-Rad)
HRP-conjugated Goat anti-rabbit IgG pAb, (Bio-Rad)
Alexa Dye 488-conjugated Goat anti-mouse IgG pAb, (Molecular Probes, OR, USA) 
Alexa Dye 488-conjugated Goat anti-rabbit IgG pAb, (Molecular Probes)
Alexa Dye 488-conjugated Goat anti-rat IgG pAb, (Molecular Probes)
Alexa Dye 594-conjugated Goat anti-mouse IgG pAb, (Molecular Probes)
Alexa Dye 594-conjugated Goat anti-rabbit IgG pAb, (Molecular Probes)
Alexa Dye 594-conjugated Goat anti-rat IgG pAb, (Molecular Probes) 
FITC-conjugated Sheep anti-mouse IgG pAb, (Amersham Pharmacia Biotech.,
Bucks, England)
FITC=conjugated Donkey anti-rabbit IgG pAb, (Amersham)
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Texas Red-conjugated Sheep anti-mouse IgG pAb, (Amersham)
Texas Red-conjugated Donkey anti-rabbit IgG pAb, (Amersham)
FITC-conjugated Goat anti-rat IgG pAb, (Caltag Laboratories, CA, USA)
3.1.6. General Reagents
0.5M EDTA (pH8.0) (Sigma Chemical Co., Dorset, England)
0.5M Tris.HCl (pH6 .8 ) (Sigma) 
l.OM Tris.HCl (pH6 .8 ) (Sigma)
1.5M Tris.HCl (pH8 .8 ) (Sigma) 
lOmM Tris.HCL (pH7.2) (Sigma)
lOOmM I.P.T.G. (Isopropyl-D-thiogalactopyranoside, Sigma) in deionised (<Li.) water 
10% Ammonium persulphate solution (BDH) in d.i. water 
10% (w/v) SDS (Sigma) in d.i. water
IX phosphate buffered saline (PBS^) (Oxoid, Hamps., England) I tablet/lOOml d.i. 
water
2.5mg ml^ Ethidium Bromide (Sigma)
2.5MNaCl(BDH)
3M Sodium acetate (pH4.6) (Sigma)
4M Ammonia solution (Sigma)
40% Formaldehyde solution (BDH)
40mg ml * X-gal (5-Br-4-Cl-3-indolyl-D-galactoside) (Sigma) in dimethylformamide 
5MNaCl(BDH)
50mg ml * carbenicillin (Sigma) made up in d.i. water 
50mM Glycine buffer (pH2.0) (BDH)
50mM HEPES (pH7.5) (Gibco-BRL)
70% (v/v) and 95% (v/v) ethanol (Fidier Sci., Leics., England) made up in d.i. water 
Acetic acid (BDH)
Agar N°. 1 (Lab M, Lancs., England)
Agarose, electrophoresis grade (Gibco-BRL)
Bacto-tryptone (Difco laboratory supplies, MI, USA)
Bacto-yeast extract (Difco)
P-Meroq)toethanol (Sigma)
Bis acrylamide 30% (w/v) (37.5:1) (Bio-Rad)
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Bi-tek agar (Difco)
Boric acid (BDH)
Bovine serum albumin (BSA) powder (Sigma)
Bromophenol Blue (Sigma)
Butanol (Fisher Scientific)
Chloroform (BDH)
Citifiuor (UKC, Canterbury, England)
Coomassie blue (BDH)
(Li. water
DEPC treated d i. water
Diethyl pyrocarbonate (DEPC) (BDH)
Dimethylformamide (Sigma)
Ethanol (Fisons Scientific Equipment, Leics., England)
Fibronectin (Sigma)
Glycerol (BDH)
Glycine (BDH)
Industrial methylated spirits (IMS) (Fisher Scientific)
Marvel (Premier beverages. Staffs, England)
Methanol (Fisons) 
mineral oil (Sigma)
Nail polish (Boots the Chemists, Notts, England)
Nonidet NP-40 (Fisons)
Phori)ol 12-Myristate 13-Acetate (PMA) (Sigma)
Polyethylene glycol (PEG) (Sigma)
Potassium oxalate (Sigma)
Propan-2-ol (Fisher Scientific)
S.O.C. medium (Gibco-BRL)
Sodium dodecyl sulphate (SDS) (Sigma)
Sodium orthovanadate (Sigma)
TEMED (Sigma)
Tris Base (Sigma)
Triton X I00 (Sigma)
Tween 20 (polyethylene sorbitan monolaurate) (Sigma)
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3.1.7. General Solutions
Coomassie Stain
- Coomassie blue 
-IMS
- Acetic acid
Made to 1 litre with d.i. water
0 .1% (w/v) 
50.0% (v/v) 
1 0 .0 % (v/v)
Slow de-stain solution
- Methanol
- Acetic acid
Made up to 1 litre in IMS
2 0 .0 % (v/v) 
7.1% (v/v)
SDS-PAGE Sample buffer (x2):
- Glycerol 11 .2% (w/v)
- IM Tris (pH6 .8 ) 8.9% (v/v)
-SDS 1.1% (w/v)
- P-Mercaptoethanol 5.0% (v/v)
- Bromophenol Blue (0.2% stock solution) 1.0% (w/v) 
Made up to 100ml with d.i. water
SDS-PAGE running buffer (xlO):
- Tris base
- Glycine 
-SDS
Made up to 1 litre with d.i. water.
0.25M 
1.92M 
1 .0 % (w/v)
Stored at room temperature and diluted 1/10 before use.
Semi-dry transfer buffer (pH9.2):
- Tris base
- Glycine
- Methanol
Made up to 1 litre with d.i. water
48mM 
39mM 
2 0 % (v/v)
PI 3-kinase buffer (2X) 
- Tris Base 
-NaCl 
-EGTA
40mM
200mM
ImM
Lysis Buffer
- Nonidet NP-40
- Sodium chloride 
-Tris.HCLpH7.2
- EDTA
- Sodium a-vanadate*
- Protease inhibitor cocktail (Sigma)
1% (v/v)
O.IM
lOmM
ImM
lOOpM
lOOpl per 1x10  ^cells
♦Optional.
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XlO TBE buffer (pH8.3)
- Tris base
- Boric acid
- 0.5M EDTA (pH8.0)
0.89M 
0.89M 
4% (v/v)
XlO DNA electrophoresis loading buffer
- Ficoll 400 
-EDTApH8.0 
-SDS
- Bromphenol blue
- Xylene Cyanol
2 0 % (v/v)
O.IM 
1 .0 % (w/v) 
0.25% (w/v) 
0.25% (w/v)
L.B. broth
- Bacto-tryptone
- Bacto-yeast extract
- Sodium chloride
Made up to 1 htre with d.i. water
1 .0 % (w/v) 
0.5% (w/v) 
0.5% (w/v)
L.B. Agar
- Agar N°. 1 1.5% (w/v) in L.B. broth
3.1.8. General Equipment
J2-MC centrifuge (Beckman Instruments Inc., CA, USA)
GS-6 R bench-top centrifuge (Beckman)
RC-5C centrifuge (Sorvall, Herts., England)
Mini-PROTEAN II electrophoresis cell (BioRad)
Model 200 power supply (BioRad)
Eppendorf 5402 refrigerated microcentrifuge (Fisher Scientific)
Eppendorf 5417C microcentrifuge (Eppendorf)
Dri-block DB-1 (Techne, Cambs., England)
WhirliMixer (Nickel Electrical Ltd., Avon, England)
PS500XT power supply (Amersham Pharmacia Biotech Ltd., Bucks., England) 
FACScan (Beckton Dickinson, Oxford, England)
Sonifier 250 (Branson Ultrasonics Corporation, CT, USA)
DNA speedvac DNAIOO (Savant Instruments Inc., NY, USA)
Packard Instantlmager™ (Canberra Packard Ltd. Berks, England)
TransBlot SD semi-dry transfer cell (BioRad)
Belly dancer (Stovall Life Science, NC, USA)
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Rotator (Stuart Scientific, Surrey, England)
Curix 60 automatic developer (AGFA-Gevaert Ltd., Middx., England)
Compact-4 automatic developer (X-Ogrgq)h Ltd., Gloucs., England)
Axioplan microscope (Zeiss)
Axiovert 35 microscope (Zeiss)
Axiovert 135 microscope (Zeiss)
OpenLab 3.0 image acquisition system (Improvision, Coventry, England)
FX-35DX 35mm SLR camera (Nikon UK Ltd., Surrey, England)
UFX-DC camera controller (Nikon)
Horizon 11.14 mini-gel DNA electrophoresis system (Gibco-BRL)
Horizon 58 midi-gel DNA electrophoresis system (Gibco-BRL)
Omnigene DNA thermocycler (Hybaid, )
PH-3 DNA thermocycler (Techne)
37°C incubator, humidified and flushed with 5% CO; (Jencons Scientific Inc., Beds., 
England)
3.1.9. General consumables
Tissue culture flasks, 25mm\ 75mm^ and I75mm\ (Nalge, Hereford, England) 
Surface™ tissue culture 6,24 and 96-well plates (Nalge)
30ml Universal centrifuge tubes (Bibby Sterilin Ltd., Staffs., England)
50ml polypropylene centrifuge tubes (Falcon)
Hybond™ ECL nitrocellulose membrane (Amersham)
Hyperfilm™ ECL autoradiographic film (Amersham)
Hyperfilm™ cassette (Amersham)
lOcm  ^Square petri dishes (Bibby Sterilin Ltd.)
Thermowell thin-wall 96-well plate model H (Costar)
30mm, 90mm and 140mm Petri dishes (Bibby Sterilin Ltd.)
14ml centrifuge tubes (Falcon)
Microbiological plate ^reader (L.I.P.) 
hmoculation loops (Starstedt)
60Â Silica gel thin layer chromatography (TLC) plates (Whatman)
1ml, 2ml, 10ml, 20ml sterile syringes (Beckton Dickinson)
Microlance 25g needles (Beckton Dickinson)
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3.2.0. Cell biology
3.2.1. Cell Culture
All reagents were supplied by Gibco-BRL unless otherwise stated. The suspension 
cell lines U937 and J774 were maintained in growth medium consisting of RPMI 
supplemented with 10% (v/v) foetal calf serum, 2mM L-glutamine, 50pg ml * 
streptomycin and 50 units ml * penicillin. The adherent Bacl, Bacl.2F5, HEK 293 
and Cos-7 cells lines were maintained in growth medium consisting of DMEM 
supplemented with 10% (v/v) foetal calf serum, 2mM L-glutamine, 50pG ml * 
streptomycin and 50 units ml * penicillin. BacI.2F5 cells were supplemented with 
lOng ml * recombinant murine M-CSF (R&D Systems). Cells were grown at 37°C, 
5% CO; in T75 tissue culture flasks (Nuncleon). Cells were subcultured as required 
by dissociation with either 0.25% Trypsin/ 0.02% EDTA in phosphate buffered saline 
(Imperial Labs.) or Accutase (Innovative Tech. Inc.), and resuspended in growth 
medium at approximately 2 x 10^  cells ml'*. (Quiescent Bacl.2F5 macrophages were 
obtained by removing M-CSF from the culture medium. Quiescent Bacl.2F5 
macrophages were re-stimulated by addition of 50 ng ml * M-CSF after 24 hours in 
the absence of M-CSF.
3.2.2. Time lapse photomicroscoDv
Bacl.2F5 cells were seeded at 1x10  ^ cells per well of a 6 -well tissue culture plate 
containing four 13mm round cover slips per well. At ^proximately 80% confluency 
cells were quiesced for at least 24 hours in normal medium in the absence of M-CSF 
growth factor. Single coverslips were removed to a 35mm petri dish and washed
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once with PBSa- PBS^ was aspirated immediately and replaced with normal medium
containing lOmM HEPES. The petri dish was placed onto a Zeiss Axiovert 130
inverted microscope. Normal culture temperature of 37®C was maintained by
localised heating of the air around the petri dish with a small electric room heater.
Growth factor and inhibitors were added drop-wise from a Pasteur pipette without
disturbing the coverslip. The experiments were documented with a Nikon FX-35DX
35mm camera controlled by a UFX-DC camera controller.
3.3.0 Protein biochemisty
3.3.1. Western blot analvsis 
Protein isobition:
Cultured, adherent cell lines were detached from tissue culture vessels with either 
Trypsin/EDTA or Accutase. The protease activity was neutralised by addition of 
fresh culture medium containing 10% FCS and cell pellets were obtained by 
centrifugation at 1,500 rpni for 8  minutes. Pellets were washed once with PBS^ and 
total cellular protein was solubilised by addition of 2x SDS sample buffer. Cells 
routinely cultured in suspension were pelleted by centrifugation at l,500rpm for 8  
minutes. Pellets were washed once with PBS^ and total cellular protein was 
solubilised by addition of 2x SDS sample buffer. Approximately 1x10  ^ cells were 
solubilised in lOOpl of 2x SDS sample buffer. All protein samples were drawn 5-6 
times through a 23-gauge needle to disperse protein aggregates and to shear DNA,
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heated to 100°C for 3 minutes, centrifuged at 14,000rpm for 5 minutes and placed on
ice prior to loading.
Electrophoretic separation of proteins:
Protein separation was carried out by one-dimensional discontinuous (Laemmli) gel 
electro-phoresis under denaturing conditions (Laemmli, 1970). All protein gels were 
carried out on a Mini-PROTEAN 11 electrophoresis cell (Biorad). Protein gels were 
cast as follows;
1. Glass plates were washed thoroughly with d.i. water and air-dried. Plates were 
wiped with a tissue soaked in IMS and left to air dry. Assembly of glass plate 
sandwich was carried out following Biorad protocol and the sandwich was locked into 
the casting stand.
2. The resolving gel was prepared for each required gel density as in Table X 
Approximately 4ml of resolving gel solution was added to each glass plate sandwich 
and 500pl of d.i. water-saturated butanol was overlayed to prevent evaporation from 
the resolving gel during polymerisation. Resolving gels were allowed to polymerise 
for 30 minutes.
3. Butanol was removed by washing with copious amounts of d.i. water. Excess 
water was removed by careful drying with a tissue. The stacking gel was prepared as 
in Table 3.3.1..
4. A 1mm 15 to o th  T e flo n  comb w as insaled in to  th e  g lass p la te  s a n d m c h  before 
addition of the stacking gel. Stacking gel was carefully added to prevent introduction
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of air bubbles until the gel completely filled the spaces and the height of the gel
solution in the sandwich reached the top of the small glass plate. Stacking gels were 
allowed to polymerise for 30 minutes.
5. The glass plate gel sandwich was carefully removed fi-om the casting rack and 
attached to the inner-cooling core of the gel running apparatus. This assembly was 
then placed in the gel tank.
6 . The gel tank was half filled with Ix SDS electrophoresis running buffer and any 
air bubbles on the bottom edge of the acrylamide gel were dispersed by agitation. 
The inner chamber was then filled with Ix SDS electrophoresis running buffer until 
the inner glass plate and comb were submerged. The Teflon casting comb was then 
carefully removed.
7. The required samples and markers were loaded onto the gel and empty wells were 
filled with lOpl of Ix SDS sample buffer. The upper and lower chambers were filled 
with Ix SDS electrophoresis buffer and the lid was assembled. The power supply 
was connected and a constant voltage of 150 volts was maintained until the protein 
samples had migrated the required distance.
8 . The gel ^>paratus was carefully disassembled and the gels were removed from the 
glass plates, discarding the stacking gel, and placed in Ix SDS electrophoresis buffer 
prior to immunoblotting to membrane.
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Immunoblotting:
Immunoblotting was carried out by electrophoretic transfer from the gel to a Hybond 
ECL nitrocellulose membrane, (Amersham) for subsequent analysis. Blotting was 
carried out in a semi-dry transfer ^)paratus as follows;
1. For transfer of one gel, six sheets of Whatmann filter paper and one sheet of 
Hybond ECL cut just larger than the gel being transferred were pre-soaked in semi­
dry transfer buffer for 10 minutes. Each gel was pre-soaked in semi-dry transfer 
buffer for 1 0  minutes.
2. Each stack of filter p^)er, membrane and gel were assembled on the bottom 
electrode of the transfer tank as follows insuring that no air bubbles were introduced;
Filter Paper
Gel
Membrane
Filter Paper
3. The transfer tank was assembled and the electrodes were attached to a power 
supply. A constant voltage of 18 volts for two gels was ^)plied for 45 minutes.
5. The transfer tank was disassembled and the nitrocellulose membrane was removed 
and placed in PBSy /^0.1% Tween prior to probing. To demonstrate efficient transfer 
of proteins, the acrylamide gel was placed in Coomassie stain for 2-3 hours to stain
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protein bands. The acrylamide gels were washed overnight in “slow” de-stain
solution to visualise protein bands > ^ch  had not been completely transferred.
Immunoprobing:
Proteins separated by SDS-PAGE and immobilised on nitrocellulose membrane were 
probed with relevant primary antibodies. Species specific secondary antibodies with 
an associated Horseradish peroxidase (HKP) activity were used to detect bound 
primary antibody. This interaction was visualised by enhanced chemiluminescence, 
ECL (Amersham). Immunoprobing was carried out as follows;
1. Membrane was washed for 5 minutes twice in waish buffer, PBSa/0.1% Tween, 
with agitation on an orbital shaker (Stovall) ^ ^ c h  was used for all further washes.
2. Wash buffer was decanted and replaced with blocking buffer, 5% (w/v) Marvel 
(Premier Beverages) in wash buffer, and membranes were incubated for 1 hour at 
room temperature with constant agitation or overnight at 4°C.
3. Blocking buffer was removed and membranes were incubated with relevant 
primary antibody, diluted to the required working concentration in incubation buffer, 
1% (w/v) Marvel in wash buffer, for ^1 hour at room temperature.
4. Primary antibody solution was decanted and membranes were washed x3 with 5 
minute incubations of wash buffer. Membranes were then incubated with suitable 
secondary antibody-HRP (Biorad) con jug^ specifically raised against the isotype of 
the primary antibody. Depending on the species of primary antibody, secondary
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antibodies were diluted 1 in 3,000-5,000 with incubation buffer and membranes were 
incubated for > 1  hour at room temperature.
5. Following incubation with secondary antibody, membranes were washed x5 with 5 
minute incubations of wash buffer. Antibody binding was visualised by ECL 
reagents. Following the final membrane wash, a 1:1 mix of ECL reagents 1 and 2 
were overlayed on the membranes for 1 minute.
6 . Membranes were blotted briefly to remove excess ECL reagent and exposed to 
autoradiographic Hyperfilm ECL (Amersham) for variable exposure times. 
Hyperfilm was developed in an automatic developer system (AGFA Curix 60 
developer or an X-ograph Imaging Systems Compact x4 developer).
Gel Composition -> 
Gel Components 'I
STACK
(4%)
RESOLVING
(7.5%)
RESOLVING
( 1 0 %)
Bis acrylamide 30% w/v 
(37.5:1)
1.3ml 5.0ml 6.67ml
d.i. water 6 .1ml 9.7ml 8 .0 ml
Tris.HCL 1.5MpH8.8 5.0ml 5.0ml
Tris.HCL 0.5MpH6.8 2.5ml
10% SDS lOOpl 2 0 0 pl 2 0 0 pl
10% APS 50pl lOOpl lOOpl
TEMED lOpl 2 0 pl 2 0 pl
Table 33.1. Composition of SDS-PAGE stack and resolving gel
33.2. Immunoprécipitation of proteins from cultured cells
Immunoprécipitation was performed to purify proteins of interest and any associated 
proteins. Adherent cells were cultured as required prior to immunoprécipitation with 
either a conjugated or unconjugated protein specific antibody. Immunoprécipitation 
was performed as follows;
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1. Adherent cells were dissociated from the tissue culture vessel with Accutase.
Protease activity was inhibited by addition of growth medium containing 10% PCS 
and cell suspension was transferred to a 25ml universal tube and centrifuged at 
l,500rpm for 8  minutes.
2. The siq>ematant was decanted and the cell pellet was resuspended in either 0.5 or 
1ml of lysis buffer (0.5ml per 1x10  ^cells or T75 flask, 1ml per 1x10  ^cells or T175 
flask) and transferred to a 1.5ml eppendorf tube. The lysis solution was gently mixed 
on a rotator at 4^C for 2 0  minutes to lyse die cells.
3. The lysate was centrifuged at 14,000rpm, 4° C for 20 minutes, supernatant was 
immediately transferred to fresh centrifuge tube, and the pellet was discarded. Cell 
lysate was pre-cleared with 50pl of a 50% slurry of agarose conjugated protein-A and 
incubated on a rotator at 4°C for 45 minutes.
4. Agarose conjugated protein-A was removed by centrifrigation at 14,000ipm, 4°C 
for 5 minutes, supernatant was decanted to fresh centrifuge tubes and the pellet was 
discarded.
5. A relevant volume (l-20pl ml'*) of immunoprecipitating antibody or 20-40pl ml * 
of a 50% slurry of immunoprecipitating antibody directly conjugated to protein-A- 
agarose was added to cell lysate and incubated on a rotator at 4°C for > 2 hours.
6 . Unconjugated immunoprecipitating antibody was c^tured by addition of 40|il of a 
50% slurry of protein A agarose and incubation on a rotator at 4°C for 1 hour.
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7. Immunocomplex bound to protein-A agarose was then collected by pulse
centrifrigation at 14,000rpm for 5 seconds. The supernatant was then discarded and 
die immunocomplex was washed three times with SOOpl of ice-cold lysis buffer.
8 . The pelleted beads were resuspended in 60pl of 2x SDS sample buffer and heated 
to lOO^C for 5 minutes to dissociate immunocomplexes frrom the beads. Samples 
were centrifuged at 14,000rpm for 5 minutes to pellet beads.
3 3 3 . Time constrained immunoprécipitation of proteins from cultured cells
The short length of time for some growth factor incubations required a rapid lysis 
step and therefore a modified protocol was used. R ^ id  immunoprécipitation was 
carried out as follows;
Adherent cells were washed once with ice-cold PBS^ and excess PBS^ was removed 
by aspiration. Ice-cold lysis buffer was added to the culture vessel, (1ml per 1x10  ^
cells or T175 flask, 0.5ml per 1x10® cells or T75 flask). Adherent cells were scraped 
fi*om the dish with a plastic cell scraper and lysis solution was then transferred to a 
centrifuge tube.
Immunoprécipitation was then carried out as for standard immunoprécipitation 
protocol.
33.4. Immunofluorescent gtaining of cultured cells
Adherent cell lines were cultured on 13mm round coverslips placed in 6  well plates at 
a seeding density of 2x10  ^ per well. To improve adherence and cell morphology.
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HEK 293 cells were cultured on 13mm round coverslips coated with fibronectin
(Sigma). Cells grown to the required density were treated as required before being 
fixed, permeabilised and stained as follows;
1. Culture medium was aspirated from the 6 -well plate and coverslips were washed 
once with PBS a- The wash solution was quickly aspirated and cells were fixed in 
3.7% formaldehyde/PBS^ at room temperature for 2 0  minutes.
2. The fixing solution was then aspirated off and the coverslips were washed twice 
with PBS^. Cells were then permeabilised with 0 .2 %Triton X-IOO/PBS^ at room 
temperature for IS minutes.
3. Coverslips were then washed three times with PBS^ pribf to incubation in 
blocking buffer 2 % BSA/PBS^ for 2 0  minutes. lOOpl of protein specific primary 
antibody diluted in blocking buffer, was overlayed onto each 13mm round coverslip 
and incubated at room temperature for 1 hour.
4. Coverslips were drained of antibody solution by dabbing onto tissue and then 
washed three times in PBS^. lOOpl of secondary antibody conjugated to a relevant 
fluorescent moiety diluted in blocking buffer was overlayed onto each 13mm round 
coverslip and incubated in the dark at room temperature for 1 hour.
5. Coverslips were drained of antibody solution by dabbing the coverslip edge onto 
tissue and then washed four times in PBS^ under low light conditions or darkness. 
Coverslips were mounted onto borosilicate glass slides with Fluor-guard and sealed 
with a dark non-fluorescent nail polish.
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6 . Specimens were examined on a Zeiss Axioplan upright microscope equipped for
fluorescence using FITC and rhodamine filter sets. Cells were documented with a
Nikon FX-35DX 35mm camera controlled by a UFX-DC camera controller.
Alternatively, specimens were examined on a Zeiss Axiovert 135 inverted microscope
using FITC and rhodamine filter sets and digitised using a Hammamatsu C1492 B/W
CCD camera and image analysis software.
33.5. Staining of F-actin in cultured cells
Adherent cell lines were cultured as before on 13mm round coverslips placed in 6  
well plates (Nuncleon) at a seeding density of 2x10® per well. Cells grown to the 
required density were treated as required before being fixed, permeabilised and 
stained as follows;
1. Culture medium was aspirated fix)m the 6 -well plate and coverslips were washed 
once with PBS^. The wash solution was quickly aspirated and cells were fixed in 
3.7% formaldehyde/PBSA at room temperature for 2 0  minutes.
2. The fixing solution was then aspirated off and the coverslips were washed twice 
with PBSa- Cells were then permeabilised with 0 .2 %Triton X-IOO/PBS^ at room 
temperature for 15 minutes.
3. Coverslips were then washed three times with PBS^. Phalloidin (Sigma) 
conjugated to either fluoroscein isothiocyanate (FITC) or tetramethyl-rhodamine 
isothiocyanate (TRTTC) at a dilution of 1/500 in PBS^ was overlayed onto each 
13mm round coverslip and incubated in the dark at room temperature for 45 minutes.
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4. Coverslips were drained of phalloidin-conjugate by dabbing the edge of the
coverslip onto tissue and then washed four times in PBS^ under low light conditions 
or darkness.
5. Coverslips were mounted onto borosilicate glass slides using either citifluor or 
Fluor-guard and sealed with a dark non-fluorescent nail poUsh. Specimens were 
examined on a Zeiss Axioplan or Axiovert microscope equipped for fluorescence.
33.6. Fluorescence activated cell sorting (FACS) analysis of cultured cells
1. Adherent cells were dissociated from culture vessels and washed with 10ml of 
PBSa. Cell suspensions were centrifuged on a Beckman GS- 6  bench-top centrifuge at 
l,400rpm for 6  minutes.
2. The supernatant was discarded and cells were resuspended at a cell density of 
2xl0®/100pl PBSa. SOOpl of cell suspension was aliquoted to 5ml FACS tubes. Cells 
were incubated with relevant protein specific antibody, on ice for 1 hour. Cells were 
washed three times with PBS^ and re-suspended in BOOpl PBS^.
3. Cells were incubated with a 1/50-100 dilution of fluorophore-labelled secondary- 
antibody specific for the primary antibody isotype at 4°C for 1 hour. Cells were 
washed three times with PBS^ and resuspended in 250pl PBS^ ready for analysis by 
FACS.
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33.7. Immunofluorescent assay for the incorporation of BrdU into DNA
Measurement of cell proliferation was performed by a non-radioactive, fluorescence
based method first proposed by (Gratzner, 1982). 5*-bromo-2*-deoxy-uridine can be
incorporated into DNA in place of thymidine during de novo DNA synthesis.
Incorporated BrdU can then be detected with a monoclonal antibody developed
against BrdU and a fluorochrome-conjugated second antibody (BrdU Detection Kit I,
Boehringer Mannheim).
1. Adherent cells were cultured on 13mm round coverslips in 6 -well tissue culture 
dishes until 50% confluent. Cells were then treated as required.
2. Cell culture medium was removed by aq)iration and replaced with 2 ml of culture 
medium containing 0.1% (v/v) BrdU labelling reagent (I). Cells were incubated at 
37°C, 5% CO2 for 1 hour.
3. Culture medium was removed by aspiration and cells were washed three times in 
washing buffer (V). Cells were fixed in ice cold 70% (v/v) ethanol/50mM Glycine 
buffer (pH2.0) at -20°C for 30 minutes.
4. Cells were washed three times in washing buffer (V) and were then covered with 
mti-BrdU working solution (H) and incubated at 37°C for 30 minutes.
5. Cells were washed three times in washing buffer (V) and were then covered with 
anti-mousc-Ig-fluorescein working solution (IV) and incubated at 37°C for 30 
minutes.
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6 . Cells were washed three times in washing buffer (V). Cover-slips were mounted
onto glass slides with Fluoro-guard and sealed with nail polish. Cells were examined
using a Zeiss Axioplan microscope using the FITC filter set and documented with a
Nikon FX-35DX 35mm camera controlled by a UFX-DC camera controller.
33.8. immunofluorescent analysis of apoptotic cells
One of the early events in most cell types during ^xxptosis is the translocation of 
phosphatidylserine fi*om the inner surface of the plasma membrane to the cell surface 
(Martin et al., 1995). Phosphatidylserine can then be easily detected in living cells 
with a FITC conjugate of annexin V. The ApoAlert ™ Annexin V Apoptosis Kit 
fi*om Clontech was used for apoptosis detection.
1. Cells were cultured on either 13mm round coverslips or in 8 -well chaniber slides 
(Nuncleon) and treated as desired.
2. Cells were washed once with PBS^ and coverslips were overlayed with lOOpl of 
Ix binding buffer containing 2.5% (v/v) enhanced annexin V-FITC (0.5|ig ml * final) 
and 2.5% (v/v) propidium iodide.
3. Cells were incubated in the dark at room temperature for 15 minutes. Cells were 
washed twice with PBS^ and fixed with 2 % (v/v) formaldehyde/PBSA for 15 minutes.
4. Cells were washed twice with PBS^ and mounted in Fluoro-guard. Fluorescence 
was observed with a Zeiss Axioplan microscope using FITC and rhodamine filter 
sets. Fluorescent images were documented with a Nikon FX-35DX 35mm camera 
controlled by a UFX-DC camera controller.
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33.9. Measurement of PI 3 Idnase activity
The activation of PI 3-kinase enzymatic activity is required for various signalling 
pathways in macrophages. PI 3-kinase activity can be isolated from cells by 
immunoprécipitation of the p85/pllO complex with antibodies raised against p85a. 
PI 3-kinase activity was measured in vitro by incorporation of ®^P-labelled yATP 
(Sigma) onto the PI 3-kinase substrates PI and PI4P.
1. Bacl.2F5 cells were cultured to 80% confluency in T75 tissue culture flasks and 
quiesced for 24 hours by depriving the cells of M-CSF. Cells were incubated as 
required, then culture medium was quickly removed by aspiration and the culture 
flasks were placed on ice.
2. 750pl of Lysis buffer was added to each T75 flask, cells were detached by 
scraping, and the lysate was transferred to a 1.5ml microcentrifuge tube. Samples 
were incubated on a rotator at 4°C for 30 minutes.
3. Lysate was centrifuged at 14,000rpm, 4°C for 30 minutes to sediment insoluble 
material and the supernatant was decanted to a fresh microcentrifuge tube. Samples 
were incubated with 50pl of a 50% slurry of anti-p85a-protein-A-agarose conjugate 
(UBI) at 4°C on a rotator for 1 hour.
4. The immunoprecipitate was collected by pulse centrifugation at 14,000rpm and 
supernatant was decanted. The immunoprecipitate was washed three times with lysis 
buffer, once with 50mM HEPES (pH7.5) and once with (XI) PI 3-kinase assay 
buffer.
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7. Immunoprecipitate was re-suspended in 25pl of (X2) PI 3-kinase buffer and lOpl
of a PI/PI4P mixed lipid micelle suspension (Img ml’*) were added. 25pi of assay 
mix were added and the samples were incubated at 37°C for 10 minutes.
8 . The reaction was quenched by adding lOOpl of 6 M HCl. 200pl of a 
chlorofbrm:methanol ( 1 :1 ) solution was added, vortexed for 2 0  seconds and 
centrifuged at 14,000rpm for 2 minutes. The iqyper aqueous phase was discarded and 
80pl of IM HChmethanol (1:1) was added, vortexed for 20 seconds and centrifriged 
at 14,000rpm for 2 minutes.
9. The iqyper aqueous phase was discarded again and the lower organic phase was 
dried down by centrifugation in a speed-vac for 4 minutes.
10. Samples were re-suspended in 20pl of chloroform and spotted onto a 60Â silica 
gel chromatography plate. Lipid standards were also spotted onto the plate for 
comparison. Plates were developed by chromatography in a solvent system 
containing 50% (v/v) chloroform, 39% (v/v) methanol and 11% (v/v) 4M ammonia 
solution.
11. Chromatography plates were air dried and lipids and lipid markers were 
visualised by exposing the plates to iodine crystals for 2-3 minutes. Radiolabelled 
lipids were detected either by autoradiogr^hy or by real-time detection on a 
Phosphoimager (Canberra Packard).
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Plate preparation:
Thin layer chromatography plates (TLC) were activated by pre-running in a solvent 
system containing 40% (v/v) methanol, ImM EDTA, 1% potassium oxalate in d i. 
water. Plates were then heated to 110°C for 20 minutes immediately before use.
Lipid preparation:
Phosphatidylinositol lipids were obtained either in chloroform solution or as 
lyophilised powder. Lipids were dried down under a stream of nitrogen and re­
suspended in chloroform to Img ml'*. The required amount of lipid was added to a 
fresh microcentrifuge tube and the lipids were dried down under a stream of nitrogen 
before being re-suspended in (XI) PI 3-kinase buffer. Lipids were re-suspended, 
ready for use, by sonication in an ice bath for 5 minutes.
Serum Delipidation:
Serum was delipidated by mixing equal volumes of foetal bovine serum (FBS) with 
chloroform/methanol (2:1 v/v) for 2 hours at room temperature. The organic and 
aqueous phases were separated by centrifugation on a Beckman J2-MC at 3,000rpm 
for 5 minutes. The dehpidated aqueous was removed and residual organic solvents 
were removed by applying a water-aspirator vacuum for 2 hours. The resultant 
delipidated FBS was filter sterilised for later use.
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3.4.0 Molecular biology
3.4.1. Isolation of total RNA
Total RNA was purified firom mammalian cells to be used as a template for reverse 
transcription-PCR of cDNA with gene specific oligonucleotide primers.
1. Cultured cells were washed twice with PBSa and 1x10® cells were lysed in lOOpl 
RNA buffer D. lOOpl of 2M sodium acetate (pH4.0) was added to the lysate and 
mixed by inversion. An equal volume of equilibrated phenol was added and the 
solution was mixed by inversion until clear.
2 . 2 0 0 pl of chloroform per ml of lysate was added, mixed by vigorous shaking for 1 0  
seconds and incubated at 4°C for 10 minutes. Lysate was centrifuged at 14,000rpm, 
4°C for 20 minutes. The aqueous phase was decanted to a fi-esh microcentrifuge tube 
and an equal volume of propan-2-ol was added and mixed. Samples were chilled to - 
20°C for ^ 1 hour and centrifiiged at 14,000rpm, 4®C for 20 minutes.
3. The RNA pellet was re-suspended in 300pl per ml of original lysate volume. An 
equal volume of propan-2-ol was added and the samples were chilled to -20°C for > 1 
hour.
4. Samples were centrifuged at 14,000rpm, 4°C for 10 minutes and the supernatant 
was decanted. The pellet was washed with 300pl 75% ethanol and centrifuged at 
14,000rpm, 4°C for 10 minutes. The supernatant was decanted and the pellet was 
dried in a speed-vac for 4 minutes.
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5. The RNA pellet was re-suspended, by pipetting, in 50pl DEPC-treated d.i. water 
by heating to 65°C to aid solubilisation.
3.4.2. Amplification of DNA bv PCR
Amplification of specific DNA fragments was carried out by polymerase chain 
reaction (Mullis and Faloona, 1987) as follows;
PCR amplification of DNA with AmpliTaq DNA polymerase:
Each PCR reaction was setup as follows;
Volume
(Li. water to a final volume of lOOpl
lOX PCR buffer lOpl
dNTPs (lOmM) 8 pl
AmpliTaq DNA polymerase 0.5|il
5'->3' Primer (Forward) Xpl
3 '^ 5 ' Primer (Reverse) Xpl
Template Xpl
Final Concentration
IX 
200pM 
2.5 Units/lOOpl 
l.OpM 
l.OpM 
Ing/lOOpl
Reactions were pulse centrifuged and overlayed with mineral oil.
Initially the volume of each primer required was cal(ndated to obtain a final 
(xmcentration of l.OpM. However, the final concentration of primers and template 
DNA were further optimised to improve the cpiality of amplified products. Negative 
œntrols were performed for each reaction and a known positive control was included 
to demonstrate that the PCR system was functioning properly. PCR was performed 
on a Techne PHC-3 air-cooled thermocycler under varying cycling parameters. A 
typical reaction set up was as follows;
Temperature Time No. Cvcles 
Dénaturation 94°C 2  m in___  xl
Dénaturation
Annealing
Extension
Extension
94°C
55°C
72°C
72°C
1 min 
1 min 
30 sec 
7 min
x32
xl
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Reverse Transcription PCR amplification with AmpliTaq DNA polymerase:
Each Reverse transcription reaction was setup as follows;
Volume Final Concent:
MgCl solution (25mM) 4pl 5mM
lOX PCR buffer n 2 pl IX
dNTPs 8 pl ImM
Rnase inhibitor Ipl lU /p l
Oligo d(T)„ Ipl 2.5 U/pl
RNA template (U937 total RNA) Ipl 1 .0 pg/2 0 pl
DEPC treated d.i. water to 2 0 pl
Reactions were pulse centrifuged and overlayed with mineral oil.
Reverse transcription was performed on a Techne PHC-3 for one cycle as follows;
Temperature Time
Pre-incubation 25°C 1 0  min
Reverse Transcribe 42®C 15 min
Denature 99®C 5 min
Cool 5®C 5  min
Each PCR reaction mix was set iq> as follows and then added to the RT reaction;
Volume Final Concen
MgCl solution (25mM) 4pl 2mM
lOX PCR buffer n 8 pl IX
d.i. water 65.5pl
AmpliTaq DNA polymerase 0.5pl 2.5 U/100|il
5'->3' Primer (Forward) Ipl 0.15pM
3'->5' Primer (Reverse) Ipl 0.15|nM
Total volume: 80pl
Reactions were pulse centrifuged and PCR amplification was performed on a Techne 
PHC-3 under the following conditions;
Dénaturation
Temperature
94°C
Time No. Cycles 
2 min x l ___
Dénaturation
A n n ea lin g
Extension
Extension
94®C
55°C
72°C
72®C
1 min
1 m in  
30 sec 
7 min
x35
x l
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Colony PCR for identification of positive clones:
Each PCR reaction was set up as follows;
Volume Final Concentration
d.i. water to a final volume of 25pl
lOX PCR buffer 2.5pl IX
dNTPs (lOmM) 2 pl 200pM
AmpliTaq DNA polymerase 0.125pl 2.5 Units/1 OOpl
5'-^3' Primer (Forward) Xpl l.OpM
3'->5' Primer (Reverse) Xpl l.OpM
Template: A single colony or 1 pi of inoculated LB broth.
Reactions were pulse centrifuged and overlayed with mineral oil.
PCR was performed on a Techne PHC-3 air-cooled thermocycler under varying 
cycling parameters. A typical reaction set up was as follows;
Dénaturation
Temperature
94°C
Time 
2 min
No. Cvcles 
xl
Dénaturation
Annealing
Extension
94®C
55®C
72°C
1 min 
1 min 
30 sec
x25
Extension 72°C 7  min xl
PCR amplification of DNA with Advantage™ KlenTaq polymerase mix:
The simultaneous use of two different DNA polymerases, a primary and proof­
reading enzyme, in a PCR reaction was employed to amplify significantly longer 
fragments, with higher fidelity and increased yield. Each PCR reaction was set iq) as 
follows;
Volume Final Concentration
d.i. water to a final volume of 50pl
lOX KlenTaq PCR reaction buffer 5pi
dNTPs (lOmM) 2pl
50X Advantage KlenTaq mix 1 pi
5'->3' Primer (Forward) Xpl
Primer (Reverse) Xpl
Template Xpl
IX
40pM
IX
0.4pM
0.4pM
lng/50pl
Reactions were pulse centrifuged and overlayed with mineral oil.
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Negative controls were performed for each reaction and a known positive control was
included to demonstrate that the PCR system was functioning properly. PCR was
performed on a Hybaid Omnigene air-cooled thermocycler under varying cycling
parameters. A typical reaction set up was as follows;
Temperature Time No. Cvcles
Dénaturation_______ 94°C_______ 1 min_______ xl
Dénaturation 94°C 30 sec
Annealing/Extension 6 8 °C_______ 6  min_______ x25
Extension 6 8 °C 5 min xl
3.43, Separation of DNA fragments bv agarose gel electrophoresis
Agarose gels for the resolving of DNA fragments were made by dissolving 0.7-1.2% 
w/v electrophoresis grade agarose (Gibco-BRL) in TBE buffer and microwaved to 
solubilise the agarose. Agarose gels were cast in either a BRL Horizon 11.14 mini- 
gel casting tray or a BRL Horizon 58 midi-gel tank. After gels had polymerised they 
were placed in TBE buffer. DNA samples were mixed with lOx DNA loading buffer 
and ^yplied to the gel. The DNA gel was run at constant voltage for the desired 
length of time. DNA fragments were visualised under ultra-violet light by including
0.5ng/pl Ediidium Bromide in the agarose gel during casting. Alternatively, DNA 
was stained following electrophoresis by submerging the gel in TBE buffer 
containing SYBER™ Green I (1:10,000 dilution) for 30 minutes. DNA agarose gels 
were visualised on a UVP transilluminator and documented with a Polaroid™ land 
camera. Molecular weight markers (IkBp ladder, Gibco-BRL) were included on all 
gels.
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3.4.4. Purification of DNA from agarose yels '
A clean source of recombinant DNA was required for downstream applications such 
as PCR, DNA ligation, bacterial transformation and sequencing. DNA was resolved 
by agarose gel electrophoresis and DNA bands of the correct molecular weight was 
excised from the gel and purified by the QIAquick method (QIAGEN) as follows;
1. Each DNA fragment was excised firom the agarose gel with a sterile scalpel and 
placed in a clean 1.5ml microcentrifuge tube and the gel slice weight was determined.
2. Three volumes of buffer QXl was added to one volume of gel, (lOOmg » lOOpl). 
Samples were incubated at 50°C for 10 minutes and were mixW by inverting the tube 
to dissolve the gel slice. One volume of room temperature isopropanol was added 
and mixed by inverting the tube.
3. A QIAquick spin column was placed in a 2ml collection tube and the sample was 
transferred firom the microcentrifuge tube to the spin column and centrifuged at 
14,00Qrpm for 1 minute. Flow-through was discarded and the spin column was 
placed back in the same collection tube.
4. 0.5ml of buffer QXl was added to the spin column and the sample was 
centrifuged at 14,000rpm for 1 minute. Flow-through was discarded and the spin 
column was placed back in the same collection tube.
5. The spin column was washed with 0.75ml of buffer PE and the sample was 
centrifuged at 14,000rpm for 1 minute. Flow-through was discarded and the spin
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column was placed back in the same collection tube and recentrifuged at 14,000rpm
for 1 minute.
6 . The QIAquick column was placed in a clean 1.5ml microcentrifuge tube and 
DNA was eluted from the column by applying 30pl of d.i. water to the middle of the 
spin column. The column was allowed to stand for 1 minute and then centrifuged at 
14,000rpm for 1 minute to collect eluted DNA.
3.4.5. Rcstrictioo enzyme digestion of DNA
Restriction enzyme digests were carried out on plasmid DNA for either diagnostic or 
sub-cloning purposes. Restriction enzymes were siq>plied with their relevant xlO 
buffers and all digests were performed (m 2-3 pi of DNA obtained from either mini- 
preps or midi-preps at 37**C fb r^  1 hour. In all reactions the glycerol concentration 
never exceeded 5% (v/v).
3.4.6. L.iyation of PCR products into pCR2.1
DNA fragments of the expected size obtained from PCR reactions were gel purified 
prior to ligation into pCR2.1 cloning vector. Ligation ratios of PCR product to 
plasmid vector of 1:1 and 1:3 were used and ligation of PCR products into pCR2.1 
was performed in 0.5ml microcentrifuge tubes at 14°C for ^ 4 hours. Ligation 
reactions were setup as follows;
Volume
Fresh PCR product X pi
lOX Ligation buffer 1 pi
pCR2.1 vector (25ng/pl) 2 pi
T4 DNA ligase (4.0 Weiss units) 1 pi 
d.i. water to 1 0  pi
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3.4.7. Transformation of Competent E. coli
Plasmid DNA containing clones of interest were transformed into the relevant E. coli 
strain. Maintenance of bacterial stocks was required for preparation of plasmid DNA 
for downstream applications such as sub-cloning, sequencing and transfection. 
Bacteria were transformed as follows;
1. Bacteria were thawed on ice and either 50 or lOOpl of competent cells were 
aliquoted into polypropylene microcentrifuge tubes.
2. 2pl of g-merc^toethanol was gently pipetted into each vial of competent cells and 
mixed by gentle stirring. 2pl of each ligation reaction was pipetted into each vial of 
Competent cells and mixed by gentle sdrm g. Vials were incubated on ice for 30 
minutes.
3. Each vial containing competent cells was heat shocked at 42°C for exactly 30 
seconds and immediately placed on ice for a further 2 minutes. 250pl of room 
temperature SOC medium was added to each vial and incubated on a rotary shaking 
incubator at 225rpm, 37°C for 1 hour.
4. 50pl and 200pl from each transformation vial were plated out on LB agar plates 
containing 50pg ml * carbenicillin. Plates were allowed to absorb the transformation 
liquid before inverting them and were incubated at 37°C for 18 hours.
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3.4.8. Selection of positive clones bv alpha-comolementation
In pCR2.1 vector there are short segments of E. coli DNA containing regulatory 
sequences and coding information for the amino-terminal 146 a.a. of the P- 
galactosidase gene {lac Z). Host cell strains, which possess coding regions of the 
carboxyl-terminal portion of the P-galactosidase gene, can then be transformed with 
pCR2.1. Both the host cell and vector portions of the P-galactosidase gene can 
associate to form a polypeptide that is enzymatically active. Bacteria that have been 
transformed with wild type vector are recognised by formation of blue colonies in the 
presence of chromogenic substrate, X-gal. However, ligation of PCR product into the 
multiple cloning site of pCR2.1 disnq>ts production of the amino-terminal fragment 
of p-galactosidase and therefore bacteria containing recombinant plasmids are 
identified as white colonies. Two E. coli strains were employed as host cells for 
cloning purposes, INVoF' and TOPlOF'. The É. coli strain INVoF' required LB 
plates spread with 40pl of a 40mg ml* stock of X-gal and TOPI OF' required' required 
LB plates spread with 40pl each of 40mg ml * X-gal and lOOmM IPTG.
3.4.9. Small scale purification of plasmid DNA
Small scale plasmid purification was performed using Qiaprep spin miniprep kit 
(Qiagen), a modification of the method introduced by Bimboim & Doly (1979).
1. Positive single colonies (> ^te) were selected and inoculated into 5ml of LB broth 
containing 50pg ml * Carbenicillin (Sigma) and incubated at 37**C with shaking for 
16-18 hours.
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2. 1.5-2.0ml of bacterial culture was centrifuged at 14,000rpm for 2 minutes in
sterile 2ml eppendorf tubes. Sijpematants were removed by aspiration. Bacterial 
pellets were resuspended completely in 250pl of buffer PI. 250pl of buffer P2 was 
added and tubes were mixed by inverting 5-6 times.
3. The lysis reaction was then stopped by addition of 350pl of buffer N3 and was 
mixed by inverting 5-6 times. The suspension was then centrifuged at 14,00Qrpm for 
10 minutes to pellet the precipitate.
4. The siq)ematant was decanted to a Qiaprep q)in column seated in a 2ml collection 
tube. The samples were centrifuged at 14,000rpm for 1 minute. Flow-through was 
discarded and 0.5ml of buffer PB was added to the. Qiaprep spin columns and 
centrifuged at 14,000rpm for 1 minute.
5. Flow-througb was discarded and 0.75ml of buffer PE was added to the Qitqnrep 
spin columns and centrifuged at 14,000rpm for 1 minute. Columns were then 
centrifuged for an additional 1 minute to remove residual wash buffa.
6. The Qiaprep spin column was then placed in a clean 1.5ml eppendorf tube. DNA 
was eluted by adding 30pl of d i. water to the centre of the Qiaprep column, leaving 
to stand for 1 minute before centrifugation at 14,000rpm for 1 minute.
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3.4.10. Medium scale purification of plasmid DNA
The HYBAID RECOVERY™ Plasmid Midi Prep Kit was employed for isolation of 
up to 200pg of plasmid DNA from high copy plasmid vectors.
1. 10-30ml of bacterial culture was prepared and the bacteria suspension was pelleted 
by centrifugation at 3,200rpm on a table top centrifuge for 12 minutes. Supernatant 
was decanted and the bacterial pellet was resuspended in 500pl d.i. water and 
transferred to a 2ml microcentrifuge tube.
2. The bacteria were pelleted by centrifugation at 14,000rpm for 30-60 seconds and 
supernatant was decanted. Pellets were further pulse centrifuged and any remaining 
liquid was removed. 200pl of pre-lysis solution was added and mixed by vortexing 
until the cells were completely resuspended.
3. 400pl of alkaline lysis solution was added and the tubes were gently inverted 15 
times. Tubes were incubated at room temperature for 3 nnnutes. 300pl of ice-cold 
neutralising solution was added and vortexed until a uniform ^ ^ te  precipitate was 
observed. The samples were then placed on ice for 5 minutes.
4. Precipitate was pelleted by centrifugation at 14,000rpm for 5 minutes. The 
supernatant was transferred to a clean 2ml microcentrifuge tube. The silica gel matrix 
in the binding buffer was resuspended by vigorous shaking and 1.2 ml was 
immediately added to the bacterial lysate.
5. The tubes were gently inverted 15 times to ensure uniform mixing. Samples were 
then incubated at room temperature for 5 minutes with further mixing on a rotator.
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The binding matrix/DNA complex was pelleted by a brief pulse spin and the
supernatant was discarded.
6. SOOpl of wash solution was added to the binding matrix/DNA complex and 
resuspended by gentle stirring with a pipette tip and by pipetting up and down. The 
suspension was then transferred to a spin filter and centrifuged at 14,000rpm for 30 
seconds to transfer wash solution into the catch tube.
7. The catch tube was emptied and another 500;zl wash solution was added to the 
spin filter and pulsed for an additional 20 seeonds. The eateh tube was emptied and 
the filter was centrifuged for 2-5 minutes to dry the filter contents.
8. The spin filter was then inserted into a new catch tube and 300pl of d,i. water was 
added to the spin filter and the binding matrix/DNA complex was resuspended by 
gentle stirring with 200pl a pipette tip. The spin filter was centrifuged at 14,000rpm 
for 5-8 minutes and eluted DNA was collected in the catch tube.
3.4.11. Large scale purification of plasmid DNA
Large scale plasmid preps for preparations of up to 500pg of DNA were performed 
using the QIAGEN Endofi:ee maxi-prep column, with the following protocol;
QIAGEN™ EndoFree Plasmid Maxi protocol:
1. 100ml of bacterial culture were centrifuged in a JC-10 rotor, on a Beckman J2-MC 
centrifuge, at 5,000rpm, 4®C for 15 minutes. The bacterial pellet was resuspended 
completely in 10ml of buffer PI.
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2. 10ml of buffer P2 was added and was mixed gently by inverting 5-6 times then
left at room temperature for 5 minutes. 10ml of chilled buffer P3 was added to the 
lysate and was mixed immediately but gently by inverting 5-6 times. The lysate was 
poured into the barrel of the QlAfilter cartridge that had been c^)ped at the outlet 
nozzle and incubated at room temperature for 10 minutes.
3. The cap on the outlet nozzle was removed to allow flow-through, the plunger was 
gently inserted, and the lysate was filtered into a 50ml Falcon tube. 2.5ml of buffer 
ER was added to the filtered lysate and mixed by inverting the tube 10 times. Lysate 
was then incubated on ice for 30 minutes.
4. A QIAGEN-tip 500 was equilibrated by applying 10ml of buffer QBT. and 
allowed to empty by gravity flow. The cleared lysate fi-om step 5 was then applied to 
the QIAGEN-tip and allowed to enter the resin by gravity flow. The QIAGEN-tip 
was then washed with two 30ml volumes of buffer QC.
5. Plasmid DNA was eluted fi"om the QIAGEN-tip into a 50ml Falcon tube with 
15ml of buffer QN. DNA was precipitated by addition, with mixing, of 10.5ml of 
room temperature isopropanol. Solution was centrifuged immediately in à JC-20 
rotor at 1 l,000rpm, 4°C for 30 minutes.
6. The supernatant was carefully decanted and the DNA pellet was washed with 
2.5ml of endotoxin fi*ee, room temperature 70% ethanol and recentrifuged at 
1 l,000rpm, 4°C for 10 minutes.
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7. The supernatant was carefully decanted so not to disturb the DNA pellet and then
the pellet was air dried for 5-10 minutes. The plasmid DNA pellet was redissolved in
500pl of endotoxin free, d.i. water and transferred to a clean microcentrifuge tube.
3.4.12. Hydrolysis of 5 -phosphate groups from DNA
During the ligation of cloned DNA into a mammalian expression vector, removal of 
the 5'-phosphate group from linearised vector DNA was required to prevent 
recircularisation and religation in the ligation reaction. The 5'-phosphate group on 
the 5'-protruding end of vector DNA was removed with calf intestinal alkaline 
phosphatase (CIAP) enzyme.
1. DNA to be dephoq)horylated was set iq> as follows in a 0.5ml microcentrifuge 
tube;
DNA (iq) to lOpmol of 5 'ends) 40|il
CIAP lOX reaction buffer 5pi
CIAP (0.01 U/pl) 5pl
2. Samples were incubated at 37°C for 30 minutes. Another 5pi of CIAP (0.01 U/pl) 
was added and the samples were incubated for a further 30 minutes at 37°C.
3. The reaction was terminated by the addition of 300pl of CIAP stop buffer and heat 
inactivated at 75°C for 10 minutes prior to gel purification of the DNA fragment.
3.4.13. Identification of positive clones bv colonv-PCR
Identification of positive clones by colony-PCR was performed v/hea either a large 
population of clones were to be screened or Wien colour selection by alpha- 
complementation was not suitable. Oligonucleotides specific for either vector
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sequence or internal, gene specific oligonucleotides were used to identify positive 
clones as follows;
1. Colonies were picked with an inoculation loop and streaked to a master plate 
before being inoculated directly into the PCR reaction. PCR reactions were set up as 
follows;
Volume Final Concentration
lOX PCR buffer 5pl IX
dNTPs (lOmM) 4pl 200pM
5'->3' Primer (Forward) Xpl l.OpM
3'->5' Primer (Reverse) Xpl l.OpM
AmpliTaq DNA polymerase 0.25pl 1.25 Units/50pl
d.i. water to a final volume of 50pl
2. PCR reactions were overlayed with mineral oil and cycled as follows;
Temperature Time No. Cvcles 
Dénaturation 94°C 2 min xl
Dénaturation
Annealing
Extension
94°C
55°C
72°C
1 min 
1 min 
1 min
x25
Extension 72°C 7 min xl
3. PCR products were analysed by DNA agarose-gel electrophoresis.
3.4.14. Site-directed mutagenesis of specific nucleotides
Point mutations were introduced into a cloned gene using the QuikChange™ site- 
directed mutagenesis (SDM) kit (Stratagene). The QuikChange SDM method was 
performed using PJu DNA polymerase and two complimentary oligonucleotide 
primers containing the desired mutation flanked by unmodified sequence, which had 
b een  lEPLC  p u rified . S ite -d irec ted  m u ta g m e s is  fo r each  m u ta tio n  site  w as p e rfo rm ed  
as follows;
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1. Sample and control reactions were set up in 0.5ml microcentrifuge tubes as 
follows;
lOX reaction buffer 5pl
dsDNA template (20ng) Xpl
5'->3' oligonucleotide primer 1 (125ng) Xpl
3 '->5 ' oligonucleotide primer 2(125ng) Xpl
dNTP mix Ipl
d.i. water to a final volume of 50pl
2. Ipl of Pfu DNA polymerase (2.5 U/pl) was added, stirred gently to mix and 
overlayed with mineral oil. Reaction tubes were placed on a Hybaid thermal cycler 
and cycling parameters were setup as follows;
Temperature Time No. Cvcles
Segment 1___  95°C_______ 30 sec xl
95°C 30 sec
Segment 2 55°C 1 min xl2
68°C ______17 min
3. After temperature-cycling, reactions were placed on ice for 2 minutes and then 1 pi 
of the restriction enzyme Dpn I (10 U/pl) was pipetted into each reaction tube, below 
the mineral oil overlay, and mixed by pipetting up and down several times.
4. The reaction tubes were centrifuged at 14,000rpm for 1 minute and incubated at 
37°C for 1 hour to digest parental supercoiled dsDNA.
5. Ipl of Dpn 1 treated DNA was transformed into 50pl of E. coli XLl-Blue
supercompetent cells. The transformation was performed as in section 3.4.6.
however, cells were heat shocked for 45 seconds at 42°C.
6. All of the transformation reaction was plated onto LB agar plates containing 50pg 
ml ' carbenicillin and the plates were allowed to absorb the transformation before
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incubation at 37°C for 18 hours. Colonies were selected and inoculated into LB-
carbenicillin broth. Plasmid mini-preps were prepared and inserts were sequenced to 
confirm clones containing required mutation.
3.4.15. Nucleotide sequence analysis
The DNA sequences of cloned DNA were determined following the ABI Prism™ 
dRhodamine terminator cycle sequencing ready reaction kit on either an ABI Prism 
310 Genetic Analyzer or an ABI Prism 377 DNA sequencer (Oswel).
DNA purification:
1. DNA prepared fi-om a QIAGEN mini-prep column was made up to 50pl with d.i. 
water and mixed with 30pl of 20% (v/v) polyethylene glycol (PEG)/2.5M NaCl and 
incubated at 4°C for 30 minutes.
2. Samples were centrifuged at 14,000rpm at 4°C for 15 minutes. The supernatant 
was decanted and the pellet was washed gently with 70% (v/v) ethanol/HzO. The 
70% ethanol/HgO was decanted and the pellet was dried in a vacuum centrifuge for 2 
minutes.
3. The DNA pellet was resuspended in 20pl of d.i. water and DNA concentration 
was calculated from an ODs^ onm absorbance reading taken on an Beckman DU-64 
spectro-photometer.
Thermal cycling with dRhodamine terminators:
1. For each reaction the following reagents were added to a 0.5ml thin-walled PCR 
tube,
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Terminator ready reaction mix 8pl
dsDNA template (0.2pg/pl) Ipl
Sequencing primer (3.2pmol/pl) 1 pi
d i. water lOpl
2. Reactions were mixed by pipetting and pulse centrifuged then overlayed with 
mineral oil. Samples were thermal cycled on a Hybaid and cycling parameters were 
as follows;
Temperature Time No. Cvcles
96°C 30 sec
50°C 15 sec x25
60°C 4 mins
4. Samples were then placed on ice prior to purification of extension products. 
Purification of extension products:
1. The 20pl PCR reaction was removed to a clean 0.5ml microcentrifuge tube 
containing lOpl of 3M sodium acetate (pH4.6) and 250pl of 95% (v/v) ethanol/HgO. 
Samples were vortexed briefly and incubated on ice for 10 minutes.
2. Samples were centrifuged at 14,000rpm, 4°C for 30 minutes. The siq>ematant was 
carefully removed by aspiration and the DNA pellet was washed gently with 250pl 
70% (v/v) ethanol/HjO, then centrifuged at 14,000rpm, 4®C for 30 minutes. 
Supernatant was carefully removed by aspiration and pellet was dried in a vacuum 
centrifuge for 2 minutes.
3. The DNA pellet was resuspended by repeated pipetting in 25pi of template 
siqqwession reagait for sequencing on the ADI 310 gcaedc analyzer or in 12pl of 
template suppression reagent for sequencing on the ABI 377 DNA sequencer.
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4. Samples prepared for sequencing on the ABI Prism 310 were denatured by heating
at 95°C for 2 minutes then were placed on ice until ready for loading. Samples for
sequencing on the ABI Prism 377 were sent immediately for sequencing to Oswel
DNA Service, Southampton, England.
3.4.16. In vitro translation
The procedure for synthesising proteins in vitro from cloned genes was first described 
by Hope and Struhl, 1985. In vitro translation involves transcription from the T7 
promoter sequence in the plasmid vector containing the gene of interest. This yields 
mKNA that is subsequently translated using Wieat germ extract or reticulocyte lysate. 
By using p^S] methionine during the translation reaction, the protein is synthesised as 
a radiolabeled species and can be analysed by SD.S-PAGE. The protocols used for. 
synthesising protein by in vitro transcription and translation are detailed below.
TnT* Coupled Wheat Germ Extract system (Promega)
1. TnT* RNA Polymerase was placed on ice and the TnT® Wheat Germ Extract was 
rapidly thawed by hand warming, then placed on ice. Other components were ^ w e d  
at room temperature, then stored on ice.
2. Reaction components were set iq) in a 1.5ml microcentrifuge tube as below.
Component Standard [^S] methionine Reaction
TnT® Quick Master Mix 40pl
methionine (lOOOCi/mmol at lOmCi/ml) 2pl
DNA template (0.5pg/pl) 2pl
Nuclease-Free Water to a final volume of 50pl
3. Reactions were incubated at 30°C for 90 minutes Üien analysed in the same way as 
products from the TnT* Coiq)led Wheat Germ Extract system.
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TnT* Coupled Wheat Germ Extract system (Promega)
1. TnT* RNA Polymerase was placed on ice and the TnT* Wheat Germ Extract was 
rq)idly thawed by hand warming, then placed on ice. Other components were thawed 
at room temperature, then stored on ice.
2. Reaction components were set up in a 1.5ml microcentrifiige tube as below.
Component Standard [” S] methionine Reaction
TnT* Wheat Germ Extract 25pl
TnT* Reaction Buffer 2pl
TnT* RNA Polymerase (T7) Ipl
Amino Acid Mixture, Minus Leucine, ImM -
Amino Acid Mixture, Minus Methionine, ImM Ipl
[^ ’S] methionine 2pl
RNasin* Ribonuclease Inhibitor, 40u/pl Ipl
DNA template 2pg
Nuclease-Free Water to a final volume of 50pl
3. The reaction was mixed gently after addition of each component and centrifuged 
briefly to collect the reaction at the bottom of the tube. Reactions were incubated at ' 
30°C for 120 minutes.
4. Once the translation reaction was complete a 5pl aliquot was removed and added 
to 20pl of 2x SDS sample buffer. liie  remainder of the reaction was stored at -20**C.
5. Samples were heated to lOO^ ’C for 2 minutes to denature the proteins then resolved 
by SDS-PAGE.
6. The protein gel was soaked in 7% (v/v) acetic acid, 7% (v/v) methanol and 1% 
(v/v) glycerol for 5 minutes. The protein gel was th«i placed on a sheet of Whatman* 
3MM filter paper, covered with plastic wrap and dried at 80°C for 30-90 minutes
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under a vacuum using a conventional gel dryer. The preserved gel was exposed to
autoradiogr^hic film at -70°C for a minimum of 4 hours.
3.4.17. Transfection of mammalian cells
Various transfection methodologies for the introduction of DNA into mammalian 
cells were analysed to determine the most reproducible and efficient method of DNA 
transfer with the lowest toxicity to the cell-line being transfected. Various chemical 
and cationic lipid transfection products were investigated including. Calcium 
phosphate (ProFection™, Promega) CellFectin^, LipoFectin™, LipoFectamine™, 
DMRIE-C™ (Gibco-BRL) and SuperFect™ (QIAGEN). The protocols for 
Protection™, Siq)erFect™ and LipoFectAMINE™ are detailed below, all other 
protocols were carried out as per manufacturers protocols.
Calcium phosphate mediated transfection:
Transfection of recombinant DNA mediated by calcium phosphate was performed 
with the ProFection™ kit based on the observation originally described by Graham 
and van der Eb, 1973.
1. Cultured cells were seeded at 2xlO^/well in a 6-well culture plate. Cells were left 
to adhere for 24-36 hours.
2. Three hours prior to transfection the culture medium was removed and replaced 
with 3ml of fi-esh growth medium. Transfection reagents were thawed, equilibrated 
to room temperature and mixed thoroughly. For each transfection two 1.5ml 
microcentrifuge tubes were set iq> as follows;
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per 6-well
Tubel DNA(lpg/pl) l-20pl
2MCaCl2 18pl
Nuclease-free water to 150pl
Tube 2 2XHBS 150pl
3. The solution in tube 1 was slowly added drop-wise to the solution in tube 2 Wiile 
air was bubbled through the solution in tube 2 with a pipette. The solution mix was 
incubated at room temperature for 30 minutes, then added to the 3ml of growth 
medium in each 6-well. Cells were incubated in a humidified incubator at 37°C/5% 
CO2 for 24 hours.
4. Growth medium was removed and cells were washed twice with PBS^ and either 
harvested for analysis of gene expression or growth medium was replaced and cells 
were cultured as desired.
LipofectAMINE™, a cationic lipid mediated transfection protocol:
LipofectAMINE reagent is a 3:1 (w/w) formulation of the polycationic lipid DOSPA 
and the neutral lipid DOPE. The use of cationic lipids for DNA transfer was first 
reported by(Felgner et al., 1987).
1. Cultured cells were seeded at l-2xl0^/well in a 6-well culture plate. Cells were left 
to adhere for 24-36 hours or were cultured until 60% confluency.
2. For each transfection two 1.5ml microcentrifuge tubes were setup as follows;
per 6-well
Tube A DNA (Ipg/pl) l-4pl
Serum/antibiotic-fi-ee medium lOOpl
Tube B LipofectAMINE 12|il
Serum/antibiotic-firee medium lOOpl
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3. Both solutions were combined with gentle mixing and incubated at room
temperature for 45 minutes. Cells were rinsed once with 2ml of serum-free growth 
medium.
4. 800pl of serum-free growth medium was added to each tube containing the DNA- 
liposome complexes and mixed gently. Culture medium was aspirated from the 
cultured cells and the diluted complex solution was overlayed and incubated at 37°C 
5% CO2 for 5 hours.
5. Following incubation with DNA-liposome complexes 1ml of growth medium 
containing 20% (v/v) FCS was added and incubation was continued. At 24 hours 
post-transfection cells were harvested for analysis of gene expression or growth 
medium was replaced and cells were cultured as desired.
SuperFecf™ mediated traiisfection:
Siq)erFect reagent is a specifically designed activated polyamidoamine dendrimer and 
was used as an alternative protocol for cells A^ch are sensitive to transfection by 
classical cationic lipid methods.
1. Cultured cells were seeded at l-2xl0^/well in a 6-well culture plate. Cells were left 
to adhere for 24-36 hours or were cultured until 60% confluency.
2. 2-20pg of DNA was diluted widi cell growth medium containing no serum, 
proteins or antibiotics to a total volume of lOOpl and mixed. 15pl of SuperFect 
transfection reagent was added to the DNA solution and was mixed by vortexing 
briefly. Samples were incubated at room temperature for 10 minutes.
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3. Growth medium was aspirated from the culture dish and cells were washed once
with 4ml of PBS^. 1ml of normal cell growth medium was added to each reaction 
tube and was mixed by pipetting up and down twice.
4. The contents of each reaction tube was pipetted to the relevant well of the culture 
dish and cells were incubated at 37°C 5% CO2 for 3 hours. Growth medium was 
removed by gentle aspiration and cells were washed once with PBS^ and was 
replaced with fresh growth medium. Cells were cultured for 24 hours and either 
harvested for analysis of gene expression or maintained in culture for as long as 
desired.
Selection of stable clones expressing a transfected gène:
Stable transfection results when cells incorporate DNA into their chromosomal DNA 
or maintain it as an episome. Selection of stable transfected cells is carried out with a 
suitable selective pressure such as antibiotic resistance. Addition of the antibiotic 
Geneticin (G418) to growth medium allows selection of cells expressing the bacterial 
gene ^ ^ c h  confers resistance to Geneticin. Stable, single clones were isolated by 
plating out a serial dilution of cells to less than 0.5 cells per well of a 24-well tissue 
culture plate and grown in medium containing Img ml ' Geneticin (Gibco-BRL).
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The expression of c-fms and expression 
of associated intracellular signalling 
proteins in unstimulated and stimulated 
BAC1.2F5 macrophages.
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4.0.0. Introduction
M-CSF stimulates the proliferation and differentiation of macrophages and their 
precursors (Stanley et al., 1994). The receptor for M-CSF, the c-fins gene product, is 
a protein tyrosine kinase expressed mainly by cells of the monocyte-macrophage 
lineage. Expression of both M-CSF and its receptor by the same cell can establish an 
autocrine signalling loop resulting in uncontrolled proliferation (Stanley et al., 1994). 
On binding of M-CSF, the c~fins receptor becomes transphosphorylated on tyrosine 
within the cytoplasmic domain. These autophosphorylation sites create potential high 
affinity  binding sites for SH2-domain containing proteins and in turn induce the 
phosphorylation of several of these cellular proteins on tyrosine (Hamilton, 1997). To 
date, several tyrosine autophosphorylation sites have been identified on c-fins 
including Y^^ in the kinase insert region, Y*®^  in the tyrosine kinase
domain, and Y^®^ in the juxtamembrane region (Reedijk et al., 1992; Tapley et al., 
1990; van der Geer and Hunter, 1990). The cellular proteins Grb2 (van der Geer and 
Hunter, 1993), PI 3-kinase (Varticovski et al., 1989), STATl (Novak et al., 1996) and 
Src (Alonso et al., 1995) have been shown to bind to these tyrosine phosphorylation 
sites, respectively. Although association of these intracellular proteins has been 
clearly demonstrated in vitro, there is no clear consensus on what cellular responses 
they mediate or how they interact with each other at the receptor complex. To date the 
published data has only demonstrated that there is a need for a better cell based model 
system for characterisation of c-fins signalling. At the very least c-fins signalling must 
be studied within the context of the haematopoietic lineage to allow clear 
interpretation of the data obtained from the particule cell lineage studied.
As a model system with which to study PI 3-kinase activity during c-fins signalling, 
the cloned SV40-immortalised mouse macrophage cell lines BAC1.2F5 was chosen
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based on a number of criteria. BAC1.2F5 cells resemble primary macrophages in
their requirement for M-CSF for both survival and proliferation. BAC1.2F5 cells 
have previously been well characterised, expressing c-fins at high levels and 
responding to M-CSF with rapid morphological changes including membrane ruffling, 
cytoskeletal reorganisation and vesicle formation as well as M-CSF stimulation of 
survival and proliferation (Boocock et al., 1989).
The overall aim of Chapter 4 was to characterise the BAC1.2F5 cell line as a model 
for M-CSF stimulated, c%/W-mediated responses. The specific aims of this chapter 
were; (a) determine the expression profile of c-fins in M-CSF stimulated or quiescent 
BAC1.2F5 cells, (b) determine the tyrosine phosphorylation state of c-fins during M- 
CSF stimulation and (c) determine which PI 3-kinase subunit isoforms were expressed 
in BAC1.2F5 cells. In addition the expression of intracellular signalling molecules, 
previously shown or thought to be involved in c-fins signalling were also investigated.
121
Results Chapter 4
4.1.0. BAC1.2F5 cells express the c-fms.
The expression of c-fins and, for comparison, the PDGFr was studied by Fluorescence 
Activated Cell Sorting (FACS) analysis (chapter 3.3.6.). BAC1.2F5 and U937 cells, 
which resemble undifferentiated macrophage progenitors, were cultured in the 
absence of growth factors for 24 hours. Cells were then cultured for a further 24 
hours in either recombinant murine M-CSF (lOOng mf% R&D Systems) or 
recombinant PDGFo/p (25ng m f \  Sigma). Cells were immunolabelled with 
antibodies raised against the murine M-CSF (Santa Cruz) and PDGF (Sigma) 
receptors and analysed by FACS. The results show that U937 cells express the M- 
CSF and PDGF receptors at constitutively high levels and treatment of U937 cells 
with either growth factor had no effect on levels of receptor expression (Fig. 4.1.1.).
Unstimulated cells 
Stimulated cells
PDGFr c-fms PDGFr c-fms
Bacl.2F5 U937
Fig. 4.1.1. FACS analysis of the expression of c-fms and PDGFr on BAC1.2F5 and U937 cells. 
U937 and BAC1.2F5 cells were cultured in the absence of growth factors for 24 hours prior to 
culture in the presence of either recombinant PDGFp (25ng ml % Sigma) or recombinant murine 
M-CSF (lOOng ml ) for a further 20 hours. 2x10^ cells were harvested, BAC1.2F5 cells were 
dissociated from plastic with Trypsin/0.02% EDTA (Imperial labs.), and labelled with either 
anti-PDGFr mAh (Sigma) or anti-c%//MX mAh (Santa Cruz). A FITC labelled goat anti-mouse 
(Amersham) second antibody was used to detect cells labelled with prim ary antibody. Cells were 
analysed by FACS analysis on a FACScan (Beckton-Dickinson).
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BAC1.2F5 cells express the c-fins (« 50% cells) but only a small proportion of the
population sampled expressed the PDGFr (< 5%) (Fig. 4.1.1.). Treatment of 
BAC1.2F5 cells with rPDGFo/p up-regulated PDGFr expression (« 30 %) (Fig.
4.1.1.). T h ere  ap p ears  to b e  a  s li^ t reduction in c-fins expression following treatment 
with rmM-CSF, which may be due to rapid receptor degradation (Boocock et al., 
1989).
4.2.0. Western blot analysis of c-fms
Western blot analysis (chapter 3.3.1.) of whole cell lysates obtained from BAC1.2F5 
cells indicated that two receptor species were present: a 130kDa immature form and a 
predominant, 165kDa mature form (Fig. 4.2.1.). A 30 minute treatment of BAC1.2F5 
cells with M-CSF resulted in a slight reduction in the detected levels of the 130kDa 
immature form of the receptor and a dramatic decrease in the levels of the mature 
165kDa form (Fig. 4.2.1.).
Stimulation of BAC1.2F5 cells with M-CSF resulted in a rapid increase in the 
detectable levels of protein phosphorylation on tyrosine (Fig. 4.2.2.). It has previously 
been demonstrated that stimulation of BAC1.2F5 cells at 4®C enhances detection of 
tyrosine phosphorylated receptor and proteins which are tyrosine phosphorylated in 
response to c-fins activation (Baccarini et al., 1991). Therefore incubation of cells at 
4®C was used to retard the usually rapid dephosphorylation of c-fins and other proteins 
phosphorylated in response to M-CSF stimulation of BAC1.2F5 cells.
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Fig. 4.2.1. SDS-PAGE analysis of total protein extracts immunoblotted for c-fms. Total cell 
lysate proteins were resolved by 7.5% SDS-PAGE and then blotted onto a nitrocellulose 
membrane prior to immunostaining with an anti-c-//wx pAb (Santa Cruz). Lysate from 
stimulated A431 (A), unstimulated BAC1.2F5 cells cultured for 30' at 37°C (B), BAC1.2F5 cells 
stimulated for 30' at 37°C (C), BAC1.2F5 cells stimulated for 2' at 37°C (D) and BAC1.2F5 cells 
stimulated for 30' at 4°C (E) were loaded onto the gel.
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2 5 0 —
190kDa
165kDa
130kr>fl 
1 1  Ok D a
80kDa
70kDa
65kDa
60kDa
Fig. 4.2.2. SDS-PAGE analysis of total protein extracts immunoblotted for tyrosine 
phosphorylated proteins. Approximately lOjig of total cell lysate proteins were resolved by 
7.5% SDS-PAGE and then blotted onto a nitrocellulose membrane prior to immunostaining 
with an anti-phosphotyrosine mAh (Transduction labs ). Lysate from stimulated A431 (A), 
unstimulated U937 (B), unstimulated BAC1.2F5 (C), BAC1.2F5 stimulated for 30' at 4°C (D) 
and BAC1.2F5 stimulated for 30 at 37°C (E) were loaded onto the gel.
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In quiescent BAC1.2F5 cells few, if any, tyrosine phosphorylated {W t^eins were
detected in whole cell lysate (Fig. 4.2.2., lane C). Only a 190kDa protein appeared to 
be phosphorylated in unstimulated cells (Fig. 4.2.2., lane C). However, stimulation 
with M-CSF at 4°C had a substantial effect on the number of tyrosine phosphorylated 
proteins detected (Fig. 4.2.2., lane D). Various tyrosine phosphorylated bands were 
detected in whole cell lysate at 190kDa, 165kDa, 120kDa, llOkDa, 80kDa, 70kDa, 
65kDa and 60kDa (Fig. 4.2.2., lane D). Stimulation of BAC1.2F5 cells for 30 minutes 
at 37°C resulted in detection of fewer phosphorylated bands, but proteins at 190kDa, 
130kDa, llOkDa, SOkDa, 70kDa and 60kDa were present (Fig. 4.2.2., lane E). A 
tyrosine phosphorylated band of 165 kDa was detected from stimulated cells which 
migrated on SDS-PAGE at an equivalent Mr to the mature form of c-fins (Fig. 4.2.2., 
lanes D and E). The absence of this band in unstimulated cell lysate (Fig. 4.2.2., lane
C) suggests that c-fms is tyrosine phosphorylated in response to M-CSF (Fig. 4.2.2., 
lanes D and E). The identity of this band was investigated further and is described in 
the next set of experiments.
Western blot analysis of c-fins immunoprecipitated (chapter 3.3.2.) from BAC1.2F5
cells was carried out from lysates obtained from either parental BACl or BAC1.2F5
cells. Immunoprecipitated protein was analysed by western blot and probed with an
antibody against the c-fms receptor (Fig. 4.2.3.). The mature 165kDa receptor form
was not detected in the parental BACl cell line, although the immature 130kDa
isoform (lower arrow) was immunoprecipitated from BACl cells (Fig. 4.2.3., lane C).
In contrast both receptor isoforms were immunoprecipitated from unstimulated
BAC1.2F5 lysate and the mature isoform appeared to be the predominantly expressed
protein in quiesced cells (Fig. 4.2.3., lane G). Treatment of cells with M-CSF at 37°C
resulted in reduced detection of mature receptor by 2 minutes (Fig. 4.2.3., lane D)
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which was more pronounced at 30 minutes (Fig. 4.2.3., lane F), but had no affect on 
detection of the immature c-fins isoform (Fig. 4.2.3., lanes D+F). Stimulation of 
BAC1.2F5 cells at 4°C blocked degradation of the immunoprecipitated, mature 
receptor isoform.
i i i f 1 6 5 k D a  1 S O k D a
Fig. 4.2.3. SDS-PAGE analysis of protein immunoprecipitated from BACl parental or 
BAC1.2F5 cell line immunoblotted for c-fms. Immunoprecipitated proteins were resolved by 
10% SDS-PAGE and then blotted onto a nitrocellulose membrane prior to immunostaining with 
an anti-c-/ms pAb (Santa Cruz). Lysate from stimulated A431 (A) and NIH 3T3 (B) cell lines 
were run as controls. Lanes C to G contain anti-c-//wx immunoprecipitates from; BACl parental 
cells with 2LVki\-c-fms antibody (C), BAC1.2F5 cells stimulated for 2' at 37°C (D), BAC1.2F5 cells 
stimulated for 30' at 4°C (E), BAC1.2F5 cells stimulated for 30' at 37°C (F) and unstimulated 
BAC1.2F5 cells (G).
4.3.0. Association of tyrosine phosphorylated proteins with c-fms
Proteins that were associated with immunoprecipitated c-fms were probed with an 
antibody against phosphotyrosine (Fig. 4.3.1.). Numerous phosphorylated proteins 
were detected including two bands at 130kDa and 165kDa which co-migrated at a 
comparable Mr to the c-fms isoforms identified in Fig. 4.2.3. In addition, 
phosphorylated proteins of 55kDa, 60kDa, SOkDa, 115kDa, 190kDa, and multiple
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proteins <40kDa were detected in unstimulated and stimulated BACL2F5 lysate (Fig.
4.3.1.). In unstimulated cells, the 165kDa c-fins isoform contained a low level of 
tyrosine phosphorylation and co-precipitated proteins with molecular weights of 
190kDa, 115kDa and several smaller phosphoproteins below 40kDa (Fig. 4.2.4., lane
D).
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Fig. 4.3.1. SDS-PAGE analysis of proteins co-immunoprecipitated with c-fms from BAC1.2F5 
cell lysates and immunoblotted for tyrosine phosphorylation. Immunoprecipitated proteins were 
resolved by 10% SDS-PAGE and then blotted onto a nitrocellulose membrane prior to 
immunostaining with an anti-phosphotyrosine mAh (Transduction Labs.). Lanes A to D contain 
proteins co-immunoprecipitated from BAC1.2F5 cells stimulated for 2' at 37°C (A), stimulated 
for 30' at 4°C (B), stimulated for 30' at 37°C (C) and unstimulated (D).
Cells which have been stimulated for 30 minutes at 37°C (Fig. 4.3.1., lane C) and at 
4°C (Fig. 4.3.1., lane B) showed increased levels of tyrosine phosphorylation of the 
165kDa receptor isoform and co-immunoprecipitated phosphoproteins with molecular 
weights of 190kDa, 115kDa and several bands below 40kDa, similar to unstimulated 
cells. Interestingly, stimulation of BAC1.2F5 cells for 2 minutes at 37°C results in
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higher levels of tyrosine phosphorylation of both c-fins isoforms, particularly the 
130kDa isoform compared to unstimulated cells (Fig. 4.3.1., lane A). At 2 minutes 
two additional phosphorylated proteins were detected at 75kDa and 55kDa (indicated 
by * and **, respectively) that were not detected in unstimulated cells or cells 
stimulated for 30 minutes at either 37°C or 4°C (Fig. 4.3.1., lane A).
4.4.0. Expression of PI 3-kinase by BAC1.2F5 cells.
Western blot analysis of BAC1.2F5 lysates was carried out with antibodies raised 
against the a ,p  and y isoforms of the p85 regulatory subunit of PI 3-kinase. It was 
observed that BAC1.2F5 cells express the p85a subunit (Fig. 4.4.1.), but do not 
express either p85P (Fig. 4.4.2.) or the 55kDa, p85y subunit (Fig. 4.4.3.) of PI 3- 
kinase.
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Fig. 4.4.1. SDS-PAGE analysis of total protein extracts immunoblotted for p85a. Total cell 
lysates were resolved by 10% SDS-PAGE and then blotted onto a nitrocellulose membrane prior 
to immunostaining with an anti-p85a pAb (Transduction labs.). Lysate from stimulated A431 
(A), unstimulated BAC1.2F5 (B), BAC1.2F5 stimulated for 30' at 4°C (C) and BAC1.2F5 
stimulated for 30' at 37°C (D) were loaded onto the gel.
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Fig. 4.4.2. SDS-PAGE analysis of total protein extracts immunoblotted for p85(3. Total cell 
lysates were resolved by 10% SDS-PAGE and then blotted onto a nitrocellulose membrane prior 
to immunostaining with an anti-p8Sp mAh (Serotec). Lysate from stimulated A431 (A), 
unstimulated BAC1.2F5 (B), BAC1.2F5 stimulated for 30' at 4°C (C) and BAC1.2F5 stimulated 
for 30' at 37°C (D) were loaded onto the gel.
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Fig. 4.4.3. SDS-PAGE analysis of total protein extracts immunoblotted for p85y. Total cell 
lysates were resolved by 10% SDS-PAGE and then blotted onto a nitrocellulose membrane prior 
to immunostaining with an anti-p85y mAh (Serotec). Lysate from human fibroblasts (A), 
unstimulated BAC1.2F5 (B), BAC1.2F5 stimulated for 30' at 4°C (C) and BAC1.2F5 stimulated 
for 30' at 37°C (D) were loaded onto the gel.
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Analysis of BAC1.2F5 expression of the catalytic subunit of PI 3-kinase revealed that 
BAC1.2F5 cells expressed the pi 10a subunit (Fig. 4.4.4.) and the G-protein 
associated pi lOy subunit (Fig. 4.4.6.), but did not appear to express the pi 10(3 subunit 
(Fig. 4.4.5.).
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Fig. 4.4.4. SDS-PAGE analysis of total protein extracts immunoblotted for p i 10a. Total cell 
lysates were resolved by 10% SDS-PAGE and then blotted onto a nitrocellulose membrane prior 
to immunostaining with an anti-p llO a pAb (Santa Cruz). Lysate from stimulated A431 (A), 
unstimulated BAC1.2F5 (B), BAC1.2F5 stimulated for 30' at 4°C (C) and BAC1.2F5 stimulated 
for 30' at 37°C (D) were loaded onto the gel.
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Fig. 4.4.5. SDS-PAGE analysis of total protein extracts immunoblotted for pllO p. Total cell 
lysates were resolved by 10% SDS-PAGE and then blotted onto a nitrocellulose membrane prior 
to immunostaining with an anti-pllOP pAb (Santa Cruz). Lysate from stimulated A431 (A), 
unstimulated BAC1.2F5 (B), BAC1.2F5 stimulated for 30' at 4°C (C) and BAC1.2F5 stimulated 
for 2' a t 37°C (D) and 30' at 37°C (E) were loaded onto the gel.
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Unlike the z-fms protein product, the PI 3-kinase subunits, p85a and pi 10a were not 
degraded following M-CSF stimulation. Any apparent difference in the detected 
levels of p85 or pi 10 subunits following treatment with M-CSF were due to unequal 
protein loading, as confirmed by Coomassie blue staining of parallel gels (data not 
shown).
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Fig. 4.4.6. SDS-PAGE analysis of total protein extracts immunoblotted for pllOy. Total cell 
lysates were resolved by 10% SDS-PAGE and then blotted onto a nitrocellulose membrane prior 
to immunostaining with an anti-pllOy pAb (Santa Cruz). Lysate from stimulated A431 (A), 
unstimulated BAC1.2F5 (B), BAC1.2F5 stimulated for 30' at 4°C (C), BAC1.2F5 stimulated for 
2' at 37°C (D) and 30' at 37°C (E) were loaded onto the gel.
4.5.0. W estern blot analysis of c-/wy-associated signalling proteins
It has previously been demonstrated that numerous intracellular signalling proteins 
bind to or are associated with z-fms including c-^rc, Grb2, STAT-1, PI 3-kinase, 
Sosl, She, SHIP, and Q-chl. To characterise the signalling proteins expressed in 
BAC1.2F5 cells western blot analysis was carried out on BAC1.2F5 whole cell lysate 
with antibodies raised against various intracellular proteins implicated in z-fms 
signalling including c-5rc, Grb2, Sosl, 0,-chl and She.
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Various combinations of these proteins exist as complexes in monocytic cells and 
binding sites for the adapter proteins Grb2 and She have been mapped to SH2 and 
PTB binding domains on the cytoplasmic tail of c-fms (Lioubin et ah, 1994). 
Analysis of BAC1.2F5 whole cell lysates has shown that this cell line expresses Grb2 
(24 kDa), Sosl (ITOkDa), She (6 6 , 52 and 46kDa), c-src (55kDa) and c-cbl (120kDa) 
(Figs. 4.5.1-5.). There is no down-regulation of expression of these proteins following 
M-CSF stimulation, any apparent differences are due to unequal protein loading as 
confirmed by Coomassie Blue staining of parallel gels (data not shown).
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Fig. 4.5.1. SDS-PAGE analysis of total protein extracts from BAC1.2F5 cells immunoblotted for 
Grb2. Proteins were resolved by 10% SDS-PAGE and then blotted onto a nitrocellulose 
membrane prior to immunostaining with an anti-Grb2 mAh (Transduction Labs.). Lanes A and 
B contain lysate obtained from stimulated A431 and NIH 3T3 cells, respectively. Lanes C and D 
contain lysate obtained BAC1.2F5 cells quiesced for 24 hours in the absence of M-CSF then 
stimulated for 30 minutes at 4°C, respectively.
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Fig. 4.5.2. SDS-PAGE analysis of total protein extracts from BAC1.2F5 cells immunoblotted for 
c-src. Proteins were resolved by 10% SDS-PAGE and then blotted onto a nitrocellulose 
membrane prior to immunostaining with an anti-c-Src pAb (Santa Cruz). Lysate from 
stimulated A431 cells (A), unstimulated BAC1.2F5 cells (B), BAC1.2F5 cells stimulated for 30' at 
4°C (C), BAC1.2F5 cells stimulated for 2' at 37°C (D) and BAC1.2F5 cells stimulated for 30' at 
37°C (E) were loaded onto the gel.
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Fig. 4.5.3. SDS-PAGE analysis of total protein extracts from BAC1.2F5 cells immunoblotted for 
c-cbl. Proteins were resolved by 10% SDS-PAGE and then blotted onto a nitrocellulose 
membrane prior to immunostaining with an anti-c-Cbl pAb (Santa Cruz). Lysate from 
stimulated A431 (A) and NIH 3T3 (B) cell lines were run as controls. Lanes C, D, E and F 
contain lysate from BAC1.2F5 cells which have been stimulated for 2' at 37°C, stimulated for 30' 
at 4°C, stimulated for 30' at 37°C and unstimulated, respectively.
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Fig. 4.5.4. SDS-PAGE analysis of total protein extracts from BAC1.2F5 cells immunoblotted for 
Sosl. Proteins were resolved by 7.5% SDS-PAGE and then blotted onto a nitrocellulose 
membrane prior to immunostaining with an anti-Sosl mAh (Transduction Labs.). Lane A 
contains lysate from stimulated A431 cells. Lanes B and C contain lysates from BAC1.2F5 cells 
quiesced for 24 hours in the absence of M-CSF then stimulated for 30 minutes at 37°C, 
respectively.
A B O D E
98 —
$4 - 2
# # #
50
6 6 kDa
^ ___  52kDa
Q  46kDa
Fig. 4.5.5. SDS-PAGE analysis of total protein extracts from BAC1.2F5 cells immunoblotted for 
She. Proteins were resolved by 10% SDS-PAGE and then blotted onto a nitrocellulose 
membrane prior to immunostaining with an anti-Shc pAb (Transduction Labs ). Lane A 
contains lysate from human fibroblasts, lanes B, C, D and E contain lysates obtained from 
BAC1.2F5 cells quiesced for 24 hours in the absence of M-CSF, stimulated for 2 minutes at 37°C, 
stimulated for 30 minutes at 37°C and stimulated for 30 minutes at 4°C, respectively.
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4.6.0. M -CSF stim ulated PI 3-kinase activity in BAC1.2F5 m acrophages
The effect of M-CSF stimulation on PI 3-kinase activity in BAC1.2F5 cells was
investigated by an in vitro PI 3-kinase activity assay (chapter 3.3.9.). PI 3-kinase
activity was immunoprecipitated from BAC1.2F5 cells with an anti-p85a antibody
immobilised on agarose beads. The immunoprecipitated PI 3-kinase activity was
quantified by its ability to catalyse the incorporation o f a y-phosphate from ^^P-
radiolabelled ATP onto either PI or PI4P to produce PI3P and Pl3,4P2, respectively.
Radiolabelled lipids were resolved by thin layer chromatography and compared to
unlabelled standard. Fig. 4.6.1. is an example of a PI 3-kinase assay carried out over
a 20 minute time-course following M-CSF stimulation of BAC1.2F5 cells.
1 1 1 1 1 1Origin
Fig. 4.6.1. In vitro PI 3-kinase activity of anti-p85a immunoprecipitates from BAC1.2F5 cells. 
Phospholipids obtained from the in vitro PI 3-kinase assays were loaded onto a thin layer 
chromatography plates and run until all lipids had been separated. Lipid standards were 
visualised by exposure to iodine crystals and are indicated. Each lane corresponds to PI 3-kinase 
activity immunoprecipitated from either unstimulated BAC1.2F5 cells (A), BAC1.2F5 cells 
stimulated with 50ng ml * M-CSF for 5 minutes (B), 10 minutes (C) 15 minutes (D) and 20 
minutes (E) at 37°C. Lane F corresponds to PI 3-kinase activity immunoprecipitated from 
BAC1.2F5 cells stimulated for 20 minutes at 4°C.
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The results obtained for the PI 3-kinase assays represented in Fig. 4.6.1. were 
quantified on an Instantlmager™ and are presented in Fig. 4.6.2. M-CSF stimulated a 
3-fold increase in PI 3-kinase activity after 5 minutes which was still present by 10 
minutes but had returned to basal levels after 15 minutes (Fig. 4.6.2.). A slight 
increase was observed at 20 minutes, but this was only a 1.5-fold increase over basal 
levels (Fig. 4.6.2.). Incubation at 4°C for 20 minutes resulted in a 5-fold increase in 
PI 3-kinase activity over basal levels (Fig. 4.6.2.). Incubation of cells at 4°C appears 
to maintain PI 3-kinase activation possibly because 4°C incubations have been 
reported to slow receptor dephosphorylation (Fig. 4.6.2.).
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Fig. 4.6.2. Quantification of in vitro PI 3-kinase activity immunoprecipitated from BAC1.2F5 
cells stimulated with M-CSF measured by PI3P formation. Radiolabelled PI3 P was quantised on 
a Phosphoimager (Packard) and expressed as counts per minute, (cpm). BAC1.2F5 cells were 
incubated with SOng ml ’ M-CSF from 0 to 20 minutes at 37°C. * indicates cells incubated at 
4°C. E rro r bars indicate SEM (n=3).
To demonstrate that the immunoprecipitated PI 3-kinase activity was sensitive to 
wortmannin or LY294002, BAC1.2F5 cells were pre-incubated with both inhibitors 
prior to stimulation with M-CSF. Following treatment with inhibitors, BAC1.2F5
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cells were incubated with 50ng ml" M-CSF for 10 minutes before 
immunoprécipitation of PI 3-kinase with an anti-p85a antibody immobilised on 
protein-A agarose beads. Fig. 4.6.3. represents a PI 3-kinase assay carried out 10 
minutes following M-CSF stimulation of BAC1.2F5 cells.
PIP
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Fig. 4.6.3. In vitro PI 3-kinase activity of anti-p85a immunoprecipitates from BAC1.2F5 cells. 
Phospholipids obtained from the in vitro PI 3-kinase assays were loaded onto a thin layer 
chromatography plates and run until all lipids had been separated. Lipid standards were 
visualised by exposure to iodine crystals and are indicated. Each lane corresponds to PI 3-kinase 
activity immunoprecipitated from either unstimulated BAC1.2F5 cells (A), BAC1.2F5 cells 
stimulated with M-CSF for 10 minutes (B), and stimulated cells pre-incubated with 30nM 
wortmannin (C) and lOpM LY294002 (D).
As observed in Fig. 4.5.1. M-CSF stimulation after 10 minutes at 37°C resulted in a 2- 
3-fold increase in PI 3-kinase activity, measured by PI3P or Pl3,4P2 formation (Fig. 
4.6.4.). Incubation of BAC1.2F5 cells with the PI 3-kinase inhibitors wortmannin 
(30nM) and LY294002 (lOpM) inhibited the M-CSF stimulated increase in PI 3- 
kinase activity to levels observed in unstimulated cells (Fig. 4.6.4.).
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Fig. 4.6.4. Quantification of in vitro PI 3-kinase activity immunoprecipitated from BAC1.2F5 
cells stimulated with M-CSF measured by PI3P and PI3 4P2 formation. Radiolabelled PI3P and 
FI3 4 F2 were quantified on a Phosphoimager (Packard) and expressed as counts per minute, 
(cpm). BAC1.2F5 cells were incubated with SOng ml ' M-CSF for 15 minutes at 37°C. Cells were 
pre-incubated with PI 3-kinase inhibitors 15 minutes prior to stimulation with M-CSF. E rro r 
bars indicate SEM (n=3).
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4.7.0. Discussion
BAC1.2F5 cells require M-CSF for their survival and proliferation (Boocock et al., 
1989). Analysis of BAC1.2F5 cells by FACS analysis showed that c-fms protein 
product is expressed on the cell surface of approximately 50% of BAC1.2F5 cells and 
on 90% on U937 positive control cells (Fig. 4.1.1.). This data may be interpreted such 
that BAC1.2F5 cultures contain a mixed population of macrophages with only a sub­
population of cells actually expressing cell surface receptor, which may occur if there 
is a reversal in cell phenotype back to the parental BAC 1 cell line, however this has 
not previously been reported. A more likely explanation is that BAC1.2F5 cells were 
routinely dissociated from tissue culture vessels by treatment with a trypsin/EDTA 
solution. Trypsin, which is a broad spectrum protease activity, may have 
enzymatically cleaved the extracellular domains of a proportion of cell surface 
receptors. This cleavage may have removed portions of the M-CSF receptor that 
contained the epitope required for antibody recognition. This may account, in part, for 
the lower levels of positive BAC1.2F5 cells detected by FACS analysis compared to 
the U937 cell controls which are not an adherent cell line (Fig. 4.1.1.).
Western blot analysis with antibodies specific for the c-fms demonstrated that 
BAC1.2F5 cells express both the immature and mature receptor isoforms (Fig. 4.2.1.) 
whereas the BACl parental cell line only express the immature receptor form (Fig.
4.2.3.). Following treatment with M-CSF for 30 minutes at 37°C there is less mature 
receptor detected in cells than in unstimulated controls (Fig. 4.2.1., lane C). However 
the rate of receptor internalisation and degradation can be reduced by incubating the 
cells with M-CSF at 4°C which was demonstrated by detected levels similar to 
unstimulated eontrols (Fig. 4.2.1., lane E). Lowering the incubation temperature also
enhanced the detection of tyrosine phosphorylated proteins in whole cell lysates (Fig.
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4.2.2). In unstimulated BAC1.2F5 cells receptor tyrosine phosphorylation was not
detected in whole cell lysate (Fig. 4.2.2). However lack of detection was probably due 
to a lack of sensitivity since a basal level of tyrosine phosphorylation of both receptor 
isoforms was detected in immunoprecipitated receptor complexes (Fig. 4.3.1.). It 
appears that both receptor isoforms contain low levels of tyrosine phosphorylation. 
Phosphorylation of the mature receptor isoform may occur as a result of opportunistic 
dimérisation which activates the tyrosine kinase activity of c-fms, however this does 
not explain the phosphorylation observed in the immature receptor isoform. Fig.
4.2.3. illustrates degradation of receptor in cells stimulated with M-CSF for 30 
minutes, which can be blocked by incubation at 4°C. Removal of M-CSF from 
culture medium has been reported to upregulate receptor expression in this cell line 
and mature receptor was readily detected (Boocock et al., 1989). Phosphorylation on 
tyrosine of proteins co-immunoprecipitated with c-fms also suggests that a low level 
of reeeptor tyrosine auto-phosphorylation occurs in unstimulated cells which again not 
present at detectable levels in whole cell lysate (Fig. 4.3.1.). Receptor activation 
stimulated the association and phosphorylation of various cellular proteins at 37°C, 
and although incubations at 4°C enhance the general levels of detectable tyrosine 
phosphorylation there was no change in the number of phosphorylated proteins 
detected (Fig. 4.3.1.). However, compared to the 30 minute incubations at either 
37°C or 4°C, two additional tyrosine phosphorylated bands at 55kDa and 80kDa are 
present in immunoprecipitates from cells stimulated for 2 minutes at 37°C. These 
two phosphoproteins remain unidentified but it is possible that the 55kDa protein may 
be She.
Identification of the specific isoforms of PI 3-kinase present in BAC1.2F5 cells was
carried out by western blot analysis. Using antibodies specific to the a , P and y
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isoforms of the p85 regulatory subunit of PI 3-kinase whole cell lysate from
BAC1.2F5s were probed for p85 isoform expression. The only detectable isoform of 
p85 from BAC1.2F5 lysates was p85a and the levels of this species was not affected 
by c-fins activation with M-CSF (Fig. 4.4.1.). Western blot analysis failed to detect 
any p85P (Fig. 4.4.2.) or p85y (Fig. 4.4.3.) in BAC1.2F5 cell lysates which were 
present in control cell lines. Immunoprobing of BAC1.2F5 whole cell lysate with 
antibodies specific to the a  and P and y isoforms of the pi 10 catalytic subunit of PI 3- 
kinase detected expression of the pi 10a and the pllOy isoforms (Fig. 4.4.4. and Fig. 
4.4.6.). Expression levels of either pi 10a or pllOy were not affected by c-fins 
activation with M-CSF. Western blot analysis failed to detect any pi lOp (Fig. 4.4.5.) 
in BAC1.2F5 cell lysate which was present in control cell lines.
Analysis of PI 3-kinase activity following M-CSF stimulation of BACI.2F5 cells 
revealed that PI3-kinase activity was increased 3-fold at 5 minutes (Figs. 4.5.1. and 
4.5.2.). This suggests that activation of PI 3-kinase occurs rapidly during c-fims 
signalling in BAC1.2F5 cells. Incubation of BAC1.2F5s at 4°C further increased the 
detected levels of PI 3-kinase activity, which is probably because low temperature 
slowed down receptor dephosphorylation (Fig. 4.5.2.). The PI 3-kinase activity 
stimulated by M-CSF is most likely to be the classic pi 10a catalytic PI 3-kinase 
species as this was the predominant isoform. Although pi lOy was detected this PI 3- 
kinase activity is regulated by G-protein coupled receptors rather than receptor 
tyrosine kinases. Incubation with wortmannin and LY294002 confirmed that the PI 3- 
kinase activity immunoprecipitated with anti-p85a antibody was sensitive to PI 3- 
kinase inhibitors (Figs. 4.5.3. and 4.5.4.). It appears that BACI.2F5 cells express the
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classical p85a/pllO a class la PI 3-kinase activity which is inhibited by the fungal
inhibitor wortmannin and the synthetic LY294002, two specific PI 3-kinase inhibitors. 
It must also be borne in mind that other p85 or pi 10 subunits may also be present but
their detection may be limited by the unavailability or limits of currently available 
reagents.
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Effect of PI 3-kinase inhibitors
wortmannin and LY294002 on M-CSF
stimulated survival and proliferation of 
BAC1.2F5 macrophages.
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5.0.0. Introduction
M-CSF is an important growth factor required for the survival, proliferation and 
differentiation of monocytes, macrophages, osteoclasts and their precursors. M-CSF 
binds with high affinity, Kd = «2x10’*^ , to murine c-fins, its specific cell-surface 
receptor which is found on virtually all mononuclear phagocytes (Das and Stanley, 
1982; Welte et al., 1985).
It has been demonstrated that p85/pl 10a PI 3-kinase activity is required by the PDGF 
and EGF receptors for induction of DNA synthesis in quiescent NIH 3T3 cells (Roche 
et al., 1994; Singh et al., 1995). However, p85/p ll0a PI 3-kinase is not required for 
the propagation of a mitogenic signal by G-protein coupled receptors Bombesin and 
Lysophosphatidic Acid (LPA) nor appears to be required for M-CSF stimulated DNA 
synthesis in NIH 3T3 cells transfected with c-fins (Roche et al., 1994).
The requirement for PI 3-kinase activity during M-CSF stimulated proliferation of
macrophages has not been investigated. However a number of M-CSF signalling
studies have been carried out in c-fins transfected cell lines, with conflicting results.
When phosphorylated, Tyr^^  ^ facilitates the binding of PI 3-kinase to the activated
receptor. However, in NIH 3T3 fibroblasts the expression of c-fins which has had the
kinase insert domain deleted does not signifieantly affect M-CSF induced cell
proliferation, suggesting that tyrosine residues (Tyr^ ^^ '^ ^^ '^^ )^, involved in PI 3-kinase
and Grb2 binding, are not essential for the mitogenic signal (Reedijk et al., 1992;
Shurtleff et al., 1990). Conversely, experiments performed in transfected rat
fibroblasts (208F) demonstrate that mutation of Tyr^^^Phe in murine c-fins resulted in
a marked decrease in the ability of c-fins to bind the SH2 domain of the p85 subunit of
PI 3-kinase with a concomitant loss in PI 3-kinase activity and proliferation (Reedijk
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et al., 1992; van der Geer and Hunter, 1993). Much of the evidence that PI 3-kinase
activity is not required is either based on studies of exogenous expression of intact c- 
fins in a cell background which is not related to the haematopoietic lineage. Therefore 
determining whether PI 3-kinase activity is required for M-CSF stimulated 
proliferation in a macrophage cell line may be useful since specific inhibitors of 
macrophage proliferation may be useful for treatment of auto-immune or 
hyperproliferative diseases.
In phagocytic cells which are deprived of growth factors such as M-CSF, cell-cycle 
arrest occurs, whilst prolonged starvation leads to cell death through apoptosis (Li and 
Stanley, 1991). If growth factors are re-introduced following short periods of 
deprivation (12-18 hrs) re-entry into the cell-cycle occurs (Li and Stanley, 1991). 
There is a continual requirement for M-CSF from initiation of immediate early gene 
expression through Gi, therefore it is believed that M-CSF acts as a progression factor 
as well as a competence factor (Sherr, 1993). In the BACI.2F5 cell line removal of 
M-CSF from cell culture results in quiescence and cell cycle arrest in Gi (Morgan et 
al., 1987).
Serum starvation or incubation with PI 3-kinase inhibitors wortmannin and LY294002 
induces apoptosis in PC 12 cells and REF52 cells but not in NIH 3T3 or Balb 3T3 cells 
(Yao and Cooper, 1996; Yao and Cooper, 1995). Protection against apoptosis is 
conferred by PKB activation in Rat-1 cells and apoptosis is accelerated by PI 3-kinase 
inhibitors wortmannin and LY294002 (Kennedy et al., 1997). Additionally, neuronal 
cells transfected with wild-type PDGFr enter into apoptosis in the absence of PDGF 
or when the receptor possesses a mutated PI 3-kinase binding site (Carpenter and
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Cantley, 1996). The role of PI 3-kinase in the prevention of apoptosis in macrophages
and in other cell lineages has still to be fully defined.
Potent inhibitors of enzyme activity are extremely useful for determining what 
function the protein has in cells. Two specific PI 3-kinase inhibitors wortmannin and 
LY294002, have been used to characterise PI 3-kinase involvement in cell signalling. 
Wortmannin, produced by Pénicillium wortmannii, specifically inhibits PI 3-kinase 
activity in vitro with an IC50 of 3nM (Arcaro and Wymann, 1993). At concentrations 
at or near IC50 wortmannin has no inhibitory effect on mammalian PI 4-kinase or S. 
pombe vps34p (Vlahos et al., 1994; Wymann et al., 1996). Once bound to PI 3- 
kinase, wortmannin blocks both the lipid and protein kinase functions of PI 3-kinase 
(Arcaro and Wymann, 1993; Barker et al., 1995; Martys et al., 1996). The Lilly 
Laboratories compound, LY294002, is a derivative of quercetin and has been shown 
to inhibit PI 3-kinase activity, in vitro, with an IC50 of I.4pM (Vlahos et al., 1994). 
Although LY294002 is not as potent as wortmannin, it has the advantages that it is 
structurally unrelated to wortmannin and inhibits PI 3-kinase by a different 
mechanism, through the ATP-binding site on pi 10. These two inhibitors of PI 3- 
kinase will allow the characterisation of PI 3-kinase activity during M-CSF stimulated 
cell responses in BAC1.2F5 cells, including apoptosis and proliferation.
The main aims of chapter 5 were to determine whether PI 3-kinase activity was
required for M-CSF stimulated proliferation in BACI.2F5 macrophages. In addition
the effect of withdrawal of serum and or M-CSF was also investigated. After
determination that BAC1.2F5 cells require M-CSF and a factor in serum for
protection against apoptosis the role of PI 3-kinase in M-CSF stimulated survival was
also investigated with the PI 3-kinase inhibitors wortmannin and LY294002.
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Although both LY294002 and wortmannin are specific inhibitors of PI 3-kinase, they
possess different properties that can be exploited. Wortmannin is a more potent 
inhibitor of PI 3-kinase activity (IC50 ~ 2-3nM) than LY294002 (IC50 ~ 1.4pM), but is 
inherently unstable with a t/, of <30 minutes whereas LY294002 has a t>/, of >1 day. 
Therefore LY294002 was used in preference for experiments lasting longer than a 
day, and wortmannin was used for experiments lasting <3 hours.
To simplify interpretation I first present data on the effect of M-CSF and serum 
starvation on cell numbers before presenting data on the effects of withdrawal of these 
factors or inhibition of PI 3-kinase activity on BAC1.2F5 apoptosis.
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5.1.0. BAC1.2F5 proliferation induced by M-CSF.
Stimulation of cell proliferation by M-CSF in BAC1.2F5 cells was characterised by 
the quantification of 5-bromo-2-deoxyuridine (BrdU) incorporation (chapter 3.3.7.) 
into de novo synthesised DNA in place of thymidine (Boehringer Mannheim). BrdU 
incorporation was detected via immunofluorescence and BrdU-positive cells were 
counted and expressed as a percentage of the total cell population. A dose response 
experiment showed that BAC1.2F5 cells proliferated in response to recombinant 
murine M-CSF (R&D systems) at concentrations as low as Ing m f’ (Fig. 5.1.1.).
0.1% 10% 0.1 1.0 2.0 5.0 10.0 20.0 50.0 100.0
Serum only 10% Serum + M-CSF (ng mf^ ^
Fig. 5.1.1. The effect of recombinant murine M-CSF on the proliferation of BAC1.2F5 
cells. BAC1.2F5 cells were seeded at a density of 1.5x10^ cells per 13mm coverslip, then cultured 
for 24 hours in DMEM/10%FCS (Gibco-BRL) without M-CSF. Cells were then exposed to 
varying concentrations (O.l-lOOng ml ') of rmM-CSF (R&D systems) in fresh medium containing 
10% foetal calf serum, cultured for a further 24 hours. Cells were labelled with BrdU and 
analysed by fluorescence microscopy. E rro r bars are +S.E.M (n=J).
The proliferative response to M-CSF was dose dependent, however addition of M- 
CSF at 50.0ng ml'* induced maximum proliferation over a 24 hour period. All further 
experiments used M-CSF at 50-100 ng m f\
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5.2.0. Requirement for PI 3-kinase during M-CSF stimulated proliferation in
BAC1.2F5 cells
To determine whether PI 3-kinase was required for the observed increase in cell 
proliferation BAC1.2F5 cells that had been starved of M-CSF for 24 hours to induce 
quiescence were cultured for a further 24 hours in the presence of 50ng ml'* M-CSF. 
During the M-CSF incubation, BAC1.2F5 cells were continually incubated with 
wortmannin at either 3 or 30nM and LY294002 at either 1.4pM or lOpM. Fig. 5.2.1. 
is a representative example of a BrdU stain, de novo synthesised DNA was stained 
green in cell nuclei. M-CSF stimulated a two fold increase in the numbers of 
proliferating cells compared to serum only controls (Fig. 5.2.2.). The PI 3-kinase 
inhibitors wortmannin and LY294002, at concentrations similar to their in vitro IC50 
values or ten fold higher had no significant effect on the M-CSF stimulated increase in 
proliferating cells. This suggests that the PI 3-kinase activity which has previously 
been reported to be activated downstream of c-fins is not necessary for the 
proliferative signal mediated by c-fms in BAC1.2F5 macrophages.
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Fig. 5.2.1. The effect of PI 3-kinase inhibitors on M-CSF stimulated proliferation in
BAC1.2F5 cells. BAC1.2F5 were seeded at a density of 1.5x10'* cells per 13mm coverslip, then 
cultured for 24 hours in DMEM/10%FCS without M-CSF. Cells were then incubated in fresh 
medium containing 10% foetal calf serum and cultured for a further 24 hours containing either 
50ng ml * M-CSF (A), no M-CSF (B), 50ng ml * M-CSF and 30nM wortmannin (C) or 50ng ml * 
M-CSF and lOpM LY294002 (D). Cells were labelled with BrdU and photographed by 
fluorescence microscopy. Bars indicate 25pm.
Unstim Stim W ort 3nM W ort30nM  LY 1.4uM LY lOuM
Fig. 5.2.2. Quantification of the effect of PI 3-kinase inhibitors on M-CSF stimulated
proliferation in BAC1.2F5 cells. BAC1.2F5 cells were seeded at a density of 1.5x10“* cells per 
13mm coverslip, and then cultured for 24 hours in DMEM/10%FCS without M-CSF. Cells were 
then incubated in fresh medium containing 10% foetal calf serum and cultured for a further 24 
hours containing either no M-CSF, 50ng ml * M-CSF or 50ng ml * M-CSF and either 3nM 
wortmannin, 30nM wortmannin, 1.4pM LY294002 or lOpM LY294002. Cells were labelled with 
BrdU and analysed by fluorescence microscopy. E rro r bars are +S.E.M (/i=i).
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5.3.0. Effect of M-CSF and/or serum withdrawal on BAC1.2F5 cell density
Routinely, BAC1.2F5 cells are cultured in medium supplimented with 10% serum and 
M-CSF therefore withdrawal of M-CSF, serum or both was investigated. Over a 
period of four days the increase in cell population was monitored by counting cells 
within a defined area. BAC1.2F5 cells cultured in the presence of 10% serum and M- 
CSF increase exponentially in cell density over time with an 8-fold increase by day 
four (Fig. 5.3.1., panel A).
Fig. 5.3.1. Effect of M-CSF on BAC1.2F5 cell density in complete medium. BAC1.2F5 cells were 
seeded at a density of 1.5x10“* cells per 13mm diameter coverslip, then cultured in 
DMEM/10%FCS containing 50ng ml * M-CSF (A) or without M-CSF (B). Culture medium was 
replaced every 24 hours. Cells were analysed by light microscopy. E rro r bars are +S.E.M {n=3).
BAC1.2F5 cells approximately double their cell density every 24 hours in the 
presenee of M-CSF. However, withdrawal of M-CSF from the eulture medium 
resulted cell a quite dramatie reduction in cell doubling to once every four days, 
compared to cells eultured with M-CSF (Fig. 5.3.1., panel B).
The role of serum factors was investigated by reducing the serum concentration to 
0.1% (Fig. 5.3.2.). Under low serum conditions and without M-CSF the cell density 
does not increase in number but actually decreases over time (Fig. 5.3.2., panel A).
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This is apparent by day 3, and results in a 40% loss in cell numbers by day four (Fig.
5.3.2., panel A). Addition of M-CSF does not rescue BAC1.2F5 cells from this 
reduction in cell numbers which suggests that a factor or factors present in serum are 
also required for BAC1.2F5 survival in culture (Fig. 5.3.2., panel B). This survival 
factor does not appear to be M-CSF.
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Fig. 5.3.2. Effect of low serum on BAC1.2F5 cell density. BAC1.2F5 cells were seeded at a 
density of 1.5x10^ cells per 13mm diameter coverslip, then cultured in DMEM/0.1%FCS 
containing 50ng ml ' M-CSF (A) or without M-CSF (B). Culture medium was replaced every 24 
hours. Cells were analysed by light microscopy. E rro r bars are +S.E.M (n=3).
5.4.0. Effect of deiipidated serum and LPA on BAC1.2F5 cell density
Recently, Koh et al have identified a noncytokine component of serum that protects 
peritoneal macrophages from serum starvation-induced apoptosis (Koh et al., 1998). 
This constituent of serum is lysophosphatidic acid, (LPA), a glycerophospholipid 
normally found in serum (Koh et al., 1998). LPA induced macrophage survival was 
reportedly blocked by wortmannin or LY294002 (Koh et al., 1998). To determine 
whether LPA was the serum survival factor for BAC1.2F5 cells, the effect of 
recombinant LPA or lipid-depleted serum on BAC1.2F5 macrophage survival was 
investigated (Fig.5.4.L).
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Fig. 5.4.1. Effects of serum, M-CSF and LPA withdrawal on BAC1.2F5 cell density after 4 
days. BAC1.2F5 cells were cultured as above for 4 days. Culture medium was replaced every 24 
hours. Cells were analysed by light microscopy. E rro r bars are +S.E.M (n=i).
In the absence of serum and M-CSF there was no increase in cell numbers. However, 
incubation with serum doubled the cell density and incubation with serum and 50ng 
ml*’ M-CSF stimulated an eight fold increase in cell density (Fig.5.4.1.). 
Supplementing cells with deiipidated serum alone increased cell density compared to 
no serum control but not to the same extent as in the presence of 10% serum 
(Fig.5.4.1.). Adding 50ng ml*’ M-CSF to the deiipidated serum did not affect the cell 
density, which suggests that a lipid component of serum may be required for cell 
proliferation (Fig.5.4.1.). Serum has been estimated to contain lOOpM LPA, therefore 
routine cell culture with 10% serum contains lOpM LPA. Cells cultured in the 
absence of normal serum were also supplemented with 1 OpM LPA, however this had
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no effect cell density except for deiipidated serum containing M-CSF where a partial
increase in cell density occurred (Fig.5.4.1.). These data suggest that a lipid 
component of serum is required for full stimulation of cell proliferation by M-CSF 
and can be partially restored by lOpM LPA. However LPA alone did not increase 
cell numbers and neither could LPA substitute for 10% serum in combination with M- 
CSF. However LPA, deiipidated serum and M-CSF stimulated a small increase in cell 
numbers compared to cells cultured in the absence of deiipidated serum. However 
this effect did not represent full reconstitution of the effects of 10% serum and M-CSF 
normally observed. These data suggest that LPA is one co-factor necessary for the 
full M-CSF-stimulated proliferative response in BAC1.2F5 cells, but there is at least 
one other factor that is absent after delipidation of serum.
5.5.0. Effect of the PI 3-kinase inhibitor LY294002 on M-CSF and serum 
stimulated BAC1.2F5 cell survival
Although M-CSF stimulated proliferation of BAC1.2F5 cells does not appear to 
require PI 3-kinase activity, PI 3-kinase activity may still be required for survival in 
culture. To investigate whether PI 3-kinase activity was required for BAC1.2F5 
survival the experiments in section 5.3.0. were repeated but in the presence of 
LY294002 at lOpM. Addition of LY294002 to BAC1.2F5 cells cultured in 0.1% 
serum without M-CSF accelerated the rate of cell death measured by gross cell counts 
(Fig. 5.5.1., panel A). On day four less than 25% of the seeded population was left 
and the effect of LY294002 was apparent as early as day 2 (Fig. 5.5.1., panel A). The 
effect of LY2940002 on cell density was not rescued by supplementing the culture 
medium with serum alone (Fig. 5.5.1., panel B), suggesting that PI 3-kinase activity is 
required for the serum factor induced survival of BAC1.2F5 macrophages.
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Fig. 5.5.1. Effect of LY294002 on cell density of BAC1.2F5 cells cultured in low serum 
without M-CSF. BAC1.2F5 cells were seeded at a density of 1.5x10“* cells per 13mm diameter 
coverslip, then cultured in 0.1%FCS (A) or 10%FCS (B) containing lOpM LY294002 without M- 
CSF. Culture medium was replaced every 24 hours. Cells were analysed by light microscopy. 
Error bars are ±S.E.M (n=3).
In addition the effect of LY2940002 on cell density was not rescued by supplementing 
the culture medium with M-CSF alone (Fig. 5.5.2., panel A), again suggesting that PI 
3-kinase activity is required during M-CSF induced survival in BAC1.2F5 
macrophages.
Fig. 5.5.2. Effect of LY294002 on BAC1.2F5 cell density in medium containing 0.1% or 
10% ECS supplemented with 50ng ml * M-CSF. BAC1.2F5 cells were seeded at a density of 
1.5x10“* cells per 13mm diameter coverslip, then cultured in 0.1% FCS (A) or 10% FCS (B) 
containing lOjiM LY294002 and 50ng ml * M-CSF. Culture medium was replaced every 24 hours 
and cells were analysed by light microscopy. Error bars are ±S.E.M (n=3).
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When LY294002 was added to BAC1.2F5 cells cultured with 10% serum and 50ng
ml ’ M-CSF, there was no cell death and a small increase in cell numbers (Fig. 5.5.2.,
panel B). However, the increase in cell numbers was not comparable to that seen in 
controls in the absence of LY 294002 (Fig. 5.3.1., panel A).
Fig. 5.5.3. compares the data from Fig. 5.3.1., panel A and Fig. 5.5.2, panel B. It is 
apparent from Fig. 5.5.3. that addition of lOpM LY294002 significantly inhibited M- 
CSF stimulated increases in BAC1.2F5 cell density (f<0.0001).
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Fig. 5.5.5. Effects of LY294002 on BAC1.2F5 cell numbers when cultured in the presence of 10% 
FCS and 50ng ml * M-CSF. This figure summarises data from Figs. 5.3.1., panel A and 5.5.2., 
panel B. f<0.0001. E rro r bars are ±S.E.M (n=3).
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5.6.0. Apoptosis induced by M -CSF and/or serum  w ithdraw al in BAC1.2F5 
cells
One of the early events during apoptosis in most cell types is the translocation of 
phosphatidylserine from the inner surface of the plasma membrane to the cell surface 
(Martin et al 1995). Phosphatidylserine can then be detected in living cells with a 
FITC conjugate of annexin V. In addition, the latter stages of apoptosis are 
characterised by living cells becoming necrotic, allowing the uptake of propidium 
iodide into DNA. This only occurs during once the plasma membrane becomes 
permeable during the late stages of apoptosis. The effects of serum and M-CSF 
withdrawal from BAC1.2F5 cultures were characterised either by annexin V or 
propidium iodide staining (chapter 3.3.8.). Comparative experiments showed that 
there was little difference in the data obtained between annexin V staining and PI 
staining, although PI staining appears shortly after annexin V staining (Fig. 5.6.1.).
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Fig. 5.6.1. Effect of M-CSF withdrawal on BAC1.2F5 apoptosis measured by Annexin V 
and Propidium Iodide staining. BAC1.2F5 cells were cultured for five days in the presence or 
absence of 50ng ml'* M-CSF. Culture medium was replaced every 24 hours. Cells were stained 
with either an Annexin V-FITC conjugate or with propidium iodide (Clontech). Positive cells 
were documented by fluorescence photomicroscopy.
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PI staining was consistently stronger than annexin V, and more easily detected by 
fluorescence microscopy, and therefore PI staining was used as a probe for apoptotic 
cells in the following series of experiments. Apoptosis induced by M-CSF withdrawal 
was detected after day 4 and was characterised by a 4-fold increase in the numbers of 
apoptotic cells detected (Fig. 5.6.1.).
To establish whether PI 3-kinase activity was required for M-CSF mediated 
BAC1.2F5 survival, replicate experiments to chapter 5.5.0. were performed except 
cells were stained with propidium iodide to identify apoptotic cells. Fig. 5.6.2. shows 
the percentage of cells undergoing apoptosis in BAC1.2F5 cells cultured in medium 
containing 10% FCS with or without 50ng m f' M-CSF. The percentage apoptosis 
was no more than 4% over the 4 days (Fig. 5.6.2., panel A).
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Fig. 5.6.2. Effect of M-CSF on BAC1.2F5 apoptosis measured by propidium iodide 
staining. BAC1.2F5 cells were cultured for four days in the presence (A) or absence (B) of SOng 
ml ‘ M-CSF. Culture medium was replaced every 24 hours. Cells were stained for 15 minutes 
with propidium iodide (Clontech). Positive cells were documented by fluorescence 
photomicroscopy. E rro r bars are ±S.E.M (/i=i).
Withdrawal of M-CSF from the culture medium should not have had a measurable 
effect by day 4 based on the observations in Fig. 5.6.1. and indeed there was no
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appreciable increase in detectable apoptosis in BAC1.2F5 cells cultured without M- 
CSF over 4 days (Fig. 5.6.2., panel B).
Cells were then cultured in 0.1% serum with and without 50 ng ml'* M-CSF to 
determine whether M-CSF alone can confer protection against apoptosis in BAC1.2F5 
cells (Fig. 5.6.3.). Removal of serum from the culture medium did not dramatically 
increase the detection of apoptotic cells although by days 3 and 4 there was an 
increase in apoptosis to a maximum of 9% (Fig. 5.6.3., panel A). Withdrawal of both 
serum and M-CSF apoptosis in BAC1.2F5 cells, but this was only detected on day 3 
(20%) and day 4 (30%) (Fig. 5.6.3., panel B).
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Fig. 5.6.4. Effect of serum withdrawal on BAC1.2F5 apoptosis measured hy propidium 
iodide staining. BAC1.2F5 cells were cultured for four days in 0.1% serum in the presence (A) or 
absence (B) of 50ng ml ' M-CSF. Culture medium was replaced every 24 hours. Cells were 
stained with propidium iodide for 15 minutes (Clontech). Positive cells were documented hy 
fluorescence photomicroscopy. E rro r bars are +S.E.M («=i).
5.7.0. Apoptosis induced by LY294002 in BAC1.2F5 cells
Removal of either serum or M-CSF from culture medium induced apoptosis in a
proportion of BAC1.2F5 cells. To determine if PI 3-kinase activity was involved in
protection against apoptosis the PI 3-kinase inhibitor LY 294002 was incubated with
BAC1.2F5 cells in the presence or absence of either serum or M-CSF or both (Figs.
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5.7.1. and 5.7.2). Incubation of LY294002 with BAC1.2F5 cells in the absence of 
serum and M-CSF induced significant levels of apoptosis (Fig. 5.7.1., panel A). 
Apoptosis was apparent by day 3 with almost 60% of the cell population being 
apoptotic, increasing to 70% by day 4 (Fig. 5.7.1., panel A).
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Fig. 5.7.1. Effect of LY294002 on apoptosis in BAC1.2F5 cells cultured in 0.1% serum 
without M-CSF measured hy propidium iodide staining. BAC1.2F5 cells were cultured for four 
days in 0.1% serum, containing lOpM LY294002 in the absence (A) or presence (B) of 50ng ml ' 
M-CSF. Culture medium was replaced every 24 hours. Cells were stained with propidium 
iodide for 15 minutes (Clontech). Positive cells were documented hy fluorescence 
photomicroscopy. E rro r bars are ±S.E.M (n=3).
Addition of M-CSF to BAC1.2F5 cells cultured in 0.1% serum and lOpM LY 294002 
reduced the LY294002 induced increase in apoptosis at day 3 to 30%, half the 
percentage observed in the absence of M-CSF (Fig. 5.7.1., panel B). However by day 
4 the percentage of apoptotic cells was almost 70%, similar to that observed on day 4 
in the absence of M-CSF (Fig. 5.7.1., panel B).
Addition of 10% serum to BAC1.2F5 cells cultured in lOpM LY 294002 reduced the 
LY294002 induced increase in apoptosis at day 3 to 15%, a quarter of the percentage 
observed in the absence of M-CSF (Fig. 5.7.2., panel A). By day 4 the percentage of
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apoptotic cells was almost 40%, not as high as that observed on day 4 in the absence 
of M-CSF (Fig. 5.7. 2., panel A). Culture of BAC1.2F5 cells in the presence of both 
serum and M-CSF significantly reduced the increase in apoptosis detected by day 4 
induced by lOpM LY294002 (Fig. 5.7. 2., panel B).
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Fig. 5.7.2. Effect of LY294002 on apoptosis in BAC1.2F5 cells cultured in 10% serum and 
50ng ml * M-CSF measured by propidium iodide staining. BAC1.2F5 cells were cultured for four 
days in 10% serum, containing lOpM LY294002 in the absence or presence of 50ng ml^ M-CSF. 
Culture medium was replaced every 24 hours. Cells were stained with propidium iodide for 15 
minutes (Clontech). Positive cells were documented by fluorescence photomicroscopy. E rro r 
bars are ±S.E.M {n=3).
Direct comparison of BAC1.2F5 cells cultured in 10% serum and 50ng ml' M-CSF to 
cells cultured identically but including lOpM LY 294002 demonstrates that, although 
in relation to the total cell population analysed there are only very subtle changes 
observed, there was a significant (f<0.0001) difference (Fig. 5.7.3.). Addition of LY 
294002 to normal BAC1.2F5 cultured cells induced a greater than 10 fold increase in 
the number of apoptotic cells by day 4 (Fig. 5.7.3.).
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Fig. 5.7.3. Effects of LY294002 on BAC1.2F5 cell survival measured by detection of
apoptotic cells. This figure is a comparison of the data represented in Figs. 5.6.2., panel A and 
5.7.2., panel B. P<0.0001. E rro r bars are ±S.E.M (n=3).
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5.8.0, Effect of delipidated serum  and LPA on BAC1.2F5 apoptosis
The effect of LPA on BAC1.2F5 macrophage apoptosis, measured by propidium 
iodide uptake, was investigated by incubating cells with lipid depleted serum over 4 
days in the presence or absence of M-CSF or LPA (Fig. 5.8.1.). In the absence of 
serum and M-CSF BAC1.2F5 macrophages become apoptotic with almost 55% of 
cells present staining positive (Fig. 5.8.1.). Addition of 10% serum almost completely 
blocked apoptosis and this was augmented by incubation with 50ng m f’ M-CSF (Fig.
5.8.1.).
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Fig. 5.8.1. Effects of sreum, M-CSF and LPA withdrawal on BAC1.2F5 apoptosis after 4 
days. BAC1.2F5 cells were cultured as above for 4 days. Culture medium was replaced every 24 
hours. Cells were analysed by fluorescence microscopy. E rro r bars are ±S.E.M (/i=i).
Cells cultured in delipidated serum were apoptotic (« 40%) but this was lower than in
the complete absence of serum and was reduced further, but not rescued completely
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with M-CSF. This suggests that a lipid factor found in serum provides a limited
protection against apoptosis in BAC1.2F5 macrophages. Addition of lOpM LPA to 
cells cultured in the absence of serum or M-CSF did not prevent apoptosis (»42%), 
however inclusion of either M-CSF or delipidated serum significantly reduced the 
number of apoptotic cells («18% and «25%, respectively) (Fig. 5.8.1.). Culture of 
BAC1.2F5 cells in delipidated serum supplemented with M-CSF and LPA reduced the 
levels of apoptosis to those seen in serum and M-CSF/serum controls (Fig. 5.8.1.). 
These data suggest that the lipid factor in serum that is required for protection against 
apoptosis in BAC1.2F5 macrophages may be LPA. However, LPA is not the only 
factor in serum required for BAC1.2F5 survival since delipidated serum also contains 
a component that prevents maximal induction of apoptosis. In addition, M-CSF and 
LPA act synergistically to inhibit apoptosis and this is further enhanced by a third 
factor or factors present in serum.
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5.9.0. Discussion
BAC1.2F5 cells are a sub-clone of the BACl cell line and depend on M-CSF for 
survival and proliferation and have previously been shown to respond in a dose 
dependent manner to increasing concentrations of recombinant murine M-CSF growth 
factor (Morgan et ah, 1987). This was confirmed for the BAC1.2F5 clone obtained 
from E. Richard Stanley (AECOM, New York) (Fig. 5.1.1.). Treatment of 
BAC1.2F5 cells with M-CSF induced cell proliferation in a dose dependent manner 
with a maximal 2-fold increase in DNA synthesis after 24 hours stimulated by 50ng 
ml ' M-CSF (Fig. 5.1.1.). All future experiments with BAC1.2F5 cells were carried 
out at either 50 or lOOng ml ' M-CSF to stimulate maximum cell activation.
It has previously been demonstrated that loss of Tyr^^  ^ of c-fins, the key binding site 
for PI 3-kinase reduced M-CSF stimulated proliferation in transfected Rat-2 cells but 
did not block DNA synthesis stimulated by M-CSF in transfected NIH 3T3 cells 
(Shurtleff et al., 1990; van der Geer and Hunter, 1993). Apart from the different cell 
backgrounds the only differences in these studies were that in Rat-2 fibroblasts, both 
the PI 3-kinase and the Grb-2 binding site were mutated but only the PI 3-kinase 
binding site in NIH 3T3 cells. Therefore it is possible that although the major PI 3- 
kinase binding site is Tyr^^ ,^ PI 3-kinase activation can occur indirectly via Grb-2 
since the Grb-2 SH2 domain has been shown to associate with activated PI 3-kinase in 
human monocytes (Saleem et al., 1995). It is also possible that only Grb2 binding is 
involved in proliferation and therefore loss of both binding sites would abrogate direct 
and indirect activation of PI 3-kinase. The possible involvement of PI 3-kinase in M- 
CSF stimulation of proliferation in macrophages was investigated in the BAC1.2F5 
cell line using the PI 3-kinase-specific inhibitors wortmannin and LY294002 (Figs.
5.2.1. and 5.2.2.). DNA synthesis was quantified by BrdU incorporation and Fig.
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5.2.1. illustrates a typical experiment. Addition of either wortmannin or LY294002 at
concentrations which have previously been reported to inhibit PI 3-kinase activity in
vitro had little or no effect on M-CSF-stimulated cell proliferation present 24 hours
after M-CSF stimulation (Fig. 5.2.2.). Therefore it appears that initiation of de novo
DNA synthesis and cell proliferation is not dependent on PI 3-kinase activation in
BACI.2F5s and probably macrophages in general.
BAC1.2F5 cells have been extensively characterised with respect to cell morphology 
and although M-CSF has been demonstrated to be required for BAC1.2F5 survival, 
the exact requirement for PI 3-kinase activity for M-CSF mediated survival has yet to 
be investigated. Before investigating the role of PI 3-kinase, the effects of M-CSF 
and serum withdrawal on BAC1.2F5 cell numbers were studied in order to 
characterise fully the normal BAC1.2F5 responses. Stimulation of quiescent 
BAC1.2F5 cells in the presence of 10% serum caused cell doubling every 24 hours 
resulting in an 8 -fold increase in cell numbers observed by day four. The absence of 
M-CSF dramatically inhibited cell proliferation and only a 2-fold increase in cell 
numbers was observed by day 4 (Fig. 5.3.1.). In addition, the net effect on cells 
cultured in low serum, (0.1%) and in the absence of M-CSF was no net gain but a 
reduction of cell numbers by day 4 (Fig. 5.3.2.). Addition of M-CSF did not rescue 
this response (Fig. 5.3.2.). Therefore, although M-CSF is required for BAC1.2F5 
proliferation, it is not the only factor required and must act synergistically with 
another factor, or factors present in foetal calf serum. Recently it has been noted that 
lysophosphatidic acid (LPA), a phospholipid constituent of serum is required by 
macrophages for protection against apoptosis mediated by a PI 3-kinase dependent 
pathway with similar potency to M-CSF (Koh et al., 1998). Incubation of BACI.2F5 
cells with delipidated serum, which does not contain LPA, but supplemented with
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either synthetic LPA or M-CSF or both did not mimic the increases in cell numbers
observed in the presence of normal serum and M-CSF (Fig. 5.4.1.). This suggests that 
although M-CSF stimulated the survival/proliferation of BAC1.2F5 macrophages in 
normal serum conditions, there is a serum factor which is removed by serum 
delipidation, that may also be required for BAC1.2F5 survival or proliferation.
Addition of the PI 3-kinase inhibitor, LY294002, induced cell death in low serum 
conditions resulting in substantial cell loss (Fig. 5.5.1., panel A). However, in the 
presence of 10% serum (Fig. 5.5.1., panel A), there was marginally less cell loss 
compared to low serum conditions (Fig. 5.5.1.). Addition of M-CSF to cells cultured 
in low serum had a similar effect on cell death as 1 0 % serum, but did not prevent the 
PI 3-kinase inhibitor from blocking cell survival (Fig. 5.5.2.). The presence of 
LY294002 blocked the 8 -fold increase in cell numbers observed in the presence of 
10% serum and M-CSF in that there was only a 2-fold doubling in cell numbers (Fig.
5.5.2.). It appears that there is another factor required in addition to M-CSF for 
BACI.2F5 survival or proliferation. What is appearing is a scenario where there is a 
balance between survival and proliferation in BAC1.2F5 cells which is not regulated 
by M-CSF alone. The increase in cell numbers of BAC1.2F5 cells after 2-3 days 
requires M-CSF and serum components which are both PI 3-kinase dependent.
The previous results showing an effect of PI 3-kinase inhibitors on M-CSF-induced 
increases in cell numbers, but little effect on proliferation, strongly suggested that a 
major effect of these inhibitors was on cell survival. To formally investigate the role 
of PI 3-kinase activity in cell survival the effect of LY294002 on apoptosis was 
investigated. It is known that PI 3-kinase activity is essential for the activation of a 
pathway, downstream of various growth factor receptors, that leads to a protection
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against apoptosis in a number of cell types. PI 3-kinase is an integral part of pathways
by which insulin and NGF prevent apoptosis (Minshall et al., 1996), and PI 3-kinase 
products bind to and activate PKB, with high affinity (Alessi et al., 1997). Activation 
of PKB in various cell lines has been shown to stimulate survival, proliferation, 
differentiation, GLUT4 translocation, glycogen synthase kinase-3 (GSK3) down- 
regulation and up-regulation of E2F transcription factor expression (Marte and 
Downward, 1997). Phospholipid vesicles containing PI3 4P2 specifically bind to PKB 
via its PH domain causing dimérisation and activation of PKB, in vitro (Franke et al., 
1997; Klippel et al., 1997). Association of Pl3,4P2 and Pl3,4 ,sP3 with the PH domain of 
PKB cause its translocation to the plasma membrane enabling the PKB kinase, PDK- 
1, to phosphorylate and activate the PKB kinase activity (Stephens et al., 1998).
Measurement of cell survival or apoptosis was carried out either by annexin V or 
propidium iodide (PI) uptake. Armexin V is a cell surface marker of one of the early 
events during apoptosis whereas PI uptake into DNA only occurs in the latter stages 
of apoptosis, in necrotic cells. Either method is a valid marker for apoptosis and both 
were used to characterise apoptosis induced by M-CSF withdrawal from BAC1.2F5 
cells (Fig. 5.6.1.). Annexin V staining indicated that apoptosis was stimulated as early 
as 24 hours after M-CSF withdrawal and increased over time, however staining was 
relatively weak. In contrast PI staining only indicated apoptosis after day 4, however 
PI staining was much stronger and so PI staining was selected in preference to 
annexin V as a marker for apoptosis in the latter experiments. Therefore in light of 
this data it is assumed that M-CSF is required for BAC1.2F5 survival. The 
experiments on BAC1.2F5 survival and apoptosis in the presence of M-CSF and 
high/low serum concentrations were replicated using the PI 3-kinase inhibitor 
wortmannin at lOOnM, which gave essentially the same results (data not shown).
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The effects of M-CSF, serum and LPA on apoptosis were investigated over a 4 day
time period. As indicated there was little or no apoptosis in the presence of both 10% 
serum and M-CSF (Fig. 5.6.2., panel A), and M-CSF withdrawal had no effect (Fig.
5.6.2., panel B) thus 10% serum alone was sufficient for protection against apoptosis 
over this time period. Withdrawal of serum did have a small effect on apoptosis by 
day 4 (« 12%) and this was augmented by the withdrawal of M-CSF as well (Fig.
5.6.4., panel B). Under these conditions apoptosis was detected by day 3 and over 
25% of cells were apoptotic by day 4. Addition of LY294002 substantially 
accelerated apoptosis in M-CSF and serum deprived BAC1.2F5 cells and apoptosis 
was detected by day 3 with almost 75% of cells being apoptotic by day 4 (Fig. 5.7.1., 
panel A). The effect of LY294002 was slightly reduced by addition of M-CSF to cells 
grown in low serum, but apoptosis was still evident and at least 70% of cells were 
apoptotic by day 4 (Fig. 5.7.1., panel B). Replacing M-CSF with serum had a more 
dramatic effect, and LY294002-induced apoptosis was reduced but not to levels 
observed in the absence of LY294002 (Figs. 5.7.2., panel A and 5.6.2., panel B). 
However this reduction in apoptosis was augmented by addition of M-CSF (Fig.
5.7.2., panel B). If the observed data is compared on a common axis (Fig. 5.7.3.) it is
obvious that inhibition of PI 3-kinase activity does block M-CSF stimulated survival
of BAC1.2F5 macrophages. However it is also evident that M-CSF alone does not
potentiate survival of BAC1.2F5 macrophages and there is a degree of synergism
between constituents of serum and M-CSF for the potentiation of BAC1.2F5 survival.
PI 3-kinase activity does appear to be required for protection against apoptosis in
BAC1.2F5 cells but it does not appear to be an absolute requirement. Since LPA has
been shown to be a factor involved in macrophage survival it is possible that this is
the serum constituent that is responsible for macrophage survival in addition to M-
CSF. Investigation of LPA has revealed that it can act alone or in concert with M-
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CSF to partially reduce apoptosis in cells cultured in low serum but does not block
apoptosis completely which suggests that there is another factor in serum which is 
required for protection against apoptosis in BAC1.2F5 macrophages. This is home 
out by the observation that M-CSF, recombinant LPA and delipidated serum together 
block apoptosis similar to levels seen in M-CSF and 10% serum treated cells. The 
data also indicates that M-CSF, LPA and the third serum factor or factors all have a 
positive effect on cell survival but only mediate their full effects together. Therefore, 
BAC1.2F5 cells differ from peritoneal macrophages, which are known to be poor 
proliferators (Yusoff et al., 1994), with regard to there requirement of serum factors 
for survival (Koh et al., 1998). In addition it is possible that other growth factors such
as GM-CSF or even M-CSF itself which may be present in serum at very low
concentrations.
In summary, these data indicate PI 3-kinase activity is:
(a) required for increases in cell numbers induced by M-CSF.
(b) not required for M-CSF stimulated proliferation.
(c) required to prevent cells undergoing apoptosis.
Thus the balance between the lack of increase in cell numbers when cells are 
stimulated with M-CSF in the presence of PI 3-kinase inhibitor is due to a preferential 
PI 3-kinase requirement for prevention of apoptosis, rather than a requirement for PI 
3-kinase activation during the proliferation signal.
In addition several co-factors for survival and proliferation are necessary to obtain 
maximal increases in cell numbers in response to M-CSF. Lack of these factors leads 
to apoptosis. Inhibition of PI 3-kinase activity can overcome the presence of these 
survival factors leading to increases in apoptosis. Thus these survival factors are
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likely to feed into a similar PI 3-kinase-dependent pathway. A combination of
survival factors with M-CSF potentiates BAC1.2F5 survival and all are required 
before M-CSF can stimulate a proliferative signal. The balance between survival and 
proliferation is therefore mediated by separate signalling pathways downstream of c- 
fins in BAC1.2F5 macrophages, with PI 3-kinase activity required for protection 
against apoptosis and therefore cell survival.
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Effect of M-CSF on BAC1.2F5 cell
morphology and vesicle formation is 
inhibited by PI 3-kinase inhibitors
wortmannin and LY294002.
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6.0.0. Introduction
Addition of M-CSF to BAC1.2F5 cells, quiesced for 24 hours in the absence of 
growth factor, stimulates rapid morphological changes including formation of lamellar 
processes and membrane ruffling within minutes of re-addition of growth factor 
(Boocock et al., 1989).
PI 3-kinase has been implicated in mediating growth factor stimulated vesicular 
membrane traffic. It is thought to mediate the earliest steps leading from ligation of 
cell surface receptors to increased cell surface ruffling. It was first demonstrated that 
PI 3-kinase activity was important for vesicle trafficking by the essential role for 
Vps34p, the yeast homolog of Pl-specific 3-kinase, in late Golgi-vacuole trafficking in 
S. cerevisiae (Herman and Emr, 1990; Roth and Stemweis, 1997; Stack and Emr, 
1994). Since Pl-specific 3-kinase is homologous to Vps34p and so only produces one 
lipid product it has been proposed that it and its product, PI3P, are important in the 
correct control of trans-golgi network-lysosome trafficking, late endosome-lysosome 
trafficking and endosomal recycling (Rameh et al., 1995). Additionally, PI3 4P2 and 
Pl3,4 ,5P3 the lipid products of the p85/pl 10 lipid kinase activity also appear to be 
involved in late endosome to lysosome trafficking and endosomal recycling 
(Downward, 1995). PI3P and Pl3,4,sP3 may have roles in vesicle trafficking, Pl3,4,5P3 
may activate an ARNO/cytohesin-l/Grp-1 family member to regulate the assembly of 
coated vesicles (Toker and Cantley, 1997).
The most compelling evidence in support of a role for PI 3-kinase activity during 
vesicle trafficking comes from studies conducted with PDGFr mutants (Zell et al., 
1996). When the PI 3-kinase binding site on the PDGFr is mutated in fibroblasts 
blockage of PDGF-dependent receptor lysosomal degradation occurs (Shpetner et al.,
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1996). Studies carried out in fibroblasts have shown that in the presence of
wortmannin, trafficking of the internalised PDGF receptor is arrested at a 
juxtamembrane site, prior to reaching the sorting endosome (Shpetner et al., 1996).
Although wortmannin inhibits PI 3-kinase activity, causing an almost complete 
decrease in cellular levels of PIs,4P2 and Pl3,4,5P], there is only a 70% decrease in the 
levels of PI3P (Shpetner et al., 1996). Any effects of wortmannin or LY 294002 at 
doses which only inhibit PI 3-kinase may preclude involvement of Pl-specific 3- 
kinase products and are therefore useful tools for studying endocytotic events. 
Wortmannin and LY294002 have been shown to inhibit fluid-phase pinocytosis and 
Fc receptor mediated phagocytosis in macrophages, but with little effect on receptor 
mediated endocytosis of LDL (Araki et al., 1996), and so PI 3-kinase activity was 
therefore implicated in macropinocytosis and not micropinocytosis. In addition Araki 
et al have concluded that PI 3-kinase is necessary for closure of macropinosomes and 
phagosomes into intracellular organelles (Araki et al., 1996). Wortmannin also 
partially inhibits transferrin receptor appearance at the cell surface in CHO cells by 
increasing the internalisation rate and decreasing receptor recycling rate and 
hypervesiculation at the recycling compartment (Martys et al., 1996). Thus it appears 
that during receptor mediated endocytosis wortmannin sensitive enzymes are present 
at three stages; internalisation; transit from early endosomes to the recycling and 
lysosomal compartments and transit from recycling compartments to the cell surface 
activities which appear to be independent of PI3P formation (Martys et al., 1996).
It is apparent that a function for PI 3-kinase activity remains to be clearly defined 
during vesicular transport particularly downstream of receptor mediated endocytosis 
in macrophages, a cell line which is particularly suited to this cellular response. The
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aims of this results chapter were two fold. Firstly to characterise the effects of PI 3-
kinase inhibitors on changes on vesicle formation and secondly to quantify the effects 
of PI 3-kinase inhibitors on cell morphology stimulated by M-CSF in the BAC1.2F5 
macrophage cell line.
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6.1.1. M-CSF stimulated morphological changes in BAC1.2F5 macrophages.
The effect of M-CSF on cell morphology was characterised by time-lapse video and 
photo-microscopy and quantified by calculating the percentage of cells containing 
vesicles in the total cell population. Prior to stimulation BAC1.2F5 cells were 
quiesced in the absence of M-CSF for 24 hours (To) (Fig. 6.1.1.). In the absence of 
M-CSF cells appear rounded with no discernible cellular structure, little or no 
membrane ruffling/activity and few if any intracellular vesicles (To) (Fig. 6.1.1.).
Fig. 6.1.1. Time-lapse photomicroscopy of the effect of M-CSF on BAC1.2F5 cells. Cells were 
quiesced for 24 hours in the absence of M-CSF (To), then stimulated with lOOng ml * M-CSF and 
recorded for 90 minutes by time-lapse photomicroscopy (Tg, T 1 5, T 3 0 , T^o and T 9 0 ). This is a 
representative example of at least three independent experiments. Bar indicates 20pm.
Within 5 minutes (T5) of M-CSF (lOOng ml ') addition small vesicles begin to 
accumulate at the plasma membrane (see Chapter 7, Figs. 7.7.1 and 7.7.2), and they 
migrate towards the periphery of the nucleus within minutes of forming (Fig. 6.1.1., 
Tis^Tso). The small vesicles tend to coalesce forming large macrovesicles which
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remained at a peri-nuclear location for up to 90 minutes after addition of M-CSF (Fig.
6.1.1., T90). Beginning 5 minutes after stimulation and continuing for up to 90 minutes 
the formation of vesicles is accompanied by cell spreading, pseudopod formation and 
upregulation of membrane activity including membrane ruffling which is associated 
with membrane internalisation (Fig. 6.1.1.). M-CSF stimulates rapid vesicle 
formation in BAC1.2F5 macrophages accompanied by increased membrane activity 
and cell spreading.
6.2.1. Effect of preincubation of LY294002 on M-CSF stimulated morphological 
changes in BAC1.2F5 macrophages
The role played by PI 3-kinase during M-CSF stimulated changes in cell morphology 
was investigated using the PI 3-kinase inhibitors wortmannin and LY294002. 
Wortmannin and LY294002 are specific inhibitors of PI 3-kinase activity at or near 
their IC50 values, (3nM and 1.4pM, respectively). Pre-incubation of BAC1.2F5 cells 
for 30 minutes with LY294002 at 1.4 pM inhibited M-CSF-mediated changes in cell 
morphology and vesicle formation (Fig. 6.2.1., top panel, T30). In the presence of 
either 1.4pM or lOpM LY294002 there was far less vesicle formation than in 
untreated cells (Fig. 6.2.1., top and bottom panels, T30). The reduction in vesicle 
formation was quantified and is presented in Fig. 6.2.3. Cells that contained vesicles 
at 30 minutes following M-CSF stimulation (T30) possessed only a few, if any, 
vesicles by 60 minutes (Teo) whereas untreated cells contained more vesicles per cell 
(Fig. 6.2.1., top and bottom panels, Tgo). In addition the rapid stimulation of 
membrane ruffling was partially inhibited by both concentrations of LY294002, 
resulting in a reduction of cell spreading and morphological changes which suggests
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Fig. 6.2.1. Time-lapse photomicroscopy of BAC1.2F5 cells pre-incubated with LY294002 prior 
to stimulation with M-CSF. Cells quiesced for 24 hours were pre-incubated (T.30) for 30 minutes 
with either 1.4pM (top panel) or lOfiM LY294002 (bottom panel). Cells were then stimulated 
with lOOng ml * M-CSF (To) and recorded for a further 60 minutes (T30 and Too). This is a 
representative example of at least three independent experiments.
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that PI 3-kinase activity is also required for M-CSF stimulated actin rearrangement in
BAC1.2F5 macrophages.
6.2.2. Effect of preincubation of w ortm annin on M -CSF stim ulated 
morphological changes in BAC1.2F5 macrophages
The effects of wortmannin were similar to LY294002 and pre-incubation of 
BAC1.2F5 cells for 30 minutes with wortmannin at either 3 or 30nM almost 
completely inhibited vesicle formation (T30) and membrane ruffling (Fig. 6.2.2., top 
and bottom panel) after M-CSF stimulation. Although a proportion of the cell 
population did form vesicles, the vesicles did not migrate towards the nucleus and 
there was only a slight change in cell morphology but neither responses were 
comparable to M-CSF control (Fig. 6.1.1.).
6.2.3. Q uantification of the effects of inhibitor pre-incubation on M-CSF 
stim ulated vesicle form ation
The effects of PI 3-kinase inhibitors wortmannin and LY294002 were quantified by 
counting the number of cells containing vesicles expressed as a percentage of the total 
cell population (Fig. 6.2.3.). Although the numbers of cells possessing vesicles at T30 
was similar between untreated cells and cells treated with inhibitors, by 60 minutes 
(Tôo) there was a substantial decrease in the numbers of cells containing vesicles (Fig.
6.2.3.). What is not apparent from the graph is that cells were scored positive if they 
contained at least one vesicle, and therefore does not represent the effect of LY294002 
or wortmannin on vesicle formation within individual cells, i.e. the amount of 
vésiculation per cell.
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Fig. 6 .2 .2 . T im e-lap se  ph otom icroscop y  o f  B A C 1.2F 5  cells pre-in cu b ated  w ith  w ortm an n in  p rior  
to stim u lation  w ith  M -C SF . C ells  q u iesced  for  24  hours w ere  pre-in cu b ated  (T .3 0 ) for  30  m inutes  
w ith 3n M  (top  p an el) or 30n M  w ortm an n in  (bottom  p anel). C ells w ere  then  stim u lated  w ith  
lOOng m l ' M -C SF  (To) an d  recorded  for  a fu rth er  60  m inutes (T 3 0  and  Too). T his is a 
rep resen tative exam p le  o f  at least three in d ep en d en t experim ents.
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Fig. 6.2.3. Quantification of vesicle translocation in BAC1.2F5 cells stimulated with M-CSF 
prior to treatm ent with PI 3-kinase inhibitors. Photomicrographs were analysed and cells ■ 
containing at least one vesicle were scored positive. E rro r bars are ±S.E.M (n=3).
6.3.1. Effect of LY294002 on morphological changes in BAC1.2F5 
macrophages after M-CSF stimulation
To investigate whether M-CSF stimulated morphological responses and vesicle 
formation in BAC1.2F5 cells were reversible the PI 3-kinase inhibitors were added 30 
minutes after stimulation with M-CSF. BAC1.2F5 cells were treated 30 minutes after 
M-CSF stimulation with LY294002 at 1.4pM or 10 pM (T30). LY294002 at 1.4pM 
had no significant effect on M-CSF stimulated increases vésiculation or 
morphological changes in BAC1.2F5 cells (Fig. 6.3.1., top panel). However, 
treatment with lOpM LY294002 inhibited the changes in morphology and induced 
cell rounding, and M-CSF stimulated vesicles were no longer present by 60 minutes 
(Fig. 6.3.2., bottom panel, Tôo).
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Fig. 6.3.1. Time-lapse photomicroscopy of BAC1.2F5 cells incubated with LY294002 after 
stimulation with M-CSF. Cells quiesced for 24 hours were stimulated for 30 minutes with lOOng 
ml ' M-CSF (To). Cells were then treated (T3 0) with either 1.4pM (top panel) or lOjiM LY294002 
(bottom panel) and recorded for a further 60 minutes (Too and T 9 0). This is a representative 
example of at least three independent experiments.
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6.3.2. Effect of wortmannin on morphological changes in BAC1.2F5 
macrophages after M-CSF stimulation
At 3nM, wortmannin significantly reduced the effect of M-CSF on cell morphology 
(Fig. 6.3.2., top panel, Teo), and the proportion of the cell population containing 
vesicles was reduced by 60 minutes (Fig. 6.3.2., top panel, Tôo). The effect of 
wortmannin was more pronounced by treatment with 30nM wortmannin (Fig. 6.3.2., 
bottom panel, Teo) which reversed the M-CSF stimulated vesicle formation observed 
at 30 minutes, prior to addition of wortmannin (Fig. 6.3.2., bottom panel, T30). At 
30nM, wortmannin also inhibited the M-CSF induced membrane ruffling and cell 
spreading (Fig. 6.3.2., bottom panel, Teo).
6.3.3. Quantification of the effects of inhibitors on vesicle formation after M- 
CSF stimulation
The effects of PI 3-kinase inhibitors wortmannin and LY294002 were quantified by 
counting the number of cells containing vesicles expressed as a percentage of the total 
cell population (Fig. 6.2.3.). Although the numbers of cells possessing vesicles at T30 
was similar between untreated cells and cells treated with inhibitors, by 60 minutes 
(Tôo) there was a substantial decrease in the numbers of cells containing vesicles (Fig.
6.2.3.). What is not apparent from the graph is that cells were scored positive if they 
contained at least one vesicle, and therefore does not represent the effect of LY294002 
or wortmannin on vesicle formation within individual cells, i.e. the vésiculation per 
cell.
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Fig. 6.3.2. Time-lapse photomicroscopy of BAC1.2F5 cells incubated with wortmannin after 
stimulation with M-CSF. Cells were quiesced for 24 hours then stimulated for 30 minutes with 
lOOng ml ' M-CSF (To). Cells were then treated (T30) with either 3nM or 30nM wortmannin. 
Cells were recorded for a further 60 minutes (Too and T90). This is a representative example of at 
least three independent experiments.
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Fig. 6.3.3. Quantification of vesicle formation in BAC1.2F5 cells stimulated with M-CSF after 
treatm ent with PI 3-kinase inhibitors. Photomicrographs were analysed and cells containing at 
least one vesicle were scored positive. The time-point of inhibitor addition are indicated by the 
asterisks. E rro r bars are ±S.E.M (n=3).
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6.4.0. Discussion
The response to M-CSF is characterised by various changes in the morphology of 
BAC1.2F5 cells. These morphological changes were orignally characterised by 
Boocock et al and have been determined to occur at concentrations of M-CSF which 
promote survival but not proliferation (Boocock et a l, 1989). The addition of M- 
CSF to BAC1.2F5 cells stimulated the rapid formation of membrane ruffles and cell 
spreading which occurs after 15 minutes (Fig. 6.1.1.). After 30 minutes small 
punctate vesicles were present at the plasma membrane and in the newly forming 
lamellar processes which are characteristic of BAC1.2F5 cell spreading (Fig. 6.1.1.). 
After 60 minutes the cells were significantly more spread out than before M-CSF 
addtion and the small, punctate vesicles had coalesced to form larger vesicles, which 
have clustered around the nucleus of the cell, these vesicles persist for up to 90 
minutes following M-CSF stimulation (Fig. 6.1.1.). The appearance of these large 
macrovesicles around the nucleus is similar to regulated macropinocytosis, which is 
different from clathrin-mediated endocytosis and is observed in many cells following 
stimulation, including macrophages (Swanson, 1989). Formation of macropinosomes 
is characterised by the formation of actin-rich ruffling at the periphery of the 
spreading cell and have been observed in M-CSF stimulated bone marrow derived 
macrophages (Racoosin and Swanson, 1989; Swanson, 1989). However, one of the 
characteristic features of macropinocytosis is that they are relatively short-lived in the 
cell, shrinking and disappearing after only 15 minutes (Swanson, 1989). Therefore, it 
is unlikely that internalisation of Q-fins occurs via regulated macropinocytosis but 
more likely via clathrin-mediated endocytosis, which is a classical characteristic of 
receptor mediated endocytosis (Swanson, 1989).
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The PI 3-kinase-specific inhibitors wortmannin and LY294002 were used to
determine whether PI 3-kinase activity was involved in any of these M-CSF 
stimulated changes in BAC1.2F5 cells. Addition of the PI 3-kinase inhibitors to 
quiescent BAC1.2F5 cells before stimulation with M-CSF significantly reduced cell 
spreading, vesicle formation and membrane ruffling at concentrations which are 
believed to be specific for PI 3-kinase (Figs. 6.2.1. and 6.2.2.). The effects of 
LY294002 were more potent compared to wortmannin and may reflect the greater 
stability of LY294002, the half-life of wortmannin being only 30 minutes in culture 
(Vlahos et al., 1994). The formation of vesicles in M-CSF stimulated cells was scored 
on the presence or absence of cytosolic vesicle appearance (Fig. 6.2.3.). Although 
there was an initial increase in the number of cells containing vesicles in the presence 
of either wortmannin or LY294002, there were at least 50% less vesicle containing 
cells at 60 minutes post-stimulation than in M-CSF controls (Fig. 6.2.3.). Addition of 
the PI 3-kinase inhibitors after initial vesicle formation (30 minutes) inhibited further 
vesicle formation and cell spreading but no observed effect on membrane ruffling was 
observed (Figs. 6.3.1. and 6.3.2.). Inhibition of further vesicle formation and cell 
spreading appeared to be dose dependent and very rapid, occuring within 15 minutes 
of inhibitor addition (Figs. 6.3.1. and 6.3.2.). Quantification of vesicle formation in 
BAC1.2F5 cells treated with PI 3-kinase inhibitors following M-CSF stimulation 
confirmed that cells treated with inhibitors contained substantially less vesicles from 
75% of cells in controls to less than 20% in the presence of inhibitors (Fig. 6.2.3.).
Together these data suggest that PI 3-kinase activity may not be required for the initial 
formation of endocytic vesicles, but may be required for their integrity and sub- 
cellular trafficking to downstream endosomal and/or lysosomal compartments in 
BAC1.2F5 macrophages. In addition wortmannin and LY294002 inhibited cell
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spreading and membrane ruffling, two cytoskeletally controlled events which suggests
that formation of PI 3-kinase products such as PI3,4,5 ^ 3  is important for reorganisation 
of the actin cytoskeleton possibly by regulation of the rho family GTPase, rac.
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Subcellular localisation of c-fms and PI
3-kinase in unstimulated and stimulated
BAC1.2F5 macrophages.
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7.0.0. Introduction
In unstimulated cells, c-yw5, present at the cell surface, is tumcd-over with a half-life 
of 2-3 hours, followed by a period of several hours during which receptors re- 
accumulate at the cell surface following de novo synthesis (Sherr, 1988). When M- 
CSF binds to e,-fms, a non-covalent receptor dimérisation event proceeds in 
conjunction with an initial wave of tyrosine phosphorylation on the receptor (Li and 
Stanley, 1991; Tapley et al., 1990). Receptor tyrosine dephosphorylation occurs in 
tandem with tyrosine phosphorylation of specific cytosolic proteins prior to 
extracellular, inter-chain disulphide linkage of receptor monomer subunits (Li and 
Stanley, 1991; Stanley et al., 1994). Inactivation of z-fms intrinsic kinase activity 
follows receptor dephosphorylation prior to modification via poly-ubiquitination and 
finally internalisation of the ligand-receptor complex (Stanley et al., 1994). 
Ubiquitination is a prerequisite for degradation of the z-fms cytoplasmic domain 
(Stanley et al., 1994). Internalisation of the ligand-receptor complex proceeds via 
clathrin coated vesicles, which are eventually transferred to secondary lysosomes for 
ligand-receptor degradation (Li and Stanley, 1991; Sherr and Stanley, 1990). Studies 
of a c.-fms chimera, where the cytoplasmic tail of 0,-fms was fused to Glycophorin A 
suggest that there are structural features in the extracellular domain that determine 
targeting of internalised receptor to the lysosome for degradation (Lee and Nienhuis, 
1992) Internalisation and degradation of e>-fms down-regulates the M-CSF signal 
(Ohtsuka et al., 1990; Rettenmier et al., 1988). As stated in chapter 5, incubation of 
BAC1.2F5 cells at 4°C slows the rate of receptor degradation and can therefore be 
applied to the investigation of internalised z-fms. In addition, M-CSF stimulation of 
BAC1.2F5 cells also stimulated cell spreading, formation of filopodia and 
lamellapodia and reorganisation of the actin cytoskeleton (Allen et al., 1997; Boocock
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et al., 1989).
The role of PI 3-kinase during internalisation of c-ftns and its subsequent trafficking 
for degradation has not been studied; however inhibitors of PI 3-kinase block 
endocytosis in macrophages by blocking completion of vesicle formation, although 
initiation of vesicle formation still occurs (Araki et al., 1996). Wortmannin and 
LY294002 also inhibit fluid-phase pinocytosis and Fc receptor mediated phagocytosis, 
therefore PI 3-kinase activity is implicated in macropinocytosis (Araki et al., 1996). A 
role for PI 3-kinase activity during c-fms internalisation, or trafficking of c-fins 
containing vesicles has yet to be determined in macrophages.
PI4 5P2 and can bind to various proteins that regulate or bind to the actin cytoskeleton 
including gelsolin, cap-2 , a-actinin and profilin and may serve as an attachment site 
for certain PH-domain containing proteins involved in regulation of the actin 
cytoskeleton (Bae et al., 1998; Rhee and Bae, 1997; Tapon and Hall, 1997). Pl4,sP2 is 
a substrate for both PI 3-kinase and PLCy, which has recently been demonstrated to be 
activated in vitro by Pl3,4,sP3 (Bae et al., 1998). Therefore stimulation of PI 3-kinase 
results in activation of pathways which appear to have the net effect of depleting 
cellular PI4 5P2 levels, in turn affecting the organisation of the actin cytoskeleton.
The rho family proteins rho and rac are responsible for cell migration in response to 
M-CSF in the BAC1.2F5 macrophage cell line (Allen et al., 1998). It is known that 
PI 3-kinase is an effector for rho, since GTP-bound rho stimulates the production of 
PI 3 ,4 ,5 -P3 in platelet lysates (see below) (Stephens et al., 1993; Zhang et al., 1993). 
The other rho family member cdc42 is required for chemotactic response to M-CSF 
but not for locomotion (Allen et al., 1998). Allen et al have clearly defined the roles
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of cdc42, rac and rho during M-CSF stimulated reorganisation of the cytoskeleton and
cell adhesion in the BAC1.2F5 cell line (Allen et al., 1997). This suggests that PI 3- 
kinase products may be involved in stimulating rho activity and re-organisation of the 
actin cytoskeleton and cell locomotion. An example of this might be profilin which 
binds to Pl3,4,sP3 and PI4 5P2 but more tightly to PI3 4P2 (Toker and Cantley, 1997). 
PI3 4P2 inhibits the ability of profilin to suppress actin polymerisation and the actin 
severing activity of gelsolin whilst stimulating actin uncapping in permeabilised 
platelets (Toker and Cantley, 1997). Although PI4 5P2 is the predominant lipid species 
found in cells, and is usually the relevant species that mediates actin assembly during 
activation of various growth factor receptors, considerable reorganisation of the actin 
cytoskeleton occurs, concomitant with the activation of PI 3-kinase, thus PI 3-kinase 
products may mediate the initial steps leading to increased membrane ruffling 
following activation of cell surface receptors such as those for PDGF and M-CSF 
(Araki et al., 1996).
Actin dynamics in lamellepodia are driven by continuous cycles of actin 
polymerisation, retrograde flow and actin depolymerisation (Welch et al., 1997). The 
leading edge of a motile cell or cells responding to a chemotactic gradient are 
composed of thin protrusions of membrane which continuously extend and retract, 
mediating the initial stage of cell movement whilst determining the direction of 
eventual movement (Welch et al., 1997). Growth factors such as PDGF stimulate 
actin reorganisation in fibroblasts and M-CSF stimulates actin reorganisation in 
BAC1.2F5 cells which leads to formation of filopodia, lamellepodia and membrane 
ruffles as well as fine actin cables within the cell. These changes in cell morphology 
are mediated by Rho family proteins that are regulated by a combination of GAPs,
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GEFs and GDIs (Allen et al., 1997). Allen et al have demonstrated that formation of
filopodia in response to M-CSF is mediated by cdc42 and formation of lamellepodia, 
membrane ruffling and focal adhesion complexes are mediated by rac which is also 
regulated indirectly by cdc42 and which also acts on rho leading to formation of actin 
cables (Allen et al., 1997). Interestingly, the formation of filopodia negatively 
regulates further lamellepodia, focal complex and actin cable formation as well as 
membrane ruffling. The role of PI 3-kinase in membrane ruffling has been 
demonstrated by the expression of a constitutively active pi 10a PI 3-kinase activity, 
which induced the formation of lamellepodia and focal complex formation and stress 
fibres in NIH 3T3 fibroblasts (Reif et al., 1996). However, PDGF-induced actin 
reorganisation is also blocked by mutation of a residue that is not involved in the 
direct binding of PI 3-kinase (Ruusala et al., 1998), which implies that multiple 
signals are necessary.
The main aims of this chapter were to characterise the subcellular localisation of c-fins 
and PI 3-kinase and the early time-course of c-ftns internalisation in BAC1.2F5 
macrophages by immunofluorescence. In addition the effects of M-CSF stimulation 
on the actin cytoskeleton were studied and the effects of the PI 3-kinase inhibitor 
LY294002 on c-fms internalisation and trafficking and the actin cytoskeleton was also 
characterised in BAC1.2F5 macrophages.
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7.1.0. Internalisation o f c-fms in BAC1.2F5 cells.
It has been reported in the literature that M-CSF is rapidly internalised into vesicles, 
through association with c-fins, upon stimulation of BAC1.2F5 cells (Boocock et ah, 
1989). However the subcellular localisation of c-fins itself during internalisation has 
not been examined to date and so the subcellular localisation of c-fms in BAC1.2F5 
cells was examined by fluorescence microscopy. In unstimulated, quiescent 
BAC1.2F5 macrophages, c-fms staining is diffuse throughout the cytosol, with limited 
plasma membrane localisation, indicated by the arrows in Fig. 7.1.1. It is apparent 
that there are also differences in the amount of c-fms detected between quiescent cells 
although it has been reported that M-CSF starvation of BAC1.2F5 cells upregulates 
expression of c-fms (Boocock et al., 1989) (Fig. 7.1.1.). Stimulation of BAC1.2F5 
cells with 50ng ml"^  M-CSF resulted in increased plasma membrane localisation of c- 
fins after 2 minutes (Fig. 7.1.2., arrow 1). In addition the accumulation of small, 
punctate areas of c-fms localisation were also observed in some cells, which tended to 
be localised on or near the plasma membrane and at the ends of lamellapodia, once 
formed (Fig. 7.1.2., arrow 2). After 20 minutes in the presence of M-CSF there was 
very little, if any, membrane staining (Fig. 7.1.3.). C-fms was now localised into ring­
like structures in the cytosol of BAC1.2F5 cells (Fig. 7.1.3., arrow 1 and 2). These 
structures correspond to phase light vesicles which characteristically appear upon M- 
CSF stimulation of BAC1.2F5 cells. These vesicles are present throughout the 
cytosol and are found in the lamellepodia, and clustered around the nucleus (Fig.
7.1.3.). Most c-fins staining is absent 30 minutes after M-CSF stimulation and what 
staining is left is in a peri-nuclear location (Fig. 6.1.4., arrow). Therefore c-fins is 
internalised rapidly into vesicles which migrate towards the nucleus where it is 
degraded with 30 minutes.
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Fig. 7.1.1. Comparative phase contrast and fluorescent micrographs of BAC1.2F5 ceils stained 
for c-fms. BAC1.2F5 cells were cultured in the absence of M-CSF for 24 hours then probed with 
anti-c-/>ns mAh (Santa Cruz). Anti-c-/ms antibody was detected by an Alexa Dye^^^-conjugated 
secondary pAb (Molecular Probes). The left panel is a phase contrast image, the panel on the 
right is the same field of view stained for c-fms. Bar indicates 10pm.
Fig. 7.1.2. Phase contrast and fluorescent micrographs of BAC1.2F5 cells stained for c-fms. 
BAC1.2F5 cells were cultured in the absence of M-CSF for 24 hours then stimulated with 50ng 
ml * M-CSF for 2 minutes at 37°C before being flxed, permeabilised and probed with anti-c-//w5 
mAh (Santa Cruz). Anti-c-fms antibody was detected by an Alexa Dye^’‘*-conjugated secondary 
pAb (Molecular Probes). The left panel is a phase contrast image, the panel on the right is the 
same field of view stained for c-fms. Bar indicates 10pm.
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Fig. 7.1.3. Phase contrast and fluorescent micrographs of BAC1.2F5 cells stained for c-fms. 
BAC1.2F5 cells were cultured in the absence of M-CSF for 24 hours then stimulated with SOng 
ml ’ M-CSF for 20 minutes at 37°C before being flxed, permeabilised and probed with 2nxX\-c-fms 
mAh (Santa Cruz). Anti-c-//«s antibody was detected by an Alexa Dye^^^-conjugated secondary 
pAb (Molecular Probes). The left panel is a phase contrast image, the panel on the right is the 
same field of view stained for c-fms. Bar indicates 10pm.
##
Fig. 7.1.4. Phase contrast and fluorescent micrographs of BAC1.2F5 cells stained for c-fms. 
BAC1.2F5 cells were cultured in the absence of M-CSF for 24 hours then stimulated with SOng 
ml ’ M-CSF for 30 minutes at 37°C before being flxed, permeabilised and probed with anti-c-/ms 
mAh (Santa Cruz). Anti-c-/ms antibody was detected by an Alexa Dye^’ ’^-conjugated secondary 
pAb (Molecular Probes). The left panel is a phase contrast image, the panel on the right is the 
same field of view stained for c-fms. Bar indicates 10pm.
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7.2.0. Incubation of BAC1.2F5 cells a t 4°C blocks receptor internalisation 
following stimulation with M-CSF
It has been reported that treatment of cells with M-CSF at 4°C slows down receptor 
internalisation as well as the very rapid increase in tyrosine phosphorylation of c-fms 
and various cytosolic proteins (Baccarini et ah, 1991). In this case, incubation of 
BAC1.2F5 cells at 4°C during stimulation with M-CSF blocked receptor 
internalisation for at least 30 minutes, indicated by the heavy plasma membrane 
staining, and the absence of internalised receptor-bearing vesicles (Fig. 7.2.1.). This 
confirms that low temperature incubation of BAC1.2F5 cells slows down receptor 
internalisation and therefore receptor degradation.
Fig. 7.2.1. Phase contrast and fluorescent micrographs of BAC1.2F5 cells stained for c-fms. 
BAC1.2F5 cells were cultured in the absence of M-CSF for 24 hours then stimulated with SOng 
ml ’ M-CSF for 30 minutes at 4°C before being flxed, permeabilised and probed with anti-c-/m5 
mAh (Santa Cruz). Anti-c-/»is antibody was detected by an Alexa Dye*’‘*-conjugated secondary 
pAb (Molecular Probes). The left panel is a phase contrast image, the panel on the right is the 
same field of view stained for c-fms. Bar indicates 10pm.
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7.3.0. Internalised c-fms is localised to phase light vesicles in BAC1.2F5 cells 
stim ulated with M-CSF
Higher magnification of internalised c-fms at 10 minutes following M-CSF 
stimulation confirmed that the receptor staining was associated with phase light 
vesicles and this represented internalisation of the activated ligand-receptor complex 
(Fig. 7.3.1.).
»
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Fig. 7.3.1. Phase contrast and fluorescent micrographs of BAC1.2F5 cells stained for c-fms. 
BAC1.2F5 cells were cultured in the absence of M-CSF for 24 hours then stimulated with SOng 
ml ’ M-CSF for 10 minutes at 37°C before being fixed, permeabilised and probed with anti-c-/ms 
mAh (Santa Cruz). Anti-c-/ms antibody was detected by an Alexa Dye^^^-conjugated secondary 
pAb (Molecular Probes). The left panel is a phase contrast image, the panel on the right is the 
same field of view stained for c-fms. Bar indicates 5pm.
In Fig. 7.3.1. the staining is found in the lamellar process which has formed following 
M-CSF stimulation. In addition the formation of slightly out of focus, small, punctate 
structures can be seen in the main body of the cell which are localised to the plasma 
membrane (Fig. 7.3.1.). The magnified inset illustrates that c-fms is localised to the 
membrane of the internalised vesicles, which vary in size (Fig. 7.3.1.). The arrows
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indicate the position of a single internalised vesicle in both phase and fluorescent 
micrographs (Fig. 7.3.1. inset).
7.4.0. Tyrosine phosphorylation in BAC1.2F5 ceils stim ulated with M-CSF
In quiescent BAC1.2F5 cells there is a low basal level of tyrosine phosphorylation 
present in anti-phosphotyrosine western blots as illustrated in chapter 4.
Fig. 7.4.1. Fluorescent micrographs of BAC1.2F5 cells stained for phosphotyrosine. BAC1.2F5 
cells were quiesced for 24 hours then immediately stained (top panels), or stimulated with SOng 
ml ’ M-CSF for 30 minutes at 4°C (bottom panels). Cells were then fixed, permeabilised and 
probed with an anti-pTyr mAh (Transduction Labs.). Anti-pTyr antibody was detected by an 
FlTC-conjugated secondary pAb (Sigma). Images were digitally captured and analysed with 
Biovision and MacHazeBuster (Improvision and Vaytek) The panels on the left are composite 
images prior to deconvolution, the middle panels are the same composite images after 
deconvolution and the panels on the right are a single Ifxm section from the deconvolved 
composite image. Bar indicates 10|im.
In the absence of M-CSF there is a low basal level of tyrosine phosphorylation 
throughout the BAC1.2F5 cell (Fig. 7.4.1., top panels). Tyrosine phosphorylation
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appears punctate throughout the cytosol with some staining present at the plasma
membrane (Fig. 7.4.1., top panel, arrow 1). Stimulation of quiescent BAC1.2F5 cells 
for 30 minutes at 4°C with M-CSF stimulated recruitment of tyrosine phosphorylated 
proteins to the plasma membrane with a concomitant reduction in the levels of 
cytosolic proteins phosphorylated on tyrosine (Fig. 7.4.1., bottom panel, arrow 2). 
This suggested that in BAC1.2F5 cells, M-CSF stimulation results in the recruitment 
of tyrosine phosphorylated proteins to the plasma membrane.
7.5.0 Localisation of p85a and p i 10a in M -CSF stim ulated cells
Recruitment of PI 3-kinase activity has been shown to be important to c-fins 
signalling. Therefore the subcellular localisation of the PI 3-kinase subunits p85a and 
pi lOa were investigated. In BACI.2F5 cells cultured in the absence of M-CSF, p85a 
staining is mainly cytosolic (Fig. 7.5.1., bottom right panel, arrow 1)., although some 
plasma membrane staining is seen in the deconvolved section (Fig. 7.5.1., bottom 
right panel, arrow 2). Stimulation of quiescent BAC1.2F5 cells for 30 minutes at 4°C 
with M-CSF stimulated recruitment of p85a to the plasma membrane (Fig. 7.5.1., top 
panels).
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Fig. 7.5.1. Fluorescent micrographs of BAC1.2F5 cells stained for p85a. BAC1.2F5 cells were 
quiesced for 24 hours then immediately stained (bottom panels), or stimulated with 50ng ml ’ M- 
CSF for 30 minutes at 4°C (top panels). Cells were then fixed, permeabilised and probed with an 
anti-p85a mAh (Transduction Labs ). Anti-p85a antibody was detected by an FITC-conjugated 
secondary pAb (Sigma). Images were digitally captured and analysed with Biovision and 
MacHazeBuster (Improvision and Vaytek) The panels on the left are composite images prior to 
deconvolution, the middle panels are the same composite images after deconvolution and the 
panels on the right are a single 1pm section from the deconvolved composite image. Bar indicates 
10pm.
BAC1.2F5 cells cultured in the presence of M-CSF showed predominantly cytosolic 
staining for the pi 10a subunit (Fig. 7.5.2., top panels, arrow 1). However, 
stimulation of quiescent BAC1.2F5 cells for 30 minutes at 4°C with M-CSF 
stimulates recruitment of pi 1 0 a  to the plasma membrane with a concomitant 
reduction in the levels of pi 10a found in the cytosol (Fig. 7.5.2., bottom panels, arrow 
2). This suggests that in BAC1.2F5 cells, M-CSF stimulation results in the 
recruitment of both p85a and pi 10a to the plasma membrane which is required for 
full PI 3-kinase activation.
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Fig. 7.5.2. Fluorescent micrographs of BAC1.2F5 cells stained for p llO a. BAC 1.2F5 cells were 
either cultured in normal medium containing M-CSF (Top panels) or in the absence of M-CSF 
for 24 hours before stimulation with 50ng ml ’ M-CSF for 30 minutes at 4°C (Bottom panels). 
Cells were then fixed, permeabilised and probed with an anti-p llO a mAh (Transduction Labs ). 
Anti-pllO a antibody was detected by either a TRITC- or FITC-conjugated secondary pAb 
(Sigma). Images were digitally captured and analysed with Biovision and MacHazeBuster 
(Improvision and Vaytek). The panels on the left are composite images prior to deconvolution, 
the middle top panel is the same composite image as top left after deconvolution and middle 
bottom and the panels on the right are single 1pm sections from the deconvolved composite 
images. Bar indicates 10pm.
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7.6.0 The BAC1.2F5 actin cytoskeleton
Stimulation of quiescent BAC1.2F5 cells has been reported to stimulate the rapid 
reorganisation of the actin cytoskeleton, which is important for maintainence of cell 
morphology (Allen et a l, 1997). The M-CSF stimulated changes in actin organisation 
was investigated in BAC1.2F5 macrophages over the early time-course concurrent 
with c-fins internalisation.
7.6.1. M-CSF stim ulated reorganisation of the BAC1.2F5 actin cytoskeleton
In normal culture conditions BAC1.2F5 cells exhibit organised actin staining with 
marked staining in the cell leading edge (Fig. 7.6.1., panel N, arrow 1). Throughout 
the cytoplasm small, punctate actin staining was observed and digital deconvolution 
revealed that this was predominantly present at the ventral face of the cell (Fig. 7.6.1., 
panel N, arrow 2), in contact with the glass coverslip, presumably corresponding to 
podosomes (Dutartre et a l, 1996; Gavazzi et a l, 1989). BAC1.2F5 cells quiesced for 
24 hours in the absence of M-CSF were noticeably rounder in appearance and had 
similar actin organisation to cells in normal culture with heavy plasma membrane 
staining (Fig. 7.6.1., panel US, arrow 1) and some cytosolic, punctate staining that 
was present on the cell membrane, in contact with the glass coverslip (Fig. 7.6.1., 
panel US, arrow 2).
Stimulation of BAC1.2F5 cells with M-CSF resulted in dramatic changes in cell 
morphology which were characterised by reorganisation of the actin cytoskeleton. 
Cells stimulated for 2 minutes with 50ng ml'  ^ M-CSF had increased actin staining in 
plasma membrane folds, indicative of membrane ruffles (Fig. 7.6.1., panel 2', arrow 
1). In addition small actin-rich filopodia were also present in some, but not all cells
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(Fig. 7.6.1., panel 2', arrow 2). WI ’n the cytoplasm of BAC1.2F5 cells major
reorganisation of the actin cytoskeleton was characterised by the formation of fine 
actin cables that organised themselves longitudinally throughout polarised cells (Fig.
7.6.1., panel 2', arrow 3) and in concentric rings in rounded cells (Fig. 7.6.1., panel 2', 
arrow 4).
After 10 minutes, long, lamellapodia had formed in the majority of the cells with some 
cells containing more than one lamellapodia (Fig. 7.6.1., panel 10', arrow 1). In 
addition the majority of BACI.2F5 cells contained abundant actin-rich filopodia and 
membrane ruffles. The cytoplasmic cytoskeleton remained well organised and the 
fine actin cabling was still apparent (Fig. 7.6.1., panel 10', arrow 2). These features of 
the actin cytoskeleton, present at 10 minutes following M-CSF stimulation were also 
observed at 30 minutes, with no observable differences (Fig. 7.6.1., panel 30', arrows 
1+ 2). Incubation with M-CSF for 30 minutes at 4°C blocked the reorganisation of the 
actin cytoskeleton and there was no formation of actin-rich membrane ruffles, 
filopodia or actin cables (data not shown).
On the following page:
7.6.1. Fluorescent micrographs of BAC1.2F5 cells stained for polymerised actin. BAC1.2F5 
cells were cultured without M-CSF for 24 hours before stimulation with SOng ml ’ M-CSF. Cells 
were treated as follows; normal culture cells (N), unstimulated (US), stimulated for 2 minutes 
(2'), 10 minutes (10 ) or 30 minutes (30'). Cells were then flxed, permeabilised and stained with a 
phalloidin-FITC conjugate (Sigma). Images were digitally captured with an OpenLab digital 
image analysis system. Left hand panels are reconstruction of 25 composite, 0.5pm sections after 
software deconvolution. The right hand panels are the same field of view but are a single 
representative section. Bar indicates 10pm.
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At higher magnification, the formation of filopodia and membrane ruffles are clearly 
visible (Fig. 7.6.2.). After 5 minutes in the presence of M-CSF actin-rich filopodia 
extend from the plasma membrane and radiate out from the cell (Fig. 7.6.2., panel A, 
arrows). In parallel, actin-rich membrane ruffles also appear and are present over the 
entire surface of the cell (Fig. 7.6.2., panel B, arrows).
Fig. 7.6.2. Fluorescent micrographs of BAC1.2F5 cells stained for polymerised actin. BAC1.2F5 
cells were cultured in the absence of M-CSF for 24 hours before stimulation with SOng ml ’ M- 
CSF. Cell were stimulated for 5 minutes at 37°C then flxed, permeabilised and stained with a 
phalloidin-FITC conjugate (Sigma). Images were digitally captured with Biovision image 
capture software (Improvision). Bar indicates 5pm
Closer examination of the formation of fine actin cables in M-CSF stimulated 
BAC1.2F5 cells was investigated using the OpenLab digital image capture system. 
Following a 10 minute stimulation with M-CSF the formation of fine actin cables 
within the cytoplasm were clearly visible and appeared to align longitudinally along 
the polarised axis of the cell, c-fms staining is shown for comparison (Fig. 7.6.3.). In 
the composite image of Fig. 7.6.3. there is a limited amount of c-fms containing 
vesicles which appear to align with the actin cables. This may represent the transport
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of internalised, clathrin-coated c-fins containing vesicles from the cell periphery or 
lamellepodia tips, towards the endosomal and lysosomal compartments in BAC1.2F5 
macrophages (Fig. 7.6.3., merged, arrows).
Fig. 7.6.3. Fluorescent micrographs of BAC1.2F5 cells stained for polymerised actin and c-fms. 
BAC1.2F5 cells were cultured in the absence of M-CSF for 24 hours before stimulation for 10 
minutes with 50ng ml * M-CSF. Cells were then fixed, permeabilised and stained with ünti-c-fms 
antibody (Santa Cruz) and counter-stained with a phalloidin-FITC conjugate (Sigma). Images 
were digitally captured and analysed with OpenLab 1.7.8. Panel A represents F-actin staining 
and panel B represents the same field of view stained for c-fms. The bottom panel is a composite 
of panel A and B. Bar indicates 10pm.
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7.6.4. Effect of LY294002 on the M-CSF stimulated reorganisation of the
BAC1.2F5 actin cvtoskeleton
In BAC1.2F5 cells cultured under normal conditions addition of LY294002 induced 
the formation of actin-rich retraction fibres in the majority of cells (Fig, 7.6.4., panel 
N, arrows 1 and 2). Throughout the cytoplasm small, punctate actin staining was 
observed and digital deconvolution revealed that this was predominantly present on 
the cell membrane, in contact with the glass coverslip but the majority of actin 
staining was at the plasma membrane (Fig. 7.6.4., panel N, arrow 2). In addition the 
organised actin cytoskeleton, observed in untreated cells was absent.
BAC1.2F5 cells quiesced for 24 hours in the absence of M-CSF were noticeably 
rounder in appearance and had similar actin organisation to untreated, unstimulated 
cells. In cells that had remained polarised addition of LY2940002 had induced 
formation of retraction fibres (Fig. 7.6.1., panel US, arrow 1). Actin staining was 
predominantly found at the plasma membrane (Fig. 7.6.4., panel US, arrow 2) as well 
some punctate cytosolic staining.
Stimulation of BAC1.2F5 cells with M-CSF still induced dramatic changes in cell 
morphology, characterised by the formation of actin-rich membrane ruffles (Fig.
7.6.4., panel 2’, arrow 1). Actin-rich filopodia were present in some (Fig. 7.6.4., panel 
2’, arrow 2), but not all cells, however the majority of actin staining was present at the 
plasma membrane (Fig. 7.6.4., panel 2', arrow 3). The reorganisation of actin into 
fine cables was inhibited by LY294002 (Fig. 7.6.4., panel 2’).
After 10 minutes retraction fibres were still present (Fig. 7.6.4., panel 10', arrow 1) as
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were the M-CSF stimulated membrane ruffles and predominant plasma membrane
staining (Fig. 7.6.4., panel 10', arrows 2 and 3). After 30 minutes. There was little 
change in the actin organisation in the presence of LY294002, with some membrane 
ruffles (Fig. 7.6.4., panel 30', arrows 1 and 2), predominant plasma membrane staining 
(Fig. 7.6.4., panel 30', arrow 3), but no actin cable formation.
O n th e fo llow in g  page:
7.6.4. F lu orescen t m icrograp h s o f  B A C 1.2F 5  cells sta in ed  for  p o lym erised  actin . B A C 1.2F 5  
cells w ere  cu ltu red  w ith o u t M -C S F  for  24 hours b efore  stim u lation  w ith  50n g  m l * M -C S F . C ells  
w ere pre-in cu b ated  w ith  lO pM  L Y 294002  fo r  10 m in utes then  treated  as fo llow s; norm al cu lture  
cells (N ), u n stim u lated  (U S ), stim u la ted  for  2 m in u tes (2 '), 10 m in utes (10 ) or  30  m in utes (30  ). 
C ells w ere  then  fixed , p erm eab ilised  and  sta in ed  w ith  a p h a llo id in -F IT C  con ju ga te  (S igm a). 
Im ages w ere  d ig ita lly  cap tu red  w ith  an O p en L ab  d ig ita l im age an a lysis  system . L eft h an d  pan els  
are recon stru ction  o f  25  com p osite , 0 .5p m  section s a fter  so ftw are d econ vo lu tion . T h e r igh t hand  
panels are th e  sam e fie ld  o f  v iew  but are a sin g le  rep resen ta tive  section . B ars in d ica te  10pm .
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At higher magnification, LY294002 induced retraction fibres up to 15 pm in length 
were clearly visible after 30 minutes in BAC1.2F5 cells (Fig. 7.6.5., arrows). It was 
also apparent that M-CSF induced membrane ruffling was not as pronounced in the 
presence of LY294002.
Fig. 7 .6 .5 . F lu orescen t m icrograp h  o f  B A C 1.2F 5  cells sta in ed  for  p o lym erised  actin . B A C 1.2F 5  
cells w ere  cu ltured  in  th e  ab sen ce o f  M -C S F  for  24 hours b efore in cu b ation  w ith  lO pM  
L Y 294002  for  15 m in u tes, fo llow ed  by stim u lation  w ith  50n g  m l * M -C S F  for  30 m in u tes. C ells  
w ere  then  fixed , p erm eab ilised  and  sta in ed  w ith  a p h a llo id in -F IT C  con ju ga te  (S igm a). Im ages  
w ere  d ig ita lly  cap tu red  and an a lysed  w ith  O p en L ab  1 .7.8.. B ar in d ica tes 10pm .
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7.7.0. The effect of LY294002 on the subcellular localisation of c-fms in
BAC1.2F5 cells
To investigate the effect of inhibition of PI 3-kinase activity on the internalisation, 
trafficking and degradation of c-fins BAC1.2F5 cells were analysed by digital 
confocal microscopy. The subcellular localisation of Q-fins was stained 
immunochemically with an anti-c-yw5 polyclonal antibody whilst F-actin organisation 
was stained for comparison.
In unstimulated cells c-fins was staining was diffuse with both cytosolic and plasma 
membrane localisation. Examination of a single 1 pm section transversely through the 
field of view by digital confocal fluorescence revealed that the majority of c-fims was 
localised at the plasma membrane (Fig. 7.7.1., left-hand US panel, arrow). After M- 
CSF stimulation was internalised into small transport vesicles (Fig. 7.7.1., arrow 1), 
which were visible at a juxtamembrane location after 10 minutes. The transport 
vesicles moved towards the nucleus and fused together to form larger, macrovesicles, 
20 minutes after M-CSF stimulation (Fig. 7.7.1., arrow 2). After 30 minutes c-fms 
staining was absent fi*om the macro vesicles clustered around the nucleus (data not 
shown), similar to Fig. 7.1.4.
Treatment of BAC1.2F5 cells with lOpM LY294002 did not block the early formation 
of small transport vesicles which were still visible in a juxtamembrane location (Fig.
7.7.2., arrow 1). However, after 20 minutes, the small vesicles were still present at the 
plasma membrane and had not translocated to the perinucleus nor had they fused to 
form large macrovesicles (Fig. 7.7.2., arrow 2).
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7 .7 .1 . F lu orescen t m icrograp h s o f  B A C 1.2F 5  cells sta in ed  for  p o lym erised  actin  and  c-fms. 
B A C 1.2F 5  cells w ere  cu ltu red  w ith o u t M -C SF  fo r  24 h ou rs b efore  stim u lation  w ith  50n g  m l * M - 
C SF  as fo llow s; u n stim u lated  (U S ), stim ulated  fo r  2 m inutes (2 ’), 10 m inu tes (10') or  30  m inutes  
(30'). C ells w ere  then  fixed , perm eab ilised  and  sta in ed  w ith  a ph a llo id in -F IT C  con ju gate  
(S igm a) and  w ith  an  anti-c-/m x pA b (Santa  C ruz). Im ages w ere  d ig ita lly  cap tu red  w ith  an  
O p en L ab  d ig ita l im age an a lysis system . L eft h and  p an els are a recon stru ction  o f  25  com p osite , 
0 .5pm  section s o f  F -actin  sta in in g  a fter so ftw are  d econ vo lu tion . T he m id d le p an els are a 
recon stru ction  o f  25  com p osite , 0 .5p m  section s o f  the sam e fie ld  o f  v iew  sta in ed  for  c-fms. T he  
righ t hand  panels are a m erged  com p osite  o f  tw o , sin g le  1pm  section s from  the F -actin  and c-fms 
com posites. B ars in d ica tes 10pm .
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7.7 .2 . F lu orescen t m icrograp h s o f  B A C 1.2F 5  cells sta in ed  for  p o lym erised  actin  and c-fms. 
B A C 1.2F 5 cells w ere  cu ltu red  w ith ou t M -C S F  fo r  24  hours before  in cu b ation  w ith  lO pM  
L Y 294002 b efore  stim u lation  w ith  50n g  m l * M -C S F  as fo llow s; u n stim u lated  (U S ), stim ulated  
for  2 m in u tes (2 '), 10 m inutes (10  ) or 30  m in utes (30'). C ells w ere  then  fixed , p erm eab ilised  and  
sta ined  w ith  a p h a llo id in -F IT C  con ju gate (S igm a) and  w ith  an an ti-c-/m s pA b (S an ta  C ruz). 
Im ages w ere  d ig ita lly  cap tu red  w ith  an O p en L ab  d ig ita l im age an a lysis  system . L eft h and  p an els  
are a recon stru ction  o f  25  com p osite , 0 .5p m  section s o f  F -actin  sta in in g  after  so ftw are  
d econ vo lu tion . T h e m id d le  panels are a recon stru ction  o f  25 com p osite , 0 .5p m  section s o f  the  
sam e fie ld  o f  v iew  sta in ed  for  c-fms. T h e  r igh t hand  p an els are a m erged  com p osite  o f  tw o, 
single  1pm  section s from  th e F -actin  and  c-fms com p osites . B ars in d ica tes 10pm .
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7.8.0. Discussion
The rapid effects of M-CSF on BAC1.2F5 cells has been extensively characterised 
with respect to cell morphology and the actin cytoskeleton (Allen et al., 1997; 
Boocock et al., 1989). It has also been demonstrated previously that upon M-CSF 
stimulation BAC1.2F5 cells form internalised vesicles which stain for M-CSF 
(Boocock et al., 1989). Studies by Boocock et al have demonstrated that M-CSF is 
rapidly internalised and trafficked to a perinuclear location (Boocock et al., 1989). 
However c-fms has not been investigated and it has been assumed that it internalises 
in a manner similar to M-CSF. This chapter formally investigated the internalisation 
of c-fms using indirect fluorescence in BAC1.2F5 cells. In unstimulated cells c-fms is 
localised to the cytosol, but predominantly the plasma membrane (Fig. 7.1.1.). This is 
enhanced by incubating cells at 4°C for 30 minutes, a process that slows down 
receptor internalisation (Fig. 7.1.5.). Stimulation with M-CSF at 37°C results in 
strong plasma membrane staining in conjunction with small punctate staining around 
the cell periphery and in the lamellar processes which have remained throughout 
quiescence (Fig. 7.1.2.). After 10-20 minutes there is extensive staining of 
internalised vesicles which tend to be larger than the early punctate staining and are 
probably the products of endosomal fusion (Figs. 7.1.3. and 7.1.4.) (Boocock et al., 
1989). These large vesicles progress from the plasma membrane along the lamellar 
processes towards the cell body, aggregating around the nucleus in a similar pattern to 
that previously published for M-CSF trafficking (Boocock et al., 1989). After 30 
minutes the majority of c-fms staining is absent, which correlates with the time-course 
of c-fms degradation observed by western blot analysis in chapter 4. Closer 
examination of internalised c-fms confirmed that c-fms co-localised with phase-light 
endocytic vesicles, which form rapidly (10 minutes) and migrate towards the nucleus
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of the cell (Fig. 7.3.1.). These data suggest that c-fins, once internalised, is trafficked
with its ligand to lysosomal compartments for degradation and does not appear to be 
recycled back to the plasma membrane.
Upon stimulation of BAC1.2F5 cells with M-CSF, the receptor and various cytosolic 
proteins are phosphorylated on tyrosine. Analysis of tyrosine phosphorylation by 
indirect fluorescence has demonstrated that there is a basal level of tyrosine 
phosphorylation which is found at the plasma membrane and throughout the cytosol 
(Fig. 7.4.1.). Stimulation at 4°C results in increased levels of tyrosine 
phosphorylation with the majority being localised to the plasma membrane and very 
little, if any, present in the cytosol (Fig. 7.4.1.). Recruitment of cytosolic proteins to a 
plasma membrane is required for their tyrosine phosphorylation and 4°C incubation 
prevents relocalisation of tyrosine phosphorylated proteins to the cytosol (Fig. 7.4.1.). 
In addition, to a localisation of tyrosine phosphorylation at the plasma membrane, 
there is also a recruitment of the p85a and pi 10a subunits of PI 3-kinase to the 
plasma membrane (Figs. 7.5.1. and 7.5.2.). These data indicate that M-CSF 
stimulation actively recruits PI 3-kinase activity to the plasma membrane and therefore 
into close proximity to substrate and various downstream mediators.
Re-arrangement of the actin cytoskeleton has been extensively investigated, 
particularly with respect to the rho family of GTPases. However, only recently have 
the functions of these proteins been studied in macrophages, where the cytoskeleton is 
critical for motility and cell morphology. It has been reported that M-CSF stimulates 
the rapid reorganisation of the actin cytoskeleton in BAC1.2F5 cells (Allen et al., 
1997; Boocock et al., 1989). This is characterised by the early formation of actin-rich
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membrane ruffles in stimulated cells and fine actin cables traversing the interior of the
cell (Allen et al., 1997). Formation of membrane ruffles and lamellapodia are 
regulated by rac which in turn regulates rho-mediated actin cable formation (Allen et 
al., 1997). M-CSF-stimulated formation of actin-rich filopodia is regulated by cdc42 
which has also been shown to inhibit rac and rho activity (Allen et al., 1997). M-CSF- 
induced rearrangement of the actin cytoskeleton was confirmed by staining cells with 
FITC-labelled phalloidin and the formation of filopodia, membrane ruffles and fine 
actin cabling was observed shortly after M-CSF stimulation of BAC1.2F5 cells (Fig.
7.6.1.). High magnification microscopy demonstrated the presence of actin-rich 
filopodia (Fig. 7.6.2., panel A) following M-CSF stimulation accompanied by 
formation of actin-rich membrane folds along the dorsal surface of BAC1.2F5 cell 
(Fig. 7.6.2., panel B). The formation of fine actin cables was also visualised by high 
magnification microscopy and were characterised as forming organised parallel 
orientated filaments along the cell axis in polarised cells (Fig. 6.6.3., panel A) and as 
parallel concentric rings in cells with a more rounded morphology (not shown).
The most striking feature of BAC1.2F5 cells treated with the PI 3-kinase inhibitor, 
LY294002 was the formation of retraction fibres in the majority of cells in normal 
culture (Fig. 7.6.4., panel N) and in M-CSF stimulated cells (Fig. 7.6.4., panels N, US 
and 10’). At higher magnification it is apparent that these retraction fibres are 
extensive, averaging 10-15pm in length (Fig. 7.6.5., arrows). The formation of actin- 
rich membrane ruffles was not completely inhibited by treatment with LY294002, 
however fewer membrane ruffles were observed in BAC1.2F5 cells (Fig. 7.6.4., panel 
2’). In addition the formation of actin cables within the cytosol was also inhibited by 
LY294002 and were still not present up to 30 minutes following M-CSF stimulation
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(Fig. 7.6.4., panel 30’). Thus PI 3-kinase activity is required for the M-CSF-
stimulated, rho-mediated formation of actin cables within the cell and inhibition of PI
3-kinase activity also partially inhibits rac-mediated membrane ruffle formation. PI 3-
kinase is necessary for the activation of rac downstream of the PDGFr (Bokoch et al.,
1996; Parker, 1995), and the results presented here indicate that PI 3-kinase activity is
required for the activation of rac and rho following M-CSF stimulation of BAC1.2F5
macrophages.
The effect of PI 3-kinase inhibition on the internalisation and trafficking of activated 
c-fms was also investigated using LY294002. Under normal conditions, M-CSF 
stimulates the rapid internalisation of the ligand receptor complex via the formation of 
small cytosolic vesicles, present at the plasma membrane 10 minutes after stimulation 
(Fig. 7.7.1., panel 10’, arrow 1). After another 10 minutes the small internalised 
vesicles have migrated to a peri-nuclear location and have fused to form large 
macrovesicles (Fig. 7.7.1., panel 20’, arrow 2).
Pre-incubation of BAC1.2F5 cells with lOpM LY294002 prior to M-CSF stimulation 
did not slow or prevent receptor internalisation into the juxtamembrane vesicles which 
were present by 10’ minutes (Fig. 7.7.2., panel 10’, arrow 1). However, LY294002 
prevented the transport of these vesicles from their juxtamembrane location to a peri­
nuclear location, and as a result, vesicle fusion did not occur either (Fig. 7.7.2., panel 
20’, arrow 2). Therefore for c-fms, PI 3-kinase activity is not required during the 
formation of receptor mediated endocytic vesicles, but is required for the correct 
trafficking through the cytosol to a juxtanuclear location where they fuse to form 
macrovesicles and c-fms is degraded. The correct trafficking of c-fms may rely on the
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production of PIsAsPs or one of its degradation products or through the activation of
other proteins that control the cellular concentrations of other phospholipids, such as 
P l4 ,s P 2 -
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8.0.0. Introduction
The use of PI 3-kinase inhibitors such as wortmannin and LY294002 has made it 
possible to investigate how PI 3-kinase activity, in general, is involved in c-fins 
signalling. Recent reports have suggested wortmannin can inhibit non-PI 3-kinase 
dependent signalling pathways, albeit at higher concentrations than were used in this 
study (Cross et al., 1995). In addition wortmannin and LY294002 are not specific for 
individual PI 3-kinase family members and it has been demonstrated that wortmannin 
can inhibit pi 10a, pi 1 Op, pi 106 and pi lOy in the low nanomolar ranges (Arcaro and 
Wymann, 1993; Koh et al., 1998; Wymann et al., 1996; Zhang et al., 1998). 
Therefore, although these inhibitors were capable of defining the M-CSF-mediated 
responses in BAC1.2F5 cells, they are unable to determine what specific PI 3-kinase 
isoform activity is stimulated or whether this activation occurs via a direct or indirect 
mechanism. Therefore the investigation into the recruitment of PI 3-kinase to the c- 
fins signalling complex needs a completely new approach and the method of choice 
was mutational analysis of the M-CSF receptor.
Recruitment of PI 3-kinase activity to the M-CSF receptor proceeds via binding of
SH2 domains in the p85 subunit to specific phosphotyrosine motifs (pYxxM) (Cantley
et al., 1991). M-CSF stimulates PI 3-kinase activity in murine bone marrow derived
macrophages maximally after ten minutes treatment (Yusoff et al., 1994). This is
comparable to the results obtained in BAC1.2F5 cells (Chapter 4, Fig. 4.5.2). In
BAC1.2F5 cells, M-CSF stimulates tyrosine phosphorylation of p85a and its stable
association with c-fins and other cytosolic proteins including p i20, p95 and p55-60
(Kanagasundaram et al., 1996). However, only a minor fraction of total cellular PI 3-
kinase activity is associated with c-fms immunoprecipitates (Kanagasundaram et al.,
1996). Therefore association of only a small proportion of the cellular pool of PI 3-
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kinase with c-fins has important implications for analysis of the activation of PI 3-
kinase and its detection when bound to activated c-fins.
The p85 subunit of PI 3-kinase contains two SH2 domains and its interactions with 
other proteins is complex, for example its association with IRS-1 requires occupancy 
of both SH2 domains for full PI 3-kinase activation (Rordorf-Nikolic et a l, 1995). 
However, only the C-terminal SH2 domain mediates association with the PDGFar 
through Tyr^^' which leaves the N-terminal SH2 domain unoccupied and capable of 
binding to other moieties (Kavanaugh et al., 1992). The binding site for PI 3-kinase 
on the PDGFpr has been mapped to not one but two residues, Tyr731 and Tyr742, 
which are both essential for PI 3-kinase activation (Yu et al., 1994). The tyrosine 
residue required for PI 3-kinase association to phosphorylated c-fins has been mapped 
in vitro to Tyr^ ^^  of the murine receptor (Reedijk et al., 1992). In close proximity to 
Tyr^ ^^  is another tyrosine phosphorylation site at Tyr^^ .^ The spacing of the these two 
tyrosine phosphorylation sites (15 amino acids) is similar to that seen in the PDGFpr 
(11 amino acids) and it is therefore is possible that both p85 SH2 domains are 
involved in PI 3-kinase association with c-fms.
In a yeast two hybrid study an autophosphorylated cytoplasmic domain of c-fins was 
used as bait to screen an expression library and clones containing the SH2 domains of 
PLCy2 were shown to interact with Tyr^ *^ (Bourette et al., 1997). In c-fins expressing 
FDC-Pl cells, M-CSF stimulated the rapid, transient phosphorylation of PLCy2 and 
activation of PLCy2 was required for activation of the PI 3-kinase pathway (Bourette 
et al., 1997). It is possible that in FDC-Pl cells the relative levels of PLCy2 and PI 3- 
kinase are different to those found in other cell types and this data may be an artefact
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of this feature, however it does indicate that it is possible that PLCy2 and PI 3-kinase
can compete for the same binding site on c-fms or alternatively, PLCy2 can provide an 
alternative mechanism for PI 3-kinase activation.
A requirement of PI 3-kinase activity during c-fins mediated responses has not been 
extensively studied in macrophages, although it is implicated in such functions as 
survival, proliferation, vesicle transport and changes in cell morphology. The reason 
for this is because almost all analysis of c-fins signalling has been carried out in 
exogenous expression studies in cell lines such as fibroblasts that are easily 
transfected and produce high levels of exogenous expression. However studies in 
fibroblasts have produced conflicting data (Shurtleff et al., 1990; Reedijk et al., 1992; 
van der Geer and Hunter, 1993). For instance, in Rat-2, or NIH 3T3 fibroblasts, 
expression of mutated human c-fins without the capacity to bind PI 3-kinase via Tyr^^  ^
were unable to activate PI 3-kinase with a concomitant loss in cell proliferation 
(Reedijk et al., 1992; van der Geer and Hunter, 1993). In a macrophage based study, 
PI 3-kinase inhibitors blocked endocytosis by preventing vesicle trafficking, rather 
than vesicle formation (Araki et al., 1996). Conversely, in FDC-Pl cells transfected 
with a KI domain c-fins mutant, cell proliferation was still stimulated by M-CSF at 
levels similar to wild type c-fins (Kanagasundaram et al., 1996). Ratification of the 
conflicting data on the involvement of PI 3-kinase in c-fins signalling was the overall 
aim of this thesis and therefore the requirement of PI 3-kinase activity in cellular 
responses such as apoptosis, vesicle transport and cytoskeletal organisation, which has 
been clearly demonstrated in the preceding chapters can only be examined in more 
detail by mutational analysis of c-fins at the residues critical for PI 3-kinase 
association.
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The main aim of this chapter was the production of two human c-fins expression
constructs, one representing the full length c-fins cDNA and the second representing 
the same cDNA but with the addition of sequence at the C-terminus corresponding to 
two epitope tags. The epitope tagged c-fins construct would then be used as a 
template for mutagenesis of those residues shown to be required or possibly involved 
in the direct association of PI 3-kinase and its activation. The two tyrosine 
phosphorylation sites at Tyr^ ®* and Tyr^^  ^ were mutated singly or in combination to 
phenylalanine. It was intended that these receptor constructs would be expressed in 
BAC1.2F5 cells or alternative cell lines to investigate further the involvement of PI 3- 
kinase in c-fms signalling. The two epitope tags were included at the C-terminus to 
facilitate downstream identification of expressed protein and to aid affinity 
purification of c-fms, and co-purification of PI 3-kinase and other associated proteins 
in M-CSF activated cells.
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8.1.0. Cloning o f human c-fms into a mammalian expression vector (I)
A construct containing the full-length human c-fins gene (pZipSV(X)/c-^5) was
kindly provided by C. Sherr (Howard Hughes Medical Institute, Memphis, TN). This
was used as a template for construction of the c-fins expression constructs and its
insertion into pcDNA3.1-based mammalian expression vectors (Invitrogen, Appendix
C).
Cloning of a full length c-fins gene by polymerase chain reaction (PCR) (Mullis and 
Faloona, 1987) alone may have introduced unwanted errors into the cloned sequence, 
therefore the initial strategy involved liberation by restriction enzyme digestion the 5’ 
end of c-fins as a 2.1kbp fragment (5’ RF). Two unique restriction enzyme sites, Eco 
RI and Xho I, conveniently situated upstream and downstream of the start codon, 
facilitated this approach. Cloning of the remainder of c-fins required cloning both an 
intact (3’PCRl) and a disrupted 3’-end (3’PCR2) by PCR with gene-specific primers. 
The 5’ primer encompassed an internal c-fins Xho I site and facilitated the cloning 
together of each c-fins fragment. The homologous, 3’PCRl product was to be 
amplified with a homologous primer containing a Hind III site, downstream of the c- 
fins stop codon. The disrupted 3’-end PCR product was to be amplified with an 
alternate 3’ primer which encompassed the sequence containing the c-fins stop codon. 
This alternate primer contained a unique Hind III restriction enzyme site in place of 
the stop codon to facilitate downstream subcloning into a pcDNA3.1 based vector. 
The two c-fins fragments, 5’RF and 3’PCR (1 and 2) would then be subcloned, in 
tandem, into the relevent expression vector linearised by restriction enzyme digestion 
with Eco RI and Hind III. Fig. 8.1.0. illustrates the cloning strategy employed.
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5'UTR
EcoRI
ATG
pZipSV (X)
2.9kbp
Xho I
3'UTR
TGA -►AAG
820bp (3’ PCR) \
Xho I
pcDNA3.1 based vector
Eco RI
IBnd III
mycftils
□ □ H
Hind III
Fig. 8.1.0. Schematic of the human c-fms cloning strategy for construction of an epitope
tagged mammalian expression construct.
8.1.1. PCR amplification of the 3’ end of hum an c-fms (I)
Initially production of 3’PCRl and 3’PCR2 was attempted by PCR amplification of 
the 3’ end of c-fms with a combination of the primers 5’ Xho I (AF-1) and 3’Hom 
(AR-2) for 3’PCRl and 5’ Xho I (AF-1) and 3’ Hind III (AR-1) for 3’PCR2 
(Appendix B) using pZipSV(X)/c-^5 as a template. Repeated attempts to amplify up 
either product failed to yield any products. Reaction conditions were altered 
including; [Mg^^], primer concentrations and thermal cycling parameters in an attempt 
to obtain product but without success (Data not shown). As an alternative to 
amplification from cDNA, RNA was prepared from U937 cells and used as an 
alternative template for amplification by reverse transcription PCR (RT-PCR). The 
two primers, AF-1 and AR-1 corresponding to 3’PCR2 amplified a product of 650 bp. 
from U937 RNA (Fig. 8.1.1.). Although smaller than expected the 650 bp product 
had been specifically amplified and it could represent a differentially spliced version 
of c-fins. The 650bp product was cloned into pCRZ.l vector and analysed by
restriction digest prior to sequence analysis.
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M l  2 3 4  5  6 M
1018 —
506/517  — 
2 98  —
650bp
SOObp
308bp
200bp
Fig. 8.1.1. Analysis by 1% gel electrophoresis of the products of the amplification of the 3' 
end of human C-fms from U937 RNA using primers AF-1 and AR-1. Lane 1 represents RT-PCR 
amplification from a U937 RNA template (primers at O.SpM). Lane 2 represents bacteriophage 
lambda positive control (500 bp). Lane 3 represents pAW109 RT-PCR positive control (308 bp). 
Lane 4 represents a second RT-PCR positive control amplification of the SH3 domain of Lyn 
tyrosine kinase (»200 bp). Lanes 5 and 6  represents a PCR and RT-PCR no template controls, 
respectively. Relevant m arker sizes are indicated and DNA was visualised by staining with l.Opg 
ml * ethidium bromide.
Unexpectedly during cloning a 1050 bp insert product was liberated from positive 
clones (Fig. 8.1.2.). Both inserts were sequenced using the dye-deoxy terminator 
cycle method. By comparison to the published c-fins sequence, the 650 bp product 
was found, overall, to be less than 35% homologous and the 1050 bp product was 
only 30% homologous to c-fms. A Blastn sequence similarity search (Altschul et al., 
1997) indicated that the 650bp and 1050bp products had low homology to various 
genes from multiple organisms including the human and murine c-fms but these 
homologies were less than 35%. As it was a possibility that c-fms mRNA was not 
present in abundance in the U937 RNA preparation, the number of PCR cycles had 
been extended. This would account for the increased likelihood of obtaining non-
227
Results Chapter 8
specific amplification products suggesting that the 650bp and 1050bp RT-PCR 
products were more likely to be PCR artefacts.
3 4
L
2036  —
1018 —
506/517  —
3.9kbp
lOSObp
650bp
Fig. 8.1.2. Analysis by 1% agarose gel electrophoresis analysis of Eco R1 digest analysis of 
putative clones containing the 650 bp PCR fragment cloned into pCR2.1. Plasmid DNA was 
isolated from positive clones and digested with Xho I and Hind III before resolving by agarose 
gel electrophoresis. Lanes 1, 3 and 4 are 650bp clones. Lane 2 is a I050bp clone. Relevant 
m arker sizes are indicated and DNA was visualised by staining with l.Opg ml * ethidium 
bromide.
8.2.1. Amplification of the 3’ end of c-fms by PCR (II)
A further attempt was made to amplify the 3’ end of c-fins. In an effort to circumvent 
potential problems with primer accessibility due to problems with secondary structure, 
pZipSV(X)/c-^5 was first linearised by enzymatic digestion with Eco RI. Original 
supercoiled plasmid DNA was also used as a template for comparison. In addition, a 
new primer directed to the 3’-end was synthesised to prevent problems associated with 
reduced annealing efficiency of the AR-2 PCR primer, which had a restriction site 
present downstream of the stop codon for cloning purposes. This new primer, AR-3 
was designed completely homologous to c-fins encompassing the stop codon of c-fins.
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Fig. 8.2.1. shows products obtained from various primer and template combinations. 
Using both primer combinations the two 3’ PCR products were amplified successfully 
from cDNA template. There was no apparent difference between the products 
obtained from linear or supercoiled template DNA.
AF-1 + + + +
AR-1 - - + +
AR-3 + + - -
Linear template + - + -
Supercoiled template - + - +
Ml  2 3 4 5 6
1636 —
1018 —
506/517— 
396 —
820bp
SOObp
Fig. 8.2.1. Analysis by gel electrophoresis products of PCR amplification of a fragment of the 3' 
end of c-fms from cDNA template. Lane 1 represents bacteriophage lambda positive PCR 
control (500 bp), lane 2 represents a no template, negative control. Lanes 3, 4, 5 and 6  represent 
amplification products. Relevant m arker sizes are indicated and DNA was visualised by staining 
with l.Opg ml * ethidium bromide.
Each product was cloned into pCR2.1, transformed into E. coli and plasmid DNA was 
prepared. At this point only clones from E. coli transformed with pCR2.1 containing 
the 3’PCR2 amplification product were chosen for subsequent analysis by restriction 
enzyme digestion and sequencing. Xho I/Hind III restriction enzyme analysis of five 
clones representing 3’PCR2 ( lanes 2, 3, 4, 6, and 7, respectively) showed they
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contained the correct sized, 820bp insert (Fig. 8.2.2). A representative clone was 
selected for further analysis by sequencing.
M 1 2 3 4 5 6 7
1018 -
506/517 -
3.9kbp
820bp
Fig. 8.2.2. Analysis by 1% gel electrophoresis of the products of a Xho I/Hind III 
restriction digest of pCR2.1(3’ c-fms). Plasmid DNA of clones isolated from E. coli transformed 
with pCR2.1 containing the 820 bp PCR product from the amplification of the 3' end of c-fms 
were digested with Xho I and Hind HI before resolving on an agarose gel. Lanes 2 to 7 contain 
positive clones. Relevant m arker sizes are indicated and DNA was visualised by staining with 
l.Opg ml * ethidium bromide.
8.3.1. Sequence analysis of 3T C R 2 product
Sequence analysis of a clone obtained from section 8.2. demonstrated sequence 
homology c-fins and possessed the required 5’ Xho I site and the c-fims stop codon 
mutated to a Hind III (Data not shown).
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8.4.1. Liberation of the 5’ portion of c-fms from  pZipSV(X)/c-/w5
The pZipSY(Xyc-fms construct contained a previously engineered Eco RI restriction 
enzyme site upstream of the start codon, within the 5’ untranslated region (UTR) of c- 
fms. However, the exact location of the Eco RI site was not indicated in the published 
sequence (Accession No. X03663). This Eco RI site was used in conjunction with the 
Xho I site at 2110bp in the c-fms coding region, to liberate a fragment containing a 
portion of the 5’ UTR as well as the first 2110bp of c-fms (5’RF) (Fig.8.1.0., 2.1kbp 
arrow).
4072
3054 2.1kbp
Fig. 8.4.1. Analysis by 1% gel electrophoresis of products of an Eco Rl/Xho I restriction enzyme 
digest of purified plasmid DNA from E. coli transformed with pZipSV-(X)/c-/ms. Lanes 1-4 
contain pZipSV-(X)/c-/ms digested with Eco RI and Xho I. Lane 5 is 3’PCR2 digested with Xho 
1/Hind HI. Relevant m arker sizes are indicated and DNA was visualised by staining with l.Opg 
ml * ethidium bromide.
Lanes 1-4 of Fig. 8.5.1. show an Eco Rl/Xho I digest of pZipSV(X)/c-^5 with five 
visible products including a band of «2.1kbp, which corresponds to the fragment of 
interest (Fig. 8.4.1.).
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8.5.1. Cloning of the 5 RF and 3 PCR2 into pcDNAS.l Myc/His
The pcDNA3.1 vector was linearised by digestion with Eco RI /Hind III and
gel purified. The 2.1kbp, 5’RF was liberated from pZipSV(X)/c-^5 by digestion on 
Eco RI and Xho I (Chapter 8, section 5.1.). The 3’ PGR product was liberated from 
pCR2.1 by digestion with Xho I and Hind III and both inserts were gel purified. The 
linearised vector, 5’RF and 3’PCR2 were ligated together and ligation products were 
transformed into E. coli. Colonies were selected, plasmid DNA was prepared and 
analysed by restriction digest with Eco RI and Hind III. Unexpectedly a 1.2kbp and a 
l.Tkbp product were liberated from pcDNA3.1^'^Afyc/His instead of the expected 
2.9kbp (data not shown). The spurious cloning results were possibly due to the 
difficulty of cloning two fragments simultaneously into the pcDNA3.1 vector. To 
simplify ligation an alternative cloning strategy was adopted that involved the use of a 
shuttle vector, which facilitated subcloning each c-fms fragment separately prior to 
subcloning as a single fragment into a pcDNA3.1 based vector.
8.6.1. Cloning of the 5* RF and 3*PCR2 into pGEM  llZ f(+ )
As an alternative strategy, the 5’ RF and 3’ PCR product were cloned into a shuttle
vector, pGEM llZf(+) (Appendix C). Figure 8.6.1. illustrates this cloning strategy.
Since it had proved too difficult to ligate both the 5'RF and 3 PCR into pcDNA3.1^'
^mycfWis simultaneously, ligation of each fragment in turn was the next logical choice.
However, the orientation and positions of restriction sites in the pcDNA3.1 multiple
cloning site (MCS) rendered it impossible to clone each fragment in separately and an
alternative strategy was designed that utilised a cDNA cloning vector with a suitable
MCS, pGEMl lZf(+). The nature of the pGEM MCS facilitated cloning of the 3’PCR
in on Xho I and Hind III enzyme sites to produce pGEM3’PCR (Fig. 8.6.1., A and B).
After successful cloning, pGEM3’PCR could then be linearised by digestion on Eco
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RI and Xho I (Fig. 8.6.1., C) to facilitate subcloning of the 5’RF fragment into 
pGEM3’PCR (Fig. 8.6.1., D and E). Positive clones containing both fragments, 
(pGEM/c-^5) could then be digested with Eco R1 and Hind 111 to liberate a fragment 
containing c-fins ready for cloning into a pcDNA3.1 based vector (Fig. 8.6.1., F).
,XholiHind III
5’RF3’PCR
pZipSV(X)
c-fmspCR2.1
V\ 7
:ho I.Hind III
5’RF3’PCR
V
Eco.RI
,Hlnd
pGEM 11Zf(+)
pGEM 11Zf(+)
v
llnd III
pGEM 11Zf(+)
Shuttle vector cloning strategy for ligating together the 5'RF and 3'PCR productFig. 8.6.1.
in a pGEM based cloning vector prior to subcloning into a pcDNA3.1 based vector.
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The pGEM 1 lZf(+) vector was linearised by digestion with Xho I and Hind III and
gel purified before insertion of the 3’PCR (data not shown). Positive pGEM3’PCR 
clones were selected and analysed by restriction enzyme digestion with Xho I and 
Hind III (data not shown). A clone containing pGEM3’PCR was linearised with Eco 
RI and Xho I and the 4.1kbp product was gel purified. The 5’RF fragment was 
liberated from pCR2.1 and gel purified prior to ligation into the gel purified 
pGEM3’PCR. Clones containing the ligation product of pGEM3'PCR and 5’RF 
(pGEM/c-^5) were selected for further analysis. Restriction digest analysis of 
selected clones with Eco RI and Hind III to liberate the full length c-fins fragment 
repeatedly and unexpectedly produced products of 3.0, 1.8 and 1.2kbp, not the 
predicted 3.2 and 2.9kbp (Data not shown).
More detailed analysis revealed that digestion of the pGEM/c-^5 with either Eco RI 
or Xho I produced a single band that migrated at the predicted molecular weight of 
6.1kbp for pGEM containing both c-fins fragments (Fig. 8.6.2., lanes 1 and 2).
Digestion with Hind III, was also expected to produce a linearised fragment, but 
repeated analysis produced a spurious bands of »I.9kbp and 4.1kbp (Fig. 8.6.2., lane 
3). A double digest was carried out with Xho I and Hind III also conflicted with the 
predicted products of 5.2kbp and 820bp and instead bands of 4.1kbp, l.Ikbp and 
820bp were present (Fig. 8.6.2., lane 4).
Taken together these data suggested that another Hind III site was present in the 5’
RF. Computer prediction of restriction enzyme sites in the human c-fins mRNA
originally predicted no Hind III sites within the c-fins coding sequence (MacDNAsis
v2.6). However a newer search revealed that a Hind III site was indeed present at
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1349bp, in the middle of the 5'RF. The presence of this Hind III site explained all the 
observed problems associated with cloning into both pcDNA3.1 ^ '^ /Myc/His and 
pGEMlIZf(+).
M 1 2  3 4
4072 —
3 0 5 4 -
2036 —
1 6 3 6 -
1018 —
506/517—
6 . 1 kbp
4.1kbp
1.9kbp
l .I k b p
820bp
Fig. 8 .6 .2 . A n a lysis  by 1% gel e lec trop h oresis prod u cts o f  d iagn ostic  restr iction  en zym e d igests  
from  p G E M  clon es. L anes 1 and  2 are p G E M  llZ f(+ ) /c - /m s  lin earised  w ith  E co R I and  X h o  I, 
resp ectively  (6.1kbp). L ane 3  rep resen ts H in d  III d igested  pG E M  llZ f(+ ) /c - /m s  (4.1kbp and  
1.9kbp) and  lane 4  represen ts X h o  I/H in d  III d igested  p G E M  llZ f(+ ) /c - /m s  (4.1kbp, l.Ik b p  and  
820b p .). R elevan t m ark er sizes are in d icated  an d  D N A  w as v isu a lised  by sta in in g  w ith  l.O pg m l 
' e th id iu m  brom ide.
Unfortunately, because of the orientation of the MCS in the pcDNA3.1^'^ vector there 
were no other available enzyme sites that would have facilitated subcloning of the full 
length c-fins from pGEM into pcDNA3.1. Thus although the full c-fins gene was 
present in pGEM, and appeared to have been cloned successfully, it was impossible 
continue and subclone into pcDNA3.1^'^wyc/His. Further cloning of c-fins into a 
pcDNA3.1 based vector required another, alternative approach.
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8.7.1. Amplification of full-length c-fms using a proof-reading DNA polymerase
The availability of molecular biology tools for the reliable amplification of DNA
fragments of S.Okbp and larger made it possible to reconsider amplification of the full
length c-fms cDNA, an approach that had originally not been chosen because of the
high probability of errors that would have resulted in non-sense mutations. Therefore
a new approach was designed around using a proofreading DNA polymerase to
amplify a cDNA encompassing the 5' Kozak consensus sequence, and the full c-fms
coding sequence. Fig. 8.7.1. is a schematic representation of the new cloning strategy.
Amplification of the full length c-fms coding sequence would allow amplification of a
completely homologous c-fms construct (WT-1), as well as amplification of a product
containing a short linker in place of the stop codon for production of a tagged
construct (MT-1). The availability of newer pcDNA3.1 based vectors with a MCS in
the positive orientation also allowed subcloning of MT-1 from a pCR2.1 cloning
vector into the new, pcDNA3.1 ^ ^^ /wy^ c/His expression vector using a 3' restriction
enzyme site other than Hind III.
y AR-2
AF-3^AF-2^ ,  AR-1
5'ura Human c-fms
(2 9 1 4 b p ) TGA
WT-1:
AF-3 + AR-1 = Full length c-fms 100% homologous (inc. Kozak consensus)
MT-1:
AF-2 4- AR-2 = Full length c-fms with Stop ->Hind III site (inc. Kozak consensus)
F ig. 8 .7 .1 . S trategy  for  c lo n in g  c-fms by P C R  am p lifica tion  u sin g  a p roo f-read in g  D N A
p olym erase.
3'UTR
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Amplification of the full-length c-fins gene from pZipSV(X)/c-^5 was carried
following the Advantage^^ KlenTaq (Clontech) PCR methodology (Chapter 3.4.11.). 
The KlenTaq DNA polymerase mix contains both a standard DNA polymerase as well 
as a polymerase with proof-reading ability. The proofreading DNA polymerase 
facilitates efficient and accurate amplification from cDNA template of products up to 
40 kbp.
PCR amplification of c-fms was carried out with primer sets AF-3 and AR-1 for 
amplification of WT-1 and AF-2 and AR-2 for amplification of MT-1 from either 
U937 cDNA library (Clontech) or cDNA containing pZipSV(X)/c-^5. Initial 
amplification from the U937 cDNA library was unsuccessful, due to the possible low 
abundance of c-fins cDNA. No amplification products were obtained from U937 
cDNA corresponding to the predicted molecular weight (Fig. 8.7.2., lanes 1 and 2) for 
either WT-1 or MT-1. The nature of the U937 cDNA library production may have 
accounted for a low abundance of c-fms cDNA since the library had been prepared by 
reverse transcription of an oligo-dT primer. The long 3'UTR of c-fins may have 
decreased the likelihood of successful synthesis of cDNA.
However, in contrast, both WT-1 and MT-1 were successfully amplified from 
pZipSV(X)/c-^5 (Fig. 8.7.2., lanes 3 and 4, respectively). Both 2.9kbp PCR products 
were gel purified for subsequent ligation into pCR2.1.
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M 1 2 3 4
4072\ ^
3 0 5 4 -  
2036 _  
1 6 3 6 -
1 0 1 8 -
5 0 6 /5 1 7 -
2.9kbp
Fig. 8 .7 .2 . A n alysis b y  1%  gel e lectrop h oresis o f  p rod u cts from  th e am p lifica tion  o f  fu ll len gth  c- 
fms  by  P C R  from  U 937  cD N A  lib rary  and  p Z ip S V (X )/c -//iis . L an es 1 and  2 rep resen t  
am p lifica tion  p rod u cts from  U 937  cD N A . L an es 3 and  4 rep resen t am p lifica tion  prod u cts from  
p lasm id  D N A  tem p late . L an es 1 an d  3 are p roducts from  p rim ers A F -2 and  A R -2 . L anes 2 and  4 
are p rod u cts o f  p rim ers A F -3  and  A R -1 . R elevan t m ark er sizes are in d ica ted  and  D N A  w as  
v isu a lised  by sta in in g  w ith  l.O pg ml'* eth id iu m  brom ide.
8.7.2. Cloning and analysis of products obtained from PCR of full length c-fms
The 100% Homologous (WT-1) and 100% Engineered (MT-1) products obtained 
from pZipSV(X)/c-^.ÿ were cloned into pCR2.1 and transformed into E.coli. 
Representative clones of WT-1 and MT-1 were then sequenced (data not shown). 
Sequence analysis confirmed that the WT-1 clones were >99% homologous to c-fins 
and the MT-1 clones were >98% homologous to c-fins only differing, as expected, at 
the engineered, 3'-site (Data not shown). The two c-fins clones were then ready for 
cloning into pcDNA based expression vectors.
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8.8.1. Sub-cloning of WT-1 into pcDNA3.1^'^
The WT-1 clone was liberated from pCR2.1 by restriction enzyme digestion with Eco 
Rl, cutting at two Eco R1 sites in the MCS of pCR2.1, one upstream the other 
downstream of c-fms, before gel purification. In addition, the pcDNA3.1 vector had 
been linearised with Eco RI and treated with calf intestinal alkaline phosphatase 
(ClAP, Promega) to remove 5'-phosphate groups and to minimise vector 
recircularisation.
Clones containing WT-1 ligated into pcDNA3.1^'^ were analysed by colony PCR 
(Chapter 3.4.11) with their amplification primers (Data not shown) and six positive 
clones were selected for further analysis by restriction enzyme digestion (Fig. 8.8.1.).
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
6108v
5090^
4 0 7 2 -
3 0 5 4 -
2 0 3 6 -
1 6 3 6 -
1 0 1 8 -
5 0 6 /5 1 7 -
m m h
» » t.
Fig. 8 .8 .1 . R estriction  en zym e an a lys is o f  p ositive  clon es con ta in in g  W T -1. S ix  clones w ere
an a lysed  by restriction  en zym e d igestion  w ith  E co R I (lan es 1-6), E co R I and  H in d  H I (lanes 7-12) 
and X ho I (lanes 13-18). T h e  p red icted  prod u cts o f  W T -1 d igestion  w ere  5 .4k b p  and  2 .9k b p  for  
Eco R I, 5 .3k b p , 1 .9kbp  and l .I k b p  fo r  the E co R I/H in d  H I d igest and  7 .5k b p  and 820b p  for  the  
X h o I d igest. R elevan t m ark er sizes are  in d ica ted  and  D N A  w as v isu a lised  by sta in in g  w ith  l.O pg  
m l ' e th id iu m  brom ide.
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Two positive clones were identified from restriction enzyme digestion. Digestion
with Eco RI liberated two bands of 5.4kbp and 2.9kbp representing the vector back­
bone and the c-fins insert (Fig. 8.8.1., lanes 2 and 3). A double digest with Eco RI and 
Flind III liberated three bands of 5.3kbp, 1.9kbp and 1.1 kbp, representing the vector 
back-bone, an Eco Rl/Hind 111 fragment containing the 5' of c-fins and a Hind 111 
fragment containing the rest of c-fins (Fig. 8.8.1., lanes 8 and 9). Digestion with Xho 
1 yielded two bands of 7.5kbp and 820bp corresponding to the Xho 1 site within c-fins 
and the 3' Xho 1 site in the vector MCS (Fig. 8.8.1., lanes 14 and 15). Restriction 
enzyme analysis also suggested that both these clones were in the correct orientation 
in pcDNA3.1^'\ Positive clones revealed by restriction digest were sequenced 
(Appendix D) and were confirmed to contain human c-fins, in the correct orientation 
as indicated by enzymatic digestion.
8.8.2. Sub-cloning of MT-1 into pcDNAS.l -wvc/His
To facilitate cloning of MT-1 into a pcDNA3.1 based vector containing a C-terminal 
myc/Uis tag, two restriction enzyme sites were chosen for cloning purposes that were 
common to the MCS of pCR2.1 and pcDNA3.1 vectors in the positive orientation (+). 
A recently available variant of the vector originally chosen for pcDNA3.1^^^-myc/His, 
facilitated sub-cloning from the pCRZ.l vector on BamH 1/Not 1, two sites unique to 
the MCS and not present in c-fins. Clones containing MT-1 in pCR2.1 digested with 
BamH 1 and Not 1 restriction enzymes and the 2.9kbp band liberated was gel purified. 
The gel purified, MT-1 was ligated, into pcDNA3.1^^^ MycfWxs (Frame C) and 
transformed into E. coli. Positive clones were screened by colony PCR with AF-2 and 
AR-2 and clones containing the correct sized insert were also analysed by restriction 
enzyme digestion (Fig. 8.8.2.).
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M 1 2 3 4 5 6 7  8 9 10 1112 13 14
5090
506/517 —
M 1 2 3 4  5 6 7  a  9 10 11 12 13 14
506/517 —
Fig. 8.8.2. Restriction enzyme analysis of positive clones MT-1 in pcDNAS.l myc/His.
Positive clones were analysed by restriction digest with either Xho I (upper lanesl-14) or Hind HI 
(lower lanesl-14). The expected digestion products of Xho I were 7.5kbp and 820bp and for 
Hind HI; 5.3kbp, 1.9kbp and l.Ikbp . Relevant m arker sizes are indicated and DNA was 
visualised by staining with l.Ofig ml ' ethidium bromide.
Eight positive clones were identified (Fig. 8.8.2., lanes 2, 3, 4, 6, 7, 9, 13 and 14) and
one clone was selected for sequence analysis. Sequence analysis of the selected clone
required detailed analysis of the C-terminus to confirm that c-fins had been cloned in
frame with the myc/His epitopes. Therefore the entire c-fins coding region was
sequenced in both forward and reverse orientations to confirm that the sequence
would code for full length c-fins. This was carried out using gene overlapping, gene
specific primers (Sequencing primers, appendix C) to generate a consensus sequence
for MT-1 (Appendix E). The consensus sequence was compared with the published
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protein sequence of human c-fins (Swiss-Prot. Accession No. P07333) using a tBlastx
sequence similarity program (Appendix F). The consensus sequence for MT-1 
translated into a 1014 amino acid protein containing the 972 amino acids of c-fins and 
read-through the mutagenised stop codon into the myclWxs epitope present 
immediately upstream of a stop codon (Appendix F). Therefore MT-1 contained the 
full length c-fins coding region with a C-terminal epitope tag in a mammalian 
expression vector under the control of the CMV promoter. This construct now 
provided the basis for site directed mutagenesis studies to introduce mutations within 
the c-fms coding sequence.
8.9.1. Introduction of single amino acid substitutions into MT-1 by site directed 
mutagenesis
The epitope tagged human c-fins construct produced in chapter 8 was used as a 
template for the introduction of single amino acid substitutions at three residues. 
Mutations were introduced at two tyrosine residues, Tyr^^* and Tyr^^ ,^ in the kinase 
insert region of c-fins by altering the nucleotide composition at the relevant tyrosine 
residue to code for a phenylalanine by site directed mutagenesis using the Stratagene 
Quick-Change SDM protocol (Chapter 3.4.14.). Mutagenesis was accomplished from 
supercoiled, dsDNA, MT-1 using two synthetic oligonucleotide primers containing 
the desired mutation. The oligonucleotide primers, each complementary to opposite 
strands of the vector, were extended by PCR to synthesise a mutated plasmid 
containing staggered nicks. After amplification, the PCR product was digested with 
the methylated DNA sensitive restriction enzyme, Dpn 1 which preferentially digested 
the methylated, parental DNA template, selecting for the synthesised DNA containing 
the desired mutation. The nicked vector DNA incorporating the desired mutations was
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then transformed into E. coli. Table 8.9.1. summarises the various c-fms mutant
constructs synthesised.
Site directed mutagenesis of Tyr^^* was carried out with primers Y708F-1 and Y708F- 
2 and mutagenesis of Tyr^^  ^ was carried out with primers Y723F-1 and Y723F-2 to 
generate MT-2 and MT-3, respectively (Appendix C). Following transformation of E. 
coli, clones were screened by sequence analysis with the diagnostic primer set SF-3 
and SR-6, and clones containing each point mutation were obtained (Appendix G). 
The double mutation construct, MT-4, was produced by repeating the mutagenesis on 
an MT-2 clone with primers Y723F-1 and Y723F-2. Again, following transformation 
of E. coli, clones were screened by sequence analysis with the diagnostic primer set 
SF-3 and SR-6, and clones containing both point mutations were identified (Appendix 
G).
In addition to mutation of the tyrosine residues involved in PI 3-kinase activation a 
single leucine residue at Leu^^\ in the fourth Ig-like loop of c-fms was mutated to 
serine. Mutation of this site had previously been demonstrated to confer transforming 
capability on c-fms expressed in NIH 3T3 cells (Roussel et al., 1988). Site directed 
mutagenesis was carried out using two homologous primers, L301S-1 and L301S-2 
(Appendix C). Three constructs were generated from clones MT-1, MT-2 and MT-3 
containing an amino acid substitution at Leu^®’ to give MT-5, MT-6 and MT-7, 
respectively (Table 8.9.1.). The clone MT-5 contained a single mutation at Leu301 
and coded for a transformed, wild-type epitope tagged human c-fms. Clones MT-6 
and MT-7 contained the Leu301Ser mutation in addition to mutations phenylalanine 
mutations at Tyr^ ®* and Tyr^^ ,^ respectively. Following transformation of E. coli, each
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clone was sequenced with the diagnostic primer set SF-1 and SR-3, and clones 
containing the single point mutation were identified (Appendix G).
Leu^^^Ser Tyr™*Phe Tyr™Phe
MT-1 - - -
MT-2 - + -
MT-3 - - +
MT-4 -
MT-5 + -
MT-6 + - +
MT-7 + - -
Table 8.9.1. Summary of human c-fnts m utant constructs.
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8.10.0. Discussion
The aim of this chapter was the construction of a c-fms construct for introduction into 
mammalian cells for expression of a full length tagged c-ftns. A variety of cloning 
approaches were employed in an attempt to clone c-fns successfully into pCDNA3.1 
based vectors. This initial strategy avoided the amplification of the entire coding 
region, which may have introduced undesired errors and also exploited the presence of 
convenient restriction sites (Fig. 8.1.0.).
The initial strategy involved PCR amplification of the 3’ portion of c-fms from a 
cDNA template, pZipSV(X)/c-^5, either as a homologous product (3’PCRl) or as a 
product with the c-fins stop codon replaced with a Hind 111 site (3’PCR2). The 5’ end 
of these PCR products contained an internal Xho 1 site that facilitated the ligation of 
the PCR product with the remainder of the 5’ end of c-fins (5’RF), liberated from the 
cDNA template by digestion with Eco Rl and Xho 1. Both the 5’RF and 3’PCRl were 
to be cloned, in tandem, into pcDNA3.1^‘\  to produce WT-1 and the 5’RF and 
3’PCR2 were to be cloned, in tandem, into pcDNA3.1 ^ '^myc/His, to produce MT-1. 
After extensive optimisation of PCR conditions the 820bp 3’PCR products were 
successfully amplified from cDNA template and their sequence was confirmed. The 
5’RF was also liberated successfully from pZipSV(X)/c-^5. Ligation of both 5’RF 
and 3’PCR2 into pcDNA3.1 ^ '^myc/His was attempted, however although cloning 
conditions had been optimised, cloning did not succeed. Therefore it was not possible 
to continue cloning c-fins into the available pcDNA3.1 vectors by this approach, and 
cloning each fragment into pcDNA3.1 separately was also not possible due to the 
negative orientation of the MCS which did not contain restriction enzyme sites in a 
suitable location.
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A modified strategy was employed to circumvent the limitations of the pcDNA3.1
MCS. This involved using a shuttle vector for cloning together of each fragment 
before subcloning the entire c-fins gene into the relevent pcDNA3.1 vector (Fig.
8.6.1.). This strategy was essentially the same as the original methodology, and 
utilised the already cloned 3’PCR2 and the 5’RF products. However, this approach 
allowed cloning of the 5’RF into a pGEM based cloning vector which had an Eco RI 
site upstream of Xho I in the MCS. In addition once the 5’RF was cloned into the 
pGEM vector, the 3’PCR2 product could then be inserted downstream of the 5’RF on 
Xho I and Hind III. The final product of these ligation reactions would then have 
been liberated from pGEM after Eco Rl Hind 111 digestion then cloned directly into 
pcDNA3.l^'^m);c/His (Fig. 8.6.1.). A similar approach would also have been 
employed for construction of WT-1.
Although the 3’PCR2 fragment was successfully cloned into pGEMllZf(+), repeated 
attempts at cloning 5’RF into pGEM3’PCR on Eco RI and Xho 1 failed. A diagnostic 
restriction digest revealed the presence of a Hind 111 site in the 5’RF. A new search of 
the published sequence did reveal a Hind 111 site at 1349bp in the human c-fins mRNA 
sequence. Why this site had not been detected initially is unclear, however the 
published c-fms sequence has been updated and it is possible that there had been an 
error in the sequence originally analysed for Hind 111. The presence of this Hind 111 
site explained why identification of clones containing the c-fins gene was confusing. 
In addition, the Hind 111 site at 1349bp also prohibited subcloning of WT-1 and MT-1 
into pcDNA3.1 vectors as had been intended.
At this point an alternative cloning strategy had to be devised that did not rely on
unique restriction enzyme sites. The recent availability of pcDNA3.1 based vectors
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with a MCS in the positive orientation facilitated the subcloning of a full-length c-fins
PCR product. Amplification of c-fins could now be accomplished with proofreading 
DNA polymerases that had greatly reduced error rates compared to Tag DNA 
polymerase, used for the original cloning attempts. Therefore the full length c-fins 
coding sequence was amplified from pZipSV(X)/c-^5 either as a completely 
homologous product (WT-1), or with the stop codon re-engineered to a Hind III site 
(MT-1). The two full-length c-fins amplification products were cloned into pCR2.1 
and positive clones identified by restriction digest analysis. WT-1 positive clones 
were digested with Eco Rl and WT-1 was subcloned into pcDNA3.1^'\ The 5’ and 3’ 
ends of two positive clones obtained from this ligation were sequenced to confirm the 
orientation of WT-1 in pcDNA3.1^'^ (Appendix D).
MT-1, liberated from pCR2.1 was successfully subcloned into pcDNA3.1^^^ myc/His 
on Bam HI and Not I. Sequence analysis of the 5’ and 3’ ends of two positive clones 
obtained from this ligation confirmed that they contained MT-1 (Data not shown) and 
more detailed sequence analysis of one clone, using contiguous gene specific primers 
in both orientations, confirmed that the expression vector contained full length c-fins, 
that read through into the myc/his tag (Appendices E).
The WT-1 and MT-1 constructs represented two novel expression constructs for
exogenous expression studies of c-fins in mammalian cells. Both the WT-1 and MT-1
constructs were designed for high levels of protein expression in mammalian cells
under the control of the cytomegalovirus promoter (CMV). In addition, MT-1 had
the additional advantage of a myc/His tag sequence at the C-terminus. Fig. 8.10.1. is a
schematic diagram of the cloned c-fins expression constructs and positions of the
mutations on MT-1 introduced through site directed mutagenesis.
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Human c-fins 
(2914bp)
Y723F
TGA
myc His
Y708F
TGA
myc His
TGA
myc His
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L
L301S
1
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myc His
L
TGA
L301S
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L
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L301S
1
Y723F
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u
TGA
.10.1. Diagrammatic representation of the WT-1 and MT-1 C-fms constructs i
mammalian expression vectors.
The myc epitope will facilitate detection of expressed protein with specific antibodies 
that recognise the myc 9E10 epitope. An alternative to c-fins specific antibody 
detection will also be preferable for discriminating between endogenous c-fins and 
recombinant expression and this is also facilitated by the myc epitope. The His tag
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will also facilitate detection of recombinant protein as well as high-affinity
purification.
The MT-1 construct was also used as a template for site directed mutagenesis of key 
residues in the c-fins extracellular and cytoplasmic domains. A series of c-fins 
constructs, mutated at a combination of Leu^^\ Tyr^ ®* and Tyr^^  ^ were produced 
(Table 9.5.1. and Fig. 8.11.1.). The MT-2 mutant contains a Tyr708Phe mutation, 
MT-3 contains a Tyr723Phe mutation and MT-4 contains mutations at both sites. 
Each construct was engineered for the investigation of PI 3-kinase binding to c-fins. 
In addition, mutation of Leu301Ser in the extracellular domain was carried out on 
MT-1, MT2 and MT-3, to produce MT-5, MT-6 and MT-7, respectively. Constructs 
containing the Leu301Ser mutation on c-fins possess transforming capability and are 
expected to be constitutively activated in transfected cells.
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9.0.0. Introduction
Exogenous expression of c-fms in a variety of mammalian cell lines has generated a 
substantial amount of conflicting data. This includes conflicting data regarding 
STAT activation, where the activation of Jak kinases in c-fms transfected fibroblasts 
was not observed in BAC1.2F5 macrophages (Novak et al., 1995). In addition, 
pl20ras*GAP is phosphorylated and associates with pl90Rho#GAP in w-fins 
transformed fibroblasts (Trouliaris et al., 1995), however pl20ras#GAP 
phosphorylation was not observed in BAC1.2F5 macrophages (Reedijk et al., 1990).
It has also been difficult to ascertain whether M-CSF stimulated responses in 
macrophages require PI 3-kinase. C-fms transfection studies, when considered 
together, only suggest that different cell lines provide a different environment of 
signalling molecules for c-fms signalling. For example, data obtained early on in c- 
fms transfection studies suggested that mutation of Tyr^ ^  ^ in the murine receptor when 
expressed in Rat-2 fibroblasts, resulted in a concomitant loss of PI 3-kinase activity 
and cell proliferation (Reedijk et al., 1992) which was also suggested by a study 
carried out in NIH 3T3 fibroblasts with a deleted c-fms K1 domain (van der Geer and 
Hunter, 1993). However, in FDC-Pl myeloid cells transfected with a c-fms mutant 
lacking the K1 domain, M-CSF continued to stimulate cell proliferation comparable to 
wild type c-fms (Kanagasundaram et al., 1996). These examples emphasise the need 
for a more relevant macrophage cell or transfection model in which c-fms signalling 
can be disseminated without the drawbacks observed with classical cell lines routinely 
chosen for transfection studies.
It is evident that common transfectable cell lines possess unique properties which are
not consistent with those found in macrophages. Although the various components of
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a signalling pathway may be present this alone does not guarantee that c-fms
signalling can be replicated. Other requirements might include the presence of correct 
signalling complexes, the correct subcellular localisation of signalling molecules as 
well as the correct numbers of molecules per cell.
Therefore to examine c-fms signalling within the context of macrophages, a 
macrophage cell line must be utilised. It would be an advantage to express c-fms 
DNA constructs in a relevant cell model such as BAC1.2F5 cell line. Studies of 
mutant c-fms constructs, over-expressed in BACI.2F5 cells in a dominant negative 
manner, would facilitate further analysis of M-CSF stimulated responses in 
BACI.2F5 cells which have now been extensively characterised, that rely on the 
direct association of PI 3-kinase with phosphorylated c-fms.
However, it has been demonstrated that established cell lines of the haematopoietic 
lineage such as T-cells and macrophages are notoriously difficult cells in which to 
express exogenous DNA. It has been demonstrated in this laboratory that T-cells are 
readily transfectable with commonly available reagents, but detection of protein 
expression has either been very poor or undetectable. In some instances activation of 
T-cells with phorbol esters has upregulated protein expression although this method of 
cell activation is undesirable for studying specific signalling pathways. Similar 
findings have also been reported for macrophage cell lines and the available 
published data on macrophage transfection suggests that viral based transfection 
systems are the most commonly used methods for attaining high levels of exogenous 
protein expression. Alternative means for introduction of protein into macrophages 
includes micro-injection which has proved successful for a number of groups (Allen et
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al., 1997). However micro-injection is a laborious technique and for biochemical
studies of receptor mutants is an impractical approach.
Therefore the overall aim of this chapter was to transfect the c-fins constructs 
produced in chapter 8, into BAC1.2F5 macrophages. This involved determination of 
a viable transfection system for macrophages and a number of commercial systems 
were investigated. Following identification of a suitable transfection methodology, 
the c-fins constructs would be introduced into BAC1.2F5 cells and once c-fms 
expression had been accomplished, a detailed biochemical and functional study was 
intended.
The presence of epitope tags at the C-terminus of each mutant construct would not 
only facilitate identification of exogenous receptor fi'om endogenous receptor, but also 
the selective precipitation of human c-fins and the co-precipitation of signalling 
molecules associated with exogenous receptor molecules. Differences in the 
association of PI 3-kinase with mutated c-fms, could then be correlated to the 
observed differences in M-CSF stimulated responses in transfected BACI.2F5 cells 
compared to untransfected cells.
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9.1.0. C haracterisation of efficient transfection protocols for the introduction of
DNA into BAC1.2F5 m acrophages
Many methods exist for the introduction of DNA into mammalian cells. These 
include calcium phosphate, electroporation and lipid mediators (Graham and Eh AJ 
van, 1973; Neumann et al., 1982; Rizzo et al., 1983). To date, there are few published 
protocols available which describe the successful transfection and expression of 
exogenous proteins in macrophage cells. In order to express the c-fms constructs in 
BAC1.2F5 cells the most favourable transfection method was determined by 
comparing various transfection techniques.
Several protocols were analysed for efficiency of transfection using a wild type 
enhanced Green Fluorescent Protein (WT eGFP) construct (appendix C) into 
BACI.2F5 cells. Efficiency of transfection was measured as a percentage of the cell 
population expressing eGFP, measured by FACS. Four lipid based methods, 
LipoFectAMINE™ (Gibco-BRL), LipoFectin™ (Gibco-BRL), CellFectin™ (Gibco- 
BRL) and DIMRJE-C™ (Gibco-BRL), a Calcium Phosphate based method 
(ProFection™, Promega) and a poly-cationic method, SuperFect™ (Qiagen) were 
compared for their transfection efficiency (Chapter 3.4.17.).
LipoFectin™, CellFectin™ and DIMRIE-C™ lipid-mediated transfection techniques 
all led to high cell mortality which resulted in a harvested cell population that was too 
small for analysis by FACS (Data not shown). LipoFectAMINE™, ProFection™ and 
SuperFect™ transfection methods were less toxic to cells and therefore FACS 
analysis was possible (Figs. 9.1.1.).
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Fig, 9.1.1. Transfection efficiency of wild-type eGFP construct into BAC1.2F5 cells. Three 
alternative transfection methods were compared directly for efficiency of transfection of a WT 
eGFP construct (Clontech). Cells were harvested 24 hours post-transfection and analysed by 
FACS. Panel A is the lipid-mediated LipoFectAM INE™  (Gibco-BRL), panel B is the Calcium 
Phosphate-based ProFection^'^ and panel C is the poly cationic-based SuperFect’ '^^  (Qiagen).
The highest transfection efficiency was observed with SuperFect™ at 26%, however 
this required the greatest concentration of DNA, (20pg ml'*). However, at comparable 
DNA concentrations ProFection™ had only 10% transfection efficiency, which 
suggested that SuperFect™ would be the more suitable choice for transfection of 
BAC1.2F5 cells if DNA was readily available. Interestingly, lipid-mediated 
transfection protocols were shown to be highly toxic to BAC1.2F5 cells, however 
LipoFectAMINE™ appeared to be the least toxic and was capable of achieving a 
reasonable transfection efficiency (13%) with 4 pg mf* DNA, which was more 
efficient than SuperFect with 5 pg ml ' DNA. Therefore, because of the low toxicity
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and high transfection efficiency, SuperFecf*"^ was chosen as the method of choice for
transfection studies in BAC1.2F5 cells where recombinant DNA was readily 
available. In the event that only small quantities of DNA were available for 
transfection purposes, LipoFectAMINE™ was also considered.
9.2.0 Expression of W T- and MT-1 in BAC1.2F5 m acrophages
The SuperFect^'^ transfection conditions, optimised in the previous section, were used 
to introduce both WT-1 and MT-I into BACI.2F5 cells. Endotoxin free plasmid 
DNA (Chapter 3.4.10) was transfected into BAC1.2F5 cells plated out at 1.5x10*  ^per 
13mm round coverslip or at 1.0x1 O'Vwell on 6-weIl tissue culture dishes. Transient 
transfections were examined either biochemically by western blot or immuno- 
fluorescent analysis with gene specific and //lyc-epitope specific antibodies. Repeated 
attempts to detect expression of either WT-1 or MT-I in BAC1.2F5 cells transfected 
by either optimised SuperFect or LipoFectAMINE transfection methods failed (Data 
not shown). Detection of expressed protein may have been hindered by either a low 
transfection efficiency or poor protein expression which was below detection 
sensitivity. It must be noted that the transfection conditions had been optimised with 
an eGFP-based construct, expression of which in mammalian cells is regulated by the 
same CMV promoter found in pcDNA3.1 based vectors. However, detection of eGFP 
expression was carried out by FACS analysis, a more sensitive detection method than 
that used for detection of WT-1 and MT-1. In other cell lines, e.g. T-cells, expression 
from the CMV promoter requires cell activation with Phorbol 12-Myristate 13-Acetate 
(PMA). Transiently transfected BAC1.2F5 cells, 18 hours post transfection were 
incubated for 5 hours with lOnM PMA prior to analysis of MT-1 expression by 
western blot analysis with gene specific antibodies. PMA activation of BAC1.2F5
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cells did not upregulate expression of exogenous c-fms to a detectable level (Data not 
shown).
9.3.0. In vitro translation of MT-1
In order to confirm that the c-fms coding sequence in the MT-1 expression construct had the capacity to 
code for full length c-fms, MT-1 was translated, in vitro, using both a Rabbit Reticulocyte and 
Wheatgerm Agglutinin in vitro translation system (Chapter 3.4.16.). The methionine labelled 
translation products from MT-1 were resolved by SDS-PAGE and detected by autoradiography (Fig.
9.3.1.). A  single product o f  approximately 130-140kDa was detected in both in vitro translation 
systems (Fig. 9.3.1.).
R W
2 50 - M
98
38
c-Jms
Fig. 9.3.1. SDS-PAGE analysis of an in vitro translation of human, epitope tagged c-fms 
(MT-1). Lane R is a rabbit reticulocyte based in vitro translation reaction and lane W is a 
comparative wheatgerm agglutinin in vitro translation. Membranes were exposed to 
autoradiography film for 22 hours.
The Mr of the immature, human c-fins is approximately ISOkDa, the additional 42 
amino acids corresponding to the C-terminal linker and epitope tags, when taken into 
account, would increase the Mr to approximately 135kDa which is comparable to that 
observed in the in vitro translation. The data from the in vitro translation indicates
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that MT-1 is capable of translating a full length product containing the entire human c-
fm s coding region and the C-terminal mycfWxs epitope tags.
9.4.0. T ransient expression of MT-1 in H EK  293 epithelial cells detected by 
western blot analysis
In order to validate MT-1 further, it was necessary to express this construct in a 
readily transfectable mammalian cell line. For this purpose the human embryonic 
kidney epithelial cell line, HEK 293 was chosen. This cell line has previously been 
demonstrated to be readily transfectable by Calcium Phosphate and have been shown 
to express exogenous protein at relatively high levels (Yang et al., 1998). Therefore 
to validate MT-1, HEK 293 cells were transfected using the ProFection™ Calcium 
Phosphate transfection protocol (Chapter 3.4.17.). Cells were lysed at 24 and 72 
hours post-transfection and analysed by SDS-PAGE. Western blot analysis 
demonstrated that tagged c-fins (MT-1) was readily detected with anti-wyc epitope 
antibody in whole cell lysates from transiently transfected HEK 293 cells (Fig. 9.4.1.).
Tagged Q-fms expression was detected as early as 24 hours post transfection (Fig.
9.4.1., lanes 3 and 4). At 24 hours post transfection tagged c-fins was expressed as
two isoforms of 135kDa and 155kDa, corresponding to the immature and mature
receptor forms, respectively (Fig. 9.4.1., lanes 3 and 4). These receptor bands are
comparable to those previously been observed for the murine receptor (Chapter 4.2.1.)
and reported for the human receptor (Sherr et al., 1990). However, the immature and
mature tagged c-fms isoforms exhibit an increased Mr on SDS-PAGE due to the
presence of the mycfWis, tags (Fig. 9.4.1., lanes 3 and 4). The immature form of
tagged c-fins is the predominant isoform present at 24 hours post transfection, and 72
hours it appears to be the only isoform present (Fig. 9.4.1., lanes 5 and 6). The 65
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kDa band, present in both untransfected and transfected cell lysate (Fig. 9.4.1.) 
corresponds to endogenous c-myc (Persson and Leder, 1984).
• mMM 4= 155kD a135kD a
^ -------  65k D a
Fig. 9.4.1. SDS-PAGE analysis of whole cell lysate from HEK 293 cells transiently 
transfected with MT-1 . Approximately lOfig of total cell lysate proteins were resolved by 7.5% 
SDS-PAGE and then blotted onto a nitrocellulose membrane prior to immunostaining with an 
anti-wijc epitope mAh (Calbiocbem). Lanes 1 and 2 represent lysates from no DNA and no 
Calcium phosphate reagent controls, respectively. Lanes 3 and 4 are lysates from duplicate 
transient 24 hour transfections (4pg ml ) and lanes 5 and 6 are comparable transfections (4p,g 
ml ') at 72 hours.
Expression of tagged c-fins was also characterised by immunoprécipitation with an 
anti-/wyc epitope antibody to demonstrate that the epitope tag would facilitate 
purification of c-fims from transfected cells. HEK cells, transiently transfected with 
tagged c-fins, were harvested at 24 hours post transfection and tagged c-fms was 
immunoprecipitated with an anti-wyc epitope antibody directly conjugated to agarose 
(Santa Cruz). SDS-PAGE analysis of immunoprecipitated tagged c-fins demonstrated 
that both immature and mature tagged c-fins were purified from HEK cell lysate and
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could be detected with an anti-myc antibody (Santa Cruz) (Fig. 9.4.2., Panel A, lanes 
3-5).
Panel A Panel B
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Fig. 9.4.2. SDS-PAGE analysis of protein immunoprecipitated HEK 293 cells transiently 
transfected with MT-1. Tagged c-fms was immunoprecipitated with an agarose-conjugated anti- 
myc mAh (Santa Cruz). Precipitated proteins were resolved by 7.5% SDS-PAGE and then 
blotted onto a nitrocellulose membrane prior to immunostaining with either an anti-myc epitope 
mAb (Calbiocbem) (Panel A) or an anti-buman c-fms pAb (Santa Cruz) (Panel B). Lanes 1 and 2 
represent lysates from no DNA and no Calcium phosphate reagent controls, respectively. Lanes 
3 8 are lysates from transient 24 hour transfections (4|ig ml )
In addition, an antibody specific for the extracellular domain of human c-fins (Santa 
Cruz) was also capable of detecting immunoprecipitated tagged c-fms (Fig. 9.4.2., 
Panel B, lanes 6-8).
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9.5.0. Im m unofluorescent analysis of HEK ceils transiently expressing MT-1
To determine whether tagged c-fms expression could be detected by 
immunofluorescence, transiently transfected HEK cells were probed with c-fms- 
speciflc and myc epitope-specific antibodies (Fig. 9.5.1.). Tagged c-fms transiently 
transfected into HEK cells was detected with both c-fms (Fig. 9.5.1., top panels) and 
c-myc (Fig. 9.5.1., bottom panels) epitope specific antibodies at 24 hours.
Hu C-fmsHu C-fmsHu C-fms
C-myc Epitope C-myc Epitope
Fig. 9.5.1. Immunofluorescent analysis of MT-1 expressed in HEK cells. Transiently 
transfected HEK cells were probed either with an anti-buman c-fms (top panels) or anti-c-wjc 
epitope (bottom panels) antibody and visualised with an Alexa'***-conjugated secondary antibody 
(Molecular Probes). Each panel is representative of at least three separate experiments. Bars 
indicate 10pm.
These data confirm that c-fms localisation can be detected by immunofluorescence and 
that both gene specific as well as epitope specific antibodies can readily detect 
exogenous protein. Further analysis of tagged c-fms transfected HEK cells for the 
subcellular localisation of tagged c-fms suggests that c-fms is localised to the plasma 
membrane and to discrete cytosolic locations 24 hours post transfection (Fig. 9.5.2.).
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Fig. 9.5.2. Immunofluorescent analysis of MT-1 expression in HEK cells. Transiently
transfected HEK cells were probed with an anti-human c-fms antibody and stained with an 
Alexa^^^-secondary antibody. Panel A is single positive HEK cell recorded by photomicrography. 
Panel B is a single 1pm deconvolved section of a comparable cell captured with a digital camera 
and processed by OpenLab 1.7.8. Bars indicate 10pm.
At higher magnification, the plasma membrane localisation of tagged c-fms can be 
visualised with an anti c-fms antibody as illustrated by panel A of Fig. 9.5.2. in 24 
hour transient transfections. The white arrows in panel A clearly indicate plasma 
membrane staining whilst the nucleus is clearly delineated and the cytosol contains 
very little positive staining (Fig. 9.5.2.). This is the anticipated staining pattern of c- 
fm s localisation and confirms that tagged c-fins is localised correctly in transfected 
HEK cells. Using a digital analysis package (OpenLab 1.7.8, Improvision) which 
allows software enhancement of a fluorescent specimen, a single 1 pm section through 
a positively stained, tagged c-fms transfected HEK cell (Fig. 9.5.2., panel B) revealed 
predominant plasma membrane staining (white arrows) as well as punctate cytosolic 
staining which extended throughout the cell. Therefore immunofluorescent detection 
of the expressed tagged c-fms construct in HEK cells confirmed that c-fms is localised 
at the plasma membrane as expected for a cell surface receptor.
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Since the expression pattern of tagged c-fins isoforms appears to vary from 24 hours 
to 72 hours post transfection as detected by western blot analysis, it seemed likely that 
this would also affect the subcellular localisation of tagged c-fins. Analysis of cells 72 
hours post-transfection indicated that tagged c-fins is not localised at the plasma 
membrane but instead is found predominantly in the cytosol (Fig. 9.5.3.). 
Investigation of tagged c-fins localisation with digital image analysis revealed that 
tagged c-fins was localised in distinct pockets around the nucleus (Fig. 9.5.3., panels 
A and B). In panel A of Fig. 9.5.3. the white arrow indicates the positively stained 
cytosolic location of tagged c-fms in a single 1pm transverse section through a 
transfected HEK cell. For comparison the location of the plasma membrane of a 
transfected HEK cell is indicated in panel B of Fig. 9.5.3.. It is evident that at 72 
hours post transfection tagged c-fms is no longer expressed at the plasma membrane.
Fig. 9.5.3. Immunofluorescent analysis of MT-1 expression in HEK cells after 72 hours.
Transiently transfected HEK cells were probed with an anti-myc epitope antibody and stained 
with an AIexa^**-secondary antibody. Panels A and B are single 1pm deconvolved sections of a 
comparable cells captured with a digital camera and processed hy OpenLab 1.7.8. Bars indicate 
10pm.
9.6.1. T ransient expression of m utant epitope tagged c-fms in HEK cells
To determine whether mutation at either Tyr^ ®^  or Tyr^^  ^ in the cytoplasmic tail 
affected tagged c-fms expression or subcellular localisation, two expression
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constructs, MT-2 and MT-3, were transiently transfected into HEK cells. Transient 
expression of MT-2 which harbours a Y708F mutation, and MT-3 which harbours a 
Y723F mutation in HEK cells was detected by western blot analysis (Fig. 9.6.1.).
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Fig. 9.6.1. SDS-PAGE analysis of whole cell lysate from HEK 293 cells transiently 
transfected with MT-2 and MT-3. Approximately lOpg of total cell lysate proteins harvested at 
48 hours post-transfection were resolved by 7.5% SDS-PAGE and then blotted onto a 
nitrocellulose membrane prior to immunostaining with an anti-myc epitope mAh (Calbiocbem). 
Lanes 1 and 2 represent lysates from no DNA and no calcium phosphate reagent controls, 
respectively. Lanes 3 and 4 are lysates from duplicate transient transfection of MT-2 (4pg ml * 
and 2pg ml ' respectively), lanes 5 and 6 are duplicate transient transfection of MT-3 (4pg ml ' 
and 2pg ml ' respectively) and lane 7 is a transient transfection of MT-1 (Ipg ml ) for 
comparison.
Expression of both the immature and mature tagged c-fins isoforms of the Y708F and 
Y723F mutants was detected in lysate from HEK cells 48 hours post transfection (Fig.
9.6.1., lanes 3 to 6). Although at 48 hours both receptor isoforms are detected, the 
predominant band corresponds to the immature isoform (135kDa). Expression of both 
mutant c-fms are comparable to the wild-type c-fms construct which is also present 
predominantly in an immature form (Fig. 9.6.1., lane 7). These data suggest that the
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that the single amino acid substitutions at the tyrosine residues involved in PI 3-kinase 
binding do not affect the processing of the immature isoform to the mature form.
9.7.1. Immunofluorescent staining of HEK 293 cells transiently expression MT- 
2 and MT-3
Confirmation of the cellular location of the Y708F and Y723F mutation containing c- 
fms constructs in HEK cells was carried out by immunofluorescent staining of 
transiently transfected HEK cells, 24 hours post-transfection (Fig. 9.7.1. and 9.7.2.). 
Examination of staining was carried out by digital confocal microscopy.
Fig. 9.7.1. Immunofluorescent analysis of MT-2 expression in HEK cells. Transiently 
transfected HEK cells were probed with an anti-myc epitope antibody and stained with an 
Alexa^**-secondary antibody. Panel A is an actin stain, panels B is an anti-myc epitope stain at 
48 hours post-transfection. Panel C is a composite photomicrograph which indicates positive and 
negatively stained cells. Panel B, is an enlargement of the area marked by a white box in panel 
B. Images were digitally recorded on an fluorescence inverted microscope and analysed with 
digital image deconvolution software (OpenLab 1.7.8). White arrows indicate plasma membrane 
(1) and cytosolic (2) staining. Bar indicates lOgm.
At 24 hours post-transfection HEK cells transfected with the Y708F c-fins mutant 
contained high levels of protein expression, characterised by considerable cytosolic
265
Results_________________________________________________________ Chapter 9
and plasma membrane staining (Fig. 9.7.1.). Enlargement B] in Fig. 9.7.1.
demonstrates clearly both plasma membrane staining (Fig. 9.7.1., arrow 1) as well as 
discrete pockets of cytosolic staining, which are localised in a juxtanuclear region 
(Fig. 9.7.1., arrow 2). This suggests that the Y708F mutant tagged c-fins expression 
construct is capable of plasma membrane localisation as observed for the wild-type, 
tagged c-fms and for endogenous c-fins.
The cellular localisation of the tagged c-fms construct containing the Y723F mutation 
appeared similar to wild-type tagged c-fms and to the Y723F mutant. Immuno­
fluorescent staining and was characterised by a similar plasma membrane (Fig. 9.7.2., 
arrow 1) and cytosolic (Fig. 9.7.2., arrow 2) staining pattern to that of the Y708F 
mutant. This suggests that both the Y708F and Y723F mutant tagged c-fins expression 
constructs are expressed in HEK cells in the anticipated manner and are found 
expressed at the plasma membrane in transient, 24 hour transfections.
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Fig. 9.7.2. Immunofluorescent analysis of MT-3 expression in HEK cells. Transiently 
transfected HEK cells were probed with an anti-wyc epitope antibody and stained with an 
Alexa^**-secondary antibody. Panel A is an actin stain, panels B is an anti-mjc epitope stain at 
24 hours post-transfection. Panel C is a composite photomicrograph which indicates positive and 
negatively stained cells. Panel Bi is an enlargement of the area marked by a white box in panel B. 
Images were digitally recorded on an fluorescence inverted microscope and analysed with digital 
image deconvolution software (OpenLab 1.7.8). White arrows indicate plasma membrane (1) 
and cytosolic (2) staining. Bar indicates 10pm.
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9.8.0. Discussion
Since transfection of macrophage cell lines has not been extensively reported in the 
present literature, it was necessary to determine the optimum method for BAC1.2F5 
transfection. Characterisation of BAC1.2F5 transfection with an eGFP containing 
vector suggested that transfection and expression of exogenous protein in 
macrophages was possible. Protein expression was detected in reasonably high 
numbers of cells (26%) transfected with SuperFect™ reagent, as determined by FACS 
analysis. This indieated that macrophages were suitable for transfection studies and 
therefore the c-fins construct, MT-1 was transfected into BAC1.2F5 cells. However, 
expression of this protein was not detected, either by western blot analysis or indireet 
immunofluorescence. FACS analysis has been demonstrated to be a very sensitive 
detection method for fluorescently labelled cells and it was possible that FACS 
detected very low levels of protein expression that were below the sensitivity level for 
western blot or fluorescence microscopy. Indeed analysis of eGFP-transfected 
BAC1.2F5 cells showed no discernible difference to untransfected BAC1.2F5 
controls (data not shown). This is the most likely explanation for the inability to 
detect tagged c-fins. It has been reported that activation of haematopoietic cells is 
required for expression of exogenous proteins regulated by the CMV promoter, but 
activation of BAC1.2F5 cells with PMA did not facilitate tagged c-fins detection. At 
this point it was necessary to demonstrate that MT-1 was capable of coding for and 
expressing a full length protein and this was confirmed by in vitro translation. In 
either rabbit reticulocyte or wheatgerm agglutinin systems a single, specific protein 
product of approximately I35kDa was translated from MT-1 (Fig. 9.3.1.). The larger 
product was predicted from sequence data and the observed immature human c-fims 
protein product and confirmed that the c-fms gene was translated and most likely
contained both gene specific and myc/Kis tag epitopes.
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To confirm that the MT-1 construct did express a protein product detectable by
western blot or immunofluorescent analysis, MT-1 had to be expressed in a suitable 
mammalian cell line. The HEK 293 cell line was chosen because they have routinely 
demonstrated high transfectability and protein expression. Analysis of whole cell 
lysate from HEK cells transfected with MT-1 with an anti-myc epitope antibody 
demonstrated that HEK cells the 135kDa and 155kDa isoforms of tagged c-fms, at 
high levels. These bands corresponded to the immature and mature receptor isoforms 
observed in murine and human cells, although their migration at a higher Mr than 
normal is due to the addition of the C-terminal tags. However, the expression profile 
was found to change over time and after 72 hours the mature receptor form was 
almost absent, but the immature receptor band was unchanged. This suggested that 
initially c-fms is expressed and post-translationally modified as expected and exists as 
a mature and immature receptor. However, after initial expression, the immature 
receptor is not modified and remains as an immature isoform. Why this occurs 
remains unclear, but it is possible that overexpression of this protein in HEK 293 cells 
affects the expression of other cellular components such that after subsequent rounds 
of de novo protein synthesis the tagged c-fms molecules are selectively not processed 
or trafficked to the plasma membrane. This may also affect expression of other 
plasma membrane localised receptors however this was not investigated. C-fins was 
successfully immunoprecipitated from HEK cell lysate with the anti-wyc epitope 
antibody which demonstrated that the mature receptor can be purified from cell lysate 
and may facilitate characterisation of receptor associated proteins.
Successful detection of tagged c-fms by western blot analysis, although capable of 
demonstrating expression, could not reveal the subcellular localisation of tagged c-fms
in HEK cells. This was aceomplished instead by indirect immunofluorescent analysis.
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MT-1 expressed in HEK cells was detected by both c-fins and myc tag specific
antibodies after 24 hours (Fig. 9.5.1.). Transiently transfected HEK cells showed 
plasma membrane and cytosolic staining after 24 hours (Fig. 9.5.1.). At higher 
magnification the plasma membrane localisation is more obvious and distinct pockets 
of staining can also be observed in the cytosol (Fig. 9.5.2.). However after 72 hours 
c-fins appears to be localised to a predominantly cytosolic compartment, in a 
juxtanuclear location which may correspond to the golgi complex (Fig. 9.5.3.). This 
difference in subcellular localisation, when considered together with the western blot 
data, suggests that cytosolic staining present in what may be the golgi complex may 
correspond to the immature c-fins isoform. Therefore the plasma membrane staining 
observed at 24 hours may be due to the correct processing and targeting of the mature 
receptor isoform.
Together these data confirm that the MT-1, tagged human c-fms construct is capable 
of full length expression in mammalian cells, recognised by both gene-specifie and 
wyc-tag antibodies. However, the expression of mature protein does appear to be 
limited to the first 24 hours following transfection in HEK cells and therefore HEK 
cells may not be a suitable cell line for selection of stable expression. A caveat to this 
is that c-fms is continuously expressed as an immature protein and it may be possible 
to up-regulate expression of the mature receptor, although this was not investigated..
To validate the expression profile of c-fms constructs containing mutations, two
representative constructs, MT-2 and MT-3, were characterised by western blot
analysis and indirect immunofluorescence similar to MT-1. Both receptor mutants
express full-length c-fms characterised by detection of both mature and immature
isoforms in whole cell lysate from HEK cells, 48 hours after transfection (Fig. 9.6.1.).
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However, the predominant form at this time point appears to be the immature form,
comparable to HEK cells transfected with the wild-type MT-1 construct (Fig. 9.6.1.). 
Expression of MT-2 and MT-3 was also characterised by indirect 
immunofluorescence (Fig. 9.7.1. and 9.7.2.). Expression of either construct appears to 
be localised to the plasma membrane and the cytosol (Figs. 9.7.1. and 9.7.2.). This 
localisation profile was similar to the wild-type tagged c-fms and demonstrated that 
mutation of the PI 3-kinase binding sites did not affect the cellular targeting or 
expression levels in transiently transfected HEK cells.
BAC1.2F5 cells have proved notoriously diffieult to transfect and detect expression of 
exogenous protein. However, these tagged c-fms constructs have now been 
characterised for expression and detection and now provide tools that will facilitate 
investigation of c-fms signalling. The epitope tags present on each construct, with the 
exeeption of WT-1, allow the detection of protein expression and distinguish 
exogenous from endogenous receptor expression. Mutant receptor constructs will 
allow characterisation of M-CSF stimulated responses where PI 3-kinase association 
with c-fins is required or not as the case may be. Finally, epitope tags will also 
facilitate precipitation and co-precipitation studies on c-fins, and, in conjunction with 
the mutant receptor constructs, will allow the eharacterisation of c-fins associated 
signalling molecules and complexes, particularly PI 3-kinase.
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10.0.0. General discussion
M-CSF is an extremely important mediator of macrophage function, involved in the 
activation of various responses including phagocytosis, enhancement of antibody- 
dependent cell-mediated cytotoxicity and tumoricidal activity (Lewis, 1992). In 
addition M-CSF stimulates macrophage survival and proliferation and actively 
recruits macrophages and monocytes. The M-CSF-deficient mouse knock-out has 
taught us a substantial amount in general about the various other functions of this 
growth factor but been less useful for the investigation of M-CSF stimulated cellular 
responses in macrophages. Analysis of aberrant activation of macrophage responses 
by M-CSF is relevant to the treatment of diseases such as rheumatoid arthritis, where 
there is excess M-CSF in rheumatoid joints and macrophage activation is undesirable. 
Thus the elucidation of M-CSF-induced signalling pathways has both scientific and 
pathological importance.
To date the mechanisms by which c-fins signalling is mediated have not been 
completely defined. Identification of c-fms as a member of the class III growth factor 
receptor family has actually added to the confusion surrounding c-fins signalling since 
it has led many researchers to draw analogies between its signalling mechanisms and 
the other family member, the PDGF receptor. This has proven to be inaccurate and 
many differences between these structurally related receptors are now evident. 
Throughout the published literature it has become increasingly apparent that 
exogenous expression studies, although informative, can also be very misleading. 
Expression of c-fms in fibroblasts or epithelial cells has demonstrated associations 
between c-fms and signalling molecules or cell responses which do not appear to exist 
in macrophages. Therefore c-fms expression studies need to be interpreted carefully, 
always bearing in mind that signalling pathways in fibroblasts do not always mimic
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those found in macrophages. C-Jms is probably not the only molecule that does not
couple correctly to downstream mediators in different cell types which is also
observed for the PDGF receptor (see chapter 1.6.0.).
The main aim of this thesis was to investigate how PI 3-kinase is involved in c-fins 
signalling. PI 3-kinase is a lipid kinase that produces membrane-bound second 
messengers that activate various downstream signalling pathways and responses in 
cells. Investigation of the involvement of PI 3-kinase in c-fins signalling, if not 
complex enough, is further compounded because PI 3-kinase is an enzyme composed 
of two subunits which also have various subunit isoforms. This added complexity 
means that c-fins has the ability to couple with more than one PI 3-kinase species in 
macrophages and this may introduce subtle differences that are not or cannot be easily 
replicated in common cell lines used for expression studies.
Therefore it is difficult to study the complex signalling pathways of c-fins without 
suitable cell models. Various cell lines have been used to investigate c-fins signalling, 
however the BAC1.2F5 murine cell line has provided researchers with a macrophage­
like cell line that is dependent on M-CSF for survival and proliferation (Morgan et al., 
1987), characteristics found in primary macrophages and monocytes. This cell line 
has been well characterised with respect to M-CSF stimulated responses such as 
mitogenesis and morphology, but has not been used to investigate c-fins signalling via 
PI 3-kinase.
In this thesis I have demonstrated;
1. Expression of p85a/p 11 Oa in BAC 1.2F5 cells.
2. M-CSF stimulation of PI 3-kinase activity.
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3. The M-CSF stimulated PI 3-kinase activity is not required for the proliferative
signal in BAC1.2F5 cells.
4. PI 3-kinase activity is required for M-CSF mediated cell survival.
5. M-CSF mediates BAC1.2F5 cell survival in concert with LPA and at least one 
other factor or factors in foetal calf serum.
6. Transport of c-yw5 -containing endocytic vesicles proceeds via a PI 3-kinase- 
dependent pathway.
7. M-CSF stimulated reorganisation of the actin cytoskeleton requires PI 3- 
kinase activity.
In addition I have also produced a series of novel human c-fins expression constructs 
containing key amino acid substitutions for the investigation of PI 3-kinase binding to 
the activated receptor and have demonstrated their expression in epithelial cells.
10.1.0. PI 3-kinase expression
I have demonstrated that BAC1.2F5 cells express the p85a/pllO a PI 3-kinase 
isoforms, representing the class la PI 3-kinase activity. Although the pllOy isoform 
was also present it is unlikely to be activated M-CSF as this has been shown to be 
activated by G-protein linked receptors. Thus the major M-CSF responsive PI 3- 
kinase activity is likely to be effected by p85a/pl 10a heterodimers. The p85a/pl 10a 
PI 3-kinase has also been demonstrated to be stimulated by M-CSF and was sensitive 
to wortmannin and LY294002 when used at concentrations at their respective I C 5 0  or 
at concentrations previously reported to only inhibit PI 3-kinase activity. This 
stimulation of activity is consistent with data showing that the p85a/pl 10a can be co- 
immunoprecipitated with c-fms from BAC1.2F5 cells (Kanagasundaram et al., 1996).
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Based on these observations the various M-CSF stimulated responses in BAC1.2F5
cells were characterised using PI 3-kinase inhibitors.
10.2.0. PI 3-kinase mediated survival and proliferation
I have demonstrated that inhibition of PI 3-kinase activity does not block the M-CSF 
stimulated c-^5-mediated proliferation signal in BAC1.2F5 cells. These data are 
similar to observations made by Kanagasundaram et al, (1996) who found no role for 
PI 3-kinase activity in M-CSF-mediated stimulation of proliferation in BACI.2F5 
macrophages. However, the proliferation assay data presented in chapter 5 was 
expressed as a percentage of the total cell population, and did not reflect the 
requirement for PI 3-kinase in M-CSF stimulated survival.
In cell density assays carried out over 4 days M-CSF induced BAC1.2F5 cell 
doubling every 24 hours, and this required the presence of foetal calf serum, which 
suggested that another factor or factors, present in serum, were required for cell 
proliferation. It had recently been demonstrated that peritoneal macrophages required 
LPA for survival and so a requirement for LPA in BAC1.2F5 cell growth was 
investigated by using delipidated serum and exogenous LPA. This revealed that 
delipidated serum contains a factor or factors other than LPA which are required for 
M-CSF stimulated increases in BAC1.2F5 cell population. Investigation of the effect 
of LY294002 on M-CSF stimulated increases in cell population confirmed PI 3- 
kinase was required for population increase over 4 days. Therefore although PI 3- 
kinase was not required for the proliferative signal it was required for cell survival 
and the observed data may represent a balance between cell death and cell 
proliferation, which are controlled by two different signalling pathways, one
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involving PKB activation and the other probably requiring PI 3-kinase independent 
ras activation, respectively and the net effects of these are summarised in Fig. 10.2.1.
No M-CSF + SERUM
Pp.OLiFExPATlOH
Cell density
M-CSF + SERUM
+ M-CSF
PI 3-kinase 
I
Akt — A p o p t o s j s
+ M-CSF
PROLJFERÀTigjj
Cell density
+ M-CSF
PI 3 'k inase  L Y 2 9 4 0 0 2
A p d p t o ';;is
+ M-CSF
PPOLIFERATION
Cell density
Fig. 10.2.1. Summary of data from chapter 5 illustrating PI 3-kinase-mediated protection against 
apoptosis and its effects on cell growth in BAC1.2F5 macrophages.
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Fig. 10.2.1. shows a graphical summary and interpretation of the data presented in
chapter 5. The investigation of BAC1.2F5 apoptosis revealed that there is a basal rate
of apoptosis in BAC1.2F5 cell of 2-4%, which increased upon M-CSF withdrawal. I
presented data that shows addition of PI 3-kinase inhibitor, LY294002, induced >65%
apoptosis in M-CSF stimulated cells which confirmed that protection against
apoptosis in BAC1.2F5 cells conferred by M-CSF is dependent on PI 3-kinase
activation (Fig. 10.2.1.). This data explains the reduction in cell population observed
in the cell density assays.
In addition it has been shown that factors in serum are required for increases in cell 
density. In corollary experiments it was demonstrated that serum contains multiple 
factors which protect BAC1.2F5 cells against apoptosis. One such factor was likely 
to be LPA but reconstitution of LPA alone was not sufficient for the protective effects 
seen in full serum. Addition of delipidated serum and LPA with M-CSF indicated 
that at least three factors, including M-CSF and LPA, act synergistically to confer 
protection against apoptosis in BAC1.2F5 cells.
Thus the model proposed for M-CSF stimulated survival and proliferation in 
BAC1.2F5 cells is that in the absence of M-CSF there is a balance between the 
apoptosis and proliferation which also depends on serum factors as well as M-CSF 
(Fig. 10.2.1., A). However, in the absence of M-CSF there is an eventual swing 
towards apoptosis. In the presence of M-CSF there are two signals, one which 
stimulates cell proliferation and is independent of PI 3-kinase activity and a second 
which protects against apoptosis in a PI 3-kinase-dependent manner, possibly through 
Akt/PKB (Fig. 10.2.1., B). If PI 3-kinase activity is inhibited in M-CSF stimulated 
cells, although the proliferative signal is still present the pathway leading to protection
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against apoptosis is blocked and therefore cells enter into apoptosis (Fig. 10.2.1., C).
Therefore the signalling pathway leading to apoptosis is the control mechanism for 
both cell survival and proliferation, for net increases in cell density can only occur if 
there is a protective anti-apoptotic signal, mediated by PI 3-kinase.
10.3.0. PI 3-kinase and c-fms trafficking
In BAC1.2F5 cells incubated with either LY294002 or wortmannin, although some 
cell spreading and increased membrane activity was observed this was substantially 
less than in untreated cells. More interestingly, formation of phase-light vesicles 
around the periphery of the cell proceeded as normal, the trafficking of these newly 
formed vesicles required PI 3-kinase activity . These data confirmed that PI 3-kinase 
activity was required for transportation of endocytic vesicles to sites of lysosomal 
degradation.
More detailed analysis of c-fins internalisation revealed that the receptor is 
internalised to small endocytic vesicles characterised by distinct punctate staining 
pattern around the cell periphery which are trafficked towards the nucleus. These 
endocytic vesicles then appear to coalesce to form substantially larger endocytic 
vesicles clustered around the nucleus. Although these endocytic vesicles remain for 
over an hour after internalisation the c-fins staining is almost completely absent by 30 
minutes, which is consistent with the observed time-course of degradation for M-CSF 
(Boocock et al., 1989).
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Intensity of fluorescence staining 
of c-fms containing vesicles;
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Fig. 10.3.1. Model for the M-CSF-stimulated formation and transport of receptor containing 
endocytic vesicles in BAC1.2F5 macrophages. Vesicle shading represents the proportion of c-fms 
staining on the vesicle membrane.
Therefore a model of c-fms internalisation can be proposed in which internalisation of 
receptor proceeds normally (Fig. 10.3.1., A) and is not affected by inhibition of PI 3- 
kinase activity resulting in receptor degradation (Fig. 10.3.1. B). However, transport 
of c-^5-containing vesicles towards the nucleus is impaired (Fig. 10.3.1., A’) and this 
also prevents receptor degradation (Fig. 10.3.1., B’). This suggests that PI 3-kinase 
activity is required during vesicle transport probably at a post-endocytic step between 
the juxtamembrane and the lysosomal compartments. These observations are 
consistent with a similar observation in fibroblasts where internalisation of the PDGFr 
is blocked at a juxtamembrane site in the presence of wortmannin (Joly et al., 1995).
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10.4.0. PI 3-kinase and the actin cytoskeleton
The actin cytoskeleton is an integral part of many macrophage responses including 
membrane activity, cell motility and vesicular transport, and BAC1.2F5 cells have 
been well characterised in this respect (Allen et a l, 1997). In some early studies on 
BAC1.2F5 cells it was observed that they responded to M-CSF with dramatic changes 
in cell shape and morphology (Boocock et al., 1989). The data presented in this thesis 
suggests that PI 3-kinase activity is required for certain aspects of actin reorganisation 
possibly mediated by rac and rho and it is proposed that the effects on the actin 
cytoskeleton may account for the effects of PI 3-kinase inhibitors on vesicle transport.
In conjunction with vesicle formation and transport there are significant M-CSF 
stimulated changes in the actin cytoskeleton, characterised by the formation of 
filopodia, membrane ruffles and fine actin cables. These actin rearrangements occur 
rapidly and the actin cables persist for at least 30 minutes, similar to the time-course 
of receptor internalisation. The localisation of c-fms containing internalised vesicles 
and the newly formed actin cables suggests that the actin cytoskeleton is employed 
during vesicular transport, which has been reported for receptor mediated endocytosis 
into clathrin-coated pits. Inhibition of PI 3-kinase activation had quite striking effects 
on vesicle transport and rearrangement of the actin cytoskeleton. LY294002 treated 
BAC1.2F5 cells possessed retraction fibres with reduced membrane ruffle formation 
and little or no actin cables. In addition, treatment of M-CSF stimulated cells blocked 
transport of newly formed endocytic vesicles from the plasma membrane where they 
remained as small punctate structures.
The absence of actin cables coincided with aberrant vesicle transport and our 
conclusion is that reorganisation of the actin cytoskeleton is a prerequisite for correct
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vesicle transport in BAC1.2F5 macrophages. The reorganisation o f  the actin
cytoskeleton appears to be mediated by PI 3-kinase activation, and although this may
explain the aberrant vesicle transport, it is possible that PI 3-kinase products are also
directly involved in vesicle trafficking.
In light of the data presented in this thesis on the requirement for PI 3-kinase activity 
for the correct reorganisation of the actin cytoskeleton, the model proposed in section
10.3.0. can be modified further to include the organisation of the actin cytoskeleton 
(Fig. 10.4.1.). Stimulation of BAC1.2F5 cells stimulates the rapid formation of Q-fms- 
containing vesicles after only 5 minutes and this is independent of PI 3-kinase (Fig.
10.4.1. A and B, 5'). Concomitantly with vesicle formation is the appearance of fine 
actin cables organised longitudinal to the direction of cell polarisation (Fig. 10.4.1. A, 
5’). This process is dependent on PI 3-kinase activity and F-actin staining in cells 
where PI 3-kinase activity is inhibited is punctate and present only on the ventral 
surface of the cell (Fig. 10.4.1. B, 5'). After 10 minutes the c-^5-containing vesicles 
have migrated towards the nucleus (Fig. 10.4.1. A, 10’) but this is absent in 
LY294002 treated cells where vesicles remain at the plasma membrane (Fig. 10.4.1. 
B, 10’). C-^5-containing vesicles tend to co-localise with the fine actin cables and it 
is possible that these structures mediate vesicle transport. After 30 minutes large 
phase light vesicles are present around the periphery of the nucleus but do not contain 
c-fms (Fig. 10.4.1. A, 30’). In cells treated with LY294002 vesicles still remain at the 
plasma membrane and still contain high levels of c-fms (Fig. 10.4.1. B, 30’). In 
human macrophages it has been demonstrated that inhibition of actin microfilament 
assembly by cytocholasin B blocks FcR-mediated phagocytosis in human 
macrophages (Newman et al, 1991). Therefore PI 3-kinase activity is required for the 
reorganisation of the actin cytoskeleton and this may be required for the correct
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trafficking of internalised receptor, via clathrin coated vesicles, to downstream 
endocytic and lysosomal compartments for eventual degradation.
+ M-CSF 
+ LY294002
B
[c-_/)«s| = o>o>0
+ M-CSF
Fig. 10.4.1. Model for c-fms internalisation and trafficking in BAC1.2F5 cells which relies on the 
correct reorganisation of the actin cytoskeleton in a PI 3-kinase-dependent manner.
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10.5.0. Production of c-fms expression constructs
The use of PI 3-kinase inhibitors has demonstrated that PI 3-kinase activation is an 
integral part of at least two signalling pathways downstream of c-fms (Fig. 10.5.1.). 
These are (a) the protection against apoptosis which possibly proceeds via Akt and 
which also has profound effects on cell proliferation and (b) the correctly regulated 
reorganisation of the actin cytoskeleton which is essential for cell motility and 
structural integrity, and may also account for the incorrect transport of endocytic 
vesicles. A summary of these PI 3-kinase mediated processes is depicted in Fig.
10.5.1.
V e s ic l e  T r a ffic k in g
M-CSF
C-FMS
PDK1
PI3A6P3 OR PI3.4P2
r
PI 3-KINASE
A c tin  C y t o s k e l e t o n
f  Pl3,^P? 
GDP-rac
GTP-rac
/ \
La m ella po dia  
M em brane  ruffles
A
ON
1  j
RHO
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Fig. 10.5.1. Summary of the PI 3-kinase dependent pathways in BAC1.2F5 macrophages.
Although the available PI 3-kinase inhibitors have revealed a substantial amount of 
information regarding PI 3-kinase mediated, M-CSF signalling in this macrophage
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cell model have two drawbacks. Firstly, these inhibitors cannot be used to
differentiate between PI 3-kinase activities from class 1 or class 3 PI 3-kinases, and
secondly we cannot obtain any information regarding the association of PI 3-kinase
with c-fms, whether that is direct or indirect via adapter molecules. Therefore new
tools for the analysis of PI 3-kinase-c-^5 interactions were required.
The approach taken in this thesis was to produce a series of novel human c-fms 
constructs containing mutations at key residues in the KI domain, involved or 
implicated in PI 3-kinase binding. These constructs would possess convenient epitope 
tags to facilitate identification and purification. The presence of an epitope tag to 
facilitate purification was important since it was intended that these constructs be 
expressed in BAC1.2F5 macrophages, hence easy identification was necessary to 
differentiate between endogenous and exogenous c-fms expression. Although all the 
human c-fms constructs were made successfully, it became apparent that difficulties 
associated with expression studies in haematopoietic lineage cells would prevent the 
intended goal. I have demonstrated that transfection of BAC1.2F5 macrophages can 
be accomplished. However, it is apparent that this does not equate to expression of 
specific heterologous proteins and in particular it appears that expression constructs 
containing the CMV promoter are not suitable for expression in these cells. As an 
alternative, three of the c-fms constructs were expressed in epithelial cells to confirm 
that, in practice, the features of these constructs were valid. Indeed, high levels of 
transient expression were detected by both western blot and immunofluorescent 
analysis by both gene and epitope-tag specific antibodies. However what became 
evident was that in HEK 293 cells at least, c-fms expression profiles change over time. 
This was characterised by a loss of expression of the mature receptor isoform and loss 
of membrane expressed receptor. These data reinforce the difficulties associated with
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exogenous expression studies in non-native cell lines, in this instance loss of
functional c-fms expression, and which leads to a need for caution when interpreting 
data.
10.6.0. Suggestions for future work
In this thesis I have defined the key areas in which PI 3-kinase activity plays a role in 
M-CSF signalling. However this area of research is far from being complete and 
requires further study.
Central to defining the PI 3-kinase mediated signalling pathways downstream of c-fms 
is the ability to define how PI 3-kinase is activated by c-fms, whether that is by direct 
interaction via receptor tyrosine phosphorylation sites or indirectly via alternative 
mechanisms whether that be through adapter molecules or further downstream, away 
from the receptor complex. This will be facilitated by the use of the receptor 
constructs generated by this thesis and it is believed that the mutant receptor 
constructs can be used to determine whether different PI 3-kinase mediated responses 
are activated via direct interaction with c-fms, indirect activation or whether both 
these mechanisms are involved in activation of different PI 3-kinase mediated 
responses.
Although the constructs produced from this thesis have had their fidelity confirmed in 
an epithelial cell line it is not desirable to further investigate c-fms signalling in this 
cellular context. It is more desirable to express these mutant constructs in a cells like 
BAC1.2F5’s. The problems associated with expression of protein may be overcome 
in a number of ways including; use of an alternative promoter in the construct such as 
an endogenous haematopoietic promoter, or alternatively transferring to a viral based
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infection system such as adenovirus which has proven successful for others. An
endogenous promoter may not provide high levels of expression, but this is more 
desirable than none at all from the present CMV promoter.
Further studies of PI 3-kinase signalling will employ novel ways of interfering with 
the normal function of specific PI 3-kinase isoforms. The cloning of each PI 3-kinase 
isoform has provided the raw materials for construction of isoform-specific dominant 
negative and constitutively active constructs which, when expressed in suitable cell 
lines will provide better tools for investigation of PI 3-kinase signalling downstream 
of activated growth factor receptors. Existing pi 10a PI 3-kinase constructs still have 
the same drawback as most other expression constructs, that they are regulated by the 
CMV promoter. Therefore they are unsuitable for use in the cell model required for 
analysis of c-fms signalling.
Investigation of the specific responses in BAC1.2F5 cells mediated by PI 3-kinase 
activation also requires further investigation. One novel way of molecularly 
differentiating between the PI 3-kinase products which are important for signalling 
can be carried out using the recently cloned lipid 5-phosphatase, synaptojanin, which 
has been demonstrated to hydrolyse Pl3,4 ,$P3 to Pfi ^Pi- It would be of interest to 
investigate the effects of synaptojanin overexpression on M-CSF stimulated responses 
in macrophages. Overexpression of this 5-phosphatase activity should lower Pl3,4,5P3 
levels, and therefore, if Pl3,4 ,5P3 is involved in cytoskeletal reorganisation and/or 
vesicle transport then this should result in a reduced response. Conversely, if PI4 .5P2 
was the key regulator of these responses then synaptojanin overexpression should 
increase the cell’s responses. However, the problems associated with transfection and 
expression in macrophages would still be significant hurdle. The problems associated
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with macrophage transfection may also be overcome using expression constructs
containing endogenous mammalian promoters. For example, real-time analysis of 
actin dynamics can be investigated with an actin-eGFP construct under the control of 
the actin promoter. Therefore further investigation of receptor-mediated endocytosis 
with mutant c-fms and PI 3-kinase expression constructs with suitable promoters will 
facilitate expression in haematopoietic cells, such as BAC1.2F5’s, and will result in 
new insights into c-^m^-mediated responses involving PI 3-kinase activation.
Other novel tools for the analysis of PI 3-kinase signalling may be found in the 
development of new drugs with specificity for the individual isoforms of PI 3-kinase. 
A drug based approach however has proved elusive and very little progress has been 
made towards new novel compounds. The existing drugs that inhibit PI 3-kinase act 
at sights crucial for enzymatic activity, but as a result are not specific for pi 10 
isoforms due to the very high homology between isoforms. Thus development of new 
drugs that interfere with pi 10 interactions with regulatory subunits or other signalling 
molecules that associate with PI 3-kinase may provide useful tools for the 
investigation of PI 3-kinase signalling and therefore, in turn, c-fms signalling.
Despite the wealth of data on c-fms signalling which has been generated over the past 
thirteen years this area of tyrosine kinase research continues to be extremely active 
and it appears that it will remain so since there is so much more about c-fms signalling 
that has yet to be elucidated.
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M u lta l in  v e r s io n  5 . 3 .3  (C o rp e t, 1988) 
Symbol co m p ariso n  t a b l e :  b lo sum 62 
Gap w e ig h t:  12 Gap l e n g th  w e ig h t:  2
Human PDGFr 
Human c - f ms
Human PDGFr 
Human c - fms
Human PDGFr 
Human c - f m s
Human PDGFr 
Human c - f ms
Human PDGFr 
Human c - f m s
Human PDGFr 
Human c - f ms
Human PDGFr 
Human c - f m s
Human PDGFr 
Human c - f m s
Human PDGFr 
Human c - f m s
Human PDGFr 
Human c - f m s
Human PDGFr 
Human c - f m s
Human PDGFr 
Human c - f m s
Human PDGFr 
Human c -fm s
Human PDGFr 
Human c - f m s
Human PDGFr 
Human c - f m s
MRLPGAMPAL A L ^E L L jgS ggjLLEPQIS Q G L g T g P ^  
'ÆpG3
51
.Dj ? ggTg
TSSgSAPa VmWRMSQEgg QEMAKAgUGT FC^VWjLTgL 
 g j  ggHgTgYSDG S ^ I g S ÿ N g
INDSRGLET DERKRLYlgQ PggTVGFLPN DAgELFQELT 
gL G gSA A jgg^ i^^R PgN V g j g g  gVjjjF5PGD 
ggVgEAGg
EKKSDVA gPVP 0 DH OiTSra SG
rgHRggPL ggHQNgSggP
DAYY- - g YgL QVSSINVSVN AVQ' 
IS g R jJ^ K V  IPGgPALTjJV gAE
iFraDRSHiwy
FiæsQ
IVIG
251 300
NggVgggWTY PgKgSGRLgjE PVTjggLlgMP gH IR Slg^IP  
Vgg-ggggFg QHNgggjAgP QQgj|H-^R gOggLTgNgD
saelQ^sS 
qSdëSb
301
GTNBBFAE
EGLNgKgM
SSjjND gQDEKAljJlT 
/gsÿ/QgK gS--TSgFgR
351
Fj^ggPPTVL WFKDNRTLGg SSAGEIALST RNVSETg 
V ^^G LQ G F g g g g g S g  HgPEPggANA gTKDTggHgF
401
gHgTMRgF HEDAEVQ0 SI 
gR g S F L ^  igPGgWI E)INVgVRg LELSESHgDS2 S B 2 S
SgPgLgPg
SglW T --F lg
451
g g y g ig S  AggD-LKgP RELPPTLgGg gSEgE-ggLE
500
TNVTYWEEEQ
gHKjjjTVQgLjl
501
EFg W STLgL QHVDRPbggR CTLRNAVGQD TQEVIw, 
TV^gEggOg QEgRAHgggg SGgWAglPig AgAHTHp|
551
igALiWgTii sgiig: 
g & L g  j g g s
IMLWQ K
I
SHS»
651 700
LMSELKIMS
LMSËLKÎMS
Jj ggPgLggggg
2 BtgkaSEB
gNK HTFgQHHSDK RRPgSgELYS NALPVGLPLP 
gp je^ jQsjGGVDgKg g g LGPSL
750
SHVSLTGESg
ailïrl
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Human PDGFr 
Human c - f m s
Human PDGFr 
Human c - f m s
Human PDGFr 
Human c - f m s
Human PDGFr 
Human c - f m s
7 5 1
G^ÎSMDMSKSE SggYVgMLDM 
8 0 1
RATLlgEgPV gSYMgVGj 
 ^Ggg
8 5 1
KLV^ CWaejff
9 0 1
8 0 0
KGDVKgADig SSNYMAPYDN YVPSAPERTC 
g-NgggSEQg jjDg-----------  -----------------
ISjgSTFggL
IzîS ^ rI !^
LPjMKWMAPESI
l p R kw m apesi
MîîîlÎL ^ l3 ÎE Ü IC E
ILG
iPYP
PYP
SFGILLWEIF
SYGILLWEIF
Human PDGFr 
Human c - f m s
Human PDGFr 
Human c - f m s
EEKFEI SSPSSfflLV
1 0 0 1
gQAgLPgFHg LRgPggTSgV
---gsggsgs
1 0 0 0
iRLLGgGYK KKY^VDgEF LRgDHPAILR 
^Eg2Q l2"”D GBERMWTg
1 0 5 0
LYTAVQPSjEg gNDYIIPLgg PKPEVADEGP
Human PDGFr 
Human c - f m s
1 0 5 1
LEGSPSLASS TLNEVNTSST
1 1 0 0
ISCDSPLEPQ DEPEPEPQLE LQVEPEPELE
Human PDGFr 
Human c-fms
1 1 1 9
QLPDSGCPAP RAEAEDSFL
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Cloning Primers
AF-1 5' Xho I GC=47.8%
^'CCACCTCGAGAAGAAATATGTCC^'
AR-1 3’ Hind III GC=46.4%
^'CGAAGCTTGCAGAACTGATAGTTGTTGG^'
AR-2 3' Horn GC=46.4%
^'CGAAGCTTTCAGCAGAACTGATAGTTGTTGG^'
AR-3 3' Horn GC=45.2%
'^a c t c c t c a g c a g a a c t g a t a g t t g t t g g '^
AF-2 5' Eco RI GC=52.0%
'^g t a g a a t t c a t a g g c c a t g g g c c c a '^
AR-4 3' Xho I GC=47.8%
^'g g a c a t a t t t c t t c t c g a g g t g g '^
AF-3 5' Horn. GC=56.5%
^'g c t a g t a g c t g a g a g c t c t g t g c '^
Analysis of full length c-fms gene
SF-1 GC=66.7% 
^GTGCTGGAAGCAGGCGTCTCG^
SF-2 GC=52.2% 
^'g t t t g a g c t c a c c c t t c g a t a c c '^
SF-3 GC=48.0%
^'t g g a a g a t c a t c g a g a g c t a t g a g g '^
SF-4 GC=44.0%
^'a t c c a c c t c g a g a a g a a a t a t g t c c '^
SF-5 GC=42.3%
^'CAGCAAGTTCTATAAACTGGTGAAGG^'
SR-1 GC=61.9% 
'^a g c a g a c a g g g c a g t a g t g c g '^
SR-2 GC=57.7%
^'t a c c a c c c g g a a g a a c a t g g a g g t g g '^ 
SR-3 GC=57.7%
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^'a c t g c a c t g c a g c c a t g t c a c g t t g g '^ 
SR-4 GC=51.9%
^'a a c t c c c a c t t c t c g t t g t a a g g c a g c '^ 
SR-5 GC=61.9% 
^'t g g c t g g a g a a g c c a c t g t c c '^
SR-6 GC=53.8%
^AAGGAAGGAGCAGATCTGCTGGAAGG^’ 
T7 Promoter GC=40.0% 
^TAATACGACTCACTATAGGG^’ 
M13/pUC Reverse GC=43.5% 
^AGCGGATAACAATTTCACACAGG^’ 
BGH Reverse GC=55.6% 
^'t a g a a g g c a c a g t c g a g g '^
Site-Directed Mutagenesis Primers
Tyr723Phe-l GC=60.0%
^'CCAGGGTGTGGACACCTTTGTGGAAGATGAGGCCTG^'
Tyr723Phe-2 GC=60.0%
^'CAGGCCTCATCTCCACAAAGGTGTCCAACACCCTGG^'
Tyr708Phe-l GC=55.0%
^'CATCCACCTCGAGAAGAAATTTGTCCGCAGGGACAGTGGC^'
Tyr708Phe-2 GC=55.0%
^'g c c a c t g t c c c t g c g g a c a a a t t t c t t c t c g a g g t g g a t g '^ 
Leu301Ser-l GC=53.8% 
^'g a g a g t g c c t a c t c g a a c t t g a g c t c '^
Leu301Ser-2 GC=53.8% 
^'g a g c t c a a g t t c g a g t a g g c a c t c t c '^
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lacZii ATG 
M13 R everse Primer I S s c I  SarrtHI I I
GAG GAA ACA OCT A IQ  AC C ATG ATT ACG CCA AGC TTG GTA CCG AQC TCG GAT CCA CTA 
GTC CTT TOT CGA TAG TG G TAC TAA TOC QGT TCG AAC CAT QQC TCG AQC CTA QGT GAT
BsIX I e<»R I EcàR I
GTA ACG QCC QCC AGT GTG CTG GAA TTC GQC T T # g # ! « M M W « B A  QCC GAA TTC TOC
CAT TOC COG COG TCA CAC GAG CTT AAG CCG T COS CTT AAG ACG
A va I 
PaeR TI
f  cofl V Bs» I Mol I Xho I Nsi\ Xba\ Apa I .
I  I I I  I I I * ________
AGA TAT CCA TCA CAC TOG COG CCG CTC GAG CAT OCA TCT AGA GOG CCC AAT TCG CCC TAT
TCT AT A GGT AGT GTG ACC QCC QQC GAG CTC GTA CGT AGA TCT CCC GOG TTA AQC GOG ATA
M13<-401 Forward PrimerM13 (-201 Forward Pnmer 
CTO QCC GTC GTT TTA ClAA C|OT CGT GAG TOG GAA AAC
GAG COG GAG CAA AAT gIt T GC A  OCA CTG ACC CTT TTG
AGT GAG TCG TAT TA C AAT TCA 
TCA CTC AQC ATA ATI G TTA AGT
Diagram of the PCR cloning vector pCR2.1 and a schematic of the multiple cloning site.
f1 ori
Amp'
/acT.
on
T7
S a c  I 
E go  R1 
S a il  
Xho I 
BamH I 
A p a  I 
X ba  I 
Not I 
N sil 
Hind III
Sp6
B. Diagram of the shuttle vector pG EM -llZf(+) and its multiple cloning site.
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AppeniHx C
e n h a n c e r  re g io n  ( ^  ' e n d  I |
6 8 9  C A TTG A C G TC  AA TG G G A G TT T G T T T T G G C A  C C A A A A TC A A  C G G G A C TTT C  C A A A A TG TC G
CAAT TATA
7 4  9 T A A C A A C TC C  G C C C C A TTG A  CG CAAATG GG  CG G TAG G C G T G TACGG TG GG  A G G T C T A T A T
Vend <)»W M V
i pHJlativc transcripdonal start
8 0 9  AAGC AG AG CT C TC TG G C TA A  C TAG AG AA CC C A C T G C T T A C  T G G C T T A T C G  A A A T T A A T A C
T7 promoter [aimer binding site
8 6 9
S h e  I Pme I Apa  I Xba I Xha  I \ „ i  I
I  I I ^  I  I
G A C T C A C T A T  AGGGAGACCC A A G C TG G C TA  G C G T T T A A A C  G G G C C C TC TA  G ACTCGAGCG
fls/X I EeoR  I H a X  I
I
Bam H  I
9 2  9 G CCG CC AC TG  T G C TG G A TA T C T G C A G A A T T  C C A C C A C A C T G GA CTA GTG G  A TC C G A G C TC
A s p l \H \  K p n \ H in d \U  A/1 W Pme \ [xD N A .V I/B G H  reverse pnming site
I I ^  I 1 I I '
9 8 9  G GTA CC AA G C T T A A G T T T A A  A C C G C TG A TC  A G C C TC G A C T G T G C C T T C T A  G TTG CCA G C C
1 0 4  9 A T C T G T T G T T  TG C C C C TC C C  C C G T G C C T T C  C T TG A C C C TG  G AAG G TGCCA C T C C C A C T G T  
B(iH polv (A ) site
I '-------1
1 1 0 9  C C T T T C C T A A  TA AA ATG AG G  A A A T T G C A T C
Diagram of the multiple cloning site of pcDNA3.1 (-)
(-) ililiiliilllili
pcDNA3.1 (-)
5.4 kb
D. Diagram of pcDNAS.l \
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Appendix C
myc epitope HiSg #1
   ^f :  fc -c  o ^  o . 0  «  ^  ^<(Lcxx^müjüjCQm<hd
pcDNA3
Diagram of pcDNA3.1^‘^ -myc/His.
♦The Apa I site is redundant in reading frame A  only. 
♦♦The Xba I site is redundant in reading frame B only.
T7 promoler/primiog site 
I  i
8 6 1  ATTAATACGA CTCACTATAG GGAGACCCAA GCTGGCTAGT
Hifti I
I
Kfjn I
TA AGC TTG GTA CCG AGC 
S e r  L e u  V a l  P r o  S e r
BamH 1 BsfX 1 EcoR 1 EcoR V BstX. 1
9 1 8 TCG GAT CCA CTA GTC CAG TGT GGT GGA ATT CTG CAG ATA TCC AGC ACA GTG
S e r A sp P r o L e u V a l G in C y s G ly  G ly l i e L e u G in l i e S e r  S e r T h r V a l
A/ofI Xho 1 SstE II Stu\ myc epitope
9 6 9 GCG GCC GCT CGA GjGT CAC c c a | TTC GAA CAA AAA CTC ATC TCA GAA GAG GAT
A la A la A la A rg  G ly  H is P r o P h e G lu G in L y s L e u l i e S e r  G lu G lu A sp
Aob 1 Polyhistidine tag Pme 1
1 0 2 0 c t g ' AAT ATG CAT ACC GGT CAT CAT CAC CAT CAC CAT TGA GTTTAAACCC
L e u A sn M et H is T h r G ly H i s H i s H i s H i s H i s H i s * * *
1 0 6 9
pcDNA3 1/BGH Reverse priming site 
GCTGATCAGC CTCGACTGTG CCTTCTAGTT GC
Multiple cloning site of pcDNA3.1 myc/His in the C reading frame.
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Appcnitix C
m yc  e p ito p e
l l l l l l l l l l l â
pcDNA3.1 
Myc-His
5.5 kb
G. Diagram of pcDNA3.1^"^^-myc/Hls.
* U nique Sac II site betw een the Apa I and the Sfu I in reading frame B. 
Unique BstE II site, but no Xba I or A pa I sites in reading frame C.
pEGFP-C1 Vector
GenBank Accession #: U55763
pUC
SnaB I
,/VAe 1(5921 
-fC047 III 15971 
/lgel(60i|
EcaOm  I
(3854)
HSVTK EGFPpoiy A
pEGFP-01
4.7 kb SV4Û
1 KanV poiy A^  Neo' n /SV40 ori
p p SV40 . ori y / ^
Stul
12577)
BsiG I (13231
MCS
(1330-1417)
M/l/1 (1642) 
III (1872)
fed il PWI ^ 1  Kpm\ 7 AfuI \ B a m H \  Xbsi’
ATC A
H .
Restriction Map and Multiple C loning Site (MCS) of pEGFP-CI.
Diagram of peGFP-Cl.
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M ultiple alignment of 5’ and 3* end of WT-1. Hum an c-fms in pcDNA3.1^
Hu c - fm s CCTGCGGAGC TAGTAGCTGA GAGCTCTGTG CCCTGGGCAC CTTGCAGCCC 269
WT-1 #1 ....... GC TAGTAGCTGA GAGCTCTGTG CCCTGGGCAC CTTGCAGCCC
WT-1 #2 ------- GC TAGTAGCTGA GAGCTCTGTG CCCTGGGCAC CTTGCAGCCC
Hu c - fm s TGCACCTGCC TGCCACTTCC CCACCGAGGC CATGGGCCCA GGAGTTCTGC 319
WT-1 #1 TGCACCTGCC TGCCACTTCC CCACCGAGGC CATGGGCCCA GGAGTTCTGC
WT-1 #2 TGCACCTGCC TGCCACTTCC CCACCGAGGC CATGGGCCCA GGAGTTCTGC
Hu c - fm s TGCTCCTGCT GGTGGCCACA GCTTGGCATG GTCAGGGAAT CCCAGTGATA 369
WT-1 #1 TGCTCCTGCT GGTGGCCACA GCTTGGCATG GTCAGGGAAT CCCAGTGATA
WT-1 #2 TGCTCCTGCT GGTGGCCACA GCTTGGCATG GTCAGGGAAT CCCAGTGATA
Hu c-■fms GAGCCCAGTG TCCCCGAGCT GGTCGTGAAG CCAGGAGCAA CGGTGACCTT 419
WT-1 #1 GAGCCCAGTG TCCCCGAGCT GGTCGTGAAG CCAGGAGCAA CGGTGACCTT
WT-1 #2 GAGCCCAGTG TCCCCGAGCT GGTCGTGAAG CCAGGAGCAA CGGTGACCTT
Hu c- fm s GCGATGTGTG GGCAATGGCA GCGTGGAATG GGATGGCCCC GCATCACCTC 469
WT-1 #1 GCGATGTGTG GGCAATGGCA GCGTGGAATG GGATGGCCCC CCATCACCTC
WT-1 #2 GCGATGTGTG GGCAATGGCA GCGTGGAATG GGATGGCCCC CCATCACCTC
Hu c-■fms ACTGGACCCT GTACTCTGAT GGCTCCAGCA GCATCCTCAG CACCAACAAC 519
WT-1 #1 ACTGGACCCT GTACTCTGAT GGCTCCAGCA GCATCCTCAG CACCAACAAC
WT-1 #2 ACTGGACCCT GTACTCTGAT GGCTCCAGCA GCATCCTCAG CACCAACAAT
Hu c-■fms GCTACCTTCC AAAACACGGG GACCTATCGC TGCACTGAGC CTGGAGACCC 569
WT-1 #1 GCTACCTTCC AAAACACGGG GACCTATCGC TGCACTGAGC CTGGAGACCC
WT-1 #2 GCTACCTTCC AAAACACGGG GACCTATCGC TGCACTGAGC CTGGATACCC
Hu c--fm s CCTGGGAGGC AGCGCCGCCA TCCACCTCTA TGTCAAAGAC CCTG-CCCGG 619
WT-1 #1 CCTGGGAGGC AGCGCCGCCA TCCATCTCTA TGTCAAAGAC CCTG-CCCGG
WT-1 #2 CCTGGGAGGC ATCGCCGCCA TCCACCTCTA TGTCAA-GAC CCTGGCCCGG
Hu c--fm s CCCTGGA 625
WT-1 #1 CCCTGGT
WT-1 #2 CCCTGG-
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Hu c - f m s  GTGCTGTTGA CCAATGGTCA TGTGGCCAAG ATTGGGGACT TCGGGCTGGC 26 9 9
WT-1 #1 -TGCTGTTGA CCAATGGTCA TGTGGCCAAG ATTGGGGACT TCGGGCTGGC
WT-1 #2 GTGCTGTTGA CCAATGGTCA TGTGGCCAAG ATTGGGGACT TCGGGCTGGC
Hu c - f m s  TAGGGACATC ATGAATGACT CCAACTACAT TGTCAAGGGC AATGCCCGCC 274 9
WT-1 #1 TAGGGACATC ATGAATGACT CCAACTACAT TGTCAAGGGC AATGCCCGCC
WT-1 #2 TAGGGACATC ATGAATGACT CCAACTACAT TGTCAAGGGC AATGCCCGCC
Hu c - f m s  TGCCTGTGAA GTGGATGGCC CCAGAGAGCA TCTTTGACTG TGTCTACACG 2799
WT-1 #1 TGCCTGTGAA GTGGATGGCC CCAGAGAGCA TCTTTGACTG TGTCTACACG
WT-1 #2 TGCCTGTGAA GTGGATGGCC CCAGAGAGCA TCTTTGACTG TGTCTACACG
Hu c - f m s  GTTCAGAGCG ACGTCTGGTC CTATGGCATC CTCCTCTGGG AGATCTTCTC 2 84 9
WT-1 #1 GTTCAGAGCG ACGTCTGGTC CTATGGCATC CTCCTCTGGG AGATCTTCTC
WT-1 #2 GTTCAGAGCG ACGTCTGGTC CTATGGCATC CTCCTCTGGG AGATCTTCTC
Hu c - f m s  ACTTGGGCTG AATCCCTACC CTGGCATCCT GGTGAACAGC AAGTTCTATA 2 8 99
WT-1 #1 ACTTGGGCTG AATCCCTACC CTGGCATCCT GGTGAACAGC AAGTTCTATA
WT-1 #2 ACTTGGGCTG AATCCCTACC CTGGCATCCT GGTGAACAGC AAGTTCTATA
Hu C - f m s  AACTGGTGAA GGATGGATAC CAAATGGCCC AGCCTGCATT TGCCCCAAAG 2 94 9
WT-1 #1 AACTGGTGAA GGATGGATAC CAAATGGCCC AGCCTGCATT TGCCCCAAAG
WT-1 #2 AACTGGTGAA GGATGGATAC CAAATGGCCC AGCCTGCATT TGCCCCAAAG
Hu c - f m s  AATATATACA GCATCATGCA GGCCTGCTGG GCCTTGGAGC CCACCCACAG 2 999
WT-1 #1 AATATATACA GCATCATGCA GGCCTGCTGG GCCTTGGAGC CCACCCACAG
WT-1 #2 AATATATACA GCATCATGCA GGCCTGCTGG GCCTTGGAGC CCACCCACAG
Hu c - f m s  ACCCACCTTC CAGCAGATCT GCTCCTTCCT TCAGGAGCAG GCCCAAGAGG 3 04 9
WT-1 #1 ACCCACCTTC CAGCAGATCT GCTCCTTCCT TCAGGAGCAG GCCCAAGAGG
WT-1 #2 ACCCACCTTC CAGCAGATCT GCTCCTTCCT TCAGGAGCAG GCCCAAGAGG
Hu c - f m s  ACAGGAGAGA GCGGGACTAT ACCAATCTGC CGAGCAGCAG CAGAAGCGGT 3 0 99
WT-1 #1 ACAGGAGAGA GCGGGACTAT ACCAATCTGC CGAGCAGCAG CAGAAGCGGT
WT-1 #2 ACAGGAGAGA GCGGGACTAT ACCAATCTGC CGAGCAGCAG CAGAAGCGGT
Hu c - f m s  GGCAGCGGCA GCAGCAGCAG TGAGCTGGAG GAGGAGAGCT CTAGTGAGCA 314 9
WT-1 #1 GGCAGCGGCA GCAGCAGCAG TGAGCTGGAG GAGGAGAGCT CTAGTGAGCA
WT-1 #2 GGCAGCGGCA GCAGCAGCAG TGAGCTGGAG GAGGAGAGCT CTAGTGAGCA
Hu c - f m s  CCTGACCTGC TGCGAGCAAG GGGATATCGC CCAGCCCTTG CTGCAGCCCA 3199
WT-1 #1 CCTGACCTGC TGCGAGCAAG GGGATATCGC CCAGCCCTTG CTGCAGCCCA
WT-1 #2 CCTGACCTGC TGCGAGCAAG GGGATATCGC CCAGCCCTTG CTGCAGCCCA
Hu c - f m s  ACAACTATCA GTTCTGCTGA GGAGTTGACG3229
WT-1 #1 ACAACTATCA GTTCTGCTGA GGAGT- 
WT-1 #2 ACAACTATCA GTTCTGCTGA GGAGT-
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Multiple sequence alignment of wild-tvpe mvc/his tagged human c-fms in pcDNA3.l\
S R - l    A ACGGCCGCCA 0T0-TG CTG 6 AATTCGGXrTT 30
T7  CGOATC CAO-GGCCCA ACGGCCGCCA 0TX3ANGCTGG AATTCGGCTT 45
SR-5........... ........ ........... ................................
SF-2........... .... .. .............................................
SR-4........... ............................. .......... ...........
SF-3     --- ................. .............
SR-3................................... .......... ............ .....
SF-1........... ......................-..... ................... ...
BOH  - - -  - ....................................................................................
SF-5    -............
SF-4........... .... ............. . -........... ..................
SR-6 -............... .................................. .
C-fms Tag CCTQGGCACC TTGCAGCCCT GCACCTGCC- -TGCCACTTC CCCACCGAGG 298
Consensus CCTOSGSAYC YWGCRGCCCW RCRSCYGCCA OTGMNRCTKS MMYWCSOIKK 300
SR-1 CCATGGGCCC ASGAGTTCTG CTGCTCCTGC TGGTGGCCAC AGCTTGGCAT 80
T7 CCATGGGCCC AGGAOTTCTG CTGCTCCTGC TGGTGGCCAC AGCTTGGCAT 95
SR-5  -.-........................
SF-2...........   -............... -.................
SR-4    -...........
SF-3..................................-.......- -...................
SR-3........... .... .............................. ..... ......... .
SF-1  - ---...... ....................... .......
BGH     -
SF-5 -...................   -.............. ....
SF-4  -..........................-.....
SR-6........... .............. .....................................
C-fms Tag CCATGGGCCC AGGAGTTCTG CTGCTCCTGC TGGTGGCCAC AGCTTGGCAT 348
Consensus CCATGGGCCC AGGAOTTCTG CTGCTCCTGC TGGTGGCCAC AGCTTGGCAT 350
SR-1 GGTCAGGGAA TCCCAGTQAT AGAGCCCAGT GTCCCCGAGC TGGTCGTQAA 130
T7 GGTCAGGGAA TCCCAGTGAT AGAGCCCAGT GTCCCCGAGC TGGICQTQAA 145
SR-5...........  -............. -............. -..............
SF-2  -..................... .........
SR-4   -................   -.......
SF-3  -........ - ...............  -
SR-3    -.................. -.......
SF-1...........   ---........... ....................
BGH    - .................. ................ ................................... ........
SF-5..................................-...............  -
SF-4......................... ... ........... ... .............. ....
SR-6  -............................. .... ..........
C-fms Tag GGTCAGGGAA TCCCAGTQAT AGAGCCCAGT GTCCCCGAGC TGGTCGTTGAA 398
Consensus GGTCAGGGAA TCCCAGTQAT AGAGCCCAGT GTCCCCGAGC TGGTCGTQAA 400
SR-1 GCCAGQAGCA ACGGTQACCT TGCQATGTGT GGGCAATGGC AGCGTGQAAT 180
T7 GCCAGQAGCA ACGGTQACCT TGCQATGTGT GGGCAATGQC AGCGTGQAAT 195
SR-5 ......... -............... -............. -.........
SF-2  -..........................................-
SR-4...........    -...........
SF-3    -.................
SR-3  - .....................
SF-1........... ......... -.............. --- --- .........
BCH - ........................................  - .................................................... ..........
SF-5......................... ........... ............... ..........
SF-4  -............... -......... ...... ...........
SR-6................. .......... ... .......... ..... ............ .
C-fms Tag GCCAGQAGCA ACGGTQACCT TGCQATGTGT GGGCAATGGC AGCGTGQAAT 448
Consensus GCCAGQAGCA ACGGTQACCT TGCQATGTGT GGGCAATGGC AGCGTGQAAT 450
SR-1 GGQATGGCCC CCCATCACCT CACTGQACCC TGTACTCTQA TGGCTCCAGC 230
T7 GGQATGGCCC CCCATCACCT CACTGQACCC TGTACTCTQA TGGCTCCAGC 245
SR-5 ............... ..... ... ............. . ...... .
SF-2 ................... ................. ... ...... ...
SR-4...........  -......... - ----- ----------- -------- -----
SF-3   ---................... ..........
SR-3 ......... ---.......................... ...... ....
SF-1   -.... ---..... .......... ................
Bcæ. ............- ....... ....... .............. .................................
SF-5.............. -...---..... -........... ...... ....... ....
SF-4........... ......... ....... ...... ..... ..... ...............
SR-6      -.
C-fms Tag GGQATGGCCC CQCATCACCT CACTGQACCC TGTACTCTQA TQGCTCCAGC 498
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Oonsansua 090)000000 OSCATOIWCOT OLCTOOAOOO TODICICTW TOOOTOOAOO 500
SS-1 JUXaOOOIGA OOACOAACAX OOODWCOTTO CAAAACAOOQ OOJWOOIAIOO 280
T7 AOaOOOICA QCACCAACAA. OOCIAOCiTC OAAAACXOOO 00)^ 0013000 295
SR-5 ....................................................................................................
SF-2 ....................................................................................................
SR-4...................... - ...........................................
SF-3 ....................................................................................................
SR-3 ....................................................................................................
SF-1 ------------- -------- ------ ------------------------------ -------- ------
SF-5 ....................................................................................................
SF-4 ....................................................................................................
SR-6 ....................................................................................................
0-fiM Tag » a a a CCtCK OCAOCAACAA OOOTRCOTTO OÜÜÜWOIOOO 00)L00!aO00 548
OonscDSUS K XXSC C K K  OCRCOUWOUl OOOI3WOOTTO CAAAAOIOOO 00)W00X)O00 550
SR-1 OIOOIWCTtaa 00100)WO)100 OOOIOOO)WaO OnOOOOOOOO AZOO)tOOTOT 330
T7 0X008010)10 OOlOOMSUr OOOIOOO)WOO 0800000000 8T00800TOT 345
SR-5
SF-2
SR-4
SF-3
SR-3
SF-1
SF-5 ....................................................................................................
SF-4 ....................................................................................................
SR-6  - —
0-fmm Tag OIO08CIO8O 0010080800 0001000800 0800000000 8T00800TOT 598
01008CI080 0010080800 0001000800 0800000000 8TOC3100ICT 600
SR-1 8IOr—A8A OCCIOOOOOO............................................................. 348
T7 ATaXG3UV808 OOOIOOOOOO O00TO088OO TO0I8O08C8 00800X0010 395
SR-5 ....................................................................................................
SF-2 ................................................................................................ ...
SR-4  - ................
SF-3 ....................................................................................................
SR-3 ....................................................................................................
SF-1 ....................................................................................................
SF-5 ....................................................................................................
SF-4 ....................................................................................................
SR-6 ....................................................................................................
0 -fu  Tag ATOT088808 OOOIOOOOOO 0001008800 TO0T8O08C31 0080010010 648
Ooomaomum AT0XC3UUtO8 OOOIOOOOOO 0001008800 TO0T8O08O8 0080010010 650
SR-1     348
T7 OIOTT008O0 8008008000 80I80TOOCO TOlClOOTOtk C3W0800000T 445
SR-5
SF-2
SR-4
SF-3
SR-3
SF-1
Sf-5 -------- ----------------------------------------
SF-4
SR-6 ....................................................................................................
0-fiBS Tag 0101100800 8008008000 80X8010000 T01C100T08 C3W0800000T 698
010X100800 8008008000 80X80X0000 TOICIOOXCX 0808COOOOX 700
SR-1      348
17 00X00880(31 MOOOXCXOOC XOOXOOOXOX QOOXQOCOOO 0CC-T@I9C 494
SR-5 ....................................................................................................
SF-2 ....................................................................................................
SR-4 ....................................................................................................
SF-3 ....................................................................................................
SR-3 ....................................................................................................
SF-1 ....................................................................................................
BOB ....................................................................................................
SF-5 —........ — ................ ............................................ ....................
SF-4 ....................................................................................................
SR-6 ....................................................................................................
0-fBS x#g 00X0088008 0000X0X000 XOOXOOOXOX OOOIOOOOOO 0000X08X00 748
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GooMOma 00X0088001 NOOOXCXOOO XOOXOOOXOX 000X000000 0C0CX08T00 750
SS-1......................      - .............   348
T7 0008C8C08X OXAL'llXTrU XOOOOOXOOO AX000XX08C 08X0080800 544
sa-5  -.
SF-2 ....................................................................................................
SR-4 ................. - ................................................................................
SF-3 ....................................................................................................
8R -3     OC A i w r r i x a i c  o u c c i m a a  22
SF-1  80X80-00 XOOOOOXOOO 888MRXX080 08X0080800 37
BOH .......................................................................................................................................
SF-5 ....................................................................................................
SF-4 ....................................................................................................
SR-6 ....................................................................................................
0-fiu  Tmg 0008C8008A Cf AOXOO i' i O  XOOOOOXOOO 8X000XXCR0 01X0080800 798
Oonaanaua O0C8O8OO8X OX8O1M0XX0 XOOOOOXOOO AIOUUri'IC80 08X0080800 800
SR-1      348
T7 OOOUtOXXOi 1X08080001 0080I8X08X TOOU3XOOOO X08X0O0X00 594
SR-5  - ....................
SF-2 ....................................................................................................
SR-4 ....................................................................................................
SF-3  - ......................................................
SR-3 000880XX08. XX-8080001 008NX8XOUÏ X0C8OX000X X08X0O-TX0 70
SF-1 0008801*101 TTC8080008 0080ÏRX08A 10080X0000 X08X0Q0X00 87
BGB .......................................................................................................................................
SF-5 ....................................................................................................
SF-4 ....................................................................................................
SR-6 —...... — ------------------------------------ -------------------------
0 - t e  T tg  0008801X01 1X08080001 008018X001 10080X0000 X08X0O0X00 848
0001801X08 1X0080001 008MX8X01R XOOlOXOOOX X08XOOOXBO 850
SR-1  - . 348
17 08008800X0 8X01-01X01 OOIXOOOOOX 08880X0 88 8880X01X00 642
SR-5 ............................................................................... - ..................
SF-2 --------------------------------------------------------------------------
SR-4 ....................................................................................................
SF-3 ....................................................................................................
SR-3 080088«X0 ATO-NOIXOI OOIXOOOOOX 0-880X0080 8880X01X00 118
SF-1 08008800X0 8XOXOG8TC8 OC8TOCQOOT 900 3^X9080 8880X08X00 137
BOB  - ......................................................
SF-5  - ......................................................................................
SF-4 ..........................................  ...................................................
SR-6     —.—............ .............................................
0-fiBS lag 08008800X0 8X0X008X01 0C8X00000X O888OX0C8O 8880X01X00 898
G8O0880HX0 8X01*08X08 008X000001 O888OX0C8R 8880X08X00 900
SR-1       348
17 88000-0000 8000XX08C8 0X00X000X0 08 800X001 QOOa iXXC-8 689
SR-5  - ..................................................................................
SF-2 ....................................................................................................
SR-4 ....................................................................................................
SF-3 ....................................................................................................
SR-3 oiooooceoc 8000XX08C8 8XXOXOCRXO 08O8OXX00X 00008X1008 168
SF-1 C80000000C 8O0CXX08C8 0X00X000X0 080800X001 00008XX008 187
BOB ....................................................................................................
SF-5 ------- ---------- -------------------------------------------------------
SF-4 ....................................................................................................
SR-6 ---------- -------- -------------------------------------------------------
0 -te i l« g  0800000000 8O00XX08C8 0X00X000X0 080800X001 00008X1008 948
Oonaanaua M80000COOC 8O00XX08C8 lOKOXOCMXO 08O8OXX00X 000931X008 950
SR-1   348
17 M00088O0X0 00-888ZMQX OXO-XC88CO 88C88O01X0 8X0XX88CH 737
SR-5 ....................................................................................................
SF-2 ....................................................................................................
SR-4 ....................................................................................................
SF-3 ....................................................................................................
SR-3 0000800X10 000808X001 OXEBIXC8O00 80080001X0 8X0XX88CX1 218
SF-1 00008000X0 000808X001 0X00X08000 80010001X0 AX0XX88CX1 237
BOH    - ........... --T
SF-5 ------- ---------------- ----------------- ---------------------------. ...
SF-4 ....................................................................................................
SR-6 ....................................................................................................
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C-flU Tag 00008000X0 00C8O8T0Or 0100X08000 80010001X0 8I0IT88CTT 998
Ooomaomum N0008ROZTO 0008883*0? OXCBIXO8S00 8R08M001'iO 8T0IT88CTT 1000
SR-1   - . 348
T7 108ZOICT-0 0T-C88C8-8 8C8AC8CT88 00X000183* 00X088-881 783
SR-5 ....................................................................................................
SF-2 .......................................................................... ...... ...................
SR-4 ....................................................................................................
bf-3 -------- ----------------------------------------
SR-3 TUAlViViTO 0X00180108 8088010X88 00X0001810 00XG318C88X 268
W-1 TU81UXCTXC 0X00880808 8088080X88 00X0001810 00X0880881 287
a n  ..............................................................................................
SF-5 ....................................................................................................
SF-4 ....................................................................................................
SR-6 —------------- ----------------------------------------------------------
c-tm m  Tig TOAXOfCXXO 0X00880808 8088080X88 00X0008810 0CXO18C88T 1048
Oonmanmum X081OXCXX0 0X00880801 8088080X88 00X000883* O0X088ai8T 1050
SR-1 —---------------    348
T7 CIO8OXXX08 T8-188R0» 3*0 88888 X0CX08O00X 01-00X0-81 828
SR-5 ....................................................................................................
SF-2 ....................................................................................................
SR-4 ....................................................................................................
SF.3 ........................................................... ........................... .............
SR-3 CXOBlOXXXai X88Î88O00X 1800888880 TOCX08000X 01800X0081 318
SF-1 0X08CXXXO1 3318X88000X 1800888880 T00XQ8O00X 08800X008X 337
BOB.......................  - ...........................................
SF-5 ....................................................................................................
SF-4......................  - ......................................................................................
SR-6 ....................................................................................................
C-tes Tig OiWCriTCA X88X88000X 1800188880 100X080001 08800X0081 1098
Oonmanmum 0X080X1X08 188188*00* XMC088888R X0CXO8C0CX 0880CX008T 1100
SR-1   348
17 *8801....................................................   833
SR-5 ....................................................................................................
SF-2 ....................................................................................................
SR-4 ....................................................................................................
SF-3 ....................................................................................................
SR-3 0010X88811 XCC88083OC 0000880X80 100X000X00 OC80C8800X 368
SF-1 0880X80811 1001808100 OOOC880X80 100X000X00 008008800X 387
BOX  - ................ - ....................
SF-5 ....................................................................................................
SF-4 ......................... ..........................................................................
SR-6
C-fiM lag C88033108X1 10C8808100 0000880X80 100X000X00 008008800X 1148
Oonmanmum *880X80811 1008801100 0000180X80 100X000X00 0080088001 1150
SR-1   348
17   833
SR-5 ....................................................................................................
SF-2 ...............................................................- ...................................
SR-4 ---- 800*880 C8MXCO10CX C-83KTTNX1 00-00X1018 0*N8N1—00 43
SF-3 ....................................................................................................
SR-3 0080000880 C80XOC800X 008X01X0X1 00000X00X8 08080X0001 418
SF-1 0080000880 C31CXeC8CCX UCAXOXXOXX 00000X00X8 08080X0001 437
BOB ....................................................................................................
SF-5 ....................................................................................................
SF-4 ....................................................................................................
SR-6 ....................................................................................................
c-fmm xig. 0080000880 C8CXOC800X 008X0X10X1 00000X00X8 08080X0001 1198
Oonmanmum 0088000180 C8BX0C8C0X 0083*X1*X1 C0000XK0X8 q*N8NX00CX 1200
SR-1 —-------    348
17   833
SR-5 ....................................................................................................
SF-2 —------ - ----------------------------------- -------------------- ------
SR-4 88XX088CXX 0801X1X0-0 0808*00X08 1OC80O80-1 080CMXOOOO 91
SF-3 ....................................................................................................
SR-3 80X10880X1 0800X0X080 C8088CCXO8 1OO80O80OX 08000X0000 468
SF-1 8CXX088CX1 0800X0X080 0808800X08 XOC80O80OX 08000X0000 487
BOB  - ...................................
SF-5 ....................................................................................................
SF-4  - ..........................................................................
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SR-6
C-tam Tmg 
Oonmanmum
JWdlOMlCTT 0800X0X080 0808800X08 TOO80O80OX 08000X0000 1248
8*rX0880XX O8anTrO80 O808*OOXO8 TOC80O80OX O8OCNX00O0 1250
SR-1
T7
SR-5
SF-2
SR-4
SF-3
SR-3
SF-1
BGH
SF-5
SF-4
SR-6
0-fimm Tag 
Oonmanmum
....................................................................................................  348
....................................................................................................  833
JUUmrreA mociCAmmOr CKfO-TOOAO OCNX8OOC80 OCNXO-N8NO 137
O80OOOOXG8 8OCXO8880X 08X00X0080 00-1800080 OOOXOC880O 517
0880000X08 8OOXC8880X 08X00X0080 00-1800088 000X008800 536
0800000X08 8COXO8880X C8XOOXOO80 000X800080 000X008800 1298
O8R0OCM1G8 8OOXO8880X 08X00X0080 OCHX800C8R 00X9X00*8*0 1300
SR-1
17
SR-5
SF-2
SR-4
SF-3
SR-3
SF-1
B (S
SF-5
SF-4
SR-6
0-finm lag  
Oonmanmum
....................................................................................................  348
 - .......................................................................................  833
1X1X880X00 800X8CXX-0 08000X1111 10800100(0 09X0800008 186
H1X88CX00 800X800X00 08000XX110 10(0080080 00X0800001 567
1X1X880X00 800X800X00 08000X1110 10800880(0 00X08000-8 585
1X1X880X00 800X800X00 08000X1110 109(0080080 00X0800001 1348
1X1X880X00 800X80X100 08000XÎ1XT 108001*0(0 09X0800008 1350
SR-1
17
SR-5
SF-2
SR-4
SF-3
SR-3
SF-1
BOB
SF-5
SF-4
SR-6
C -tam  lag 
Oonmanmum
....................................................................................................  348
............................................................................................  833
*00X100X3(8 10XX800800 8800808081 80(0008080 0X10800910 236
800X100X88 100X800(00 8800808081 803(0008080 0X10(00010 617
8009100X88 100X8*0(00 880090803(1 808*018080 OX-0880010 634
800X100X88 100X800(00 8800808081 803(0008080 CTiOAOOOlC 1398
*009100X88 102X8*0800 8800908081 8O(*Q99808C 01708*0910 1400
SR-1
17
SR-5
SF-2
SR-4
SF-3
SR-3
SF-1
B(B
SF-5
SF-4
SR-6
0-fimm lag  
Oonmanmum
....................................................................................................  348
....................................................................................................  833
IVll'fOCOOO 00X1088000 OXOXO80OOX 0OOOOOX8OX 00X100X000 286
xcxcxoeeec oeexo880ee exeiOASoex ooooooxawox ocxicoxooo 667
ICXCXOCOOO OOOX088-*C 010X08*OOX OOOOOOX8MX 00X100X000 683
10X0100000 000X088000 OXCXO80OOX 000000X801 00X100X000 1448
10X1100000 00X10880*0 0X0X08*081 000000X8*1 OOXIOOXOOS 1450
SR-1
17
SR-5
SF-2
SR-4
SF-3
SR-3
SF-1
BOB
SF-5
..............................................................................................................  348
..............................................................................................................  833
03(08880008 00800*1008 0800X01080 0X110800X0 8000X10081 336
0808880008 008000X008 0800X0X080 0X1X0800X0 8000X10081 717
088888*008 8O80OMXOGK -880X0X080 -111080000 8800X1-08- 729
303
SF-4
SR-6
C-fin# Tag
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0(08880008 @080001008 O8OOT0T080 OITTO80CXC 800CTT008T 
08R888H0CX R0800MIOGB9 08R01CI080 011X0800X0 8M00ITOO8T
1498
1500
SR-1
T7
SR-5
SF-2
SR-4
SF-3
SR-3
SF-1
BGB
SF-5
SF-4
SR-6
C -fam  Tag 
Oonaansus
.........................................................................................TOC8-C
----------------------    ACEH c x c r a a a > - c
8000000808 00X8800010 833(11008081 108X088000 0X01000800
8000000808 00X88000X0 8IT1M08C8T TC3O088..........
M80C000888 00088-00X0 8N8T-OOC3(8 108-088000 0-
8000000808 00X88000X0 8X81O08O8T TO(X088000 0X0X000800 
WSX*CCC8R8 00*8800010 809X310*0819 T08T088000 OXOXKOCMOO
348
833
5
13
386
754
767
1548
1550
SR-1
T7
SR-5
SF-2
SR-4
SF-3
SR-3
SF-1
B(B
SF-5
SF-4
SR-6
0-fiaa Tag
OOTTXOXOXO -TOOCTXT-O 0X3(0000080 -009880X08 083O0XT-H9 
OilTlOXOIO 0X88810X00 0X80000080 000(800X08 08X000X008 
cm 101010 0X000X0X00 OO(OOOOC3(0 0008800X08 mOOOXOCA
-0X00 0-- -AM CO-
348
833
51
63
436
754
776
CriTXOXOIO 0X000X0X00 0X80000080 000(800X08 C3(XO0CXO(A 1598 
CXXriOlOXO OXRMRXXXOO OX3(OOOOC3(M 0000090X91 08X002XCB09 1600
SR-1
17
SR-5
SF-2
SR-4
SF-3
SR-3
SF-1
BIB
SF-5
SF-4
SR-6
0-fiaa Tag
OXOO80X-OO C3(C8HT08Z8 0-1X9X08X08 00000880X0 '1T0CA0O1T1 
OXOC80XOOO C3(C8CX08X8 00X0X08X08 00000880X0 OXOO80OTOT 
0X0080X000 08C8CIO8131 O0XOXGB(X08 00000(80X0 CTO(3(O0TCX
0X0080X000 08080X08331 00X0X08X08 00000880X0 OXOO80OXOX 
0X0080X000 08C3(MXO8I8 00IMXO8X08 00000880X0 XTOC80OXXT
348
833
99
113
486
754
776
1648
1650
SR-1
T7
SR-5
SF-2
SR-4
sr-3
SR-3
SF-1
BIB
SF-5
SF-4
SR-6
0-fina Tag 
Oamflnmia
-OGB(XQ8O00 8X8009X080 -109X08000 8UU80OI39TT 0080880010 
0008X08000 8X8000X080 0X00X08000 80U80lXXTr 00808800X0 
OOAXnOOO ja8OKXO80 0X00X08000 80080OKXT 00808800X0
348
833
147
163
536
754
776
0008X08000 8X8000X080 0X00X08000 8008000011 00808800X0 1698 
0008X08000 8X8009X080 0X09X08000 8008000*0 00888800X0 1700
SR-1
17
SR-5
SF-2
SR-4
SF-3
SR-3
SF-1
8000X00808 MCTT0OXO8T TOIT08QMCO TT8080C8O8 *0088800X8 
8000X00808 000X00X080 10X1080800 TT8080C8O8 80088800T8 
8000X00808 000X00X080 10X108080; TT8080O8C8 80088800X8
348
833
197
213
586
754
776
304
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SF-5 ....................................................................................................
SF-4 ....................................................................................................
SR-6...................... ....................................................................................................
c -te i Tag RoagiacMB occiacicnc Tonmmcc TTMaKOCRcx accaaaocia 174S 
AOOOTOCaiOA NCXTOCXOMT TOirOAGMCC TTA0A9CACA MCOUUWCXHA 1750
SR-1   348
T7   833
SR-5 0080X00809 0C0C8C88CA 000X000080 XOOOXCTIOO OOOXXG8X8C 247
SF-2 0080X00800 0C0C8C88C8 000X000080 T00CXOCXO0 OOOXXC8I8C 263
SR-4 0080X00800 0000(08808 000X000080 T0OOXOOXO0 0OOXTO8Z8O 636
SF-3 ....................................................................................................
SR-3     754
SF-1     — ----------------------      776
KB ..............................................................................
SF-5...................... ....................................................................................................
SF-4 ....................................................................................................
SR-6 ....................................................................................................
c-fias Tag 0080X00800 0000808801 000X000080 TOOOTOCXO0 000XXC8X80 1798
Oonaanaua 0080X00800 0000808808 000X000080 TO0OXCXTO0 S00XT08Z80 1800
SR-1 ..................— --------     348
T7   833
SR-5 OCATCXCXOO 8008000080 8O008TO000 O0GB(3O80IT 0CXCTT08CX 297
SF-2 OCATOXCXOO 8008000080 8O0O8TOOOO 0008108011 OCXOTTCACA 313
SR-4 CC8IOXCXOO 8008000080 80008X0000 O008T080XT O0XCTTC808 686
SF-3  - ...........
SR-3   754
SF-1    776
KB ....................................................................................................
SF-5 ....................................................................................................
SF-4  - ...........
SR-6 ....................................................................................................
0-fiaa Tag OC8IOTOXOO 8008000080 8O0O8TOOOO O008X080XT 00X0X10808 1848
Oonaanaua O08IOXCX00 8008000080 8000(10000 O008I080XT OCXOXT08O8 1850
SR-1 ....................................................................................................  348
T7 ---------------- ------------ ---------------------------------------------- 833
SR-5 0080100X00 TOOOCT0C8T 0X00810(10 0OCXXBCX0C TBCXQCXOCI 347
SF-2 0080X00X00 XO0OOTOO8T 0XOC8XC3(X0 0OOXT0OX0O T0OX0OX0OX 363
SR-4 00(0X00X00 TO0OOXOO8T 0X00(1X08X0 0OOXXOOXOO TOOXOOXOCX 736
SF-3^  ..................- ...................................................... - ........................
SR-3 ---------------------------- ------------ ---------------------------------  754
SF-1 ------------- --------------- ------------------------------ -- ------------ 776
KB ....................................................................................................
SF-5 ....................................................................................................
SF-4 ................................................... ....... ... .....................................
SR-6     —...................... ......................
C-fmm Tag 0080X00X00 10000X0081 0X00(108X0 0OOXXOOXOO TOOXOOXOOX 1898
0080X00X09 TO0OOXOO8T 0X008X08X0 OOOXXOOT0O TOOXOOXOOX 1900
SR-1   348
T7        833
SR-5 00X00X00X8 TTOX8C880X 8X88008088 0000880X80 C3(0OXOOQCX 397
SF-2 OCXOCXOCX8 TTOXACAAOX 8X88008088 0000880X80 G80OXOO9CT 413
SR-4 00X00X00X8 TXOX8C880X 8X8A0C8088 0000880X80 0800-........  780
SF-3 ....................................................................................................
SR-3 ..................- ................................................................................  754
SF-1        776
KB ....................................................................................................
SF-5 ---------------- ------------ ---------------------------------------------
SF-4 ....................................................................................................
SR-6 ....................................................................................................
0-&# rm g 00X00X00X8 TXQX8C880X 8X88008088 0000880X80 O800XOO9OX 1948
Oonaenaus 00X00X00X8 TTOX8a(80X 8X8A0O8088 00008800(0 O80QXOO9OX 1950
SR-1   348
T7   833
SR-5 008808X081 0080800X81 0800008808 0XX8X8CTTT 0(10080000 447
SF-2 008808X081 0080800X81 0800008808 0XX8X80TTT 08X0080000 463
SR-4   780
SF-3 ....................................................................................................
SR-3   754
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s r - i 776
s r - 5
SF-4
8R-6
C-fiBB T»g 
CooMOBua
aCMOaCKT OOMOMaCKAT GAOGnCAACA (RZAXACTTT CAXOaAOCOC U 9 8  
OaAAaATCAT OQAQAOCIAT QAOOOCAACA (RTAXMCTTT CMOaAOOOC 2000
ax-1
T7
SR-5
8F-2
SR-4
8F-3
SR-3
SF-1
BOB
SF-5
SF-4
SR-6
C-ftiB Tag 
OonBflnsuB
ACOCA0CIOC CTTACAACOA 0880100080 TTOCOOOOQ8 8C88CCXOC8 
800C80CTOC Cn8C88O08 0880100080 TTOCXgOOOA 8C88CCI0C8
008 8CMCCX0C8
348
833
497
513
780
13
754
776
8OOC80CIOC CTZ8C88C08 0880100080 tTOC000008 ACA80CZ0CA 2048 
800C80CTOC CTT8C88008 0880X00080 TTORXXSOOA 8C880CX0C8 2050
SR-1
T7
SR-5
s r -2
SR-4
s r - 3
SR-3
SF-1
BOB
s r -5
s r -4
SR-6
C-tmm Tag 
OanscBsuB
0ITTO0T88O 8CC9CTG0080 CI00800C— —TTT0008A 00X00X0080 
OTROBXaUWO 800000080 CXO08OCC TT100088 00X00X0080
OITIO0È880 ACC000080 0X008000 TTT0008A 00X00X0080
348
833
543
559
780
59
754
776
...................................- ...............COTT TOrrTOOCAA 00-............... 16
OXTTO0X88O 8000X00080 CX008000TT TO OOAA 00X00X0080 2094
0XTTO0X88O 8000X00080 OX008000XT XOXTXQ0S88 00X00X0080 2100
SR-1
T7
SR-5
SP-2
SR-4
s r - 3
SR-3
s r -1
BOB
s r - 5
s r - 4
SR-6
C-fiBB Tag. 
OonBanaus
OOOWOOOOOT XTO0TOXOOO C88OO80O8T 00X0X00X08 800XOOOXOT 
OOCBOOnor XXOOXCXOOO CM008008T OOXOXOOXCB 8O0XOQOXOX
OOOU3O0OOT XXOOXCXOOO C88008008T 00X0X00X51 800X000X01
-------------------------------------- 008X OIT-XOOT-A 8O0XOOMT-T
OOaOOOOCT TXO0TOXOO0 C88008008T 00X0X00X08 800X000X01 
OOC8O0QNCX XXOOXCXOOO G88008008T OXT0XOOXO8 800XOOIX0r
348
833
593
609
780
109
754
776
37
2144
2150
SR-1
T7
SR-5
s r  2
SR-4
s r -3
SR-3
s r -1
BGE
s r -5
sr-4
SR-6
C-fiBB Tag
OoaaBBOBUB
08808X00X0 AJUJXraUCOQ OOG8XQCIOA 0080880080 0000X08X01 
08808X00X0 A80XOC8OO0 00-8X00X08 XO8B880Q80 OOC-TC8T0T
08808X00X0 880X008000 0008X00X08 TO80880GM0 OOOOmXOT
0-8UU1TCX8 880-OC8-O0 OOO8X0XT-8 XO-008008- OœCMX83XV 
08808X00X0 880XOC8O00 0008X00X08 TO80880O80 OOOOXO8X0T 
O880RXKCXR 880X008000 SO08X0XXO8 TO8MR80O80 000C9IZ8XMII
348
833
643
657
780
159
754
776
81
2194
2200
SR-1
T7
SR-5
s r -2
SR-4
s r - 3
----------------------------------------------   348
..............................................................................................................  833
000800X088 O8XC8X080O 0800X00000 8008008088 08X00X0880 693
00-800X088 H8XM8XO80O 08X0X0000- 8808008088 C8X0-X0888 704
..............................................................................................................  780
000800X088 O8XC8XO80O 0800X00000 8008008088 C8XC0XO88O 209
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SR-3
s r -1
BCE
s r -5
s r -4
SR-6
C-fiaa Tag 
Oonaansua
  754
  776
OOQA0TT 88 H8TC-TDI0C GKCTTQQOCC 8OC8-M8088 C8T-0IG80C 127
C0S89CT088 08X08X0800 0800X00000 8008008088 08X00X0880 2244
000805X088 M81M8TPIBC O8HTX0GBCC 8RO8CM8088 08X00X08101 2250
SR-1
T7
SR-5
s r -2
SR-4
s r -3
SR-3
s r -1
BOH
s r - 5
s r - 4
SR-6
C -tam  Tag 
Oomaamaua
...............................................................................................   348
....................................................................................................  833
01X0X00080 00X0X80008 XOO80OOOOT 0X80X00X08 70800080X8 743
01X0X00088 00X01X80008 XOO80OOOOT 0X80X00008 X08000-OX8 753
....................................................................................................  780
CTXOX00080 00X0X800(8 XOO80OOOOT OX8OX00XC8 70800080X8 259
....................................................................................................  754
....................................................................................................  776
CTTTXOO—8 OOXOX8-OC8 TXO80OOa»X 0N8XX00XC8 XO8OOO80I8 174 
01X0X00080 00X0X80001 XOO80a(%rX 0X80X00X08 XO8OOO80X8 2294 
CITXX0008R 00X0X00001 XR080OSC0X (M8TX0QM08 TO8OOO80X8 2300
SR-1
T7
SR-5
s r -2
SR-4
s r -3
SR-3
s r -1
BCE
s r -5
s r -4
SR-6
O-f0a Tag
...............................................................................................................................  348
...............................................................................................................................  833
CXOXXOOX8T 0000800X00 T088OXTX0T 0008800880 00X0800001 793
C-OXXOO-8T 00-0880X00 -OUtOXTXOX OOUUI0O880 O-XM80O-O8 797
.................................................................................... - ....................... - ..............  780
CX0XX90X8T 0000800X00 T088OITT0X 0008800880 00X0800008 309
....................................................................................................  754
...........................................................- ....................................... 776
CXOXXOOX8T OOOO8C0XO- XC880XTTTT 0008800880 00X0800008 223
CXOXTOOiRT 0000800X00 TC88OXTX0X 0008800880 00X0800001 2344
CXOXXOOX8T 00008MRO0 X088OTTTST OCR880O880 00X0800008 2350
SR-1
T7
SR-5
sr-2
SR-4
s r -3
SR-3
s r -1
BCE
s r - 5
s r - 4
SR-6
O-tea Tag
SR-1
T7
SR-5
s r -2
SR-4
s r -3
SR-3
s r -1
BCB
sr-5
s r -4
SR-6
C -tam  Tag 
Oanaanaua
   - ...............................................................................  348
...............................................................................................................................  833
1001000800 08000X0800 0000-.................................................. 817
T-CI0Q08-0 08800X8800 0000-.................................................. 819
...............................................................................................................................  780
TOOX000800 08000X0800 000000000 8000008000 80000X0080 359
....................................................................................................  754
....................................................................................................  776
TOOTOO-800 C80OXXO80O OOOOOOC80O 8000008000 80000X0080 272
100X000800 C80OOXO80O 0000000800 8000008000 80000X0080 2394
1001000800 C8ROrXR80O OO8OOOC80O 8000008000 80000X0080 2400
/
...............................................................................................................................  348
....................................................     833
...............................................................................................................................  817
....................................................................................................  819
...................................- .......................................................................................... 780
I8Z88088C8 T0C8O0XO08 O880888Z8T 0X00008000 8O80XOOOIT 409
....................................................................................................  754
...............................................................................................................................  776
1838808808 TOG80CX008 (388088A18T 0X00008000 8O80XOOOXX 322 
X8388088C8 100800X008 O88088838T 0X00008000 8080X000X1 2444
X8388088O8 T0C8OCXO08 O88088838T 0X00008000 8O80XOOOXT 2450
SR-1
X7
SR-5
s r -2
SR-4
...............................................................................  348
...............................................................................  833
...............................................................................  817
...............................................................................  819
...............................................................................  780
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SF-3 C1OC80CCUI oararooR C x Œ X M O ioax cuaoM saocr o ic ic c m c tt 459
SR-3   754
s r - 1     776
a s  ..............................................................................................
s r - 5 ............................ - ...............................................................................................................
s r -4    - - -  0 8  08X0890001 QH88CC8CTT 22
8R-6 0X00800080 00X0X00808 00X8X0X008 08X080000X OXOXO080TT 372
0 -f iB B  Tag CX00890C80 00X0X00801 00X8X0X008 08X080000T OXCXCOWOXT 2494
Oonaansua OX008GKX8ir 00X0X00808 00X8X0X008 08X080000T @OORC80TX 2500
SR-1 -----   — ------   348
T7     833
SR-5   817
sr-2   0880800 CM80— --------------- 830
SR-4 -     - — .... —  780
sr-3 CXTC888X08 CTOCITOXCX 0800880800 1008088008 008X008000 509
SR-3 -................................................  754
sr-1      776
a s  ...............................................................................................................................
s r - 5  ...............................................................................................................................
sr-4 0X10888308 CXOUITOTCX 0800880800 1008088008 008X008000 72
SR-6 CTX0888X08 OTOOiTOXOX 0800880800 1008088008 008X008000 422
0-fiaa Tag 0X10888X08 CltXTJCiCT 08X880800 TOQ8C880Q8 008X008000 2544
0X10888X08 CXœriOTCX 0800880800 1051008008 008X008000 2550
SR-1 -------------------- ------ ----------------------------------------------- 348
17 ---------------- :----------------------------------------------------------  833
SR-5 --------------------------------------------------------------------------- 817
sr—2 ——— — —008— — — — —OOO— — — — ———TC80X—— ———8——T88— —— — — — —88—— 847
SR-4 ------------- -------------------------------------------------------------  780
s r - 3  0000X00800 1CO00O8OOX 00XTC8OX1C 1008000880 180000500 559
SR-3   ;-------  754
sr-1 ------------- --------------- -- --------------------------- --------------- 776
as--------------------------0800 TOOOOO-OOX O-TTO88XX0 lCOWO-0880 180000100- 40
s r - 5   - .........................................................— — .............................. ...........
sr-4 0000X00800 XCO0OO8CCT OOXXOlOXTO 1008000880 X8OOOO89O0 122
SR-6 0000X00800 1CO00O8OOX OOTT080XXC TOC8900889 X8OOOOWOO0 472
0 -te l Tag 0000X00800 TOO0OO8OOX O0XXG80XT0 TOC8OCC880 X8OOOC8O00 2594
0000X00800 TOOO0O8OOT 00X1080110 100800X880 X8OOOC8RO0 2600
SR-1 —........ — --------------- -------------------------- ------------- —— 348
17  - ....................  833
SR-5     ;- 817
sr-2      847
SR-4   - 780
sr-3 C8XOO0OITO CXO0OXTOO8 8088X10081 0080000080 OIO0-88COO 608
SR-3      754
s r - 1        776
a s  081-000X10 CiWmOCA 05üIX10C8T OC8-O00O88 0X00080000 88
s r - 5  ................................................................................................................................
sr-4 O8XO0OOTTO 0X000X100 1 8O88XT0C81 OC8OO00O8C 0X00089000 172
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Appendix F
.301Sequence analysis of mutations at Leu
C-fms CTCGATCAAG TAGATTTCCA ACATQCCGOC AACTACTCCT OCOTOOCCAO 1142
W T-IR CTCGATCAAG TAGATTTCCA ACATGCCGGC AACTACTCCT GCGTGGCCAG 3 6 1
W T-IF CTCGATCAAG TAGATTTCCA ACATGCCGGC AACTACTCCT GCGTGGCCAG 380
M T-5F CTCGATCAAG TAGATTTCCA ACATGCCGGC AACTACTCCT GCGTGGCCAG 4 2 3
MT-5R TTCGATCAAG TAGATTTCCA ACATGCCGGC ^C TA C TC CT GCGTGGCCAG 395
M T-6F CTCGATCAAG TAGATTTCCA ACATGCCGGC AACTACTCCT GCGTGGCCAG 4 2 4
MT-6R TTCGATCAAG TAGATTTCCA ACATGCCGGC AACTACTCCT GCGTGGCCAG 39 1
M T-7F CTCGATCAAG TAGATTTCCA ACATGCCGGC AACTACTCCT GCGTGGCCAG 4 1 2
MT-7R TTCGATCAAG TAGATTTCCA ACATGCCGGC AACTACTCCT GCGTGGCCAG 396
C-fms CAACOTGCAO GGCAAGCACT CCACCTCCAT GTTCTTCCOG GTOOTAGAGA 1192
W T-IR CAACGTGCAG GGCAAGCACT CCACCTCCAT GTTCTTCCGG GTGGTAGAGA 4 1 1
W T-IF CAACGTGCAG GGCAAGCACT CCACCTCCAT GTTCTTCCGG GTGGTAGAGA 4 3 0
M T-5F CAACGTGCAG GGCAAGCACT CCACCTCCAT GTTCTTCCGG GTGGTAGAGA 4 7 3
MT-5R CAACGTGCAG GGCAAGCACT CCACCTCCAT GTTCTTCCGG GTGGTAGAGA 44'5
M T-6F CAACGTGCAG GGCAAGCACT CCACCTCCAT GTTCTTCCGG GTGGTAGAGA 4 7 4
MT-6R CAACGTGCAG GGCAAGCACT CCACCTCCAT GTTCTTCCGG GTGGTAGAGA 4 4 1
MT-7R CAACGTGCAG GGCAAGCACT CCACCTCCAT GTTCTTCCGG GTGGTAGAGA 46 2
M T-7F CAACGTGCAG GGCAAGCACT CCACCTCCAT GTTCTTCCGG GTGGTAGAGA 44 6
C-fms OTGCCTACTT GAACTTOAOC TCTGAGCAGA ACCTCATCCA GOAGGTGACC 1242
W T-IR GTGCCTACrpj GAACTTGAGC TCTGAGCAGA ACCTCATCCA GGAGGTGACC 4 6 1
W T-IF GTGCCTACTgj GAACTTGAGC TCTGAGCAGA ACCTCATCCA GOAGGTGACC 4 8 0
M T-5F GTGCCTAC^ GAACTTGAGC TCTGAGCAGA ACCTCATCCA GGAGGTGACC 523
MT-5R GTGCCTACTg GAACTTGAGC TCTGAGCAGA ACCTCATCCA GGAGGTGACC 49 5
M T-6F GTGCCTACTS GAACTTGAGC TCTGAGCAGA ACCTCATCCA AGAGGTGACC 524
MT-6R GTGCCTACTg GAACTTGAGC TCTGAGCAGA ACCTCATCCA GGAGGTGACC 4 9 1
M T-7F GTGCCTACTS GAACTTGAGC TCTGAGCAGA ACCTCATCCA GGAGGTGACC 512
MT-7R GTGCCTACIg GAACTTGAGC TCTGAGCAGA ACCTCATCCA GGAGGTGACC 49 6
C-fms OTOGOGGAGO GGCTCAACCT CAAAGTCATG GTGGAGGCCT ACCCAGGCCT 1292
W T-IR GTGGGGGAGG GGCTCAACCT CAAAGTCATG GTGGAGGC-T ACCCAGGCCT 511
W T-IF GTGGGGGAGG GGCTCAACCT CAAAGTCATG GTGGAGGC-T ACCCAGGCCT 530
M T-5P GTGGGGGAAG GGCTCAACCT CAAAGTCATG GTGGAGGCCT ACCCAAGCCT 573
MT-5R GTGGGGGAGG GGCTCAACCT CAAAGTCATG GTGGAGGCCT ACCCAGGCCT 545
M T-6F CTCCCCCAAG GGCTCAACCT CAAAGTCATG GTGGAGGC-T AACCAGGCCT 573
MT-6R GTGGGGGAGG GGCTCAACCT CAAAGTCATG GTGGAGGCCT ACCCAGGCCT 541
M T-7F GTGGGGGAAG GGCTCAACCT CAAAGTCATG GTGGAGGCCT ACCCAGGCCT 562
MT-7R GTGGGGGAGG GGCTCAACCT CAAAGTCATG GTGGAGGCCT ACCCAGGCCT 546
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C - f m s CACX3GAGTA- CTGTTGCTAT GGCGACCTG- CTCAACTTTC TGCGAAGGAA 233 3
M T -IF CACXX3AGTA- CTGTTGCTAT GGCGACCTG- CTCAACTTTC TGCGAAGGAA 300
M T-IR CACX3GAGTA- CTGTTGCTAT GGCGACNTG--- TCAACTTTT TGCGAAGGAA 176
MT-2F CACGGAGTA- CTGTTGCTAT GGCGACCTTG CTCAACTTTC TGCGAAGGAA 342
MT-3R CACGGAGTAA TTGTTGNNAT GGCGACTTG- CTCAACTTTT TGCGAAGGAA 156
MT-3F CACGGAGTA- CTGTTGCTAT GGCGACC-TG CTCAACTTTC TGCGAAGGAA 359
MT-4R CACGGAGTA- CTGTTGCTAT GGCGACC-TG CTCAACTTTC TGCGAAGGAA 360
MT-4F AACGGAGTAN ÏTGTTGTTAT GGCGRCCTKG -TAAACTTTT TGNGAAGGAA 126
MT-5R NAGGGAGTAC TTGTTGNTAT GGCGACCTTG CTCAACTTTC TGCGAAGGAA 159
MT-5F CACGGAGTA- CTGTTGCTAT GGCGACC-TG CTCAACTTTC TGCGAAGGAA 359
MT-6R CACGGAGTA- CTGTTGCTAT GGCGACC-TG CTCAACTTTC TGCGAAGGAA 354
C - f m s GG-CTGAGGC CA-TGCTGGG ACCCAGCCTG AGCCCC-GGC CAGGACCCCG 2 3 8 0
M T -IF GG-CTGAGGC CA-TGCTGGG ACCCAGCCTG AGCCCC-GGC CAGGACCCCG 350
M T-IR GG-CTGAGGC CA-TGCTGG- ACCCAGCTTG AGCCCC-GGC CAGGACCCCG 226
M T-2F GG-CTGAGGC CA-TGCTGGG ACCCAGCCTG AGCCCC-GGC CAGGACCCCG 392
MT-3R GG-CTGAGCC CA-TGTTGGG ACCCAGCTTG AGCCCC-GGC CAGGACCCGG 203
M T-3F GG-CTGAGGC CA-TGCTGGG ACCCAGCCTG AGCCCC-GGC CAGGACCCCG 406
MT-4R GG-CTGAGGC CA-TGCTGGG ACCCAGCCTG AGCCCC-GGC CAGGACCCCG 40 7
M T-4F GGGTTGAGCC CATTGCT-GG ACCCAGCTTG AGCCCCGG-C CAGGACCCCG 174
MT-5R GG-CTGAGCC CAT-GCTGGG ACCCAGCTTG AGCCCCGGGC CAGGACCCCG 207
M T-5F GG-CTGAGGC CA-TGCTGGG ACCCAGCCTG AGCCCC-GGC CAGGACCCCG 406
MT-6R GG-CTGAGGC CA-TGCTGGG ACCCAGCCTG AGCCCC-GGC CAGGACCCCG 40 1
C - f m s  AGGGAGGCGT CGACTA-TAA GAACATCCAC CTCGAGAAGA AAT^TGTCCG 2 4 2 9
M T -IF AGGGAGGCGT CGACTA-TAA GAACATCCAC CTCGAGAAGA a a tS t g t c c g 400
M T-IR AGGGAGGCGT CGACTA-TAA GAACATCCAC CTCGAGAAGA AAT^TGTCCG 276
M T-2F AGGGAGGCGT CGACTA-TAA GAACATCCAC CTCGAGAAGA AAT0TGTCCG 442
MT-3R AGGGAGGCGT CGACTATTAA GAACATCCAC CTCGAGAAGA AATpTGTCCG 253
M T-3F AGGGAGGCGT CGACTA-TAA GAACATCCAC CTCGAGAAGA AAT^TGTCCG 4 5 5
MT-4R AGGGAGGCGT CGACTA-TAA GAACATCCAC CTCGAGAAGA AATfflTGTCCG 456
M T-4F AGGGAGGCGT CGACTAT-AA GAACATCCAC CTCGAGAAGA AATgTGTCCG 223
MT-5R AGGGAGGCGT CGACTAT-AG GAACATCCAC TTCGAGAAGA AAT0TGTCCG 256
M T-5F AGGGAGGCGT CGACTA-TAA GAACATCCAC CTCGAGAAGA AATgTGTCCG 45 5
MT-6R AGGGAGGCGT CGACTA-TAA GAACATCCAC CTCGAGAAGA a a tS t g t c c g 45 0
313
Appendix G
c - f m s CAGGGACAGT GGCTTCTCCA GCCAGGGTGT GGACACCTgT GTGGAGATGA 245 0
M T -IF
M T-IR
CAGGGACAGT
CAGGGACAGT
GGCTTCTCCA
GGCTTCTCCA
GCCANGGTGT
GCCAGGGTGT
GGACACCT^
GGACACCTAT
GTGGAGATGA
GTGGAGATGA
450
326
M T-2F CAGGGACA-T GGCTTCTCCA GCCAGGGTGT GGACACCTgT GTGGNGATGA 492
MT-3R
M T-3F
CAGGGACAGT
CAGGGACAGT
GGCTTCTCCA
GGCTTCTCCA
GCCAGGGTGT
GCCAGGGTGT
GGACACClfflT
GGACACCTgT
GTGGAGATGA
GTGGAGATGA
274
505
MT-4R
M T-4F
CAGGGACAGT
CAGGGACAGT
GGCTTCTCCA
GGCTTCTCCA
GCCAGGGTGT
GCCAGGGTGT
GGACACCTgT
GGACACCIgT
GTGGAGATGA
GTGGAGATGA
506
273
MT-5R
M T-5F
CAGGGACAGT
CAGGGACAGT
GGCTTCTCCA
GGCTTCTCCA
GCCAGGGTGT
GCCAGGGTGT
GGACACCTAT
GGACACCTAT
GTGGAGATGA
GTGGAGATGA
277
505
MT-6R CAGGGACAGT GGCTTCTCCA GCCAGGGTGT GGACACCTgT GTGGAGATGA 500
C - f m s GGCCTGTCTC CACTTCTTCA AATGACTCCT TCTCTGAGCA AGACCTGGAC 24 9 7
M T -IF GGCCTGTCTC CACTTCTTCA AATGACTCCT TCTCTGAGCA AGACCTGGAC 500
M T-IR GGCCTGTCTC CACTTCTTCA AATGACTCCT TCTCTGAGCA AGACCTGGAC 376
M T-2F GGC-TGTCTC CACTTCTTCA AATGA-TCCT TCTCTGAACA AGACCTGGAC 542
MT-3R
M T-3F
GGCCTGTCTC
GGCCTGTCTC
CACTTCTTCA
CACTTCTTCA
AATGACTCCT
AATGACTCCT
TCTCTGAGCA
TCTCTGAGCA
AGACCTGGAC
AGACCTGGAC
321
523
MT-4R
M T-4F
GGCCTGTCTC
GGCCTGTCTC
CACTTCTTCA
CACTTCTTCA
AATGACTCCT
AATGACTCCT
TCTCTGAGCA
TCTCTGAGCA
AGACCTGGAC
AGACCTGGAC
323
556
MT-5R
M T-5F
GGCCTGTCTC
GGCCTGTCTC
CACTTCTTCA
CACTTCTTCA
AATGACTCCT
AATGACTCCT
TCTCTGAGCA AGACCTGGAC 
TCTCTGAGCA AGACCTGGAC
523
324
MT-6R GGCCTGTCTC CACTTCTTCA AATGACTCCT TCTCTGAGCA AGACCTGGAC 518
C - f m s AAGGAGGATG GACGGCCC 252 1
M T -IF
M T-IR
AAGGAGGATG
AAGGAGGATG
GACGG-----
GACGGCCC
524
426
M T-2F AAGGAGGATG GACGGCCC 592
MT-3R
M T-3F
AAGGAGGATG
AAGGAGGATG
GACGGCCC 
GA-----------
345
541
MT-4R
M T-4F
AAGGAGGATG
AAGGAGGATG
GACGGCCC
GACGGCCC
347
580
MT-5R
M T-5F
AAGGAGGATG
AAGGAGGATG
GACGGCCC 
GA-----------
348
541
MT-6R AAGGAGGATG GA----------- 536
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Appendix H
Alignment of translated MT-1 with the published human c-fms sequence
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OFRK0RQSVQ KRESTKGEGG EERRGRGRGR EEAEGTAARL KGEEEDQPKE 50
........................................................  50
EEEENKTNSQ CRGEERVSSV PIPAELVAES SVPWAPCSPA PACHFPTEAM 100
........ -    M 1
 M 100
GPGVLLLLLV ATAWHGQGIP VIEPSVPELV VKPGATVTLR CVŒTOSVEWD 150
GPQVLLLLLV ATAWHGQGIP VIEPSVPELV VKPGATVTLR CVGNGSVEWD 51
GPGVLLLLLV ATAWHGQGIP VIEPSVPELV VKPGATVTLR CVGNGSVEWD 150
GPASPHWTLY SDGSSSILST NNATFQNTGT YRCTEPGDPL GGSAAIHLYV 200
GPASPHWTLY SDGSSSILST NNATFQNTGT YRCTEPGDPL GGSAAIHLYV 101
GPASPHWTLY SDGSSSILST NNATFQNTGT YRCTEPGDPL GGSAAIHLYV 200
KDPARPWNVL AQEVWFEDQ DALLPCLLTD PVLEAGVSLV RVRGRPLMRH 250
KDPARPWNVL AQEVWFEDQ DALLPCLLTD PVLEAGVSLV RVRGRPLMRH 151
KDPARPWNVL AQEVWFEDQ DALLPCLLTD PVLEAGVSLV RVRGRPUfRH 250
TNYSFSPWHG FTIHRAKFIQ SQDYQCSALM GGRKVMSISI RLKVQKVIPG 300
TNYSFSPWHG FTIHRAKFIQ SQDYQCSAUi GGRKVMSISI RLKVQKVIPG 201
TNYSFSPWHG FTIHRAKFIQ SQDYQCSALM GGRKVMSISI RLKVQKVIPG 300
PPALTLVPAE LVRIRGEAAQ IVCSASSVDV NFDVFLQHNN TKLAIPQQSD 350
PPALTLVPAE (.VRIRGEAAQ IVCSASSVDV NFDVFLQHNN TKLAIPQQSD 251
PPALTLVPAE LVRIRGEAAQ IVCSASSVDV NFDVFLQHNN TKLAIPQQSD 350
FHNNRYQKVL TLNLDQVDFQ HAŒïYSCVAS NVQGKHSTSM FFRWESAYL 400
FHNNRYQKVL TLNLDQVDFQ HAGNYSCVAS NVQGKHSTSM FFRWESAYL 301
FHNNRYQKVL TLNLDQVDFQ HAGNYSCVAS NVQGKHSTSM FFRWESAYL 400
NLSSEQNLIQ EVTVGEGLNL KVMVEAYPGL QGFNWTYLGP FSDHQPEPKL 450
NLSSEQNLIQ EVTVGEGLNL KVMVEAYPGL QGFNWTYLGP FSDHQPEPKL 351
NLSSEQNLIQ EVTVGEGLNL KVMVEAYPGL QGFNWTYLGP FSDHQPEPKL 450
ANATTKDTYR HTFTLSLPRL KPSEAGRYSF LARNPGGWRA LTFELTLRYP 500
ANATTKDTYR HTFTLSLPRL KPSEAGRYSF LARNPGGWRA LTFELTLRYP 401
ANATTKDTYR HTFTLSLPRL KPSEAGRYSF LARNPGGWRA LTFELTLRYP 500
PEVSVIWTFI NGSGTLLCAA SGYPQPNVTW LQCSGHTDRC DEAQVLQVWD 550
PEVSVIWTFI NGSGTLLCAA SGYPQPNVTW LQCSGHTDRC DEAQVLQVWD 451
PEVSVIWTFI NGSGTLLCAA SGYPQPNVTW LQCSGHTDRC DEAQVLQVWD 550
DPYPEVLSQE PFHKVTVQSL LTVETLEHNQ TYECRAHNSV GSGSWAFIPI 600
DPYPEVLSQE PFHKVTVQSL LTVETLEHNQ TYECRAHNSV GSGSWAFIPI 501
DPYPEVLSQE PFHKVTVQSL LTVETLEHNQ TYECRAHNSV GSGSWAFIPI 600
SAGAHTHPPD EFLFTPVWA CMSIMALLLL T.I.LLLLYKYK QKPKYQVRWK 650
SAGAHTHPPD EFLFTPVWA CMSIMALLLL LLLLLLYKYK QKPKYQVRWK 551
SAGAHTHPPD EFLFTPVWA CMSIMALLLL LLLLLLYKYK QKPKYQVRWK 650
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Published c-fms
Appendix H
IIESYEGNSY TFIDPTQLPY NEKWEFPRNN LQFOKTLGA0 AFOKWEÀTA 700
IIBSYEGNSY TFIDPTQLPY NEKWEFPRNN LQFOKTLGAO AFOKWEATA 601
Consensus IIESYEGNSY TFIDPTQLPY NEKWEFPRNN LQFGKTLGAG AFGKWEATA 700
C-fms Tagged 
Published c-fms
FGLGKEDAVL KVAVKMLKST AHADEKEALM SELKINSHLG QHENIVNLLG 
FGLGKEDAVL KVAVKMLKST AHADEKEAIM SELKINSHLG QHENIVNLLG
750
651
Consensus FGLGKEDAVL KVAVKMLKST AHADEKEAIM SELKINSHLG QHENIVNLLG 750
C-fms Tagged 
Published c-fms
ACTHOGPVLV ITEYCCYŒL LNFLRRKAEA NLGPSLSPGQ DPBGGVDYKN 
ACTHGGPVLV ITEYCCYGDL LNFLRRKAEA NLGPSLSPGQ DPBGGVDYKN
800
701
Consensus ACTHGGPVLV ITEYCCYGDL LNFLRRKAEA NLGPSLSPGQ DPBGGVDYKN 800
C-fms Tagged 
Published c-fms
IHLEKXYVRR DSGFSSQGVD TYVEMRPVST SSNDSFSEQD LDKEDGRPLE 
IHLEKKYVRR DSGFSSQGVD TYVEMRPVST SSNDSFSEQD LDKEDGRPLE
850
751
Consensus IHLEKKYVRR DSGFSSQGVD TYVEMRPVST SSNDSFSEQD LDKEDGRPLE 850
C-fms Tagged 
Published c-fms
LRDLLHFSSQ VAQC34AFLAS KNCIHRDVAA RNVLLTNGHV AKIGDFGLAR 
LRDLLHFSSQ VAQOfAFLAS KNCIHRDVAA RNVLLTNGHV AKIGDFGLAR
900
801
Consensus LRDLLHFSSQ VAQCMAFLAS KNCIHRDVAA RNVLLTNŒIV AKIGDFGLAR 900
C-fms Tagged 
Published c-fms
DINNDSNYIV KOIARLPVKW NAPESIFDCV YTVQSDVWSY GILLWEIFSL 
DIMNDSNYIV KGNARLPVKW NAPESIFDCV YTVQSDVWSY GILLWEIFSL
950
851
Consensus DIMNDSNYIV KOIARLPVKW NAPESIFDCV YTVQSDVWSY GILLWEIFSL 950
C-fms Tagged 
Published c-fms
GLNPYPGILV NSKFYKLVKD GYQMAQPAFA PKNIYSIMQA CWALEPTHRP 
GLNPYPGILV NSKFYKLVKD GYWAQPAFA PKNIYSIMQA CWALEPTHRP
1000
901
Consensus GLNPYPGILV NSKFYKLVKD GYWAQPAFA PKNIYSIMQA CWALEPTHRP 1000
C-fms Tagged 
Published c-fms
TFQQICSFLQ EQAQEDRRER DYTNLPSSSR SGGSGSSSSE LEEESSSEHL 
TFQQICSFLQ EQAQEDRRER DYTNLPSSSR SGGSGSSSSE LEEESSSEHL
1050
951
Consensus TFQQICSFLQ EQAQEDRRER DYTNLPSSSR SGGSGSSSSE LEEESSSEHL 1050
C-fms Tagged 
Published c-fms
TCCEQGDIAQ PLLQPNNYQF CKLRSRILQI SITLAAARGH PFEQKLISEE 
TCCEQOTIAQ PLLQPNNYQF C*------------------- -----------
1100
972
Consensus TCCEQGDIAQ PLLQPNNYQF C. 1100
C-fms Tagged 
Published c-fms
DLNMHTGHHH HHH 1113 
............... 972
Consensus 1113
316
Appendix I
Diagram of epitope tags present in MT-1 construct protein translation.
SEQUENCE: 1014aa 112837 predicted MW
G P G V L L L L L V A T A W H G Q G I P V I E P S V P E L V V K P G A T V T L R C V G N G S V E W
D G P A S P H W T L Y S D G S S S I L S T N N A T F Q N T G T Y R C T E P G D P L G G S A A I H L Y
K D P A R P W N V L A Q E V V V F E D Q D A L L P C L L T D P V L E A G V S L V R V R G R P L M R
H T N Y S F S P W H G F T I H R A K F I Q S Q D Y Q C S A L M G G R K V M S I S I R L K V Q K V I P
G P P A L T L V P A E L V R I R G E A A Q I V C S A S S V D V N F D V F L Q H N N T K L A I P Q Q S
D F H N N R Y Q K V L T L N L D Q V D F Q H A G N Y S C V A S N V Q G K H S T S M F F R V V E S A Y
L N L S S E Q N L I Q E V T V G E G L N L K V M V E A Y P G L Q G F N W T Y L G P F S D H Q P E P K
L A N A T T K D T Y R H T F T L S L P R L K P S E A G R Y S F L A R N P G G W R A L T F E L T L R Y
P P E V G V I W T F I N C S C T L L C A A S G Y P Q P N V T W L Q C S G H T D R C n E A Q V L Q V W
D D P Y P E V L S Q E P F H K V T V Q S L L T V E T L E H N Q T Y E C R A H N S V G S G S W A F I P
I S A G A H T H P P D E F L F T P V V V A C M S I M A L L L L L L L L L L Y K Y K Q K P K Y Q V R W
K I l E S Y E G N S Y T F I D P T Q L P Y N E K W E F P R N N L Q F G K T L G A G A F G K V V E A T
F G L G K E D A V L K V A V K M L K S T A H A D E K E A L M S E L K I M S H L G Q H E N I V N L L
G A C T H G G P V L V I T E Y C C Y G D L L N F L R R K A E A M L G P S L S P G Q D P E G G V D Y K
I H L E K K Y V R R D S G F S S Q G V D T Y V E M R P V S T S S N D S F S E Q D L D K E D G R P L
E L R D L L H F S S Q V A Q G M A F L A S K N C I H R D V A A R N V L L T N G H V A K I G D F G L A
R D I M N D S N Y I V K G N A R L P V K W M A P E S I F D C V Y T V Q S D V W S Y G I L L W E I F S
L G L N P Y P G I L V N S K F Y K L V K D G Y Q M A Q P A F A P K N I Y S I M Q A C W A L E P T H R
P T F Q Q I C S F L Q E Q A Q E D R R E R D Y T N L P S S S R S G G S G S S S S E L E E E S S S E H
L T C C E Q G D I A Q P L L Q P N N Y Q F C K L R S R I L Q I S I T L A A A R G H P F E Q K L I S E
E D L N M H T G H H H H H H
C-fms
Linker
myc-epitope 
Hie-epitope
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